Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelsystem.org.

Overview for Request: cder_mpl1r_wp313, Report 1

Request ID: cder_mpl1r_wp313_nsdp_v01

Request Description: In this report, we characterized dispensing and administration patterns of 27 New Molecular Entities (NMEs) approved from January 1, 2021, to June 30, 2021, stratified by age and sex in the Sentinel Distributed Database (SDD).

Sentinel Routine Querying Module: Cohort Identification and Descriptive Analysis module (CIDA), version 14.2.0.

Data Source: We distributed this request to 13 Sentinel Data Partners on September 3, 2025. We included aggregate results from all 13 Data Partners in this report. The study period included data from January 1, 2021, to April 30, 2025. Report 2 includes NMEs approved from July 1, 2021 to December 31, 2021. Please see Appendix A for a list of available data dates for each Data Partner**.**

Study Design: We identified individuals initiating any of the 27 NMEs of interest. We described demographic and clinical characteristics for individuals initiating each NME based on history recorded in the six months prior to initiation of treatment with the relevant drug. The analyses characterized dispensing patterns by examining cumulative exposure episode duration, first exposure episode duration, all exposure episode durations, days supplied per dispensing, and lengths of gaps between episodes, overall and stratified by age group and sex. This was a Type 5 analysis in the Query Request Package (QRP) documentation.

Exposures of Interest: Our exposures of interest were NMEs approved between January 1, 2021, and June 30, 2021, administered or dispensed in any care setting. These were defined using Healthcare Common Procedure Coding System (HCPCS) procedure codes and National Drug Codes (NDCs). Please see Appendix B for a list of non-proprietary and proprietary names of medical products and Appendix C for a list of procedure codes used to define exposures in this request. All valid exposure episodes were included.

Cohort Eligibility Criteria: We defined index exposure as the first qualifying administration or dispensing of a given NME to an individual during the study period. We required individuals to be enrolled in health plans with both medical and drug coverage for at least 183 days prior to their index exposure, during which gaps in coverage of up to 45 days were allowed. The following age groups were included: 0-17, 18-24 ,25-40, 41-64, 65+ years.

Baseline Characteristics: We described demographic characteristics such as sex, age, and calendar year on the day of each index NME exposure. We also described 33 clinical characteristics based on history recorded in the six months prior to the index exposure. The set of clinical characteristics included 26 chronic conditions and 7 lifestyle-related conditions. Chronic conditions were defined using Centers for Medicare and Medicaid Services' (CMS) Chronic Conditions Data Warehouse[1] (CCW) algorithms and included: acute myocardial infarction, Alzheimer's disease, Non-Alzheimer's Dementia, atrial fibrillation, diabetes, heart failure, hyperlipidemia, hypertension, depression, ischemic heart disease, rheumatoid arthritis/osteoarthritis, stroke/transient ischemic attack (TIA), breast cancer, colorectal cancer, prostate cancer, lung cancer, endometrial cancer, acquired hypothyroidism, anemia, asthma, benign prostatic hyperplasia, chronic kidney disease, chronic obstructive pulmonary disease (COPD) and bronchiectasis, glaucoma, osteoporosis, and liver disease. Lifestyle-related conditions included: obesity, overweight, smoking, alcohol abuse or dependence, drug abuse or dependence, history of cardiac arrest, and history of coronary angioplasty or bypass. International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS) procedure codes, HCPCS procedure codes, Current Procedural Terminology, Fourth Edition (CPT-4) procedure codes, and NDCs were used to define the clinical characteristics. Please see Appendix D for a list of diagnosis and procedure codes and Appendix E for a list of non-proprietary and proprietary names of medical products used to define baseline characteristics in this request.

Please refer to Appendices F, G and H for the specifications of parameters used in this request, baseline characteristics used in this request, and a design diagram.

Limitations: Algorithms used to define exposures and inclusion criteria are imperfect; thus, it is possible that there may be misclassification. Therefore, data should be interpreted with this limitation in mind.   **Notes:** Please contact the Sentinel Operations Center (info@sentinelsystem.org) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel's routine querying modules, please refer to the documentation (https://dev.sentinelsystem.org/projects/SETINEL/repos/sentinel-routine-querying-tool-documentation/browse).

[1]Chronic Conditions Data Warehouse. Condition Categories -Chronic Conditions Data Warehouse.
https://www.ccwdata.org/web/guest/condition-categories

Table of Contents	
Glossary (CIDA)	List of Terms to Define the Cohort Identification and Descriptive Analysis (CIDA) Found in this Report

Table of Contents

	Table of Contents

Table of Contents

Amount Supplied - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing.

Blackout Period - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.

Care Setting - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms the Care Setting/PDX parameter.

> **Ambulatory Visit (AV) -** includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

> **Emergency Department (ED) -** includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

> **Inpatient Hospital Stay (IP) -** includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

> **Non-Acute Institutional Stay (IS) -** includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

> **Other Ambulatory Visit (OA) -** includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Charlson/Elixhauser Combined Comorbidity Score - calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).

Code Days - the minimum number of times the diagnosis must be found during the evaluation period in order to fulfill the algorithm to identify the corresponding patient characteristic.

Cohort Definition (drug/exposure) - indicates how the cohort will be defined: 01: Cohort includes only the first valid treatment episode during the query period; 02: Cohort includes all valid treatment episodes during the query period; 03: Cohort includes all valid treatment episodes during the query period until an event occurs.

Computed Start Marketing Date - represents the first observed dispensing date among all valid users within a GROUP (scenario) within each Data Partner site.

Days Supplied - number of days supplied for all dispensings in qualifying treatment episodes.

Eligible Members - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.

Enrollment Gap - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled" sequence.

Episodes - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.

Episode Gap - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.

Event Deduplication - specifies how events are counted by the Modular Program (MP) algorithm: 0: Counts all occurrences of a health outcome of interest (HOI) during an exposure episode; 1: de-duplicates occurrences of the same HOI code and code type on the same day; 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).

Exposure Episode Length - number of days after exposure initiation that is considered "exposed time."

Exposure Extension Period - number of days post treatment period in which the outcomes/events are counted for a treatment episode. Extensions are added after any episode gaps have been bridged.

Lookback Period - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).

Maximum Episode Duration - truncates exposure episodes after a requester-specified number of exposed days. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Member-Years - sum of all days of enrollment with medical and drug coverage in the query period preceded by an exposure washout period all divided by 365.25.

Minimum Days Supplied - specifies a minimum number of days in length of the days supplied for the episode to be considered.

Minimum Episode Duration - specifies a minimum number of days in length of the episode for it to be considered. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Monitoring Period - used to define time periods of interest for both sequential analysis and simple cohort characterization requests.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Caresetting/PDX parameter.

Query Period - period in which the modular program looks for exposures and outcomes of interest.

Switch Evaluation Step Value - value used to differentiate evaluation step. Each switch pattern can support up to 2 evaluation steps (0 = switch pattern evaluation start; 1 = first evaluation; 2 = second evaluation).

Switch Gap Inclusion Indicator - indicator for whether gaps in treatment episodes that are included in a switch episode will be counted as part of the switch episode duration.

Switch Pattern Cohort Inclusion Date - indicates which date to use for inclusion into the switch pattern cohort of interest as well as optionally as the index date of the treatment episode initiating the switch pattern. Valid options are the product approval date, product marketing date, other requester defined date, or computed start marketing date.

Switch Pattern Cohort Inclusion Strategy - indicates how the switch pattern cohort inclusion date will be used: 01: used only as a switch cohort entry date. First treatment episode dispensing date is used as index for computing time to first switch; 02: used as switch cohort entry date and as initial switch step index date for computing time to first switch.

Treatment Episode Truncation Indicator - indicates whether the exposure episode will be truncated at the occurrence of a requester-specified code.

Washout Period (drug/exposure) - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.

Washout Period (event/outcome) - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.

Years at Risk - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

*all terms may not be used in this report

Table 1a. Aggregated Characteristics of vericiguat in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Patient Characteristics	vericiguat	
	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	9,873	N/A[2]
Demographic Characteristics		
Age (years)	73.6	11.0
Age		
0-17 years	0	0.0%
18-24 years	12	0.1%
25-40 years	123	1.2%
41-64 years	1,819	18.4%
≥ 65 years	7,919	80.2%
Sex		
Female	3,439	34.8%
Male	6,434	65.2%
Race[3]		
American Indian or Alaska Native	19	0.2%
Asian	440	4.5%
Black or African American	1,424	14.4%
Multi-racial	29	0.3%
Native Hawaiian or Other Pacific Islander	17	0.2%
Unknown	1,172	11.9%
White	6,772	68.6%
Hispanic origin		
Yes	329	3.3%
No	7,820	79.2%
Unknown	1,724	17.5%
Year		
2021	1,070	10.8%
2022	2,297	23.3%
2023	3,061	31.0%
2024	3,349	33.9%
2025	96	1.0%
Health Characteristics		
Acute Myocardial Infarction	973	9.9%
Alzheimer's Disease	183	1.9%
Non-Alzheimer's Dementia	747	7.6%
Atrial Fibrillation	4,839	49.0%
Diabetes Mellitus	5,222	52.9%
Heart Failure	9,413	95.3%
Hyperlipidemia	7,374	74.7%
Hypertension	8,597	87.1%
Depression	2,158	21.9%
Ischemic Heart Disease	7,643	77.4%
Rheumatoid Arthritis/Osteoarthritis	2,264	22.9%
Stroke/TIA[4]	720	7.3%
Breast Cancer	290	2.9%

Table 1a. Aggregated Characteristics of vericiguat in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Health Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Colorectal Cancer	130	1.3%
Prostate Cancer	445	4.5%
Lung Cancer	160	1.6%
Endometrial Cancer	20	0.2%
Acquired Hypothyroidism	2,022	20.5%
Anemia	4,560	46.2%
Asthma	690	7.0%
Benign Prostatic Hyperplasia	1,506	15.3%
Chronic Kidney Disease	4,904	49.7%
COPD[5] and Bronchiectasis	2,806	28.4%
Glaucoma	1,064	10.8%
Osteoporosis	482	4.9%
Obesity: diagnosed or identified by weight management procedures	3,313	33.6%
Obesity: identified by weight management-related dispensings	720	7.3%
Overweight	1,507	15.3%
Smoking: diagnosed or identified by smoking cessation procedures	3,793	38.4%
Smoking: identified by smoking-related dispensings	57	0.6%
Alcohol Abuse or Dependence	336	3.4%
Drug Abuse or Dependence	435	4.4%
History of Cardiac Arrest	226	2.3%
History of Coronary Angioplasty or Bypass	3,718	37.7%
Liver Disease Based on CCW[6] Definition	831	8.4%
Liver Disease Extended Definition (CCW + Additional Codes)	845	8.6%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	21.2	15.8
Mean number of emergency room encounters	0.9	1.8
Mean number of inpatient hospital encounters	0.8	1.2
Mean number of non-acute institutional encounters	0.1	0.5
Mean number of other ambulatory encounters	10.6	15.4
Mean number of filled prescriptions	33.9	23.4
Mean number of generics dispensed	14.0	6.1
Mean number of unique drug classes dispensed	12.9	5.2

[1]Value represents standard deviation if % doesn't follow the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

[6] CCW: Chronic Conditions Data Warehouse; https://www2.ccwdata.org/web/guest/home/

Table 1b. Aggregated Characteristics of cabotegravir in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Patient Characteristics	cabotegravir	
	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	14,260	N/A[2]
Demographic Characteristics		
Age (years)	46.8	12.4
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	5,317	37.3%
41-64 years	6,453	45.3%
≥ 65 years	1,980	13.9%
Sex		
Female	2,383	16.7%
Male	11,877	83.3%
Race[3]		
American Indian or Alaska Native	42	0.3%
Asian	228	1.6%
Black or African American	3,456	24.2%
Multi-racial	416	2.9%
Native Hawaiian or Other Pacific Islander	19	0.1%
Unknown	5,648	39.6%
White	4,451	31.2%
Hispanic origin		
Yes	1,179	8.3%
No	6,582	46.2%
Unknown	6,499	45.6%
Year		
2021	1,299	9.1%
2022	3,069	21.5%
2023	4,228	29.6%
2024	5,247	36.8%
2025	417	2.9%
Health Characteristics		
Acute Myocardial Infarction	35	0.2%
Alzheimer's Disease	12	0.1%
Non-Alzheimer's Dementia	109	0.8%
Atrial Fibrillation	211	1.5%
Diabetes Mellitus	1,505	10.6%
Heart Failure	529	3.7%
Hyperlipidemia	3,020	21.2%
Hypertension	3,381	23.7%
Depression	4,048	28.4%
Ischemic Heart Disease	889	6.2%
Rheumatoid Arthritis/Osteoarthritis	1,172	8.2%
Stroke/TIA[4]	112	0.8%
Breast Cancer	33	0.2%
Colorectal Cancer	74	0.5%

Table 1b. Aggregated Characteristics of cabotegravir in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	cabotegravir	
Health Characteristics	**Number/Mean**	**Percent/ Standard Deviation[1]**
Prostate Cancer	145	1.0%
Lung Cancer	17	0.1%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	412	2.9%
Anemia	1,464	10.3%
Asthma	608	4.3%
Benign Prostatic Hyperplasia	515	3.6%
Chronic Kidney Disease	1,063	7.5%
COPD[5] and Bronchiectasis	536	3.8%
Glaucoma	459	3.2%
Osteoporosis	165	1.2%
Obesity: diagnosed or identified by weight management procedures	2,558	17.9%
Obesity: identified by weight management-related dispensings	760	5.3%
Overweight	1,373	9.6%
Smoking: diagnosed or identified by smoking cessation procedures	2,500	17.5%
Smoking: identified by smoking-related dispensings	244	1.7%
Alcohol Abuse or Dependence	581	4.1%
Drug Abuse or Dependence	1,262	8.8%
History of Cardiac Arrest	17	0.1%
History of Coronary Angioplasty or Bypass	243	1.7%
Liver Disease Based on CCW[6] Definition	357	2.5%
Liver Disease Extended Definition (CCW + Additional Codes)	365	2.6%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	11.2	13.5
Mean number of emergency room encounters	0.4	1.3
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	3.6	7.8
Mean number of filled prescriptions	19.5	19.0
Mean number of generics dispensed	7.2	5.5
Mean number of unique drug classes dispensed	6.6	5.0

[1] Value represents standard deviation if % doesn't follow the value.

[2] N/A: Not Applicable

[3] Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4] TIA: Transient Ischemic Attack

[5] COPD: Chronic Obstructive Pulmonary Disease

[6] CCW: Chronic Conditions Data Warehouse; https://www2.ccwdata.org/web/guest/home/

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1c. Aggregated Characteristics of voclosporin in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Patient Characteristics	voclosporin	
	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	945	N/A[2]
Demographic Characteristics		
Age (years)	38.7	12.5
Age		
0-17 years	*****	*****
18-24 years	128	13.5%
25-40 years	472	49.9%
41-64 years	296	31.3%
≥ 65 years	*****	*****
Sex		
Female	810	85.7%
Male	135	14.3%
Race[3]		
American Indian or Alaska Native	*****	*****
Asian	63	6.7%
Black or African American	254	26.9%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	446	47.2%
White	154	16.3%
Hispanic origin		
Yes	156	16.5%
No	410	43.4%
Unknown	379	40.1%
Year		
2021	345	36.5%
2022	178	18.8%
2023	200	21.2%
2024	202	21.4%
2025	20	2.1%
Health Characteristics		
Acute Myocardial Infarction	12	1.3%
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	*****	*****
Atrial Fibrillation	21	2.2%
Diabetes Mellitus	89	9.4%

Table 1c. Aggregated Characteristics of voclosporin in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	voclosporin	
Heart Failure	110	11.6%
Hyperlipidemia	209	22.1%
Health Characteristics	**Number/Mean**	**Percent/ Standard Deviation[1]**
Hypertension	531	56.2%
Depression	191	20.2%
Ischemic Heart Disease	74	7.8%
Rheumatoid Arthritis/Osteoarthritis	141	14.9%
Stroke/TIA[4]	26	2.8%
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	88	9.3%
Anemia	512	54.2%
Asthma	41	4.3%
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	861	91.1%
COPD[5] and Bronchiectasis	24	2.5%
Glaucoma	37	3.9%
Osteoporosis	29	3.1%
Obesity: diagnosed or identified by weight management procedures	216	22.9%
Obesity: identified by weight management-related dispensings	15	1.6%
Overweight	86	9.1%
Smoking: diagnosed or identified by smoking cessation procedures	121	12.8%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	43	4.6%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	13	1.4%
Liver Disease Based on CCW[6] Definition	44	4.7%
Liver Disease Extended Definition (CCW + Additional Codes)	46	4.9%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	16.0	11.6
Mean number of emergency room encounters	0.9	1.6
Mean number of inpatient hospital encounters	0.4	0.8

Table 1c. Aggregated Characteristics of voclosporin in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	voclosporin	
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	7.5	12.9

	Number/Mean	Standard Deviation[1]
Health Service Utilization Intensity Metrics	**Number/Mean**	**Percent/ Standard Deviation[1]**
Mean number of filled prescriptions	26.3	17.3
Mean number of generics dispensed	10.9	6.0
Mean number of unique drug classes dispensed	10.3	5.3

[1] Value represents standard deviation if % doesn't follow the value.

[2] N/A: Not Applicable

[3] Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4] TIA: Transient Ischemic Attack

[5] COPD: Chronic Obstructive Pulmonary Disease

[6] CCW: Chronic Conditions Data Warehouse; https://www2.ccwdata.org/web/guest/home/

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1d. Aggregated Characteristics of tepotinib in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Patient Characteristics	tepotinib	
	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	476	N/A[2]
Demographic Characteristics		
Age (years)	75.2	9.3
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	417	87.6%
Sex		
Female	298	62.6%
Male	178	37.4%
Race[3]		
American Indian or Alaska Native	0	0.0%
Asian	41	8.6%
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	68	14.3%
White	329	69.1%
Hispanic origin		
Yes	*****	*****
No	363	76.3%
Unknown	*****	*****
Year		
2021	*****	*****
2022	85	17.9%
2023	128	26.9%
2024	191	40.1%
2025	*****	*****
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	19	4.0%
Atrial Fibrillation	76	16.0%
Diabetes Mellitus	83	17.4%

Table 1d. Aggregated Characteristics of tepotinib in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	tepotinib	
Heart Failure	75	15.8%
Hyperlipidemia	226	47.5%
Health Characteristics	**Number/Mean**	**Percent/ Standard Deviation[1]**
Hypertension	279	58.6%
Depression	93	19.5%
Ischemic Heart Disease	135	28.4%
Rheumatoid Arthritis/Osteoarthritis	105	22.1%
Stroke/TIA[4]	33	6.9%
Breast Cancer	38	8.0%
Colorectal Cancer	*****	*****
Prostate Cancer	22	4.6%
Lung Cancer	469	98.5%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	98	20.6%
Anemia	218	45.8%
Asthma	22	4.6%
Benign Prostatic Hyperplasia	43	9.0%
Chronic Kidney Disease	82	17.2%
COPD[5] and Bronchiectasis	101	21.2%
Glaucoma	41	8.6%
Osteoporosis	51	10.7%
Obesity: diagnosed or identified by weight management procedures	54	11.3%
Obesity: identified by weight management-related dispensings	*****	*****
Overweight	58	12.2%
Smoking: diagnosed or identified by smoking cessation procedures	225	47.3%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	21	4.4%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	30	6.3%
Liver Disease Based on CCW[6] Definition	66	13.9%
Liver Disease Extended Definition (CCW + Additional Codes)	68	14.3%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	28.1	13.6
Mean number of emergency room encounters	0.7	1.2
Mean number of inpatient hospital encounters	0.7	1.1
Mean number of non-acute institutional encounters	0.1	0.3

Table 1d. Aggregated Characteristics of tepotinib in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	tepotinib	
Mean number of other ambulatory encounters	11.1	12.0

Health Service Utilization Intensity Metrics	Number/Mean	Percent/ Standard Deviation[1]
Mean number of filled prescriptions	23.2	14.8
Mean number of generics dispensed	11.0	5.5
Mean number of unique drug classes dispensed	10.1	4.7

[1]Value represents standard deviation if % doesn't follow the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

[6]CCW: Chronic Conditions Data Warehouse; https://www2.ccwdata.org/web/guest/home/

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1e. Aggregated Characteristics of umbralisib in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Patient Characteristics	umbralisib	
	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	79	N/A[2]
Demographic Characteristics		
Age (years)	73.8	8.3
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	0	0.0%
41-64 years	13	16.5%
≥ 65 years	66	83.5%
Sex		
Female	37	46.8%
Male	42	53.2%
Race[3]		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	65	82.3%
Hispanic origin		
Yes	*****	*****
No	67	84.8%
Unknown	*****	*****
Year		
2021	52	65.8%
2022	27	34.2%
2023	0	0.0%
2024	0	0.0%
2025	0	0.0%
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	*****	*****
Atrial Fibrillation	*****	*****
Diabetes Mellitus	13	16.5%

Table 1e. Aggregated Characteristics of umbralisib in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	umbralisib	
Heart Failure	*****	*****
Hyperlipidemia	26	32.9%
Health Characteristics	**Number/Mean**	**Percent/ Standard Deviation[1]**
Hypertension	37	46.8%
Depression	18	22.8%
Ischemic Heart Disease	15	19.0%
Rheumatoid Arthritis/Osteoarthritis	11	13.9%
Stroke/TIA[4]	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	*****	*****
Anemia	47	59.5%
Asthma	*****	*****
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	14	17.7%
COPD[5] and Bronchiectasis	11	13.9%
Glaucoma	*****	*****
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	*****	*****
Obesity: identified by weight management-related dispensings	0	0.0%
Overweight	*****	*****
Smoking: diagnosed or identified by smoking cessation procedures	24	30.4%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****
Liver Disease Based on CCW[6] Definition	*****	*****
Liver Disease Extended Definition (CCW + Additional Codes)	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	27.1	17.3
Mean number of emergency room encounters	0.5	0.9
Mean number of inpatient hospital encounters	0.7	1.2
Mean number of non-acute institutional encounters	0.1	0.4

Table 1e. Aggregated Characteristics of umbralisib in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	umbralisib	
Mean number of other ambulatory encounters	12.6	14.2

Health Service Utilization Intensity Metrics	Number/Mean	Percent/ Standard Deviation[1]
Mean number of filled prescriptions	22.5	12.4
Mean number of generics dispensed	10.2	5.5
Mean number of unique drug classes dispensed	9.5	5.0

[1]Value represents standard deviation if % doesn't follow the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

[6]CCW: Chronic Conditions Data Warehouse; https://www2.ccwdata.org/web/guest/home/

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1f. Aggregated Characteristics of evinacumab-dgnb in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Patient Characteristics	evinacumab-dgnb	
	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	139	N/A[2]
Demographic Characteristics		
Age (years)	58.3	11.8
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	49	35.3%
≥ 65 years	68	48.9%
Sex		
Female	108	77.7%
Male	31	22.3%
Race[3]		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	30	21.6%
White	93	66.9%
Hispanic origin		
Yes	*****	*****
No	97	69.8%
Unknown	*****	*****
Year		
2021	34	24.5%
2022	*****	*****
2023	34	24.5%
2024	43	30.9%
2025	*****	*****
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	*****	*****
Atrial Fibrillation	*****	*****
Diabetes Mellitus	19	13.7%

Table 1f. Aggregated Characteristics of evinacumab-dgnb in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	evinacumab-dgnb	
Heart Failure	22	15.8%
Hyperlipidemia	133	95.7%
Health Characteristics	**Number/Mean**	**Percent/ Standard Deviation[1]**
Hypertension	58	41.7%
Depression	27	19.4%
Ischemic Heart Disease	101	72.7%
Rheumatoid Arthritis/Osteoarthritis	25	18.0%
Stroke/TIA[4]	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	0	0.0%
Prostate Cancer	*****	*****
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	18	12.9%
Anemia	18	12.9%
Asthma	11	7.9%
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	*****	*****
COPD[5] and Bronchiectasis	*****	*****
Glaucoma	*****	*****
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	39	28.1%
Obesity: identified by weight management-related dispensings	12	8.6%
Overweight	14	10.1%
Smoking: diagnosed or identified by smoking cessation procedures	23	16.5%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	37	26.6%
Liver Disease Based on CCW[6] Definition	*****	*****
Liver Disease Extended Definition (CCW + Additional Codes)	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	16.7	12.3
Mean number of emergency room encounters	0.3	0.7
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.1

Table 1f. Aggregated Characteristics of evinacumab-dgnb in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	evinacumab-dgnb	
Mean number of other ambulatory encounters	4.2	4.7

Health Service Utilization Intensity Metrics	Number/Mean	Percent/ Standard Deviation[1]
Mean number of filled prescriptions	21.6	16.8
Mean number of generics dispensed	9.1	5.6
Mean number of unique drug classes dispensed	8.7	5.1

[1]Value represents standard deviation if % doesn't follow the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

[6] CCW: Chronic Conditions Data Warehouse; https://www2.ccwdata.org/web/guest/home/

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1g. Aggregated Characteristics of trilacicilib in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Patient Characteristics	trilacicilib	
	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	2,028	N/A[2]
Demographic Characteristics		
Age (years)	71.7	7.1
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	1,741	85.8%
Sex		
Female	1,065	52.5%
Male	963	47.5%
Race[3]		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	129	6.4%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	170	8.4%
White	1,710	84.3%
Hispanic origin		
Yes	14	0.7%
No	1,673	82.5%
Unknown	341	16.8%
Year		
2021	138	6.8%
2022	465	22.9%
2023	618	30.5%
2024	782	38.6%
2025	25	1.2%
Health Characteristics		
Acute Myocardial Infarction	36	1.8%
Alzheimer's Disease	12	0.6%
Non-Alzheimer's Dementia	78	3.8%
Atrial Fibrillation	329	16.2%
Diabetes Mellitus	587	28.9%

Table 1g. Aggregated Characteristics of trilacicilib in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	trilacicilib	
Heart Failure	393	19.4%
Hyperlipidemia	1,283	63.3%
Health Characteristics	**Number/Mean**	**Percent/ Standard Deviation[1]**
Hypertension	1,492	73.6%
Depression	554	27.3%
Ischemic Heart Disease	855	42.2%
Rheumatoid Arthritis/Osteoarthritis	475	23.4%
Stroke/TIA[4]	145	7.1%
Breast Cancer	142	7.0%
Colorectal Cancer	60	3.0%
Prostate Cancer	112	5.5%
Lung Cancer	1,858	91.6%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	349	17.2%
Anemia	956	47.1%
Asthma	112	5.5%
Benign Prostatic Hyperplasia	221	10.9%
Chronic Kidney Disease	372	18.3%
COPD[5] and Bronchiectasis	1,228	60.6%
Glaucoma	126	6.2%
Osteoporosis	122	6.0%
Obesity: diagnosed or identified by weight management procedures	512	25.2%
Obesity: identified by weight management-related dispensings	55	2.7%
Overweight	334	16.5%
Smoking: diagnosed or identified by smoking cessation procedures	1,760	86.8%
Smoking: identified by smoking-related dispensings	48	2.4%
Alcohol Abuse or Dependence	113	5.6%
Drug Abuse or Dependence	137	6.8%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	315	15.5%
Liver Disease Based on CCW[6] Definition	553	27.3%
Liver Disease Extended Definition (CCW + Additional Codes)	556	27.4%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	24.8	13.8
Mean number of emergency room encounters	1.0	1.7
Mean number of inpatient hospital encounters	0.8	0.9
Mean number of non-acute institutional encounters	0.1	0.3

Table 1g. Aggregated Characteristics of trilacicilib in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	trilacicilib	
Mean number of other ambulatory encounters	8.5	10.6

Health Service Utilization Intensity Metrics	Number/Mean	Percent/ Standard Deviation[1]
Mean number of filled prescriptions	24.9	16.4
Mean number of generics dispensed	12.7	5.9
Mean number of unique drug classes dispensed	11.6	5.1

[1]Value represents standard deviation if % doesn't follow the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

[6]CCW: Chronic Conditions Data Warehouse; https://www2.ccwdata.org/web/guest/home/

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1h. Aggregated Characteristics of casimersen in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Patient Characteristics	casimersen	
	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	143	N/A[2]
Demographic Characteristics		
Age (years)	15.0	7.5
Age		
0-17 years	103	72.0%
18-24 years	26	18.2%
25-40 years	*****	*****
41-64 years	0	0.0%
≥ 65 years	*****	*****
Sex		
Female	*****	*****
Male	*****	*****
Race[3]		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	67	46.9%
White	59	41.3%
Hispanic origin		
Yes	31	21.7%
No	71	49.7%
Unknown	41	28.7%
Year		
2021	109	76.2%
2022	13	9.1%
2023	*****	*****
2024	*****	*****
2025	*****	*****
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease	0	0.0%
Non-Alzheimer's Dementia	0	0.0%
Atrial Fibrillation	0	0.0%
Diabetes Mellitus	*****	*****

Table 1h. Aggregated Characteristics of casimersen in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	casimersen	
Heart Failure	28	19.6%
Hyperlipidemia	*****	*****
Health Characteristics	**Number/Mean**	**Percent/ Standard Deviation[1]**
Hypertension	*****	*****
Depression	*****	*****
Ischemic Heart Disease	0	0.0%
Rheumatoid Arthritis/Osteoarthritis	0	0.0%
Stroke/TIA[4]	0	0.0%
Breast Cancer	0	0.0%
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	*****	*****
Anemia	*****	*****
Asthma	*****	*****
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	0	0.0%
COPD[5] and Bronchiectasis	0	0.0%
Glaucoma	*****	*****
Osteoporosis	12	8.4%
Obesity: diagnosed or identified by weight management procedures	*****	*****
Obesity: identified by weight management-related dispensings	*****	*****
Overweight	*****	*****
Smoking: diagnosed or identified by smoking cessation procedures	*****	*****
Smoking: identified by smoking-related dispensings	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	0	0.0%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	0	0.0%
Liver Disease Based on CCW[6] Definition	0	0.0%
Liver Disease Extended Definition (CCW + Additional Codes)	0	0.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	15.3	19.8
Mean number of emergency room encounters	0.3	0.8
Mean number of inpatient hospital encounters	0.0	0.3
Mean number of non-acute institutional encounters	0.0	0.1

Table 1h. Aggregated Characteristics of casimersen in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	casimersen	
Mean number of other ambulatory encounters	31.0	50.0

Health Service Utilization Intensity Metrics	Number/Mean	Percent/ Standard Deviation[1]
Mean number of filled prescriptions	15.8	15.9
Mean number of generics dispensed	4.6	4.2
Mean number of unique drug classes dispensed	4.4	3.8

[1]Value represents standard deviation if % doesn't follow the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

[6] CCW: Chronic Conditions Data Warehouse; https://www2.ccwdata.org/web/guest/home/

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1i. Aggregated Characteristics of fosdenopterin in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Patient Characteristics	fosdenopterin	
	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	*****	N/A[2]
Demographic Characteristics		
Age (years)	5.0	6.3
Age		
0-17 years	*****	*****
18-24 years	0	0.0%
25-40 years	0	0.0%
41-64 years	0	0.0%
≥ 65 years	0	0.0%
Sex		
Female	*****	*****
Male	*****	*****
Race[3]		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	*****	*****
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	0	0.0%
Year		
2021	*****	*****
2022	0	0.0%
2023	0	0.0%
2024	0	0.0%
2025	0	0.0%
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease	0	0.0%
Non-Alzheimer's Dementia	0	0.0%
Atrial Fibrillation	0	0.0%
Diabetes Mellitus	0	0.0%

Table 1i. Aggregated Characteristics of fosdenopterin in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	fosdenopterin	
Heart Failure	0	0.0%
Hyperlipidemia	0	0.0%
Health Characteristics	**Number/Mean**	**Percent/ Standard Deviation[1]**
Hypertension	0	0.0%
Depression	0	0.0%
Ischemic Heart Disease	0	0.0%
Rheumatoid Arthritis/Osteoarthritis	0	0.0%
Stroke/TIA[4]	0	0.0%
Breast Cancer	0	0.0%
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	*****	*****
Anemia	0	0.0%
Asthma	0	0.0%
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	0	0.0%
COPD[5] and Bronchiectasis	0	0.0%
Glaucoma	0	0.0%
Osteoporosis	0	0.0%
Obesity: diagnosed or identified by weight management procedures	0	0.0%
Obesity: identified by weight management-related dispensings	0	0.0%
Overweight	0	0.0%
Smoking: diagnosed or identified by smoking cessation procedures	*****	*****
Smoking: identified by smoking-related dispensings	0	0.0%
Alcohol Abuse or Dependence	0	0.0%
Drug Abuse or Dependence	0	0.0%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	0	0.0%
Liver Disease Based on CCW[6] Definition	0	0.0%
Liver Disease Extended Definition (CCW + Additional Codes)	0	0.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	35.0	9.9
Mean number of emergency room encounters	3.5	4.9
Mean number of inpatient hospital encounters	0.5	0.7
Mean number of non-acute institutional encounters	0.0	NaN

Table 1i. Aggregated Characteristics of fosdenopterin in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	fosdenopterin	
Mean number of other ambulatory encounters	114.0	26.9

Health Service Utilization Intensity Metrics	Number/Mean	Percent/ Standard Deviation[1]
Mean number of filled prescriptions	64.5	40.3
Mean number of generics dispensed	15.0	5.7
Mean number of unique drug classes dispensed	12.5	4.9

[1]Value represents standard deviation if % doesn't follow the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

[6]CCW: Chronic Conditions Data Warehouse; https://www2.ccwdata.org/web/guest/home/

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*NaN: Not a number

Table 1j. Aggregated Characteristics of melphalan flufenamide in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Patient Characteristics	melphalan flufenamide	
	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	100	N/A[2]
Demographic Characteristics		
Age (years)	72.4	6.7
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	0	0.0%
41-64 years	17	17.0%
≥ 65 years	83	83.0%
Sex		
Female	53	53.0%
Male	47	47.0%
Race[3]		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	15	15.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	*****	*****
White	72	72.0%
Hispanic origin		
Yes	*****	*****
No	81	81.0%
Unknown	*****	*****
Year		
2021	*****	*****
2022	0	0.0%
2023	*****	*****
2024	0	0.0%
2025	0	0.0%
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease	0	0.0%
Non-Alzheimer's Dementia	*****	*****
Atrial Fibrillation	16	16.0%
Diabetes Mellitus	27	27.0%

Table 1j. Aggregated Characteristics of melphalan flufenamide in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	melphalan flufenamide	
Heart Failure	30	30.0%
Hyperlipidemia	39	39.0%
Health Characteristics	**Number/Mean**	**Percent/ Standard Deviation[1]**
Hypertension	62	62.0%
Depression	15	15.0%
Ischemic Heart Disease	25	25.0%
Rheumatoid Arthritis/Osteoarthritis	22	22.0%
Stroke/TIA[4]	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	18	18.0%
Anemia	75	75.0%
Asthma	*****	*****
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	29	29.0%
COPD[5] and Bronchiectasis	*****	*****
Glaucoma	*****	*****
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	16	16.0%
Obesity: identified by weight management-related dispensings	0	0.0%
Overweight	19	19.0%
Smoking: diagnosed or identified by smoking cessation procedures	26	26.0%
Smoking: identified by smoking-related dispensings	0	0.0%
Alcohol Abuse or Dependence	0	0.0%
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****
Liver Disease Based on CCW[6] Definition	*****	*****
Liver Disease Extended Definition (CCW + Additional Codes)	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	39.4	19.4
Mean number of emergency room encounters	0.4	0.8
Mean number of inpatient hospital encounters	0.6	1.1
Mean number of non-acute institutional encounters	0.1	0.4

Table 1j. Aggregated Characteristics of melphalan flufenamide in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	melphalan flufenamide	
Mean number of other ambulatory encounters	12.8	16.9

Health Service Utilization Intensity Metrics	Number/Mean	Percent/ Standard Deviation[1]
Mean number of filled prescriptions	30.1	17.1
Mean number of generics dispensed	13.3	5.3
Mean number of unique drug classes dispensed	12.3	4.7

[1]Value represents standard deviation if % doesn't follow the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

[6]CCW: Chronic Conditions Data Warehouse; https://www2.ccwdata.org/web/guest/home/

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1k. Aggregated Characteristics of tivozanib in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Patient Characteristics	tivozanib	
	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	1,550	N/A[2]
Demographic Characteristics		
Age (years)	70.0	8.3
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	318	20.5%
≥ 65 years	1,220	78.7%
Sex		
Female	416	26.8%
Male	1,134	73.2%
Race[3]		
American Indian or Alaska Native	*****	*****
Asian	30	1.9%
Black or African American	66	4.3%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	198	12.8%
White	1,245	80.3%
Hispanic origin		
Yes	45	2.9%
No	1,274	82.2%
Unknown	231	14.9%
Year		
2021	*****	*****
2022	391	25.2%
2023	433	27.9%
2024	456	29.4%
2025	*****	*****
Health Characteristics		
Acute Myocardial Infarction	26	1.7%
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	32	2.1%
Atrial Fibrillation	213	13.7%
Diabetes Mellitus	496	32.0%

Table 1k. Aggregated Characteristics of tivozanib in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	tivozanib	
Heart Failure	269	17.4%
Hyperlipidemia	700	45.2%
Health Characteristics	**Number/Mean**	**Percent/ Standard Deviation[1]**
Hypertension	1,163	75.0%
Depression	302	19.5%
Ischemic Heart Disease	444	28.6%
Rheumatoid Arthritis/Osteoarthritis	304	19.6%
Stroke/TIA[4]	84	5.4%
Breast Cancer	39	2.5%
Colorectal Cancer	19	1.2%
Prostate Cancer	92	5.9%
Lung Cancer	130	8.4%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	774	49.9%
Anemia	868	56.0%
Asthma	73	4.7%
Benign Prostatic Hyperplasia	202	13.0%
Chronic Kidney Disease	710	45.8%
COPD[5] and Bronchiectasis	164	10.6%
Glaucoma	108	7.0%
Osteoporosis	50	3.2%
Obesity: diagnosed or identified by weight management procedures	291	18.8%
Obesity: identified by weight management-related dispensings	32	2.1%
Overweight	175	11.3%
Smoking: diagnosed or identified by smoking cessation procedures	521	33.6%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	24	1.5%
Drug Abuse or Dependence	68	4.4%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	132	8.5%
Liver Disease Based on CCW[6] Definition	200	12.9%
Liver Disease Extended Definition (CCW + Additional Codes)	213	13.7%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	28.4	16.4
Mean number of emergency room encounters	0.7	1.3
Mean number of inpatient hospital encounters	0.6	1.0
Mean number of non-acute institutional encounters	0.1	0.3

Table 1k. Aggregated Characteristics of tivozanib in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	tivozanib	
Mean number of other ambulatory encounters	10.0	12.7

	Number/Mean	Standard Deviation[1]
Health Service Utilization Intensity Metrics	**Number/Mean**	**Percent/ Standard Deviation[1]**
Mean number of filled prescriptions	30.7	17.3
Mean number of generics dispensed	12.8	5.7
Mean number of unique drug classes dispensed	11.8	5.0

[1]Value represents standard deviation if % doesn't follow the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

[6] CCW: Chronic Conditions Data Warehouse; https://www2.ccwdata.org/web/guest/home/

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1l. Aggregated Characteristics of ponesimod in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Patient Characteristics	ponesimod	
	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	181	N/A[2]
Demographic Characteristics		
Age (years)	48.3	10.6
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	53	29.3%
41-64 years	108	59.7%
≥ 65 years	*****	*****
Sex		
Female	138	76.2%
Male	43	23.8%
Race[3]		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	53	29.3%
White	105	58.0%
Hispanic origin		
Yes	*****	*****
No	107	59.1%
Unknown	*****	*****
Year		
2021	39	21.5%
2022	72	39.8%
2023	57	31.5%
2024	*****	*****
2025	*****	*****
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease	0	0.0%
Non-Alzheimer's Dementia	*****	*****
Atrial Fibrillation	*****	*****
Diabetes Mellitus	11	6.1%

Table 1l. Aggregated Characteristics of ponesimod in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	ponesimod	
Heart Failure	*****	*****
Hyperlipidemia	30	16.6%
Health Characteristics	**Number/Mean**	**Percent/ Standard Deviation[1]**
Hypertension	39	21.5%
Depression	56	30.9%
Ischemic Heart Disease	*****	*****
Rheumatoid Arthritis/Osteoarthritis	17	9.4%
Stroke/TIA[4]	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	11	6.1%
Anemia	22	12.2%
Asthma	*****	*****
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	*****	*****
COPD[5] and Bronchiectasis	*****	*****
Glaucoma	11	6.1%
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	43	23.8%
Obesity: identified by weight management-related dispensings	*****	*****
Overweight	*****	*****
Smoking: diagnosed or identified by smoking cessation procedures	30	16.6%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	0	0.0%
Liver Disease Based on CCW[6] Definition	*****	*****
Liver Disease Extended Definition (CCW + Additional Codes)	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	12.2	9.5
Mean number of emergency room encounters	0.3	0.9
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.2

Table 1l. Aggregated Characteristics of ponesimod in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	ponesimod	
Mean number of other ambulatory encounters	4.1	8.7

Health Service Utilization Intensity Metrics	Number/Mean	Percent/ Standard Deviation[1]
Mean number of filled prescriptions	17.1	17.3
Mean number of generics dispensed	7.3	5.4
Mean number of unique drug classes dispensed	6.9	4.9

[1]Value represents standard deviation if % doesn't follow the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

[6]CCW: Chronic Conditions Data Warehouse; https://www2.ccwdata.org/web/guest/home/

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1m. Aggregated Characteristics of dasiglucagon in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Patient Characteristics	dasiglucagon	
	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	1,399	N/A[2]
Demographic Characteristics		
Age (years)	47.4	16.5
Age		
0-17 years	200	14.3%
18-24 years	122	8.7%
25-40 years	220	15.7%
41-64 years	470	33.6%
≥ 65 years	387	27.7%
Sex		
Female	756	54.0%
Male	643	46.0%
Race[3]		
American Indian or Alaska Native	*****	*****
Asian	16	1.1%
Black or African American	86	6.1%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	687	49.1%
White	595	42.5%
Hispanic origin		
Yes	60	4.3%
No	456	32.6%
Unknown	883	63.1%
Year		
2021	205	14.7%
2022	590	42.2%
2023	192	13.7%
2024	164	11.7%
2025	248	17.7%
Health Characteristics		
Acute Myocardial Infarction	13	0.9%
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	43	3.1%
Atrial Fibrillation	77	5.5%
Diabetes Mellitus	1,273	91.0%

Table 1m. Aggregated Characteristics of dasiglucagon in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	dasiglucagon	
Heart Failure	165	11.8%
Hyperlipidemia	577	41.2%
Health Characteristics	**Number/Mean**	**Percent/Standard Deviation[1]**
Hypertension	582	41.6%
Depression	322	23.0%
Ischemic Heart Disease	245	17.5%
Rheumatoid Arthritis/Osteoarthritis	182	13.0%
Stroke/TIA[4]	44	3.1%
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	13	0.9%
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	233	16.7%
Anemia	243	17.4%
Asthma	74	5.3%
Benign Prostatic Hyperplasia	46	3.3%
Chronic Kidney Disease	305	21.8%
COPD[5] and Bronchiectasis	79	5.6%
Glaucoma	98	7.0%
Osteoporosis	41	2.9%
Obesity: diagnosed or identified by weight management procedures	366	26.2%
Obesity: identified by weight management-related dispensings	192	13.7%
Overweight	132	9.4%
Smoking: diagnosed or identified by smoking cessation procedures	222	15.9%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	31	2.2%
Drug Abuse or Dependence	53	3.8%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	79	5.6%
Liver Disease Based on CCW[6] Definition	61	4.4%
Liver Disease Extended Definition (CCW + Additional Codes)	63	4.5%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	14.5	17.5
Mean number of emergency room encounters	0.7	1.6
Mean number of inpatient hospital encounters	0.2	0.6
Mean number of non-acute institutional encounters	0.0	0.2

Table 1m. Aggregated Characteristics of dasiglucagon in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	dasiglucagon	
Mean number of other ambulatory encounters	6.0	12.7

Health Service Utilization Intensity Metrics	Number/Mean	Percent/ Standard Deviation[1]
Mean number of filled prescriptions	24.7	24.3
Mean number of generics dispensed	9.8	6.3
Mean number of unique drug classes dispensed	8.5	5.5

[1]Value represents standard deviation if % doesn't follow the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

[6] CCW: Chronic Conditions Data Warehouse; https://www2.ccwdata.org/web/guest/home/

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1n. Aggregated Characteristics of viloxazine in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Patient Characteristics	viloxazine	
	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	37,791	N/A[2]
Demographic Characteristics		
Age (years)	22.3	13.4
Age		
0-17 years	21,640	57.3%
18-24 years	3,854	10.2%
25-40 years	6,852	18.1%
41-64 years	4,824	12.8%
≥ 65 years	621	1.6%
Sex		
Female	16,622	44.0%
Male	21,169	56.0%
Race[3]		
American Indian or Alaska Native	132	0.3%
Asian	574	1.5%
Black or African American	1,845	4.9%
Multi-racial	1,713	4.5%
Native Hawaiian or Other Pacific Islander	19	0.1%
Unknown	14,564	38.5%
White	18,944	50.1%
Hispanic origin		
Yes	2,071	5.5%
No	17,038	45.1%
Unknown	18,682	49.4%
Year		
2021	8,283	21.9%
2022	5,583	14.8%
2023	11,356	30.0%
2024	11,619	30.7%
2025	950	2.5%
Health Characteristics		
Acute Myocardial Infarction	15	0.0%
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	52	0.1%
Atrial Fibrillation	106	0.3%
Diabetes Mellitus	887	2.3%

Table 1n. Aggregated Characteristics of viloxazine in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	viloxazine	
Heart Failure	228	0.6%
Hyperlipidemia	1,606	4.2%
Health Characteristics	**Number/Mean**	**Percent/ Standard Deviation[1]**
Hypertension	1,867	4.9%
Depression	13,280	35.1%
Ischemic Heart Disease	359	0.9%
Rheumatoid Arthritis/Osteoarthritis	970	2.6%
Stroke/TIA[4]	61	0.2%
Breast Cancer	68	0.2%
Colorectal Cancer	11	0.0%
Prostate Cancer	18	0.0%
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	863	2.3%
Anemia	1,262	3.3%
Asthma	1,179	3.1%
Benign Prostatic Hyperplasia	119	0.3%
Chronic Kidney Disease	226	0.6%
COPD[5] and Bronchiectasis	277	0.7%
Glaucoma	260	0.7%
Osteoporosis	91	0.2%
Obesity: diagnosed or identified by weight management procedures	3,449	9.1%
Obesity: identified by weight management-related dispensings	908	2.4%
Overweight	1,271	3.4%
Smoking: diagnosed or identified by smoking cessation procedures	2,087	5.5%
Smoking: identified by smoking-related dispensings	206	0.5%
Alcohol Abuse or Dependence	1,183	3.1%
Drug Abuse or Dependence	2,056	5.4%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	72	0.2%
Liver Disease Based on CCW[6] Definition	253	0.7%
Liver Disease Extended Definition (CCW + Additional Codes)	257	0.7%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	11.4	13.5
Mean number of emergency room encounters	0.3	0.9
Mean number of inpatient hospital encounters	0.0	0.3
Mean number of non-acute institutional encounters	0.0	0.2

Table 1n. Aggregated Characteristics of viloxazine in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	viloxazine	
Mean number of other ambulatory encounters	4.0	11.5

Health Service Utilization Intensity Metrics	Number/Mean	Percent/ Standard Deviation[1]
Mean number of filled prescriptions	13.5	14.0
Mean number of generics dispensed	5.1	4.5
Mean number of unique drug classes dispensed	4.9	4.1

[1]Value represents standard deviation if % doesn't follow the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

[6]CCW: Chronic Conditions Data Warehouse; https://www2.ccwdata.org/web/guest/home/

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1o. Aggregated Characteristics of drospirenone and estetrol in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Patient Characteristics	drospirenone and estetrol	
	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	13,397	N/A[2]
Demographic Characteristics		
Age (years)	29.4	9.7
Age		
0-17 years	1,358	10.1%
18-24 years	4,110	30.7%
25-40 years	5,877	43.9%
41-64 years	2,040	15.2%
≥ 65 years	12	0.1%
Sex		
Female	13,375	99.8%
Male	22	0.2%
Race[3]		
American Indian or Alaska Native	*****	*****
Asian	562	4.2%
Black or African American	600	4.5%
Multi-racial	862	6.4%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	6,430	48.0%
White	4,909	36.6%
Hispanic origin		
Yes	1,089	8.1%
No	3,648	27.2%
Unknown	8,660	64.6%
Year		
2021	845	6.3%
2022	2,671	19.9%
2023	4,531	33.8%
2024	4,853	36.2%
2025	497	3.7%
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease	0	0.0%
Non-Alzheimer's Dementia	*****	*****
Atrial Fibrillation	*****	*****
Diabetes Mellitus	138	1.0%

Table 1o. Aggregated Characteristics of drospirenone and estetrol in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	drospirenone and estetrol	
Heart Failure	*****	*****
Hyperlipidemia	374	2.8%
Health Characteristics	**Number/Mean**	**Percent/ Standard Deviation[1]**
Hypertension	248	1.9%
Depression	2,140	16.0%
Ischemic Heart Disease	27	0.2%
Rheumatoid Arthritis/Osteoarthritis	173	1.3%
Stroke/TIA[4]	*****	*****
Breast Cancer	23	0.2%
Colorectal Cancer	*****	*****
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	340	2.5%
Anemia	960	7.2%
Asthma	279	2.1%
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	19	0.1%
COPD[5] and Bronchiectasis	14	0.1%
Glaucoma	76	0.6%
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	1,491	11.1%
Obesity: identified by weight management-related dispensings	301	2.2%
Overweight	741	5.5%
Smoking: diagnosed or identified by smoking cessation procedures	315	2.4%
Smoking: identified by smoking-related dispensings	13	0.1%
Alcohol Abuse or Dependence	81	0.6%
Drug Abuse or Dependence	127	0.9%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****
Liver Disease Based on CCW[6] Definition	70	0.5%
Liver Disease Extended Definition (CCW + Additional Codes)	73	0.5%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	7.0	8.2
Mean number of emergency room encounters	0.2	0.6
Mean number of inpatient hospital encounters	0.0	0.3
Mean number of non-acute institutional encounters	0.0	0.0

Table 1o. Aggregated Characteristics of drospirenone and estetrol in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	drospirenone and estetrol	
Mean number of other ambulatory encounters	1.5	3.4

Health Service Utilization Intensity Metrics	Number/Mean	Percent/ Standard Deviation[1]
Mean number of filled prescriptions	6.9	8.1
Mean number of generics dispensed	3.7	3.5
Mean number of unique drug classes dispensed	3.5	3.2

[1]Value represents standard deviation if % doesn't follow the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

[6] CCW: Chronic Conditions Data Warehouse; https://www2.ccwdata.org/web/guest/home/

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1p. Aggregated Characteristics of dostarlimab-gxly in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Patient Characteristics	dostarlimab-gxly	
	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	2,701	N/A[2]
Demographic Characteristics		
Age (years)	70.4	8.2
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	476	17.6%
≥ 65 years	2,186	80.9%
Sex		
Female	2,534	93.8%
Male	167	6.2%
Race[3]		
American Indian or Alaska Native	*****	*****
Asian	56	2.1%
Black or African American	371	13.7%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	403	14.9%
White	1,849	68.5%
Hispanic origin		
Yes	53	2.0%
No	1,957	72.5%
Unknown	691	25.6%
Year		
2021	19	0.7%
2022	78	2.9%
2023	767	28.4%
2024	1,767	65.4%
2025	70	2.6%
Health Characteristics		
Acute Myocardial Infarction	24	0.9%
Alzheimer's Disease	13	0.5%
Non-Alzheimer's Dementia	58	2.1%
Atrial Fibrillation	222	8.2%
Diabetes Mellitus	768	28.4%

Table 1p. Aggregated Characteristics of dostarlimab-gxly in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	dostarlimab-gxly	
Heart Failure	264	9.8%
Hyperlipidemia	1,320	48.9%
Health Characteristics	**Number/Mean**	**Percent/ Standard Deviation[1]**
Hypertension	1,753	64.9%
Depression	548	20.3%
Ischemic Heart Disease	483	17.9%
Rheumatoid Arthritis/Osteoarthritis	495	18.3%
Stroke/TIA[4]	64	2.4%
Breast Cancer	242	9.0%
Colorectal Cancer	366	13.6%
Prostate Cancer	29	1.1%
Lung Cancer	93	3.4%
Endometrial Cancer	2,309	85.5%
Acquired Hypothyroidism	536	19.8%
Anemia	1,134	42.0%
Asthma	216	8.0%
Benign Prostatic Hyperplasia	37	1.4%
Chronic Kidney Disease	415	15.4%
COPD[5] and Bronchiectasis	163	6.0%
Glaucoma	219	8.1%
Osteoporosis	157	5.8%
Obesity: diagnosed or identified by weight management procedures	1,175	43.5%
Obesity: identified by weight management-related dispensings	103	3.8%
Overweight	316	11.7%
Smoking: diagnosed or identified by smoking cessation procedures	693	25.7%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	34	1.3%
Drug Abuse or Dependence	55	2.0%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	94	3.5%
Liver Disease Based on CCW[6] Definition	334	12.4%
Liver Disease Extended Definition (CCW + Additional Codes)	336	12.4%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	21.8	11.8
Mean number of emergency room encounters	0.7	1.4
Mean number of inpatient hospital encounters	0.6	0.8
Mean number of non-acute institutional encounters	0.1	0.3

Table 1p. Aggregated Characteristics of dostarlimab-gxly in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	dostarlimab-gxly	
Mean number of other ambulatory encounters	6.8	9.1

Health Service Utilization Intensity Metrics	Number/Mean	Percent/ Standard Deviation[1]
Mean number of filled prescriptions	17.7	13.0
Mean number of generics dispensed	10.2	5.3
Mean number of unique drug classes dispensed	9.4	4.7

[1]Value represents standard deviation if % doesn't follow the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

[6]CCW: Chronic Conditions Data Warehouse; https://www2.ccwdata.org/web/guest/home/

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1q. Aggregated Characteristics of loncastuximab tesirine-lpyl in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Patient Characteristics	loncastuximab tesirine-lpyl	
	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	806	N/A[2]
Demographic Characteristics		
Age (years)	75.2	9.7
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	80	9.9%
≥ 65 years	714	88.6%
Sex		
Female	345	42.8%
Male	461	57.2%
Race[3]		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	40	5.0%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	85	10.5%
White	658	81.6%
Hispanic origin		
Yes	22	2.7%
No	650	80.6%
Unknown	134	16.6%
Year		
2021	*****	*****
2022	267	33.1%
2023	247	30.6%
2024	207	25.7%
2025	*****	*****
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	45	5.6%
Atrial Fibrillation	193	23.9%
Diabetes Mellitus	214	26.6%

Table 1q. Aggregated Characteristics of loncastuximab tesirine-lpyl in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	loncastuximab tesirine-lpyl	
Heart Failure	192	23.8%
Hyperlipidemia	386	47.9%
Health Characteristics	**Number/Mean**	**Percent/ Standard Deviation[1]**
Hypertension	479	59.4%
Depression	187	23.2%
Ischemic Heart Disease	266	33.0%
Rheumatoid Arthritis/Osteoarthritis	154	19.1%
Stroke/TIA[4]	43	5.3%
Breast Cancer	42	5.2%
Colorectal Cancer	21	2.6%
Prostate Cancer	49	6.1%
Lung Cancer	20	2.5%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	140	17.4%
Anemia	578	71.7%
Asthma	54	6.7%
Benign Prostatic Hyperplasia	110	13.6%
Chronic Kidney Disease	180	22.3%
COPD[5] and Bronchiectasis	115	14.3%
Glaucoma	71	8.8%
Osteoporosis	55	6.8%
Obesity: diagnosed or identified by weight management procedures	145	18.0%
Obesity: identified by weight management-related dispensings	*****	*****
Overweight	85	10.5%
Smoking: diagnosed or identified by smoking cessation procedures	275	34.1%
Smoking: identified by smoking-related dispensings	0	0.0%
Alcohol Abuse or Dependence	13	1.6%
Drug Abuse or Dependence	27	3.3%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	83	10.3%
Liver Disease Based on CCW[6] Definition	119	14.8%
Liver Disease Extended Definition (CCW + Additional Codes)	120	14.9%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	34.7	16.3
Mean number of emergency room encounters	0.8	1.3
Mean number of inpatient hospital encounters	1.2	1.6
Mean number of non-acute institutional encounters	0.1	0.3

Table 1q. Aggregated Characteristics of loncastuximab tesirine-lpyl in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	loncastuximab tesirine-lpyl	
Mean number of other ambulatory encounters	13.4	15.3

Health Service Utilization Intensity Metrics	Number/Mean	Percent/ Standard Deviation[1]
Mean number of filled prescriptions	28.4	17.5
Mean number of generics dispensed	13.4	6.4
Mean number of unique drug classes dispensed	12.1	5.4

[1]Value represents standard deviation if % doesn't follow the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

[6]CCW: Chronic Conditions Data Warehouse; https://www2.ccwdata.org/web/guest/home/

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1r. Aggregated Characteristics of serdexmethylphenidate and dexmethylphenidate in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Patient Characteristics	serdexmethylphenidate and dexmethylphenidate	
	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	31,666	N/A[2]
Demographic Characteristics		
Age (years)	23.9	14.5
Age		
0-17 years	16,119	50.9%
18-24 years	3,712	11.7%
25-40 years	6,718	21.2%
41-64 years	4,759	15.0%
≥ 65 years	358	1.1%
Sex		
Female	14,864	46.9%
Male	16,802	53.1%
Race[3]		
American Indian or Alaska Native	*****	*****
Asian	445	1.4%
Black or African American	888	2.8%
Multi-racial	1,684	5.3%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	14,810	46.8%
White	13,784	43.5%
Hispanic origin		
Yes	1,261	4.0%
No	10,065	31.8%
Unknown	20,340	64.2%
Year		
2021	816	2.6%
2022	3,338	10.5%
2023	13,429	42.4%
2024	13,420	42.4%
2025	663	2.1%
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	26	0.1%
Atrial Fibrillation	37	0.1%
Diabetes Mellitus	621	2.0%

Table 1r. Aggregated Characteristics of serdexmethylphenidate and dexmethylphenidate in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	serdexmethylphenidate and dexmethylphenidate	
Heart Failure	59	0.2%
Hyperlipidemia	1,120	3.5%
Health Characteristics	**Number/Mean**	**Percent/ Standard Deviation[1]**
Hypertension	1,129	3.6%
Depression	9,658	30.5%
Ischemic Heart Disease	142	0.4%
Rheumatoid Arthritis/Osteoarthritis	680	2.1%
Stroke/TIA[4]	37	0.1%
Breast Cancer	71	0.2%
Colorectal Cancer	11	0.0%
Prostate Cancer	17	0.1%
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	603	1.9%
Anemia	877	2.8%
Asthma	750	2.4%
Benign Prostatic Hyperplasia	52	0.2%
Chronic Kidney Disease	136	0.4%
COPD[5] and Bronchiectasis	90	0.3%
Glaucoma	192	0.6%
Osteoporosis	58	0.2%
Obesity: diagnosed or identified by weight management procedures	2,661	8.4%
Obesity: identified by weight management-related dispensings	859	2.7%
Overweight	1,058	3.3%
Smoking: diagnosed or identified by smoking cessation procedures	993	3.1%
Smoking: identified by smoking-related dispensings	71	0.2%
Alcohol Abuse or Dependence	450	1.4%
Drug Abuse or Dependence	727	2.3%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	20	0.1%
Liver Disease Based on CCW[6] Definition	157	0.5%
Liver Disease Extended Definition (CCW + Additional Codes)	158	0.5%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	8.7	10.7
Mean number of emergency room encounters	0.1	0.5
Mean number of inpatient hospital encounters	0.0	0.2
Mean number of non-acute institutional encounters	0.0	0.1

Table 1r. Aggregated Characteristics of serdexmethylphenidate and dexmethylphenidate in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	serdexmethylphenidate and dexmethylphenidate	
Mean number of other ambulatory encounters	1.7	5.6

Health Service Utilization Intensity Metrics	Number/Mean	Percent/ Standard Deviation[1]
Mean number of filled prescriptions	11.4	11.6
Mean number of generics dispensed	4.5	4.0
Mean number of unique drug classes dispensed	4.3	3.7

[1]Value represents standard deviation if % doesn't follow the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

[6]CCW: Chronic Conditions Data Warehouse; https://www2.ccwdata.org/web/guest/home/

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1s. Aggregated Characteristics of pegcetacoplan in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Patient Characteristics	pegcetacoplan	
	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	32,242	N/A[2]
Demographic Characteristics		
Age (years)	82.5	7.6
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	287	0.9%
≥ 65 years	31,913	99.0%
Sex		
Female	21,919	68.0%
Male	10,323	32.0%
Race[3]		
American Indian or Alaska Native	97	0.3%
Asian	222	0.7%
Black or African American	121	0.4%
Multi-racial	44	0.1%
Native Hawaiian or Other Pacific Islander	19	0.1%
Unknown	1,374	4.3%
White	30,365	94.2%
Hispanic origin		
Yes	176	0.5%
No	28,197	87.5%
Unknown	3,869	12.0%
Year		
2021	43	0.1%
2022	30	0.1%
2023	16,389	50.8%
2024	15,547	48.2%
2025	233	0.7%
Health Characteristics		
Acute Myocardial Infarction	221	0.7%
Alzheimer's Disease	458	1.4%
Non-Alzheimer's Dementia	1,429	4.4%
Atrial Fibrillation	5,785	17.9%
Diabetes Mellitus	6,978	21.6%

Table 1s. Aggregated Characteristics of pegcetacoplan in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	pegcetacoplan	
Heart Failure	5,492	17.0%
Hyperlipidemia	14,547	45.1%
Health Characteristics	**Number/Mean**	**Percent/ Standard Deviation**[1]
Hypertension	18,774	58.2%
Depression	5,460	16.9%
Ischemic Heart Disease	8,431	26.1%
Rheumatoid Arthritis/Osteoarthritis	7,601	23.6%
Stroke/TIA[4]	952	3.0%
Breast Cancer	1,285	4.0%
Colorectal Cancer	346	1.1%
Prostate Cancer	946	2.9%
Lung Cancer	445	1.4%
Endometrial Cancer	106	0.3%
Acquired Hypothyroidism	5,720	17.7%
Anemia	7,328	22.7%
Asthma	1,162	3.6%
Benign Prostatic Hyperplasia	1,751	5.4%
Chronic Kidney Disease	5,417	16.8%
COPD[5] and Bronchiectasis	3,552	11.0%
Glaucoma	5,876	18.2%
Osteoporosis	2,981	9.2%
Obesity: diagnosed or identified by weight management procedures	5,327	16.5%
Obesity: identified by weight management-related dispensings	791	2.5%
Overweight	3,116	9.7%
Smoking: diagnosed or identified by smoking cessation procedures	5,931	18.4%
Smoking: identified by smoking-related dispensings	48	0.1%
Alcohol Abuse or Dependence	405	1.3%
Drug Abuse or Dependence	519	1.6%
History of Cardiac Arrest	53	0.2%
History of Coronary Angioplasty or Bypass	2,377	7.4%
Liver Disease Based on CCW[6] Definition	755	2.3%
Liver Disease Extended Definition (CCW + Additional Codes)	781	2.4%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	15.7	12.1
Mean number of emergency room encounters	0.3	0.8
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.2

Table 1s. Aggregated Characteristics of pegcetacoplan in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	pegcetacoplan	
Mean number of other ambulatory encounters	3.9	7.6

Health Service Utilization Intensity Metrics	Number/Mean	Percent/ Standard Deviation[1]
Mean number of filled prescriptions	17.2	14.0
Mean number of generics dispensed	8.0	4.8
Mean number of unique drug classes dispensed	7.6	4.4

[1]Value represents standard deviation if % doesn't follow the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

[6]CCW: Chronic Conditions Data Warehouse; https://www2.ccwdata.org/web/guest/home/

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1t. Aggregated Characteristics of amivantamab-vmjw in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Patient Characteristics	amivantamab-vmjw	
	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	1,419	N/A[2]
Demographic Characteristics		
Age (years)	70.4	8.4
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	16	1.1%
41-64 years	282	19.9%
≥ 65 years	1,121	79.0%
Sex		
Female	948	66.8%
Male	471	33.2%
Race[3]		
American Indian or Alaska Native	*****	*****
Asian	149	10.5%
Black or African American	98	6.9%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	237	16.7%
White	924	65.1%
Hispanic origin		
Yes	30	2.1%
No	1,046	73.7%
Unknown	343	24.2%
Year		
2021	92	6.5%
2022	222	15.6%
2023	219	15.4%
2024	862	60.7%
2025	24	1.7%
Health Characteristics		
Acute Myocardial Infarction	16	1.1%
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	21	1.5%
Atrial Fibrillation	141	9.9%
Diabetes Mellitus	228	16.1%

Table 1t. Aggregated Characteristics of amivantamab-vmjw in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	amivantamab-vmjw	
Heart Failure	173	12.2%
Hyperlipidemia	537	37.8%
Health Characteristics	**Number/Mean**	**Percent/ Standard Deviation[1]**
Hypertension	692	48.8%
Depression	268	18.9%
Ischemic Heart Disease	280	19.7%
Rheumatoid Arthritis/Osteoarthritis	237	16.7%
Stroke/TIA[4]	94	6.6%
Breast Cancer	90	6.3%
Colorectal Cancer	13	0.9%
Prostate Cancer	45	3.2%
Lung Cancer	1,386	97.7%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	255	18.0%
Anemia	654	46.1%
Asthma	92	6.5%
Benign Prostatic Hyperplasia	92	6.5%
Chronic Kidney Disease	216	15.2%
COPD[5] and Bronchiectasis	179	12.6%
Glaucoma	131	9.2%
Osteoporosis	100	7.0%
Obesity: diagnosed or identified by weight management procedures	157	11.1%
Obesity: identified by weight management-related dispensings	19	1.3%
Overweight	143	10.1%
Smoking: diagnosed or identified by smoking cessation procedures	461	32.5%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	38	2.7%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	55	3.9%
Liver Disease Based on CCW[6] Definition	163	11.5%
Liver Disease Extended Definition (CCW + Additional Codes)	167	11.8%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	28.9	13.2
Mean number of emergency room encounters	0.7	1.4
Mean number of inpatient hospital encounters	0.5	0.9
Mean number of non-acute institutional encounters	0.0	0.2

Table 1t. Aggregated Characteristics of amivantamab-vmjw in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	amivantamab-vmjw	
Mean number of other ambulatory encounters	8.7	9.5

Health Service Utilization Intensity Metrics	Number/Mean	Percent/ Standard Deviation[1]
Mean number of filled prescriptions	23.2	14.9
Mean number of generics dispensed	11.6	5.7
Mean number of unique drug classes dispensed	10.6	4.9

[1]Value represents standard deviation if % doesn't follow the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

[6]CCW: Chronic Conditions Data Warehouse; https://www2.ccwdata.org/web/guest/home/

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1v. Aggregated Characteristics of sotorasib in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Patient Characteristics	sotorasib	
	Number/Mean	Percent/Standard Deviation[1]
Unique patients	2,597	N/A[2]
Demographic Characteristics		
Age (years)	71.2	8.2
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	1,994	76.8%
Sex		
Female	1,596	61.5%
Male	1,001	38.5%
Race[3]		
American Indian or Alaska Native	*****	*****
Asian	44	1.7%
Black or African American	247	9.5%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	266	10.2%
White	2,023	77.9%
Hispanic origin		
Yes	27	1.0%
No	2,105	81.1%
Unknown	465	17.9%
Year		
2021	640	24.6%
2022	777	29.9%
2023	607	23.4%
2024	547	21.1%
2025	26	1.0%
Health Characteristics		
Acute Myocardial Infarction	54	2.1%
Alzheimer's Disease	16	0.6%
Non-Alzheimer's Dementia	98	3.8%
Atrial Fibrillation	390	15.0%
Diabetes Mellitus	585	22.5%

Table 1v. Aggregated Characteristics of sotorasib in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	sotorasib	
Heart Failure	457	17.6%
Hyperlipidemia	1,198	46.1%
Health Characteristics	**Number/Mean**	**Percent/ Standard Deviation[1]**
Hypertension	1,538	59.2%
Depression	698	26.9%
Ischemic Heart Disease	844	32.5%
Rheumatoid Arthritis/Osteoarthritis	516	19.9%
Stroke/TIA[4]	215	8.3%
Breast Cancer	183	7.0%
Colorectal Cancer	197	7.6%
Prostate Cancer	116	4.5%
Lung Cancer	2,414	93.0%
Endometrial Cancer	12	0.5%
Acquired Hypothyroidism	564	21.7%
Anemia	1,361	52.4%
Asthma	117	4.5%
Benign Prostatic Hyperplasia	216	8.3%
Chronic Kidney Disease	448	17.3%
COPD[5] and Bronchiectasis	1,121	43.2%
Glaucoma	180	6.9%
Osteoporosis	185	7.1%
Obesity: diagnosed or identified by weight management procedures	382	14.7%
Obesity: identified by weight management-related dispensings	27	1.0%
Overweight	253	9.7%
Smoking: diagnosed or identified by smoking cessation procedures	1,896	73.0%
Smoking: identified by smoking-related dispensings	48	1.8%
Alcohol Abuse or Dependence	104	4.0%
Drug Abuse or Dependence	148	5.7%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	245	9.4%
Liver Disease Based on CCW[6] Definition	326	12.6%
Liver Disease Extended Definition (CCW + Additional Codes)	330	12.7%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	29.1	13.6
Mean number of emergency room encounters	0.9	1.6
Mean number of inpatient hospital encounters	0.7	1.1
Mean number of non-acute institutional encounters	0.1	0.4

Table 1v. Aggregated Characteristics of sotorasib in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	sotorasib	
Mean number of other ambulatory encounters	11.3	13.9

Health Service Utilization Intensity Metrics	Number/Mean	Percent/ Standard Deviation[1]
Mean number of filled prescriptions	27.5	18.0
Mean number of generics dispensed	12.3	6.3
Mean number of unique drug classes dispensed	11.2	5.4

[1]Value represents standard deviation if % doesn't follow the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

[6]CCW: Chronic Conditions Data Warehouse; https://www2.ccwdata.org/web/guest/home/

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1u. Aggregated Characteristics of piflufolastat F 18 in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Patient Characteristics	piflufolastat F 18	
	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	159,348	N/A[2]
Demographic Characteristics		
Age (years)	74.3	7.1
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	11,728	7.4%
≥ 65 years	147,604	92.6%
Sex		
Female	170	0.1%
Male	159,178	99.9%
Race[3]		
American Indian or Alaska Native	269	0.2%
Asian	2,162	1.4%
Black or African American	16,849	10.6%
Multi-racial	595	0.4%
Native Hawaiian or Other Pacific Islander	269	0.2%
Unknown	16,750	10.5%
White	122,454	76.8%
Hispanic origin		
Yes	2,094	1.3%
No	127,374	79.9%
Unknown	29,880	18.8%
Year		
2021	134	0.1%
2022	41,828	26.2%
2023	55,693	35.0%
2024	60,003	37.7%
2025	1,690	1.1%
Health Characteristics		
Acute Myocardial Infarction	772	0.5%
Alzheimer's Disease	1,154	0.7%
Non-Alzheimer's Dementia	3,918	2.5%
Atrial Fibrillation	18,323	11.5%
Diabetes Mellitus	35,733	22.4%

Table 1u. Aggregated Characteristics of piflufolastat F 18 in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	piflufolastat F 18	
Heart Failure	15,794	9.9%
Hyperlipidemia	70,403	44.2%
Health Characteristics	**Number/Mean**	**Percent/ Standard Deviation[1]**
Hypertension	83,700	52.5%
Depression	15,941	10.0%
Ischemic Heart Disease	41,417	26.0%
Rheumatoid Arthritis/Osteoarthritis	24,008	15.1%
Stroke/TIA[4]	3,576	2.2%
Breast Cancer	3,794	2.4%
Colorectal Cancer	1,929	1.2%
Prostate Cancer	141,489	88.8%
Lung Cancer	1,467	0.9%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	10,619	6.7%
Anemia	32,216	20.2%
Asthma	3,863	2.4%
Benign Prostatic Hyperplasia	42,640	26.8%
Chronic Kidney Disease	21,110	13.2%
COPD[5] and Bronchiectasis	9,912	6.2%
Glaucoma	18,303	11.5%
Osteoporosis	3,135	2.0%
Obesity: diagnosed or identified by weight management procedures	29,884	18.8%
Obesity: identified by weight management-related dispensings	3,913	2.5%
Overweight	17,874	11.2%
Smoking: diagnosed or identified by smoking cessation procedures	36,944	23.2%
Smoking: identified by smoking-related dispensings	271	0.2%
Alcohol Abuse or Dependence	3,485	2.2%
Drug Abuse or Dependence	2,743	1.7%
History of Cardiac Arrest	330	0.2%
History of Coronary Angioplasty or Bypass	13,209	8.3%
Liver Disease Based on CCW[6] Definition	4,389	2.8%
Liver Disease Extended Definition (CCW + Additional Codes)	4,435	2.8%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	14.9	11.8
Mean number of emergency room encounters	0.3	0.8
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.2

Table 1u. Aggregated Characteristics of piflufolastat F 18 in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	piflufolastat F 18	
Mean number of other ambulatory encounters	3.6	5.9

Health Service Utilization Intensity Metrics	Number/Mean	Percent/ Standard Deviation[1]
Mean number of filled prescriptions	14.2	12.1
Mean number of generics dispensed	7.0	4.5
Mean number of unique drug classes dispensed	6.6	4.1

[1]Value represents standard deviation if % doesn't follow the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

[6]CCW: Chronic Conditions Data Warehouse; https://www2.ccwdata.org/web/guest/home/

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1w. Aggregated Characteristics of infigratinib in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
	infigratinib	
Unique patients	36	N/A[2]
Demographic Characteristics		
Age (years)	65.2	13.2
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	23	63.9%
Sex		
Female	22	61.1%
Male	14	38.9%
Race[3]		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	*****	*****
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	*****	*****
Year		
2021	14	38.9%
2022	22	61.1%
2023	0	0.0%
2024	0	0.0%
2025	0	0.0%
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease	0	0.0%
Non-Alzheimer's Dementia	0	0.0%
Atrial Fibrillation	*****	*****
Diabetes Mellitus	*****	*****

Table 1w. Aggregated Characteristics of infigratinib in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	infigratinib	
Heart Failure	*****	*****
Hyperlipidemia	18	50.0%
Health Characteristics	**Number/Mean**	**Percent/ Standard Deviation[1]**
Hypertension	23	63.9%
Depression	*****	*****
Ischemic Heart Disease	*****	*****
Rheumatoid Arthritis/Osteoarthritis	*****	*****
Stroke/TIA[4]	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	*****	*****
Anemia	22	61.1%
Asthma	*****	*****
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	*****	*****
COPD[5] and Bronchiectasis	*****	*****
Glaucoma	*****	*****
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	*****	*****
Obesity: identified by weight management-related dispensings	0	0.0%
Overweight	*****	*****
Smoking: diagnosed or identified by smoking cessation procedures	11	30.6%
Smoking: identified by smoking-related dispensings	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	0	0.0%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****
Liver Disease Based on CCW[6] Definition	20	55.6%
Liver Disease Extended Definition (CCW + Additional Codes)	20	55.6%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	27.9	15.1
Mean number of emergency room encounters	0.5	0.8
Mean number of inpatient hospital encounters	0.7	1.1
Mean number of non-acute institutional encounters	0.1	0.4

Table 1w. Aggregated Characteristics of infigratinib in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	infigratinib	
Mean number of other ambulatory encounters	11.9	12.9

Health Service Utilization Intensity Metrics	Number/Mean	Percent/ Standard Deviation[1]
Mean number of filled prescriptions	19.1	11.2
Mean number of generics dispensed	9.4	5.2
Mean number of unique drug classes dispensed	8.6	4.6

[1]Value represents standard deviation if % doesn't follow the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

[6] CCW: Chronic Conditions Data Warehouse; https://www2.ccwdata.org/web/guest/home/

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1x. Aggregated Characteristics of olanzapine and samidorphan in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Patient Characteristics	olanzapine and samidorphan	
	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	12,692	N/A[2]
Demographic Characteristics		
Age (years)	45.1	14.0
Age		
0-17 years	86	0.7%
18-24 years	933	7.4%
25-40 years	4,267	33.6%
41-64 years	6,174	48.6%
≥ 65 years	1,232	9.7%
Sex		
Female	7,092	55.9%
Male	5,600	44.1%
Race[3]		
American Indian or Alaska Native	113	0.9%
Asian	275	2.2%
Black or African American	1,444	11.4%
Multi-racial	102	0.8%
Native Hawaiian or Other Pacific Islander	16	0.1%
Unknown	2,458	19.4%
White	8,284	65.3%
Hispanic origin		
Yes	656	5.2%
No	9,171	72.3%
Unknown	2,865	22.6%
Year		
2021	1,244	9.8%
2022	3,434	27.1%
2023	3,885	30.6%
2024	3,973	31.3%
2025	156	1.2%
Health Characteristics		
Acute Myocardial Infarction	26	0.2%
Alzheimer's Disease	86	0.7%
Non-Alzheimer's Dementia	399	3.1%
Atrial Fibrillation	155	1.2%
Diabetes Mellitus	2,339	18.4%

Table 1x. Aggregated Characteristics of olanzapine and samidorphan in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	olanzapine and samidorphan	
Heart Failure	495	3.9%
Hyperlipidemia	3,083	24.3%
Health Characteristics	**Number/Mean**	**Percent/ Standard Deviation[1]**
Hypertension	3,539	27.9%
Depression	8,550	67.4%
Ischemic Heart Disease	627	4.9%
Rheumatoid Arthritis/Osteoarthritis	1,089	8.6%
Stroke/TIA[4]	140	1.1%
Breast Cancer	117	0.9%
Colorectal Cancer	19	0.1%
Prostate Cancer	14	0.1%
Lung Cancer	16	0.1%
Endometrial Cancer	11	0.1%
Acquired Hypothyroidism	1,565	12.3%
Anemia	1,611	12.7%
Asthma	900	7.1%
Benign Prostatic Hyperplasia	212	1.7%
Chronic Kidney Disease	590	4.6%
COPD[5] and Bronchiectasis	814	6.4%
Glaucoma	463	3.6%
Osteoporosis	143	1.1%
Obesity: diagnosed or identified by weight management procedures	4,570	36.0%
Obesity: identified by weight management-related dispensings	698	5.5%
Overweight	972	7.7%
Smoking: diagnosed or identified by smoking cessation procedures	3,549	28.0%
Smoking: identified by smoking-related dispensings	247	1.9%
Alcohol Abuse or Dependence	1,216	9.6%
Drug Abuse or Dependence	2,033	16.0%
History of Cardiac Arrest	19	0.1%
History of Coronary Angioplasty or Bypass	103	0.8%
Liver Disease Based on CCW[6] Definition	419	3.3%
Liver Disease Extended Definition (CCW + Additional Codes)	426	3.4%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	15.5	16.3
Mean number of emergency room encounters	0.8	2.0
Mean number of inpatient hospital encounters	0.2	0.6
Mean number of non-acute institutional encounters	0.2	0.6

Table 1x. Aggregated Characteristics of olanzapine and samidorphan in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	olanzapine and samidorphan	
Mean number of other ambulatory encounters	7.2	14.8

Health Service Utilization Intensity Metrics	Number/Mean	Percent/ Standard Deviation[1]
Mean number of filled prescriptions	38.2	27.9
Mean number of generics dispensed	10.8	6.4
Mean number of unique drug classes dispensed	10.1	5.7

[1] Value represents standard deviation if % doesn't follow the value.

[2] N/A: Not Applicable

[3] Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4] TIA: Transient Ischemic Attack

[5] COPD: Chronic Obstructive Pulmonary Disease

[6] CCW: Chronic Conditions Data Warehouse; https://www2.ccwdata.org/web/guest/home/

Table 1y. Aggregated Characteristics of ibrexafungerp in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Patient Characteristics	ibrexafungerp	
	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	2,617	N/A[2]
Demographic Characteristics		
Age (years)	37.2	11.7
Age		
0-17 years	19	0.7%
18-24 years	427	16.3%
25-40 years	1,256	48.0%
41-64 years	883	33.7%
≥ 65 years	32	1.2%
Sex		
Female	2,606	99.6%
Male	11	0.4%
Race[3]		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	274	10.5%
Multi-racial	123	4.7%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	1,271	48.6%
White	869	33.2%
Hispanic origin		
Yes	169	6.5%
No	765	29.2%
Unknown	1,683	64.3%
Year		
2021	430	16.4%
2022	1,238	47.3%
2023	857	32.7%
2024	92	3.5%
2025	0	0.0%
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease	0	0.0%
Non-Alzheimer's Dementia	*****	*****
Atrial Fibrillation	13	0.5%
Diabetes Mellitus	186	7.1%

	ibrexafungerp	
Heart Failure	17	0.6%
Hyperlipidemia	197	7.5%
Health Characteristics	**Number/Mean**	**Percent/ Standard Deviation[1]**
Hypertension	192	7.3%
Depression	467	17.8%
Ischemic Heart Disease	23	0.9%
Rheumatoid Arthritis/Osteoarthritis	105	4.0%
Stroke/TIA[4]	*****	*****
Breast Cancer	22	0.8%
Colorectal Cancer	*****	*****
Prostate Cancer	0	0.0%
Lung Cancer	*****	*****
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	117	4.5%
Anemia	250	9.6%
Asthma	97	3.7%
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	12	0.5%
COPD[5] and Bronchiectasis	19	0.7%
Glaucoma	41	1.6%
Osteoporosis	12	0.5%
Obesity: diagnosed or identified by weight management procedures	377	14.4%
Obesity: identified by weight management-related dispensings	121	4.6%
Overweight	184	7.0%
Smoking: diagnosed or identified by smoking cessation procedures	114	4.4%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	20	0.8%
Drug Abuse or Dependence	27	1.0%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	*****	*****
Liver Disease Based on CCW[6] Definition	31	1.2%
Liver Disease Extended Definition (CCW + Additional Codes)	34	1.3%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	11.2	11.1
Mean number of emergency room encounters	0.3	0.9
Mean number of inpatient hospital encounters	0.0	0.2
Mean number of non-acute institutional encounters	0.0	0.0

Table 1y. Aggregated Characteristics of ibrexafungerp in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	ibrexafungerp	
Mean number of other ambulatory encounters	3.2	7.0

Health Service Utilization Intensity Metrics	Number/Mean	Percent/ Standard Deviation[1]
Mean number of filled prescriptions	15.2	15.4
Mean number of generics dispensed	7.6	5.6
Mean number of unique drug classes dispensed	7.1	5.0

[1]Value represents standard deviation if % doesn't follow the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

[6] CCW: Chronic Conditions Data Warehouse; https://www2.ccwdata.org/web/guest/home/

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1z. Aggregated Characteristics of aducanumab-avwa in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Patient Characteristics	aducanumab-avwa	
	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	458	N/A[2]
Demographic Characteristics		
Age (years)	74.3	6.4
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	0	0.0%
41-64 years	*****	*****
≥ 65 years	436	95.2%
Sex		
Female	252	55.0%
Male	206	45.0%
Race[3]		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	28	6.1%
White	415	90.6%
Hispanic origin		
Yes	*****	*****
No	407	88.9%
Unknown	*****	*****
Year		
2021	14	3.1%
2022	352	76.9%
2023	71	15.5%
2024	21	4.6%
2025	0	0.0%
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease	411	89.7%
Non-Alzheimer's Dementia	352	76.9%
Atrial Fibrillation	21	4.6%
Diabetes Mellitus	67	14.6%

Table 1z. Aggregated Characteristics of aducanumab-avwa in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	aducanumab-avwa	
Heart Failure	19	4.1%
Hyperlipidemia	200	43.7%
Health Characteristics	**Number/Mean**	**Percent/ Standard Deviation[1]**
Hypertension	195	42.6%
Depression	118	25.8%
Ischemic Heart Disease	74	16.2%
Rheumatoid Arthritis/Osteoarthritis	80	17.5%
Stroke/TIA[4]	21	4.6%
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	21	4.6%
Lung Cancer	0	0.0%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	55	12.0%
Anemia	81	17.7%
Asthma	*****	*****
Benign Prostatic Hyperplasia	31	6.8%
Chronic Kidney Disease	49	10.7%
COPD[5] and Bronchiectasis	17	3.7%
Glaucoma	48	10.5%
Osteoporosis	20	4.4%
Obesity: diagnosed or identified by weight management procedures	51	11.1%
Obesity: identified by weight management-related dispensings	*****	*****
Overweight	57	12.4%
Smoking: diagnosed or identified by smoking cessation procedures	61	13.3%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	17	3.7%
Liver Disease Based on CCW[6] Definition	*****	*****
Liver Disease Extended Definition (CCW + Additional Codes)	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	15.7	9.9
Mean number of emergency room encounters	0.2	0.6
Mean number of inpatient hospital encounters	0.0	0.2
Mean number of non-acute institutional encounters	0.0	0.1

Table 1z. Aggregated Characteristics of aducanumab-avwa in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	aducanumab-avwa	
Mean number of other ambulatory encounters	3.3	3.5

Health Service Utilization Intensity Metrics	Number/Mean	Percent/ Standard Deviation[1]
Mean number of filled prescriptions	15.0	10.6
Mean number of generics dispensed	7.1	4.4
Mean number of unique drug classes dispensed	6.8	4.1

[1]Value represents standard deviation if % doesn't follow the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

[6] CCW: Chronic Conditions Data Warehouse; https://www2.ccwdata.org/web/guest/home/

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1aa. Aggregated Characteristics of asparaginase erwinia chrysanthemi (recombinant)-rywn in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Patient Characteristics	asparaginase erwinia chrysanthemi (recombinant)-rywn	
	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	280	N/A[2]
Demographic Characteristics		
Age (years)	16.0	15.2
Age		
0-17 years	203	72.5%
18-24 years	32	11.4%
25-40 years	22	7.9%
41-64 years	*****	*****
≥ 65 years	*****	*****
Sex		
Female	94	33.6%
Male	186	66.4%
Race[3]		
American Indian or Alaska Native	0	0.0%
Asian	13	4.6%
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	164	58.6%
White	88	31.4%
Hispanic origin		
Yes	15	5.4%
No	68	24.3%
Unknown	197	70.4%
Year		
2021	*****	*****
2022	79	28.2%
2023	82	29.3%
2024	91	32.5%
2025	*****	*****
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease	0	0.0%
Non-Alzheimer's Dementia	0	0.0%
Atrial Fibrillation	*****	*****

Table 1aa. Aggregated Characteristics of asparaginase erwinia chrysanthemi (recombinant)-rywn in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	asparaginase erwinia chrysanthemi (recombinant)-rywn	
Diabetes Mellitus	24	8.6%
Heart Failure	*****	*****
Health Characteristics	**Number/Mean**	**Percent/ Standard Deviation[1]**
Hyperlipidemia	23	8.2%
Hypertension	79	28.2%
Depression	37	13.2%
Ischemic Heart Disease	*****	*****
Rheumatoid Arthritis/Osteoarthritis	*****	*****
Stroke/TIA[4]	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	0	0.0%
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	*****	*****
Anemia	258	92.1%
Asthma	31	11.1%
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	*****	*****
COPD[5] and Bronchiectasis	*****	*****
Glaucoma	*****	*****
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	29	10.4%
Obesity: identified by weight management-related dispensings	*****	*****
Overweight	11	3.9%
Smoking: diagnosed or identified by smoking cessation procedures	21	7.5%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	*****	*****
Liver Disease Based on CCW[6] Definition	70	25.0%
Liver Disease Extended Definition (CCW + Additional Codes)	70	25.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	29.7	15.2
Mean number of emergency room encounters	1.9	2.2

Table 1aa. Aggregated Characteristics of asparaginase erwinia chrysanthemi (recombinant)-rywn in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	asparaginase erwinia chrysanthemi (recombinant)-rywn	
Mean number of inpatient hospital encounters	2.7	1.9
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	8.9	14.0
Mean number of filled prescriptions	24.2	13.7
Health Service Utilization Intensity Metrics	**Number/Mean**	**Percent/ Standard Deviation[1]**
Mean number of generics dispensed	12.4	5.6
Mean number of unique drug classes dispensed	11.5	4.9

[1]Value represents standard deviation where n % follows the value

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

[6]CCW: Chronic Conditions Data Warehouse; https://www2.ccwdata.org/web/guest/home/

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 2a. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	Total Number of Dispensings[1]	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
vericiguat	59,028	44,425	75.3%	1,776	3.0%	12,768	21.6%	59	0.1%
cabotegravir	96,581	72,978	75.6%	23,560	24.4%	*****	*****	*****	*****
voclosporin	6,681	*****	*****	*****	*****	*****	*****	0	0.0%
tepotinib	2,585	2,547	98.5%	*****	*****	*****	*****	*****	*****
umbralisib	272	272	100.0%	0	0.0%	0	0.0%	0	0.0%
evinacumab-dgnb	1,891	1,843	97.5%	48	2.5%	0	0.0%	0	0.0%
trilacicilib	20,063	20,063	100.0%	0	0.0%	0	0.0%	0	0.0%
casimersen	2,841	2,841	100.0%	0	0.0%	0	0.0%	0	0.0%
fosdenopterin	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
melphalan flufenamide	231	231	100.0%	0	0.0%	0	0.0%	0	0.0%
tivozanib	7,429	7,418	99.9%	11	0.1%	0	0.0%	0	0.0%
ponesimod	1,935	1,812	93.6%	*****	*****	101	5.2%	*****	*****
dasiglucagon	2,555	2,378	93.1%	48	1.9%	129	5.0%	0	0.0%
viloxazine	150,522	137,605	91.4%	3,495	2.3%	9,323	6.2%	99	0.1%
drospirenone and estetrol	55,757	34,745	62.3%	1,919	3.4%	19,031	34.1%	62	0.1%
dostarlimab-gxly	15,637	15,612	99.8%	25	0.2%	0	0.0%	0	0.0%
loncastuximab tesirine-lpyl	3,403	3,403	100.0%	0	0.0%	0	0.0%	0	0.0%
serdexmethylphenidate and dexmethylphenidate	151,262	149,765	99.0%	*****	*****	941	0.6%	*****	*****
pegcetacoplan	174,477	174,408	100.0%	*****	*****	*****	*****	0	0.0%
amivantamab-vmjw	14,341	14,341	100.0%	0	0.0%	0	0.0%	0	0.0%
piflufolastat F 18	193,176	193,176	100.0%	0	0.0%	0	0.0%	0	0.0%
sotorasib	14,990	14,916	99.5%	46	0.3%	28	0.2%	0	0.0%

Table 2a. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	Total Number of Dispensings[1]	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
infigratinib	130	130	100.0%	0	0.0%	0	0.0%	0	0.0%
olanzapine and samidorphan	91,985	88,294	96.0%	*****	*****	1,984	2.2%	*****	*****
ibrexafungerp	4,359	4,341	99.6%	*****	*****	*****	*****	0	0.0%
aducanumab-avwa	2,823	2,823	100.0%	0	0.0%	0	0.0%	0	0.0%
asparaginase erwinia chrysanthemi (recombinant)-rywn	4,061	4,061	100.0%	0	0.0%	0	0.0%	0	0.0%

[1]For drugs requiring clinical administration and identified by procedure codes (rather than pharmacy claims with NDCs), days supplied are not recorded. A default of 1 day supplied was assigned per administration for summary purposes.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

	Total Number of Dispensings[1]	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
vericiguat	59,028	1	30	30	30	180	41.0	26.3
cabotegravir	96,581	1	1	1	30	219	21.2	23.4
voclosporin	6,681	1	30	30	30	90	29.1	4.4
tepotinib	2,585	1	30	30	30	105	29.1	5.8
umbralisib	272	3	30	30	30	30	29.3	3.4
evinacumab-dgnb	1,891	1	1	1	1	56	4.7	10.8
trilacicilib	20,063	1	1	1	1	21	1.0	0.5
casimersen	2,841	1	1	1	7	28	5.5	8.7
fosdenopterin	*****	5	7	28	30	30	21.3	11.9
melphalan flufenamide	231	1	1	1	1	28	2.3	5.8
tivozanib	7,429	1	28	28	28	56	27.1	3.7
ponesimod	1,935	1	30	30	30	180	32.2	14.9
dasiglucagon	2,555	1	1	7	30	90	18.2	21.6
viloxazine	150,522	1	30	30	30	180	32.3	16.4
drospirenone and estetrol	55,757	1	28	28	84	364	46.6	27.1
dostarlimab-gxly	15,637	1	1	1	1	42	1.2	2.5
loncastuximab tesirine-lpyl	3,403	1	1	1	1	21	1.3	2.5
serdexmethylphenidate and dexmethylphenidate	151,262	1	30	30	30	180	29.0	7.1
pegcetacoplan	174,477	1	1	1	1	84	1.4	3.3
amivantamab-vmjw	14,341	1	1	1	1	28	1.2	2.4
piflufolastat F 18	193,176	1	1	1	1	1	1.0	0.0
sotorasib	14,990	1	30	30	30	90	29.1	5.1
infigratinib	130	8	28	28	28	28	27.3	3.0
olanzapine and samidorphan	91,985	1	30	30	30	180	29.5	10.9
ibrexafungerp	4,359	1	1	1	1	90	2.8	7.4

Table 2b. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	Total Number of Dispensings[1]	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
aducanumab-avwa	2,823	1	1	1	1	30	1.1	1.4
asparaginase erwinia chrysanthemi (recombinant)-rywn	4,061	1	1	1	1	28	1.0	0.9

[1]For drugs requiring clinical administration and identified by procedure codes (rather than pharmacy claims with NDCs), days supplied are not recorded. A default of 1 day supplied was assigned per administration for summary purposes.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

| | | Number of Dispensings by Days Supplied | | | | | | | |
| | | 1-30 Days | | 31-60 Days | | 61-90 Days | | 91+ Days | |
	Total Number of Dispensings[1]	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
vericiguat	**59,028**	**44,425**	**100.0%**	**1,776**	**100.0%**	**12,768**	**100.0%**	**59**	**100.0%**
Female	21,160	16,324	36.7%	627	35.3%	4,190	32.8%	19	32.2%
Male	37,868	28,101	63.3%	1,149	64.7%	8,578	67.2%	40	67.8%
cabotegravir	**96,581**	**72,978**	**100.0%**	**23,560**	**100.0%**	*****	*****	*****	*****
Female	16,196	11,497	15.8%	*****	*****	*****	*****	0	0.0%
Male	80,385	61,481	84.2%	*****	*****	*****	*****	*****	*****
voclosporin	**6,681**	*****	*****	*****	*****	*****	*****	*****	*****
Female	5,307	*****	*****	*****	*****	*****	*****	0	NaN
Male	1,374	*****	*****	*****	*****	0	0.0%	0	NaN
tepotinib	**2,585**	**2,547**	**100.0%**	*****	*****	*****	*****	*****	*****
Female	1,743	1,727	67.8%	*****	*****	*****	*****	0	0.0%
Male	842	820	32.2%	*****	*****	*****	*****	*****	*****
umbralisib	**272**	**272**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	133	133	48.9%	0	NaN	0	NaN	0	NaN
Male	139	139	51.1%	0	NaN	0	NaN	0	NaN
evinacumab-dgnb	**1,891**	**1,843**	**100.0%**	**48**	**100.0%**	**0**	**NaN**	**0**	**NaN**
Female	1,466	1,418	76.9%	48	100.0%	0	NaN	0	NaN
Male	425	425	23.1%	0	0.0%	0	NaN	0	NaN
trilacicilib	**20,063**	**20,063**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	10,736	10,736	53.5%	0	NaN	0	NaN	0	NaN
Male	9,327	9,327	46.5%	0	NaN	0	NaN	0	NaN

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

| | | Number of Dispensings by Days Supplied | | | | | | | |
| | | 1-30 Days | | 31-60 Days | | 61-90 Days | | 91+ Days | |
	Total Number of Dispensings[1]	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
casimersen	**2,841**	**2,841**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN
fosdenopterin	*****	*****	*****	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN
melphalan flufenamide	**231**	**231**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	119	119	51.5%	0	NaN	0	NaN	0	NaN
Male	112	112	48.5%	0	NaN	0	NaN	0	NaN
tivozanib	**7,429**	**7,418**	**100.0%**	**11**	**100.0%**	**0**	**NaN**	**0**	**NaN**
Female	1,946	*****	*****	*****	*****	0	NaN	0	NaN
Male	5,483	*****	*****	*****	*****	0	NaN	0	NaN
ponesimod	**1,935**	**1,812**	**100.0%**	*****	*****	**101**	**100.0%**	*****	*****
Female	1,363	1,261	69.6%	*****	*****	*****	*****	*****	*****
Male	572	551	30.4%	*****	*****	*****	*****	0	0.0%
dasiglucagon	**2,555**	**2,378**	**100.0%**	**48**	**100.0%**	**129**	**100.0%**	**0**	**NaN**
Female	1,450	1,354	56.9%	20	41.7%	76	58.9%	0	NaN
Male	1,105	1,024	43.1%	28	58.3%	53	41.1%	0	NaN
viloxazine	**150,522**	**137,605**	**100.0%**	**3,495**	**100.0%**	**9,323**	**100.0%**	**99**	**100.0%**
Female	61,434	56,109	40.8%	1,444	41.3%	3,848	41.3%	33	33.3%
Male	89,088	81,496	59.2%	2,051	58.7%	5,475	58.7%	66	66.7%

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

		Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
	Total Number of Dispensings[1]	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
drospirenone and estetrol	**55,757**	**34,745**	**100.0%**	**1,919**	**100.0%**	**19,031**	**100.0%**	**62**	**100.0%**
Female	55,687	*****	*****	*****	*****	18,995	99.8%	62	100.0%
Male	70	*****	*****	*****	*****	36	0.2%	0	0.0%
dostarlimab-gxly	**15,637**	**15,612**	**100.0%**	**25**	**100.0%**	**0**	**NaN**	**0**	**NaN**
Female	14,582	*****	*****	*****	*****	0	NaN	0	NaN
Male	1,055	*****	*****	*****	*****	0	NaN	0	NaN
loncastuximab tesirine-lpyl	**3,403**	**3,403**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	1,456	1,456	42.8%	0	NaN	0	NaN	0	NaN
Male	1,947	1,947	57.2%	0	NaN	0	NaN	0	NaN
serdexmethylphenidate and dexmethylphenidate	**151,262**	**149,765**	**100.0%**	*****	*****	**941**	**100.0%**	*****	*****
Female	65,604	65,024	43.4%	*****	*****	404	42.9%	*****	*****
Male	85,658	84,741	56.6%	*****	*****	537	57.1%	*****	*****
pegcetacoplan	**174,477**	**174,408**	**100.0%**	*****	*****	*****	*****	**0**	**NaN**
Female	118,536	118,482	67.9%	*****	*****	*****	*****	0	NaN
Male	55,941	55,926	32.1%	*****	*****	*****	*****	0	NaN
amivantamab-vmjw	**14,341**	**14,341**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	10,165	10,165	70.9%	0	NaN	0	NaN	0	NaN
Male	4,176	4,176	29.1%	0	NaN	0	NaN	0	NaN

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

| | | Number of Dispensings by Days Supplied | | | | | | | |
| | | 1-30 Days | | 31-60 Days | | 61-90 Days | | 91+ Days | |
	Total Number of Dispensings[1]	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
piflufolastat F 18	**193,176**	**193,176**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	174	174	0.1%	0	NaN	0	NaN	0	NaN
Male	193,002	193,002	99.9%	0	NaN	0	NaN	0	NaN
sotorasib	**14,990**	**14,916**	**100.0%**	**46**	**100.0%**	**28**	**100.0%**	**0**	**NaN**
Female	9,146	9,099	61.0%	35	76.1%	12	42.9%	0	NaN
Male	5,844	5,817	39.0%	11	23.9%	16	57.1%	0	NaN
infigratinib	**130**	**130**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	69	69	53.1%	0	NaN	0	NaN	0	NaN
Male	61	61	46.9%	0	NaN	0	NaN	0	NaN
olanzapine and samidorphan	**91,985**	**88,294**	**100.0%**	*****	*****	**1,984**	**100.0%**	*****	*****
Female	46,907	45,143	51.1%	*****	*****	1,036	52.2%	*****	*****
Male	45,078	43,151	48.9%	*****	*****	948	47.8%	*****	*****
ibrexafungerp	**4,359**	**4,341**	**100.0%**	*****	*****	*****	*****	**0**	**NaN**
Female	4,326	4,308	99.2%	*****	*****	*****	*****	0	NaN
Male	33	33	0.8%	0	0.0%	0	0.0%	0	NaN
aducanumab-avwa	**2,823**	**2,823**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	1,446	1,446	51.2%	0	NaN	0	NaN	0	NaN
Male	1,377	1,377	48.8%	0	NaN	0	NaN	0	NaN

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

| | | Number of Dispensings by Days Supplied | | | | | | | |
| | | 1-30 Days | | 31-60 Days | | 61-90 Days | | 91+ Days | |
	Total Number of Dispensings[1]	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
asparaginase erwinia chrysanthemi (recombinant)-rywn	**4,061**	**4,061**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	1,218	1,218	30.0%	0	NaN	0	NaN	0	NaN
Male	2,843	2,843	70.0%	0	NaN	0	NaN	0	NaN

[1]For drugs requiring clinical administration and identified by procedure codes (rather than pharmacy claims with NDCs), days supplied are not recorded. A default of 1 day supplied was assigned per administration for summary purposes.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*NaN: Not a number

Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Dispensings[1]	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
vericiguat	**59,028**	**1**	**30**	**30**	**30**	**180**	**41.0**	**26.3**
Female	21,160	1	30	30	30	118	39.6	25.6
Male	37,868	1	30	30	42	180	41.7	26.6
cabotegravir	**96,581**	**1**	**1**	**1**	**30**	**219**	**21.2**	**23.4**
Female	16,196	1	1	28	56	84	25.5	23.2
Male	80,385	1	1	1	30	219	20.3	23.3
voclosporin	**6,681**	**1**	**30**	**30**	**30**	**90**	**29.1**	**4.4**
Female	5,307	1	30	30	30	90	29.0	4.6
Male	1,374	4	30	30	30	45	29.4	3.2
tepotinib	**2,585**	**1**	**30**	**30**	**30**	**105**	**29.1**	**5.8**
Female	1,743	1	30	30	30	90	29.1	5.1
Male	842	1	30	30	30	105	29.1	7.0
umbralisib	**272**	**3**	**30**	**30**	**30**	**30**	**29.3**	**3.4**
Female	133	17	30	30	30	30	29.7	1.7
Male	139	3	30	30	30	30	29.0	4.5
evinacumab-dgnb	**1,891**	**1**	**1**	**1**	**1**	**56**	**4.7**	**10.8**
Female	1,466	1	1	1	1	56	5.4	11.8
Male	425	1	1	1	1	30	2.5	6.1
trilacicilib	**20,063**	**1**	**1**	**1**	**1**	**21**	**1.0**	**0.5**
Female	10,736	1	1	1	1	21	1.0	0.6
Male	9,327	1	1	1	1	21	1.0	0.4
casimersen	**2,841**	**1**	**1**	**1**	**7**	**28**	**5.5**	**8.7**
Female	*****	1	1	1	1	1	1.0	NaN
Male	*****	1	1	1	7	28	5.5	8.7
fosdenopterin	*****	**5**	**7**	**28**	**30**	**30**	**21.3**	**11.9**

Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Dispensings[1]	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Female	*****	5	5	28	28	28	20.3	13.3
Male	*****	7	7	30	30	30	22.3	13.3
melphalan flufenamide	**231**	**1**	**1**	**1**	**1**	**28**	**2.3**	**5.8**
Female	119	1	1	1	1	28	2.6	6.4
Male	112	1	1	1	1	28	2.0	5.0
tivozanib	**7,429**	**1**	**28**	**28**	**28**	**56**	**27.1**	**3.7**
Female	1,946	1	28	28	28	31	26.9	4.0
Male	5,483	1	28	28	28	56	27.2	3.6
ponesimod	**1,935**	**1**	**30**	**30**	**30**	**180**	**32.2**	**14.9**
Female	1,363	1	30	30	30	180	32.9	16.4
Male	572	3	30	30	30	90	30.4	10.6
dasiglucagon	**2,555**	**1**	**1**	**7**	**30**	**90**	**18.2**	**21.6**
Female	1,450	1	1	6	30	90	18.0	21.7
Male	1,105	1	1	10	30	90	18.4	21.4
viloxazine	**150,522**	**1**	**30**	**30**	**30**	**180**	**32.3**	**16.4**
Female	61,434	1	30	30	30	180	32.4	16.3
Male	89,088	1	30	30	30	180	32.3	16.4
drospirenone and estetrol	**55,757**	**1**	**28**	**28**	**84**	**364**	**46.6**	**27.1**
Female	55,687	1	28	28	84	364	46.6	27.1
Male	70	8	28	68	84	84	56.2	28.9
dostarlimab-gxly	**15,637**	**1**	**1**	**1**	**1**	**42**	**1.2**	**2.5**
Female	14,582	1	1	1	1	42	1.2	2.4
Male	1,055	1	1	1	1	42	1.4	3.0
loncastuximab tesirine-lpyl	**3,403**	**1**	**1**	**1**	**1**	**21**	**1.3**	**2.5**
Female	1,456	1	1	1	1	21	1.3	2.4

Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Dispensings[1]	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Male	1,947	1	1	1	1	21	1.3	2.5
serdexmethylphenidate and dexmethylphenidate	**151,262**	**1**	**30**	**30**	**30**	**180**	**29.0**	**7.1**
Female	65,604	1	30	30	30	180	29.0	7.0
Male	85,658	1	30	30	30	180	29.1	7.1
pegcetacoplan	**174,477**	**1**	**1**	**1**	**1**	**84**	**1.4**	**3.3**
Female	118,536	1	1	1	1	84	1.3	3.1
Male	55,941	1	1	1	1	84	1.5	3.8
amivantamab-vmjw	**14,341**	**1**	**1**	**1**	**1**	**28**	**1.2**	**2.4**
Female	10,165	1	1	1	1	28	1.2	2.5
Male	4,176	1	1	1	1	28	1.2	2.2
piflufolastat F 18	**193,176**	**1**	**1**	**1**	**1**	**1**	**1.0**	**0.0**
Female	174	1	1	1	1	1	1.0	0.0
Male	193,002	1	1	1	1	1	1.0	0.0
sotorasib	**14,990**	**1**	**30**	**30**	**30**	**90**	**29.1**	**5.1**
Female	9,146	1	30	30	30	90	29.1	4.9
Male	5,844	1	30	30	30	90	29.1	5.5
infigratinib	**130**	**8**	**28**	**28**	**28**	**28**	**27.3**	**3.0**
Female	69	8	28	28	28	28	26.9	3.9
Male	61	21	28	28	28	28	27.8	1.2
olanzapine and samidorphan	**91,985**	**1**	**30**	**30**	**30**	**180**	**29.5**	**10.9**
Female	46,907	1	30	30	30	180	29.6	11.0
Male	45,078	1	30	30	30	180	29.4	10.8

Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Dispensings[1]	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
ibrexafungerp	**4,359**	**1**	**1**	**1**	**1**	**90**	**2.8**	**7.4**
Female	4,326	1	1	1	1	90	2.7	7.3
Male	33	1	1	3	29	30	13.0	13.4
aducanumab-avwa	**2,823**	**1**	**1**	**1**	**1**	**30**	**1.1**	**1.4**
Female	1,446	1	1	1	1	30	1.1	2.0
Male	1,377	1	1	1	1	1	1.0	0.0
asparaginase erwinia chrysanthemi (recombinant)-rywn	**4,061**	**1**	**1**	**1**	**1**	**28**	**1.0**	**0.9**
Female	1,218	1	1	1	1	1	1.0	0.0
Male	2,843	1	1	1	1	28	1.0	1.1

[1]For drugs requiring clinical administration and identified by procedure codes (rather than pharmacy claims with NDCs), days supplied are not recorded. A default of 1 day supplied was assigned per administration for summary purposes.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*NaN: Not a number

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Dispensings[1]	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
vericiguat	**59,028**	**44,425**	**100.0%**	**1,776**	**100.0%**	**12,768**	**100.0%**	**59**	**100.0%**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	41	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	536	404	0.9%	*****	*****	*****	*****	0	0.0%
41-64 years	10,577	8,154	18.4%	*****	*****	2,140	16.8%	*****	*****
≥ 65 years	47,874	*****	*****	1,475	83.1%	10,513	82.3%	*****	*****
cabotegravir	**96,581**	**72,978**	**100.0%**	**23,560**	**100.0%**	*****	*****	*****	*****
0-17 years	25	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	2,524	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	29,730	26,206	35.9%	*****	*****	*****	*****	0	0.0%
41-64 years	48,288	35,392	48.5%	12,874	54.6%	*****	*****	*****	*****
≥ 65 years	16,014	9,113	12.5%	6,882	29.2%	*****	*****	*****	*****
voclosporin	**6,681**	*****	*****	*****	*****	*****	*****	**0**	**NaN**
0-17 years	18	18	0.3%	0	0.0%	0	0.0%	0	NaN
18-24 years	884	*****	*****	*****	*****	*****	*****	0	NaN
25-40 years	3,002	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	2,436	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	341	341	5.1%	0	0.0%	0	0.0%	0	NaN
tepotinib	**2,585**	**2,547**	**100.0%**	*****	*****	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%

| | | Number of Dispensings by Days Supplied | | | | | | | |
| | | 1-30 Days | | 31-60 Days | | 61-90 Days | | 91+ Days | |
	Total Number of Dispensings[1]	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
41-64 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
≥ 65 years	2,242	2,204	86.5%	*****	*****	*****	*****	*****	*****
umbralisib	**272**	**272**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	37	37	13.6%	0	NaN	0	NaN	0	NaN
≥ 65 years	235	235	86.4%	0	NaN	0	NaN	0	NaN
evinacumab-dgnb	**1,891**	**1,843**	**100.0%**	**48**	**100.0%**	**0**	**NaN**	**0**	**NaN**
0-17 years	69	69	3.7%	0	0.0%	0	NaN	0	NaN
18-24 years	21	21	1.1%	0	0.0%	0	NaN	0	NaN
25-40 years	187	187	10.1%	0	0.0%	0	NaN	0	NaN
41-64 years	763	739	40.1%	24	50.0%	0	NaN	0	NaN
≥ 65 years	851	827	44.9%	24	50.0%	0	NaN	0	NaN
trilacicilib	**20,063**	**20,063**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	18	18	0.1%	0	NaN	0	NaN	0	NaN
41-64 years	2,443	2,443	12.2%	0	NaN	0	NaN	0	NaN
≥ 65 years	17,602	17,602	87.7%	0	NaN	0	NaN	0	NaN
casimersen	**2,841**	**2,841**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	1,854	1,854	65.3%	0	NaN	0	NaN	0	NaN

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

| | | Number of Dispensings by Days Supplied | | | | | | | |
| | | 1-30 Days | | 31-60 Days | | 61-90 Days | | 91+ Days | |
	Total Number of Dispensings[1]	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
18-24 years	585	585	20.6%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
fosdenopterin	*****	*****	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	*****	*****	100.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
flufenamide	**231**	**231**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	37	37	16.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	194	194	84.0%	0	NaN	0	NaN	0	NaN
tivozanib	**7,429**	**7,418**	**100.0%**	**11**	**100.0%**	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	1,380	1,380	18.6%	0	0.0%	0	NaN	0	NaN
≥ 65 years	6,020	*****	*****	*****	*****	0	NaN	0	NaN

	Total Number of Dispensings[1]	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
ponesimod	1,935	1,812	100.0%	*****	*****	101	100.0%	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	30	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	492	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	1,203	1,122	61.9%	*****	*****	65	64.4%	*****	*****
≥ 65 years	210	192	10.6%	*****	*****	*****	*****	0	0.0%
dasiglucagon	2,555	2,378	100.0%	48	100.0%	129	100.0%	0	NaN
0-17 years	506	478	20.1%	*****	*****	*****	*****	0	NaN
18-24 years	243	222	9.3%	*****	*****	*****	*****	0	NaN
25-40 years	432	389	16.4%	*****	*****	*****	*****	0	NaN
41-64 years	877	822	34.6%	16	33.3%	39	30.2%	0	NaN
≥ 65 years	497	467	19.6%	13	27.1%	17	13.2%	0	NaN
viloxazine	150,522	137,605	100.0%	3,495	100.0%	9,323	100.0%	99	100.0%
0-17 years	97,203	89,087	64.7%	2,068	59.2%	5,972	64.1%	76	76.8%
18-24 years	13,492	12,130	8.8%	*****	*****	1,010	10.8%	*****	*****
25-40 years	21,950	20,110	14.6%	644	18.4%	1,184	12.7%	12	12.1%
41-64 years	15,965	14,555	10.6%	*****	*****	1,011	10.8%	*****	*****
≥ 65 years	1,912	1,723	1.3%	*****	*****	146	1.6%	*****	*****
estetrol	55,757	34,745	100.0%	1,919	100.0%	19,031	100.0%	62	100.0%
0-17 years	6,571	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	17,672	11,107	32.0%	*****	*****	5,994	31.5%	*****	*****
25-40 years	22,941	14,004	40.3%	874	45.5%	8,039	42.2%	24	38.7%

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

| | | Number of Dispensings by Days Supplied | | | | | | | |
| | | 1-30 Days | | 31-60 Days | | 61-90 Days | | 91+ Days | |
	Total Number of Dispensings[1]	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
41-64 years	8,539	5,292	15.2%	314	16.4%	2,917	15.3%	16	25.8%
≥ 65 years	34	*****	*****	0	0.0%	*****	*****	0	0.0%
dostarlimab-gxly	**15,637**	**15,612**	**100.0%**	**25**	**100.0%**	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	13	13	0.1%	0	0.0%	0	NaN	0	NaN
25-40 years	195	195	1.2%	0	0.0%	0	NaN	0	NaN
41-64 years	2,543	2,543	16.3%	0	0.0%	0	NaN	0	NaN
≥ 65 years	12,886	12,861	82.4%	25	100.0%	0	NaN	0	NaN
loncastuximab tesirine-lpyl	**3,403**	**3,403**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	305	305	9.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	3,055	3,055	89.8%	0	NaN	0	NaN	0	NaN
serdexmethylphenidate and dexmethylphenidate	**151,262**	**149,765**	**100.0%**	*****	*****	**941**	**100.0%**	*****	*****
0-17 years	84,276	83,527	55.8%	272	49.3%	477	50.7%	0	0.0%
18-24 years	15,350	15,149	10.1%	*****	*****	134	14.2%	*****	*****
25-40 years	28,155	27,918	18.6%	*****	*****	127	13.5%	*****	*****
41-64 years	21,858	21,592	14.4%	93	16.8%	173	18.4%	0	0.0%

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

| | Total Number of Dispensings[1] | Number of Dispensings by Days Supplied | | | | | | | |
| | | 1-30 Days | | 31-60 Days | | 61-90 Days | | 91+ Days | |
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
≥ 65 years	1,623	1,579	1.1%	*****	*****	30	3.2%	*****	*****
pegcetacoplan	**174,477**	**174,408**	**100.0%**	*****	*****	*****	*****	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	81	81	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	408	*****	*****	0	0.0%	*****	*****	0	NaN
41-64 years	1,715	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	172,273	172,207	98.7%	*****	*****	*****	*****	0	NaN
amivantamab-vmjw	**14,341**	**14,341**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	78	78	0.5%	0	NaN	0	NaN	0	NaN
41-64 years	2,418	2,418	16.9%	0	NaN	0	NaN	0	NaN
≥ 65 years	11,845	11,845	82.6%	0	NaN	0	NaN	0	NaN
piflufolastat F 18	**193,176**	**193,176**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	13,590	13,590	7.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	179,569	179,569	93.0%	0	NaN	0	NaN	0	NaN
sotorasib	**14,990**	**14,916**	**100.0%**	**46**	**100.0%**	**28**	**100.0%**	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

| | Total Number of Dispensings[1] | Number of Dispensings by Days Supplied | | | | | | | |
| | | 1-30 Days | | 31-60 Days | | 61-90 Days | | 91+ Days | |
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
25-40 years	30	30	0.2%	0	0.0%	0	0.0%	0	NaN
41-64 years	3,004	2,989	20.0%	*****	*****	*****	*****	0	NaN
≥ 65 years	11,956	11,897	79.8%	*****	*****	*****	*****	0	NaN
infigratinib	**130**	**130**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	24	24	18.5%	0	NaN	0	NaN	0	NaN
41-64 years	35	35	26.9%	0	NaN	0	NaN	0	NaN
≥ 65 years	71	71	54.6%	0	NaN	0	NaN	0	NaN
olanzapine and samidorphan	**91,985**	**88,294**	**100.0%**	*****	*****	**1,984**	**100.0%**	*****	*****
0-17 years	365	343	0.4%	*****	*****	*****	*****	0	0.0%
18-24 years	5,612	5,363	6.1%	*****	*****	163	8.2%	*****	*****
25-40 years	31,749	30,376	34.4%	766	45.1%	*****	*****	*****	*****
41-64 years	46,144	44,369	50.3%	*****	*****	1,027	51.8%	*****	*****
≥ 65 years	8,115	7,843	8.9%	99	5.8%	173	8.7%	0	0.0%
ibrexafungerp	**4,359**	**4,341**	**100.0%**	*****	*****	*****	*****	**0**	**NaN**
0-17 years	29	29	0.7%	0	0.0%	0	0.0%	0	NaN
18-24 years	631	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	2,150	*****	*****	*****	*****	*****	*****	0	NaN
41-64 years	1,493	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	56	56	1.3%	0	0.0%	0	0.0%	0	NaN

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

		Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
	Total Number of Dispensings[1]	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
aducanumab-avwa	**2,823**	**2,823**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	2,699	2,699	95.6%	0	NaN	0	NaN	0	NaN
asparaginase erwinia chrysanthemi (recombinant)-rywn	**4,061**	**4,061**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	3,142	3,142	77.4%	0	NaN	0	NaN	0	NaN
18-24 years	442	442	10.9%	0	NaN	0	NaN	0	NaN
25-40 years	339	339	8.3%	0	NaN	0	NaN	0	NaN
41-64 years	50	50	1.2%	0	NaN	0	NaN	0	NaN
≥ 65 years	88	88	2.2%	0	NaN	0	NaN	0	NaN

[1]For drugs requiring clinical administration and identified by procedure codes (rather than pharmacy claims with NDCs), days supplied are not recorded. A default of 1 day supplied was assigned per administration for summary purposes.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*NaN: Not a number

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Dispensings[1]	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
vericiguat	**59,028**	**1**	**30**	**30**	**30**	**180**	**41.0**	**26.3**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	41	4	28	30	30	90	38.6	24.8
25-40 years	536	1	30	30	30	90	40.2	25.6
41-64 years	10,577	1	30	30	30	120	40.1	25.6
≥ 65 years	47,874	1	30	30	32	180	41.2	26.4
cabotegravir	**96,581**	**1**	**1**	**1**	**30**	**219**	**21.2**	**23.4**
0-17 years	25	1	1	1	1	60	9.4	19.4
18-24 years	2,524	1	1	1	28	90	12.6	19.2
25-40 years	29,730	1	1	1	28	90	13.0	19.4
41-64 years	48,288	1	1	17	56	112	22.6	23.7
≥ 65 years	16,014	1	1	30	56	219	33.3	23.6
voclosporin	**6,681**	**1**	**30**	**30**	**30**	**90**	**29.1**	**4.4**
0-17 years	18	13	30	30	30	30	29.1	4.0
18-24 years	884	1	30	30	30	90	29.2	4.3
25-40 years	3,002	1	30	30	30	60	28.9	4.5
41-64 years	2,436	1	30	30	30	90	29.2	4.3
≥ 65 years	341	2	30	30	30	30	28.9	4.3
tepotinib	**2,585**	**1**	**30**	**30**	**30**	**105**	**29.1**	**5.8**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	30	30	30	30	30	30.0	0.0
41-64 years	*****	3	30	30	30	30	29.2	3.3
≥ 65 years	2,242	1	30	30	30	105	29.1	6.1
umbralisib	**272**	**3**	**30**	**30**	**30**	**30**	**29.3**	**3.4**

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Dispensings[1]	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	37	3	30	30	30	30	29.1	4.5
≥ 65 years	235	3	30	30	30	30	29.4	3.2
evinacumab-dgnb	**1,891**	**1**	**1**	**1**	**1**	**56**	**4.7**	**10.8**
0-17 years	69	1	1	1	1	1	1.0	0.0
18-24 years	21	1	1	1	1	1	1.0	0.0
25-40 years	187	1	1	1	1	30	1.9	4.8
41-64 years	763	1	1	1	1	56	6.3	12.0
≥ 65 years	851	1	1	1	1	56	4.4	11.0
trilacicilib	**20,063**	**1**	**1**	**1**	**1**	**21**	**1.0**	**0.5**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	18	1	1	1	1	1	1.0	0.0
41-64 years	2,443	1	1	1	1	21	1.0	0.7
≥ 65 years	17,602	1	1	1	1	21	1.0	0.5
casimersen	**2,841**	**1**	**1**	**1**	**7**	**28**	**5.5**	**8.7**
0-17 years	1,854	1	1	1	1	28	3.8	7.9
18-24 years	585	1	1	1	14	28	7.8	11.2
25-40 years	*****	1	7	7	14	28	10.0	5.5
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	*****	1	1	1	1	1	1.0	NaN
fosdenopterin	*****	**5**	**7**	**28**	**30**	**30**	**21.3**	**11.9**
0-17 years	*****	5	7	28	30	30	21.3	11.9

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Dispensings[1]	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
melphalan flufenamide	**231**	**1**	**1**	**1**	**1**	**28**	**2.3**	**5.8**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	37	1	1	1	1	1	1.0	0.0
≥ 65 years	194	1	1	1	1	28	2.5	6.3
tivozanib	**7,429**	**1**	**28**	**28**	**28**	**56**	**27.1**	**3.7**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	9	9	28	28	28	21.7	11.0
25-40 years	*****	10	28	28	28	34	26.9	4.5
41-64 years	1,380	1	28	28	28	30	27.0	4.0
≥ 65 years	6,020	1	28	28	28	56	27.1	3.6
ponesimod	**1,935**	**1**	**30**	**30**	**30**	**180**	**32.2**	**14.9**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	30	4	30	30	30	90	34.3	20.5
25-40 years	492	1	30	30	30	90	30.7	12.1
41-64 years	1,203	1	30	30	30	180	32.4	15.3
≥ 65 years	210	5	30	30	30	90	33.9	17.3
dasiglucagon	**2,555**	**1**	**1**	**7**	**30**	**90**	**18.2**	**21.6**
0-17 years	506	1	1	2	30	90	15.7	21.2
18-24 years	243	1	1	15	30	90	19.5	22.5

	Total Number of Dispensings[1]	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
25-40 years	432	1	1	25	30	90	21.2	24.4
41-64 years	877	1	1	10	30	90	18.1	20.8
≥ 65 years	497	1	1	14	30	90	17.7	19.8
viloxazine	**150,522**	**1**	**30**	**30**	**30**	**180**	**32.3**	**16.4**
0-17 years	97,203	1	30	30	30	180	32.3	16.4
18-24 years	13,492	1	30	30	30	180	33.4	17.2
25-40 years	21,950	1	30	30	30	180	31.7	15.6
41-64 years	15,965	1	30	30	30	180	32.3	16.2
≥ 65 years	1,912	1	30	30	30	100	33.3	17.1
drospirenone and estetrol	**55,757**	**1**	**28**	**28**	**84**	**364**	**46.6**	**27.1**
0-17 years	6,571	1	28	28	84	112	45.2	26.5
18-24 years	17,672	1	28	28	84	252	46.6	27.1
25-40 years	22,941	1	28	28	84	364	47.2	27.2
41-64 years	8,539	1	28	28	84	168	46.6	27.2
≥ 65 years	34	24	28	28	28	84	37.8	21.7
dostarlimab-gxly	**15,637**	**1**	**1**	**1**	**1**	**42**	**1.2**	**2.5**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	13	1	1	1	1	1	1.0	0.0
25-40 years	195	1	1	1	1	1	1.0	0.0
41-64 years	2,543	1	1	1	1	21	1.0	0.9
≥ 65 years	12,886	1	1	1	1	42	1.3	2.7
loncastuximab tesirine-lpyl	**3,403**	**1**	**1**	**1**	**1**	**21**	**1.3**	**2.5**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	3	1.1	0.3

	Total Number of Dispensings[1]	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
41-64 years	305	1	1	1	1	21	2.4	5.1
≥ 65 years	3,055	1	1	1	1	21	1.2	2.0
serdexmethylphenidate and dexmethylphenidate	**151,262**	**1**	**30**	**30**	**30**	**180**	**29.0**	**7.1**
0-17 years	84,276	1	30	30	30	90	29.0	6.9
18-24 years	15,350	1	30	30	30	120	29.2	7.6
25-40 years	28,155	1	30	30	30	180	28.8	6.8
41-64 years	21,858	1	30	30	30	90	29.2	7.4
≥ 65 years	1,623	1	30	30	30	180	30.1	10.6
pegcetacoplan	**174,477**	**1**	**1**	**1**	**1**	**84**	**1.4**	**3.3**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	81	1	28	28	28	28	27.1	4.4
25-40 years	408	1	28	28	28	84	26.5	6.9
41-64 years	1,715	1	1	1	28	84	11.9	13.4
≥ 65 years	172,273	1	1	1	1	84	1.2	2.5
amivantamab-vmjw	**14,341**	**1**	**1**	**1**	**1**	**28**	**1.2**	**2.4**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	78	1	1	1	1	1	1.0	0.0
41-64 years	2,418	1	1	1	1	28	1.3	2.7
≥ 65 years	11,845	1	1	1	1	28	1.2	2.3
piflufolastat F 18	**193,176**	**1**	**1**	**1**	**1**	**1**	**1.0**	**0.0**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Dispensings[1]	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
41-64 years	13,590	1	1	1	1	1	1.0	0.0
≥ 65 years	179,569	1	1	1	1	1	1.0	0.0
sotorasib	**14,990**	**1**	**30**	**30**	**30**	**90**	**29.1**	**5.1**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	30	15	30	30	30	30	27.6	5.2
41-64 years	3,004	1	30	30	30	69	28.4	5.2
≥ 65 years	11,956	1	30	30	30	90	29.3	5.1
infigratinib	**130**	**8**	**28**	**28**	**28**	**28**	**27.3**	**3.0**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	24	28	28	28	28	28	28.0	0.0
41-64 years	35	10	28	28	28	28	27.3	3.2
≥ 65 years	71	8	28	28	28	28	27.1	3.4
olanzapine and samidorphan	**91,985**	**1**	**30**	**30**	**30**	**180**	**29.5**	**10.9**
0-17 years	365	2	30	30	30	90	31.1	15.2
18-24 years	5,612	1	30	30	30	180	29.9	12.1
25-40 years	31,749	1	30	30	30	180	29.4	10.6
41-64 years	46,144	1	30	30	30	120	29.6	10.9
≥ 65 years	8,115	1	30	30	30	90	29.3	10.7
ibrexafungerp	**4,359**	**1**	**1**	**1**	**1**	**90**	**2.8**	**7.4**
0-17 years	29	1	1	1	1	30	2.1	5.4
18-24 years	631	1	1	1	1	31	2.1	5.1
25-40 years	2,150	1	1	1	1	90	2.7	7.7
41-64 years	1,493	1	1	1	1	90	3.2	7.9

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Dispensings[1]	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	56	1	1	1	1	30	4.5	9.1
aducanumab-avwa	**2,823**	**1**	**1**	**1**	**1**	**30**	**1.1**	**1.4**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	*****	1	1	1	1	1	1.0	0.0
≥ 65 years	2,699	1	1	1	1	30	1.1	1.5
asparaginase erwinia chrysanthemi (recombinant)-rywn	**4,061**	**1**	**1**	**1**	**1**	**28**	**1.0**	**0.9**
0-17 years	3,142	1	1	1	1	28	1.0	1.1
18-24 years	442	1	1	1	1	1	1.0	0.0
25-40 years	339	1	1	1	1	1	1.0	0.0
41-64 years	50	1	1	1	1	1	1.0	0.0
≥ 65 years	88	1	1	1	1	1	1.0	0.0

[1]For drugs requiring clinical administration and identified by procedure codes (rather than pharmacy claims with NDCs), days supplied are not recorded. A default of 1 day supplied was assigned per administration for summary purposes.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*NaN: Not a number

Table 3a. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration								
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
vericiguat	9,873	1,748	17.7%	2,170	22.0%	3,637	36.8%	1,660	16.8%	658	6.7%
cabotegravir	14,260	7,956	55.8%	1,480	10.4%	2,789	19.6%	1,421	10.0%	614	4.3%
voclosporin	945	198	21.0%	232	24.6%	353	37.4%	111	11.7%	51	5.4%
tepotinib	476	114	23.9%	126	26.5%	193	40.5%	*****	*****	*****	*****
umbralisib	79	20	25.3%	27	34.2%	32	40.5%	0	0.0%	0	0.0%
evinacumab-dgnb	139	111	79.9%	15	10.8%	*****	*****	*****	*****	*****	*****
trilaciclib	2,028	1,995	98.4%	*****	*****	*****	*****	0	0.0%	0	0.0%
casimersen	143	68	47.6%	*****	*****	36	25.2%	*****	*****	*****	*****
fosdenopterin	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	0.0%
melphalan flufenamide	100	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
tivozanib	1,550	343	22.1%	522	33.7%	595	38.4%	72	4.6%	18	1.2%
ponesimod	181	19	10.5%	23	12.7%	71	39.2%	45	24.9%	23	12.7%
dasiglucagon	1,399	1,068	76.3%	233	16.7%	*****	*****	*****	*****	*****	*****
viloxazine	37,791	13,554	35.9%	10,539	27.9%	10,529	27.9%	2,607	6.9%	562	1.5%
drospirenone and estetrol	13,397	1,805	13.5%	3,852	28.8%	5,761	43.0%	1,691	12.6%	288	2.1%
dostarlimab-gxly	2,701	2,667	98.7%	14	0.5%	20	0.7%	0	0.0%	0	0.0%
loncastuximab tesirine-lpyl	806	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
serdexmethylphenidate and dexmethylphenidate	31,666	9,697	30.6%	8,153	25.7%	11,137	35.2%	2,488	7.9%	191	0.6%
pegcetacoplan	32,242	32,028	99.3%	67	0.2%	77	0.2%	38	0.1%	32	0.1%
amivantamab-vmjw	1,419	1,331	93.8%	76	5.4%	*****	*****	*****	*****	0	0.0%
piflufolastat F 18	159,348	159,348	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%

Table 3a. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

| | | Number of Patients by Cumulative Treatment Episode Duration | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
sotorasib	2,597	559	21.5%	813	31.3%	922	35.5%	224	8.6%	79	3.0%
infigratinib	36	*****	*****	14	38.9%	*****	*****	*****	*****	0	0.0%
olanzapine and samidorphan	12,692	3,467	27.3%	2,742	21.6%	3,896	30.7%	1,839	14.5%	748	5.9%
ibrexafungerp	2,617	2,543	97.2%	55	2.1%	19	0.7%	0	0.0%	0	0.0%
aducanumab-avwa	458	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
asparaginase erwinia chrysanthemi (recombinant)-rywn	280	250	89.3%	*****	*****	*****	*****	0	0.0%	0	0.0%

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 3b. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
vericiguat	9,873	1	60	150	354	1,499	244.9	255.9
cabotegravir	14,260	1	4	19	180	1,438	142.8	234.3
voclosporin	945	1	51	120	270	1,290	205.5	234.3
tepotinib	476	6	42	90	210	1,061	158.1	169.6
umbralisib	79	3	30	87	150	330	101.0	72.6
evinacumab-dgnb	139	1	4	11	26	1,323	64.4	189.3
trilacicilib	2,028	1	6	9	12	180	10.0	9.3
casimersen	143	1	7	40	116	1,136	109.3	203.7
fosdenopterin	*****	61	61	64	67	67	64.0	4.2
melphalan flufenamide	100	1	1	2	3	140	5.3	16.5
tivozanib	1,550	1	47	84	140	1,199	129.9	144.5
ponesimod	181	1	104	230	528	1,200	343.9	301.8
dasiglucagon	1,399	1	1	10	30	791	33.2	62.4
viloxazine	37,791	1	30	60	150	1,338	128.7	163.4
drospirenone and estetrol	13,397	1	60	134	266	1,354	194.1	184.9
dostarlimab-gxly	2,701	1	3	5	8	252	7.1	14.7
loncastuximab tesirine-lpyl	806	1	2	3	6	442	5.5	19.9
serdexmethylphenidate and dexmethylphenidate	31,666	1	30	90	188	1,186	138.7	146.4
pegcetacoplan	32,242	1	2	5	7	1,424	7.5	38.1
amivantamab-vmjw	1,419	1	4	7	12	642	12.4	29.5
piflufolastat F 18	159,348	1	1	1	1	10	1.2	0.6
sotorasib	2,597	3	51	90	208	1,245	167.9	199.3
infigratinib	36	10	53	84	140	448	98.6	79.1

Table 3b. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
olanzapine and samidorphan	12,692	1	30	100	300	1,189	214.0	246.3
ibrexafungerp	2,617	1	1	1	2	356	4.6	18.2
aducanumab-avwa	458	1	2	4	8	215	6.6	11.9
asparaginase erwinia chrysanthemi (recombinant)-rywn	280	1	5	10	24	112	15.0	14.9

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 3c. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

| | | Number of Patients by Cumulative Treatment Episode Duration | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
vericiguat	**9,873**	**1,748**	**100.0%**	**2,170**	**100.0%**	**3,637**	**100.0%**	**1,660**	**100.0%**	**658**	**100.0%**
Female	3,439	619	35.4%	759	35.0%	1,265	34.8%	564	34.0%	232	35.3%
Male	6,434	1,129	64.6%	1,411	65.0%	2,372	65.2%	1,096	66.0%	426	64.7%
cabotegravir	**14,260**	**7,956**	**100.0%**	**1,480**	**100.0%**	**2,789**	**100.0%**	**1,421**	**100.0%**	**614**	**100.0%**
Female	2,383	1,070	13.4%	313	21.1%	588	21.1%	292	20.5%	120	19.5%
Male	11,877	6,886	86.6%	1,167	78.9%	2,201	78.9%	1,129	79.5%	494	80.5%
voclosporin	**945**	**198**	**100.0%**	**232**	**100.0%**	**353**	**100.0%**	**111**	**100.0%**	**51**	**100.0%**
Female	810	176	88.9%	213	91.8%	300	85.0%	85	76.6%	36	70.6%
Male	135	22	11.1%	19	8.2%	53	15.0%	26	23.4%	15	29.4%
tepotinib	**476**	**114**	**100.0%**	**126**	**100.0%**	**193**	**100.0%**	*****	*****	*****	*****
Female	298	68	59.6%	82	65.1%	116	60.1%	*****	*****	*****	*****
Male	178	46	40.4%	44	34.9%	77	39.9%	*****	*****	*****	*****
umbralisib	**79**	**20**	**100.0%**	**27**	**100.0%**	**32**	**100.0%**	**0**	**NaN**	**0**	**NaN**
Female	37	*****	*****	*****	*****	15	46.9%	0	NaN	0	NaN
Male	42	*****	*****	*****	*****	17	53.1%	0	NaN	0	NaN
evinacumab-dgnb	**139**	**111**	**100.0%**	**15**	**100.0%**	*****	*****	*****	*****	*****	*****
Female	108	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Male	31	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
trilacicilib	**2,028**	**1,995**	**100.0%**	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**
Female	1,065	1,045	52.4%	*****	*****	*****	*****	0	NaN	0	NaN
Male	963	950	47.6%	*****	*****	*****	*****	0	NaN	0	NaN

Table 3c. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
casimersen	**143**	**68**	**100.0%**	*****	*****	**36**	**100.0%**	*****	*****	*****	*****
Female	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Male	*****	*****	*****	*****	*****	36	100.0%	*****	*****	*****	*****
fosdenopterin	*****	**0**	**NaN**	*****	*****	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	*****	0	NaN	*****	*****	0	NaN	0	NaN	0	NaN
Male	*****	0	NaN	*****	*****	0	NaN	0	NaN	0	NaN
melphalan flufenamide	**100**	*****	*****	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**
Female	53	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	47	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
tivozanib	**1,550**	**343**	**100.0%**	**522**	**100.0%**	**595**	**100.0%**	**72**	**100.0%**	**18**	**100.0%**
Female	416	95	27.7%	137	26.2%	166	27.9%	*****	*****	*****	*****
Male	1,134	248	72.3%	385	73.8%	429	72.1%	*****	*****	*****	*****
ponesimod	**181**	**19**	**100.0%**	**23**	**100.0%**	**71**	**100.0%**	**45**	**100.0%**	**23**	**100.0%**
Female	138	*****	*****	*****	*****	58	81.7%	27	60.0%	*****	*****
Male	43	*****	*****	*****	*****	13	18.3%	18	40.0%	*****	*****
dasiglucagon	**1,399**	**1,068**	**100.0%**	**233**	**100.0%**	*****	*****	*****	*****	*****	*****
Female	756	572	53.6%	134	57.5%	*****	*****	*****	*****	*****	*****
Male	643	496	46.4%	99	42.5%	*****	*****	*****	*****	0	0.0%
viloxazine	**37,791**	**13,554**	**100.0%**	**10,539**	**100.0%**	**10,529**	**100.0%**	**2,607**	**100.0%**	**562**	**100.0%**
Female	16,622	6,406	47.3%	4,555	43.2%	4,457	42.3%	1,027	39.4%	177	31.5%
Male	21,169	7,148	52.7%	5,984	56.8%	6,072	57.7%	1,580	60.6%	385	68.5%
drospirenone and estetrol	**13,397**	**1,805**	**100.0%**	**3,852**	**100.0%**	**5,761**	**100.0%**	**1,691**	**100.0%**	**288**	**100.0%**

Table 3c. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

| | Total Number of Patients | Number of Patients by Cumulative Treatment Episode Duration | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Female	13,375	*****	*****	*****	*****	*****	*****	*****	*****	288	100.0%
Male	22	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
dostarlimab-gxly	**2,701**	**2,667**	**100.0%**	**14**	**100.0%**	**20**	**100.0%**	**0**	**NaN**	**0**	**NaN**
Female	2,534	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	167	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
lpyl	**806**	*****	*****	*****	*****	*****	*****	*****	*****	**0**	**NaN**
Female	345	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
Male	461	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
serdexmethylphenidate and dexmethylphenidate	**31,666**	**9,697**	**100.0%**	**8,153**	**100.0%**	**11,137**	**100.0%**	**2,488**	**100.0%**	**191**	**100.0%**
Female	14,864	4,883	50.4%	3,958	48.5%	4,953	44.5%	1,004	40.4%	66	34.6%
Male	16,802	4,814	49.6%	4,195	51.5%	6,184	55.5%	1,484	59.6%	125	65.4%
pegcetacoplan	**32,242**	**32,028**	**100.0%**	**67**	**100.0%**	**77**	**100.0%**	**38**	**100.0%**	**32**	**100.0%**
Female	21,919	21,790	68.0%	43	64.2%	48	62.3%	19	50.0%	19	59.4%
Male	10,323	10,238	32.0%	24	35.8%	29	37.7%	19	50.0%	13	40.6%
amivantamab-vmjw	**1,419**	**1,331**	**100.0%**	**76**	**100.0%**	*****	*****	*****	*****	**0**	**NaN**
Female	948	882	66.3%	*****	*****	*****	*****	*****	*****	0	NaN
Male	471	449	33.7%	*****	*****	*****	*****	*****	*****	0	NaN
piflufolastat F 18	**159,348**	**159,348**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	170	170	0.1%	0	NaN	0	NaN	0	NaN	0	NaN
Male	159,178	159,178	99.9%	0	NaN	0	NaN	0	NaN	0	NaN
sotorasib	**2,597**	**559**	**100.0%**	**813**	**100.0%**	**922**	**100.0%**	**224**	**100.0%**	**79**	**100.0%**
Female	1,596	349	62.4%	521	64.1%	537	58.2%	139	62.1%	50	63.3%

Table 3c. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Male	1,001	210	37.6%	292	35.9%	385	41.8%	85	37.9%	29	36.7%
infigratinib	**36**	*****	*****	**14**	**100.0%**	*****	*****	*****	*****	**0**	**NaN**
Female	22	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
Male	14	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
olanzapine and samidorphan	**12,692**	**3,467**	**100.0%**	**2,742**	**100.0%**	**3,896**	**100.0%**	**1,839**	**100.0%**	**748**	**100.0%**
Female	7,092	2,078	59.9%	1,573	57.4%	2,178	55.9%	927	50.4%	336	44.9%
Male	5,600	1,389	40.1%	1,169	42.6%	1,718	44.1%	912	49.6%	412	55.1%
ibrexafungerp	**2,617**	**2,543**	**100.0%**	**55**	**100.0%**	**19**	**100.0%**	**0**	**NaN**	**0**	**NaN**
Female	2,606	*****	*****	55	100.0%	*****	*****	0	NaN	0	NaN
Male	11	*****	*****	0	0.0%	*****	*****	0	NaN	0	NaN
aducanumab-avwa	**458**	*****	*****	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**
Female	252	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	206	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
asparaginase erwinia chrysanthemi (recombinant)-rywn	**280**	**250**	**100.0%**	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**
Female	94	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
Male	186	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*NaN: Not a number

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
vericiguat	**9,873**	**1**	**60**	**150**	**354**	**1,499**	**244.9**	**255.9**
Female	3,439	1	60	149	347	1,499	243.7	257.0
Male	6,434	1	60	150	358	1,366	245.6	255.4
cabotegravir	**14,260**	**1**	**4**	**19**	**180**	**1,438**	**142.8**	**234.3**
Female	2,383	1	6	58	240	1,273	172.7	245.0
Male	11,877	1	4	14	169	1,438	136.8	231.6
voclosporin	**945**	**1**	**51**	**120**	**270**	**1,290**	**205.5**	**234.3**
Female	810	1	46	101	245	1,290	189.8	219.9
Male	135	12	65	180	431	1,290	299.3	290.5
tepotinib	**476**	**6**	**42**	**90**	**210**	**1,061**	**158.1**	**169.6**
Female	298	6	49	90	240	1,061	170.3	189.0
Male	178	6	30	90	186	739	137.5	128.6
umbralisib	**79**	**3**	**30**	**87**	**150**	**330**	**101.0**	**72.6**
Female	37	25	54	60	180	300	106.8	76.2
Male	42	3	30	90	150	330	95.9	69.9
evinacumab-dgnb	**139**	**1**	**4**	**11**	**26**	**1,323**	**64.4**	**189.3**
Female	108	1	5	11	26	1,323	73.2	209.1
Male	31	1	3	11	30	484	33.9	87.6
trilacicilib	**2,028**	**1**	**6**	**9**	**12**	**180**	**10.0**	**9.3**
Female	1,065	1	6	9	12	180	10.3	9.7
Male	963	1	5	9	12	162	9.8	8.8
casimersen	**143**	**1**	**7**	**40**	**116**	**1,136**	**109.3**	**203.7**
Female	*****	1	1	1	1	1	1.0	NaN
Male	*****	1	8	42	116	1,136	110.0	204.2

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
fosdenopterin	*****	**61**	**61**	**64**	**67**	**67**	**64.0**	**4.2**
Female	*****	61	61	61	61	61	61.0	NaN
Male	*****	67	67	67	67	67	67.0	NaN
melphalan flufenamide	**100**	**1**	**1**	**2**	**3**	**140**	**5.3**	**16.5**
Female	53	1	1	1	3	140	5.8	20.3
Male	47	1	1	2	3	56	4.7	11.1
tivozanib	**1,550**	**1**	**47**	**84**	**140**	**1,199**	**129.9**	**144.5**
Female	416	1	51	84	140	1,199	126.0	138.5
Male	1,134	4	47	84	140	1,064	131.3	146.6
ponesimod	**181**	**1**	**104**	**230**	**528**	**1,200**	**343.9**	**301.8**
Female	138	1	91	210	493	1,200	324.9	305.6
Male	43	12	166	379	622	1,122	404.9	284.3
dasiglucagon	**1,399**	**1**	**1**	**10**	**30**	**791**	**33.2**	**62.4**
Female	756	1	2	13	30	791	34.6	67.9
Male	643	1	1	8	30	559	31.6	55.1
viloxazine	**37,791**	**1**	**30**	**60**	**150**	**1,338**	**128.7**	**163.4**
Female	16,622	1	30	60	148	1,255	119.7	151.3
Male	21,169	1	30	60	158	1,338	135.8	172.0
drospirenone and estetrol	**13,397**	**1**	**60**	**134**	**266**	**1,354**	**194.1**	**184.9**
Female	13,375	1	61	134	266	1,354	194.1	184.9
Male	22	9	28	140	252	681	178.9	175.4
dostarlimab-gxly	**2,701**	**1**	**3**	**5**	**8**	**252**	**7.1**	**14.7**
Female	2,534	1	3	5	8	252	7.0	14.3
Male	167	1	3	6	8	189	8.7	20.1

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
loncastuximab tesirine-lpyl	**806**	**1**	**2**	**3**	**6**	**442**	**5.5**	**19.9**
Female	345	1	2	3	5	295	5.4	17.1
Male	461	1	1	3	6	442	5.6	21.7
serdexmethylphenidate and dexmethylphenidate	**31,666**	**1**	**30**	**90**	**188**	**1,186**	**138.7**	**146.4**
Female	14,864	1	30	69	178	1,169	127.9	137.4
Male	16,802	1	30	90	210	1,186	148.2	153.4
pegcetacoplan	**32,242**	**1**	**2**	**5**	**7**	**1,424**	**7.5**	**38.1**
Female	21,919	1	2	5	7	1,424	7.2	34.4
Male	10,323	1	2	5	7	1,252	8.3	44.9
amivantamab-vmjw	**1,419**	**1**	**4**	**7**	**12**	**642**	**12.4**	**29.5**
Female	948	1	4	7	13	642	13.3	31.7
Male	471	1	4	7	10	420	10.6	24.5
piflufolastat F 18	**159,348**	**1**	**1**	**1**	**1**	**10**	**1.2**	**0.6**
Female	170	1	1	1	1	2	1.0	0.2
Male	159,178	1	1	1	1	10	1.2	0.6
sotorasib	**2,597**	**3**	**51**	**90**	**208**	**1,245**	**167.9**	**199.3**
Female	1,596	3	49	90	205	1,245	166.8	199.9
Male	1,001	3	54	90	210	1,241	169.7	198.5
infigratinib	**36**	**10**	**53**	**84**	**140**	**448**	**98.6**	**79.1**
Female	22	10	28	80	140	168	84.3	52.8
Male	14	28	56	84	168	448	121.1	107.1

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
olanzapine and samidorphan	**12,692**	**1**	**30**	**100**	**300**	**1,189**	**214.0**	**246.3**
Female	7,092	1	30	90	270	1,189	195.8	231.6
Male	5,600	1	32	120	353	1,162	237.0	262.1
ibrexafungerp	**2,617**	**1**	**1**	**1**	**2**	**356**	**4.6**	**18.2**
Female	2,606	1	1	1	2	356	4.5	17.1
Male	11	1	1	2	4	319	39.1	96.9
aducanumab-avwa	**458**	**1**	**2**	**4**	**8**	**215**	**6.6**	**11.9**
Female	252	1	2	3	7	215	6.6	14.7
Male	206	1	2	4	8	36	6.7	7.2
asparaginase erwinia chrysanthemi (recombinant)-rywn	**280**	**1**	**5**	**10**	**24**	**112**	**15.0**	**14.9**
Female	94	1	4	6	22	90	13.0	13.6
Male	186	1	6	12	25	112	16.0	15.5

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*NaN: Not a number

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

| | Total Number of Patients | Number of Patients by Cumulative Treatment Episode Duration | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
vericiguat	**9,873**	**1,748**	**100.0%**	**2,170**	**100.0%**	**3,637**	**100.0%**	**1,660**	**100.0%**	**658**	**100.0%**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	12	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	123	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	1,819	312	17.8%	430	19.8%	677	18.6%	*****	*****	*****	*****
≥ 65 years	7,919	1,408	80.5%	1,708	78.7%	2,901	79.8%	1,350	81.3%	552	83.9%
cabotegravir	**14,260**	**7,956**	**100.0%**	**1,480**	**100.0%**	**2,789**	**100.0%**	**1,421**	**100.0%**	**614**	**100.0%**
0-17 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	77	2.8%	*****	*****	*****	*****
25-40 years	5,317	3,737	47.0%	476	32.2%	810	29.0%	*****	*****	*****	*****
41-64 years	6,453	3,345	42.0%	672	45.4%	1,291	46.3%	765	53.8%	380	61.9%
≥ 65 years	1,980	517	6.5%	274	18.5%	611	21.9%	407	28.6%	171	27.9%
voclosporin	**945**	**198**	**100.0%**	**232**	**100.0%**	**353**	**100.0%**	**111**	**100.0%**	**51**	**100.0%**
0-17 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	128	*****	*****	*****	*****	54	15.3%	*****	*****	*****	*****
25-40 years	472	108	54.5%	127	54.7%	169	47.9%	*****	*****	*****	*****
41-64 years	296	53	26.8%	72	31.0%	106	30.0%	38	34.2%	27	52.9%
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
tepotinib	**476**	**114**	**100.0%**	**126**	**100.0%**	**193**	**100.0%**	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

| | Total Number of Patients | Number of Patients by Cumulative Treatment Episode Duration | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
41-64 years	*****	*****	*****	21	16.7%	*****	*****	*****	*****	0	0.0%
≥ 65 years	417	102	89.5%	105	83.3%	174	90.2%	*****	*****	*****	*****
umbralisib	**79**	**20**	**100.0%**	**27**	**100.0%**	**32**	**100.0%**	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	13	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	66	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
evinacumab-dgnb	**139**	**111**	**100.0%**	**15**	**100.0%**	*****	*****	*****	*****	*****	*****
0-17 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	49	35	31.5%	*****	*****	0	0.0%	*****	*****	*****	*****
≥ 65 years	68	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
trilacicilib	**2,028**	**1,995**	**100.0%**	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
≥ 65 years	1,741	1,710	85.7%	*****	*****	*****	*****	0	NaN	0	NaN
casimersen	**143**	**68**	**100.0%**	*****	*****	**36**	**100.0%**	*****	*****	*****	*****
0-17 years	103	54	79.4%	*****	*****	*****	*****	*****	*****	0	0.0%

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

| | | Number of Patients by Cumulative Treatment Episode Duration | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
18-24 years	26	*****	*****	*****	*****	12	33.3%	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 65 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
fosdenopterin	*********	**0**	**NaN**	*********	*********	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	*****	0	NaN	*****	*****	0	NaN	0	NaN	0	NaN
18-24 years	0	0	NaN	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	0	0	NaN	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	0	0	NaN	0	0.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	0	0	NaN	0	0.0%	0	NaN	0	NaN	0	NaN
melphalan flufenamide	**100**	*********	*********	*********	*********	*********	*********	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
tivozanib	**1,550**	**343**	**100.0%**	**522**	**100.0%**	**595**	**100.0%**	**72**	**100.0%**	**18**	**100.0%**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	318	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	1,220	255	74.3%	410	78.5%	481	80.8%	*****	*****	*****	*****

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

| | | Number of Patients by Cumulative Treatment Episode Duration | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
ponesimod	**181**	**19**	**100.0%**	**23**	**100.0%**	**71**	**100.0%**	**45**	**100.0%**	**23**	**100.0%**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	0	0.0%	*****	*****	*****	*****	0	0.0%
25-40 years	53	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	108	*****	*****	*****	*****	40	56.3%	28	62.2%	*****	*****
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
dasiglucagon	**1,399**	**1,068**	**100.0%**	**233**	**100.0%**	*****	*****	*****	*****	*****	*****
0-17 years	200	141	13.2%	40	17.2%	*****	*****	*****	*****	0	0.0%
18-24 years	122	87	8.1%	20	8.6%	15	16.7%	0	0.0%	0	0.0%
25-40 years	220	160	15.0%	42	18.0%	*****	*****	*****	*****	*****	*****
41-64 years	470	351	32.9%	85	36.5%	*****	*****	*****	*****	0	0.0%
≥ 65 years	387	329	30.8%	46	19.7%	*****	*****	*****	*****	0	0.0%
viloxazine	**37,791**	**13,554**	**100.0%**	**10,539**	**100.0%**	**10,529**	**100.0%**	**2,607**	**100.0%**	**562**	**100.0%**
0-17 years	21,640	6,813	50.3%	6,096	57.8%	6,453	61.3%	1,802	69.1%	476	84.7%
18-24 years	3,854	1,473	10.9%	1,061	10.1%	1,069	10.2%	*****	*****	*****	*****
25-40 years	6,852	2,935	21.7%	1,896	18.0%	1,698	16.1%	296	11.4%	27	4.8%
41-64 years	4,824	2,026	14.9%	1,350	12.8%	1,170	11.1%	248	9.5%	30	5.3%
≥ 65 years	621	307	2.3%	136	1.3%	139	1.3%	*****	*****	*****	*****
drospirenone and estetrol	**13,397**	**1,805**	**100.0%**	**3,852**	**100.0%**	**5,761**	**100.0%**	**1,691**	**100.0%**	**288**	**100.0%**
0-17 years	1,358	*****	*****	*****	*****	*****	*****	*****	*****	47	16.3%
18-24 years	4,110	529	29.3%	1,130	29.3%	1,782	30.9%	590	34.9%	79	27.4%
25-40 years	5,877	814	45.1%	1,753	45.5%	2,565	44.5%	640	37.8%	105	36.5%

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

		Number of Patients by Cumulative Treatment Episode Duration								
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
41-64 years	2,040	280	15.5%	591	15.3%	870	15.1%	242	14.3%	57	19.8%
≥ 65 years	12	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
dostarlimab-gxly	**2,701**	**2,667**	**100.0%**	**14**	**100.0%**	**20**	**100.0%**	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	476	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
≥ 65 years	2,186	*****	*****	*****	*****	20	100.0%	0	NaN	0	NaN
loncastuximab tesirine-lpyl	**806**	*****	*****	*****	*****	*****	*****	*****	*****	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
41-64 years	80	*****	*****	0	0.0%	0	0.0%	*****	*****	0	NaN
≥ 65 years	714	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
serdexmethylphenidate and dexmethylphenidate	**31,666**	**9,697**	**100.0%**	**8,153**	**100.0%**	**11,137**	**100.0%**	**2,488**	**100.0%**	**191**	**100.0%**
0-17 years	16,119	4,368	45.0%	4,048	49.7%	6,099	54.8%	1,464	58.8%	140	73.3%
18-24 years	3,712	1,324	13.7%	966	11.8%	1,196	10.7%	*****	*****	*****	*****
25-40 years	6,718	2,321	23.9%	1,802	22.1%	2,177	19.5%	392	15.8%	26	13.6%
41-64 years	4,759	1,551	16.0%	1,252	15.4%	1,559	14.0%	383	15.4%	14	7.3%
≥ 65 years	358	133	1.4%	85	1.0%	106	1.0%	*****	*****	*****	*****
pegcetacoplan	**32,242**	**32,028**	**100.0%**	**67**	**100.0%**	**77**	**100.0%**	**38**	**100.0%**	**32**	**100.0%**

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

| | | Number of Patients by Cumulative Treatment Episode Duration | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	0	0.0%	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	287	*****	*****	*****	*****	21	27.3%	*****	*****	*****	*****
≥ 65 years	31,913	31,779	99.2%	56	83.6%	42	54.5%	21	55.3%	15	46.9%
amivantamab-vmjw	**1,419**	**1,331**	**100.0%**	*****	*****	*****	*****	*****	*****	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
41-64 years	*****	*****	*****	*****	*****	0	0.0%	*****	*****	0	NaN
≥ 65 years	1,121	1,041	78.2%	*****	*****	*****	*****	*****	*****	0	NaN
piflufolastat F 18	**159,348**	**159,348**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	11,728	11,728	7.4%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	147,604	147,604	92.6%	0	NaN	0	NaN	0	NaN	0	NaN
sotorasib	**2,597**	**559**	**100.0%**	**813**	**100.0%**	**922**	**100.0%**	**224**	**100.0%**	**79**	**100.0%**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	*****	*****	*****	*****	*****	*****	*****	34	15.2%	11	13.9%

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

| | | Number of Patients by Cumulative Treatment Episode Duration | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
≥ 65 years	1,994	428	76.6%	613	75.4%	695	75.4%	190	84.8%	68	86.1%
infigratinib	**36**	*********	*********	**14**	**100.0%**	*********	*********	*********	*********	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	0	0.0%	*****	*****	*****	*****	*****	*****	0	NaN
41-64 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	23	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
olanzapine and samidorphan	**12,692**	**3,467**	**100.0%**	**2,742**	**100.0%**	**3,896**	**100.0%**	**1,839**	**100.0%**	**748**	**100.0%**
0-17 years	86	30	0.9%	*****	*****	28	0.7%	*****	*****	*****	*****
18-24 years	933	262	7.6%	*****	*****	296	7.6%	*****	*****	*****	*****
25-40 years	4,267	1,136	32.8%	937	34.2%	1,288	33.1%	652	35.5%	254	34.0%
41-64 years	6,174	1,657	47.8%	1,280	46.7%	1,924	49.4%	906	49.3%	407	54.4%
≥ 65 years	1,232	382	11.0%	274	10.0%	360	9.2%	158	8.6%	58	7.8%
ibrexafungerp	**2,617**	**2,543**	**100.0%**	**55**	**100.0%**	**19**	**100.0%**	**0**	**NaN**	**0**	**NaN**
0-17 years	19	19	0.7%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	427	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
25-40 years	1,256	1,222	48.1%	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	883	854	33.6%	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	32	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
aducanumab-avwa	**458**	*********	*********	*********	*********	*********	*********	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

| | | Number of Patients by Cumulative Treatment Episode Duration | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
≥ 65 years	436	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
asparaginase erwinia chrysanthemi (recombinant)-rywn	280	250	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	203	179	71.6%	*****	*****	*****	*****	0	NaN	0	NaN
18-24 years	32	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
≥ 65 years	15	15	6.0%	0	0.0%	0	0.0%	0	NaN	0	NaN

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a number

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
vericiguat	**9,873**	**1**	**60**	**150**	**354**	**1,499**	**244.9**	**255.9**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	12	30	62	114	191	319	131.8	85.0
25-40 years	123	4	37	108	256	998	175.3	194.4
41-64 years	1,819	1	60	135	337	1,350	232.9	243.4
≥ 65 years	7,919	1	60	150	360	1,499	249.0	259.5
cabotegravir	**14,260**	**1**	**4**	**19**	**180**	**1,438**	**142.8**	**234.3**
0-17 years	*****	1	2	4	60	60	23.3	27.6
18-24 years	*****	1	3	7	60	1,015	63.2	133.0
25-40 years	5,317	1	3	7	61	1,177	72.4	149.5
41-64 years	6,453	1	5	30	232	1,438	168.6	257.9
≥ 65 years	1,980	1	30	169	424	1,423	268.2	285.0
voclosporin	**945**	**1**	**51**	**120**	**270**	**1,290**	**205.5**	**234.3**
0-17 years	*****	30	45	90	217	313	130.8	127.1
18-24 years	128	11	47	120	270	1,080	202.0	213.6
25-40 years	472	2	40	93	240	1,097	184.1	210.6
41-64 years	296	1	60	120	317	1,290	240.1	273.6
≥ 65 years	*****	11	60	150	273	1,191	219.3	233.2
tepotinib	**476**	**6**	**42**	**90**	**210**	**1,061**	**158.1**	**169.6**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	30	30	75	120	120	75.0	63.6
41-64 years	*****	12	53	90	300	660	173.4	168.9
≥ 65 years	417	6	37	94	208	1,061	156.4	170.0

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
umbralisib	**79**	**3**	**30**	**87**	**150**	**330**	**101.0**	**72.6**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	13	30	54	60	120	153	82.8	48.3
≥ 65 years	66	3	30	90	150	330	104.5	76.3
evinacumab-dgnb	**139**	**1**	**4**	**11**	**26**	**1,323**	**64.4**	**189.3**
0-17 years	*****	2	8	9	9	41	13.8	15.5
18-24 years	*****	2	2	11	19	19	10.5	12.0
25-40 years	*****	1	2	13	30	141	23.4	35.6
41-64 years	49	1	5	16	36	952	98.1	229.1
≥ 65 years	68	1	5	9	22	1,323	54.5	185.3
trilacicilib	**2,028**	**1**	**6**	**9**	**12**	**180**	**10.0**	**9.3**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	3	3	9	15	15	9.0	8.5
41-64 years	*****	1	5	9	12	63	8.8	6.1
≥ 65 years	1,741	1	6	9	12	180	10.2	9.7
casimersen	**143**	**1**	**7**	**40**	**116**	**1,136**	**109.3**	**203.7**
0-17 years	103	2	7	26	87	606	68.5	98.9
18-24 years	26	1	22	116	164	1,119	175.5	277.2
25-40 years	*****	1	4	58	637	1,136	308.2	424.7
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	*****	1	1	1	1	1	1.0	NaN

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
fosdenopterin	*****	**61**	**61**	**64**	**67**	**67**	**64.0**	**4.2**
0-17 years	*****	61	61	64	67	67	64.0	4.2
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
melphalan flufenamide	**100**	**1**	**1**	**2**	**3**	**140**	**5.3**	**16.5**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	17	1	1	2	3	5	2.2	1.1
≥ 65 years	83	1	1	2	3	140	5.9	18.1
tivozanib	**1,550**	**1**	**47**	**84**	**140**	**1,199**	**129.9**	**144.5**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	65	65	65	65	65	65.0	NaN
25-40 years	*****	10	26	34	84	224	63.5	62.6
41-64 years	318	5	28	84	140	874	117.0	132.2
≥ 65 years	1,220	1	53	84	161	1,199	133.9	147.8
ponesimod	**181**	**1**	**104**	**230**	**528**	**1,200**	**343.9**	**301.8**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	14	59	221	456	574	257.3	251.2
25-40 years	53	30	91	214	450	1,200	285.0	243.2
41-64 years	108	1	104	276	592	1,192	361.1	313.2
≥ 65 years	*****	14	97	356	765	1,107	444.8	385.6

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
dasiglucagon	**1,399**	**1**	**1**	**10**	**30**	**791**	**33.2**	**62.4**
0-17 years	200	1	2	21	48	384	39.6	64.7
18-24 years	122	1	2	24	56	330	38.8	58.1
25-40 years	220	1	2	28	32	791	41.7	85.3
41-64 years	470	1	1	6	31	559	33.7	63.6
≥ 65 years	387	1	1	2	30	367	22.7	40.5
viloxazine	**37,791**	**1**	**30**	**60**	**150**	**1,338**	**128.7**	**163.4**
0-17 years	21,640	1	30	67	178	1,338	145.1	182.3
18-24 years	3,854	2	30	60	150	1,255	116.9	139.1
25-40 years	6,852	1	30	60	120	975	101.4	122.6
41-64 years	4,824	1	30	60	120	975	106.9	134.3
≥ 65 years	621	1	30	33	120	923	102.6	134.5
drospirenone and estetrol	**13,397**	**1**	**60**	**134**	**266**	**1,354**	**194.1**	**184.9**
0-17 years	1,358	1	58	140	336	1,266	218.5	212.8
18-24 years	4,110	1	69	140	280	1,156	200.2	183.3
25-40 years	5,877	1	57	121	252	1,354	184.1	176.2
41-64 years	2,040	1	58	133	255	1,127	194.9	190.7
≥ 65 years	12	24	28	84	84	560	107.0	148.8
dostarlimab-gxly	**2,701**	**1**	**3**	**5**	**8**	**252**	**7.1**	**14.7**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	5	5	7	8	8	6.5	2.1
25-40 years	*****	1	2	5	8	12	5.3	3.5
41-64 years	476	1	2	5	8	42	5.6	4.5
≥ 65 years	2,186	1	3	5	8	252	7.5	16.2

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
loncastuximab tesirine-lpyl	**806**	**1**	**2**	**3**	**6**	**442**	**5.5**	**19.9**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	3	3	5	6	6	4.5	2.1
25-40 years	*****	1	1	3	6	10	3.6	2.9
41-64 years	80	1	1	2	4	442	9.0	49.1
≥ 65 years	714	1	2	3	6	295	5.1	13.3
serdexmethylphenidate and dexmethylphenidate	**31,666**	**1**	**30**	**90**	**188**	**1,186**	**138.7**	**146.4**
0-17 years	16,119	1	30	90	210	1,186	151.8	155.5
18-24 years	3,712	1	30	60	159	1,021	120.8	132.0
25-40 years	6,718	1	30	60	150	1,020	120.7	130.7
41-64 years	4,759	1	30	73	180	948	134.0	141.6
≥ 65 years	358	1	30	60	180	822	136.3	153.0
pegcetacoplan	**32,242**	**1**	**2**	**5**	**7**	**1,424**	**7.5**	**38.1**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	56	82	252	486	813	314.0	265.6
25-40 years	*****	4	56	150	560	1,095	309.3	339.5
41-64 years	287	1	2	4	9	1,152	70.9	198.2
≥ 65 years	31,913	1	2	5	7	1,424	6.6	28.7
amivantamab-vmjw	**1,419**	**1**	**4**	**7**	**12**	**642**	**12.4**	**29.5**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	16	1	2	5	7	10	4.9	3.0
41-64 years	282	1	4	7	10	642	11.1	38.8

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	1,121	1	4	7	13	441	12.8	26.9
piflufolastat F 18	**159,348**	**1**	**1**	**1**	**1**	**10**	**1.2**	**0.6**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	NaN
25-40 years	*****	1	1	1	1	2	1.1	0.3
41-64 years	11,728	1	1	1	1	7	1.2	0.5
≥ 65 years	147,604	1	1	1	1	10	1.2	0.6
sotorasib	**2,597**	**3**	**51**	**90**	**208**	**1,245**	**167.9**	**199.3**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	22	38	83	162	240	103.4	77.9
41-64 years	*****	3	45	90	172	1,126	143.4	171.2
≥ 65 years	1,994	3	55	90	210	1,245	175.5	206.8
infigratinib	**36**	**10**	**53**	**84**	**140**	**448**	**98.6**	**79.1**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	56	56	168	448	448	224.0	201.9
41-64 years	*****	10	84	95	140	168	95.6	49.3
≥ 65 years	23	18	28	75	112	196	83.6	53.6
olanzapine and samidorphan	**12,692**	**1**	**30**	**100**	**300**	**1,189**	**214.0**	**246.3**
0-17 years	86	2	30	60	180	1,090	132.2	169.8
18-24 years	933	1	30	90	243	1,135	180.0	208.7
25-40 years	4,267	1	30	103	321	1,162	218.8	249.8
41-64 years	6,174	1	30	115	320	1,189	221.0	252.4

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	1,232	1	30	90	270	1,140	193.3	229.7
ibrexafungerp	**2,617**	**1**	**1**	**1**	**2**	**356**	**4.6**	**18.2**
0-17 years	19	1	1	1	2	30	3.2	6.6
18-24 years	427	1	1	1	2	114	3.1	8.2
25-40 years	1,256	1	1	1	2	356	4.6	16.7
41-64 years	883	1	1	1	2	342	5.4	22.7
≥ 65 years	32	1	1	1	2	180	7.8	31.9
aducanumab-avwa	**458**	**1**	**2**	**4**	**8**	**215**	**6.6**	**11.9**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	*****	1	1	3	8	33	5.9	7.3
≥ 65 years	436	1	2	4	8	215	6.7	12.1
asparaginase erwinia chrysanthemi (recombinant)-rywn	**280**	**1**	**5**	**10**	**24**	**112**	**15.0**	**14.9**
0-17 years	203	1	6	12	25	112	16.1	15.7
18-24 years	32	1	5	9	23	41	13.8	11.5
25-40 years	22	1	4	13	23	57	15.4	14.0
41-64 years	*****	1	1	3	7	28	6.3	9.2
≥ 65 years	*****	1	1	2	8	24	5.9	8.3

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*NaN: Not a number

Table 4a. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

		Number of Treatment Episodes by Duration								
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
vericiguat	25,759	12,029	46.7%	8,129	31.6%	4,515	17.5%	866	3.4%	220	0.9%
cabotegravir	67,155	53,233	79.3%	8,641	12.9%	4,612	6.9%	564	0.8%	105	0.2%
voclosporin	3,051	1,819	59.6%	820	26.9%	370	12.1%	*****	*****	*****	*****
tepotinib	1,097	622	56.7%	290	26.4%	170	15.5%	*****	*****	*****	*****
umbralisib	134	78	58.2%	36	26.9%	20	14.9%	0	0.0%	0	0.0%
evinacumab-dgnb	1,737	1,691	97.4%	*****	*****	*****	*****	*****	*****	*****	*****
trilacicilib	7,087	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
casimersen	2,176	2,077	95.5%	49	2.3%	*****	*****	*****	*****	0	0.0%
fosdenopterin	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
melphalan flufenamide	225	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
tivozanib	3,372	1,885	55.9%	962	28.5%	500	14.8%	25	0.7%	0	0.0%
ponesimod	588	292	49.7%	147	25.0%	114	19.4%	*****	*****	*****	*****
dasiglucagon	2,030	1,718	84.6%	250	12.3%	*****	*****	*****	*****	*****	*****
viloxazine	78,736	49,342	62.7%	19,702	25.0%	8,433	10.7%	1,054	1.3%	205	0.3%
drospirenone and estetrol	25,172	8,275	32.9%	9,953	39.5%	5,992	23.8%	853	3.4%	99	0.4%
dostarlimab-gxly	15,488	15,448	99.7%	28	0.2%	12	0.1%	0	0.0%	0	0.0%
loncastuximab tesirine-lpyl	3,367	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
serdexmethylphenidate and dexmethylphenidate	94,565	71,012	75.1%	17,425	18.4%	5,617	5.9%	470	0.5%	41	0.0%
pegcetacoplan	172,157	171,809	99.8%	179	0.1%	124	0.1%	33	0.0%	12	0.0%
amivantamab-vmjw	13,047	13,021	99.8%	15	0.1%	11	0.1%	0	0.0%	0	0.0%
piflufolastat F 18	193,162	193,162	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%

Table 4a. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	Total Number of Episodes	Number of Treatment Episodes by Duration								
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
sotorasib	5,637	2,962	52.5%	1,592	28.2%	958	17.0%	102	1.8%	23	0.4%
infigratinib	58	23	39.7%	*****	*****	*****	*****	0	0.0%	0	0.0%
olanzapine and samidorphan	30,475	16,543	54.3%	7,749	25.4%	4,790	15.7%	1,084	3.6%	309	1.0%
ibrexafungerp	3,992	3,943	98.8%	37	0.9%	12	0.3%	0	0.0%	0	0.0%
aducanumab-avwa	2,817	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
asparaginase erwinia chrysanthemi (recombinant)-rywn	4,055	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 4b. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
vericiguat	25,759	1	30	51	90	1,499	93.9	130.7
cabotegravir	67,155	1	1	1	30	1,318	30.3	74.0
voclosporin	3,051	1	30	30	60	1,050	63.6	81.1
tepotinib	1,097	1	30	30	79	780	68.6	84.9
umbralisib	134	3	30	30	90	270	59.5	48.4
evinacumab-dgnb	1,737	1	1	1	1	1,323	5.2	42.2
trilacicilib	7,087	1	3	3	3	84	2.9	1.7
casimersen	2,176	1	1	1	1	497	7.2	31.5
fosdenopterin	*****	28	28	33	67	67	42.7	21.2
melphalan flufenamide	225	1	1	1	1	140	2.3	10.9
tivozanib	3,372	1	28	28	64	726	59.7	63.8
ponesimod	588	1	30	42	102	1,162	105.9	157.8
dasiglucagon	2,030	1	1	2	30	791	22.9	41.3
viloxazine	78,736	1	30	30	60	1,296	61.8	84.5
drospirenone and estetrol	25,172	1	28	84	112	1,188	103.3	114.4
dostarlimab-gxly	15,488	1	1	1	1	210	1.2	4.7
loncastuximab tesirine-lpyl	3,367	1	1	1	1	147	1.3	4.3
serdexmethylphenidate and dexmethylphenidate	94,565	1	30	30	30	1,156	46.4	53.3
pegcetacoplan	172,157	1	1	1	1	1,424	1.4	12.6
amivantamab-vmjw	13,047	1	1	1	1	253	1.3	5.3
piflufolastat F 18	193,162	1	1	1	1	5	1.0	0.0
sotorasib	5,637	1	30	30	90	1,241	77.4	102.1
infigratinib	58	10	28	56	84	336	61.2	48.3
olanzapine and samidorphan	30,475	1	30	30	90	1,189	89.1	134.7

Table 4b. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
ibrexafungerp	3,992	1	1	1	1	356	3.0	12.5
aducanumab-avwa	2,817	1	1	1	1	155	1.1	3.1
asparaginase erwinia chrysanthemi (recombinant)-rywn	4,055	1	1	1	1	84	1.0	1.4

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
vericiguat	**25,759**	**12,029**	**100.0%**	**8,129**	**100.0%**	**4,515**	**100.0%**	**866**	**100.0%**	**220**	**100.0%**
Female	9,119	4,360	36.2%	2,814	34.6%	1,566	34.7%	303	35.0%	76	34.5%
Male	16,640	7,669	63.8%	5,315	65.4%	2,949	65.3%	563	65.0%	144	65.5%
cabotegravir	**67,155**	**53,233**	**100.0%**	**8,641**	**100.0%**	**4,612**	**100.0%**	**564**	**100.0%**	**105**	**100.0%**
Female	10,093	7,192	13.5%	1,854	21.5%	903	19.6%	122	21.6%	22	21.0%
Male	57,062	46,041	86.5%	6,787	78.5%	3,709	80.4%	442	78.4%	83	79.0%
voclosporin	**3,051**	**1,819**	**100.0%**	**820**	**100.0%**	**370**	**100.0%**	*****	*****	*****	*****
Female	2,525	1,527	83.9%	673	82.1%	299	80.8%	*****	*****	*****	*****
Male	526	292	16.1%	147	17.9%	71	19.2%	*****	*****	*****	*****
tepotinib	**1,097**	**622**	**100.0%**	**290**	**100.0%**	**170**	**100.0%**	*****	*****	*****	*****
Female	719	408	65.6%	191	65.9%	*****	*****	*****	*****	*****	*****
Male	378	214	34.4%	99	34.1%	*****	*****	*****	*****	0	0.0%
umbralisib	**134**	**78**	**100.0%**	**36**	**100.0%**	**20**	**100.0%**	**0**	**NaN**	**0**	**NaN**
Female	64	36	46.2%	*****	*****	*****	*****	0	NaN	0	NaN
Male	70	42	53.8%	*****	*****	*****	*****	0	NaN	0	NaN
evinacumab-dgnb	**1,737**	**1,691**	**100.0%**	*****	*****	*****	*****	*****	*****	*****	*****
Female	1,325	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Male	412	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
trilacicilib	**7,087**	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	3,808	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	3,279	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
casimersen	**2,176**	**2,077**	**100.0%**	**49**	**100.0%**	*****	*****	*****	*****	**0**	**NaN**
Female	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Male	*****	*****	*****	49	100.0%	*****	*****	*****	*****	0	NaN
fosdenopterin	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	*****	0	0.0%	*****	*****	0	NaN	0	NaN	0	NaN
flufenamide	225	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Female	115	*****	*****	0	0.0%	*****	*****	0	NaN	0	NaN
Male	110	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
tivozanib	3,372	1,885	100.0%	962	100.0%	500	100.0%	25	100.0%	0	NaN
Female	904	512	27.2%	253	26.3%	*****	*****	*****	*****	0	NaN
Male	2,468	1,373	72.8%	709	73.7%	*****	*****	*****	*****	0	NaN
ponesimod	588	292	100.0%	147	100.0%	114	*****	*****	*****	*****	*****
Female	427	214	73.3%	109	74.1%	*****	*****	*****	*****	*****	*****
Male	161	78	26.7%	38	25.9%	*****	*****	*****	*****	*****	*****
dasiglucagon	2,030	1,718	100.0%	250	100.0%	*****	*****	*****	*****	*****	*****
Female	1,142	980	57.0%	126	50.4%	*****	*****	*****	*****	*****	*****
Male	888	738	43.0%	124	49.6%	26	44.1%	0	0.0%	0	0.0%
viloxazine	78,736	49,342	100.0%	19,702	100.0%	8,433	100.0%	1,054	100.0%	205	100.0%
Female	33,616	21,455	43.5%	8,266	42.0%	3,455	41.0%	391	37.1%	49	23.9%
Male	45,120	27,887	56.5%	11,436	58.0%	4,978	59.0%	663	62.9%	156	76.1%
estetrol	25,172	8,275	100.0%	9,953	100.0%	5,992	100.0%	853	100.0%	99	100.0%
Female	25,127	8,256	99.8%	*****	*****	*****	*****	*****	*****	99	100.0%
Male	45	19	0.2%	*****	*****	*****	*****	*****	*****	0	0.0%
dostarlimab-gxly	15,488	15,448	100.0%	28	100.0%	12	100.0%	0	NaN	0	NaN

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

| | | Number of Treatment Episodes by Duration | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Female	14,445	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	1,043	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
tesirine-lpyl	3,367	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Female	1,446	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	1,921	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
serdexmethylphenidate and dexmethylphenidate	94,565	71,012	100.0%	17,425	100.0%	5,617	100.0%	470	100.0%	41	100.0%
Female	41,987	31,748	44.7%	7,685	44.1%	2,355	41.9%	187	39.8%	12	29.3%
Male	52,578	39,264	55.3%	9,740	55.9%	3,262	58.1%	283	60.2%	29	70.7%
pegcetacoplan	172,157	171,809	100.0%	179	100.0%	124	100.0%	33	100.0%	12	100.0%
Female	117,200	116,997	68.1%	105	58.7%	75	60.5%	*****	*****	*****	*****
Male	54,957	54,812	31.9%	74	41.3%	49	39.5%	*****	*****	*****	*****
amivantamab-vmjw	13,047	13,021	100.0%	15	100.0%	11	100.0%	0	NaN	0	NaN
Female	9,316	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	3,731	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
piflufolastat F 18	193,162	193,162	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	174	174	0.1%	0	NaN	0	NaN	0	NaN	0	NaN
Male	192,988	192,988	99.9%	0	NaN	0	NaN	0	NaN	0	NaN
sotorasib	5,637	2,962	100.0%	1,592	100.0%	958	100.0%	102	100.0%	23	100.0%
Female	3,539	1,871	63.2%	1,030	64.7%	564	58.9%	*****	*****	*****	*****
Male	2,098	1,091	36.8%	562	35.3%	394	41.1%	*****	*****	*****	*****
infigratinib	58	*****	*****	29	100.0%	*****	*****	0	NaN	0	NaN

		Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Female	33	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	25	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
olanzapine and samidorphan	**30,475**	**16,543**	**100.0%**	**7,749**	**100.0%**	**4,790**	**100.0%**	**1,084**	**100.0%**	**309**	**100.0%**
Female	16,538	9,216	55.7%	4,173	53.9%	2,478	51.7%	531	49.0%	140	45.3%
Male	13,937	7,327	44.3%	3,576	46.1%	2,312	48.3%	553	51.0%	169	54.7%
ibrexafungerp	**3,992**	**3,943**	**100.0%**	**37**	**100.0%**	**12**	**100.0%**	**0**	**NaN**	**0**	**NaN**
Female	3,977	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	15	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
aducanumab-avwa	**2,817**	*****	*****	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**
Female	1,440	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	1,377	1,377	48.9%	0	0.0%	0	0.0%	0	NaN	0	NaN
asparaginase erwinia chrysanthemi (recombinant)-rywn	**4,055**	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	1,217	1,217	30.0%	0	0.0%	0	NaN	0	NaN	0	NaN
Male	2,838	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*NaN: Not a number

Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
vericiguat	**25,759**	**1**	**30**	**51**	**90**	**1,499**	**93.9**	**130.7**
Female	9,119	1	30	44	90	1,499	91.9	130.6
Male	16,640	1	30	55	90	1,363	95.0	130.8
cabotegravir	**67,155**	**1**	**1**	**1**	**30**	**1,318**	**30.3**	**74.0**
Female	10,093	1	1	9	56	1,119	40.8	84.6
Male	57,062	1	1	1	30	1,318	28.5	71.8
voclosporin	**3,051**	**1**	**30**	**30**	**60**	**1,050**	**63.6**	**81.1**
Female	2,525	1	30	30	60	1,016	60.9	72.6
Male	526	9	30	30	90	1,050	76.8	112.8
tepotinib	**1,097**	**1**	**30**	**30**	**79**	**780**	**68.6**	**84.9**
Female	719	1	30	30	78	780	70.6	90.4
Male	378	1	30	30	90	649	64.8	73.1
umbralisib	**134**	**3**	**30**	**30**	**90**	**270**	**59.5**	**48.4**
Female	64	17	30	30	89	210	61.7	49.6
Male	70	3	30	30	90	270	57.5	47.5
evinacumab-dgnb	**1,737**	**1**	**1**	**1**	**1**	**1,323**	**5.2**	**42.2**
Female	1,325	1	1	1	1	1,323	6.0	48.0
Male	412	1	1	1	1	144	2.6	10.7
trilacicilib	**7,087**	**1**	**3**	**3**	**3**	**84**	**2.9**	**1.7**
Female	3,808	1	3	3	3	84	2.9	2.0
Male	3,279	1	3	3	3	63	2.9	1.3
casimersen	**2,176**	**1**	**1**	**1**	**1**	**497**	**7.2**	**31.5**
Female	*****	1	1	1	1	1	1.0	NaN
Male	*****	1	1	1	1	497	7.2	31.5
fosdenopterin	*****	**28**	**28**	**33**	**67**	**67**	**42.7**	**21.2**

Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Female	*****	28	28	31	33	33	30.5	3.5
Male	*****	67	67	67	67	67	67.0	NaN
melphalan flufenamide	**225**	**1**	**1**	**1**	**1**	**140**	**2.3**	**10.9**
Female	115	1	1	1	1	140	2.7	13.4
Male	110	1	1	1	1	56	2.0	7.4
tivozanib	**3,372**	**1**	**28**	**28**	**64**	**726**	**59.7**	**63.8**
Female	904	1	28	28	58	588	58.0	58.4
Male	2,468	1	28	28	67	726	60.3	65.7
ponesimod	**588**	**1**	**30**	**42**	**102**	**1,162**	**105.9**	**157.8**
Female	427	1	30	30	90	1,162	105.0	163.6
Male	161	5	30	44	120	791	108.1	141.9
dasiglucagon	**2,030**	**1**	**1**	**2**	**30**	**791**	**22.9**	**41.3**
Female	1,142	1	1	2	30	791	22.9	45.9
Male	888	1	1	3	30	360	22.9	34.5
viloxazine	**78,736**	**1**	**30**	**30**	**60**	**1,296**	**61.8**	**84.5**
Female	33,616	1	30	30	60	1,225	59.2	76.6
Male	45,120	1	30	30	60	1,296	63.7	89.9
drospirenone and estetrol	**25,172**	**1**	**28**	**84**	**112**	**1,188**	**103.3**	**114.4**
Female	25,127	1	28	84	112	1,188	103.3	114.4
Male	45	8	28	59	84	420	87.4	101.5
dostarlimab-gxly	**15,488**	**1**	**1**	**1**	**1**	**210**	**1.2**	**4.7**
Female	14,445	1	1	1	1	210	1.2	4.7
Male	1,043	1	1	1	1	126	1.4	5.5
loncastuximab tesirine-lpyl	**3,367**	**1**	**1**	**1**	**1**	**147**	**1.3**	**4.3**
Female	1,446	1	1	1	1	105	1.3	3.9

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Male	1,921	1	1	1	1	147	1.3	4.5
serdexmethylphenidate and dexmethylphenidate	**94,565**	**1**	**30**	**30**	**30**	**1,156**	**46.4**	**53.3**
Female	41,987	1	30	30	30	1,119	45.3	49.7
Male	52,578	1	30	30	36	1,156	47.4	56.0
pegcetacoplan	**172,157**	**1**	**1**	**1**	**1**	**1,424**	**1.4**	**12.6**
Female	117,200	1	1	1	1	1,424	1.3	11.2
Male	54,957	1	1	1	1	1,232	1.6	15.2
amivantamab-vmjw	**13,047**	**1**	**1**	**1**	**1**	**253**	**1.3**	**5.3**
Female	9,316	1	1	1	1	253	1.4	5.2
Male	3,731	1	1	1	1	224	1.3	5.4
piflufolastat F 18	**193,162**	**1**	**1**	**1**	**1**	**5**	**1.0**	**0.0**
Female	174	1	1	1	1	1	1.0	0.0
Male	192,988	1	1	1	1	5	1.0	0.0
sotorasib	**5,637**	**1**	**30**	**30**	**90**	**1,241**	**77.4**	**102.1**
Female	3,539	1	30	30	90	1,191	75.2	99.5
Male	2,098	1	30	30	90	1,241	81.0	106.3
infigratinib	**58**	**10**	**28**	**56**	**84**	**336**	**61.2**	**48.3**
Female	33	10	28	56	84	168	56.2	36.4
Male	25	28	28	56	84	336	67.8	60.8
olanzapine and samidorphan	**30,475**	**1**	**30**	**30**	**90**	**1,189**	**89.1**	**134.7**
Female	16,538	1	30	30	90	1,189	84.0	125.9
Male	13,937	1	30	30	90	1,162	95.2	144.2
ibrexafungerp	**3,992**	**1**	**1**	**1**	**1**	**356**	**3.0**	**12.5**
Female	3,977	1	1	1	1	356	2.9	11.8

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Male	15	1	1	1	4	261	28.7	69.7
aducanumab-avwa	**2,817**	**1**	**1**	**1**	**1**	**155**	**1.1**	**3.1**
Female	1,440	1	1	1	1	155	1.1	4.3
Male	1,377	1	1	1	1	1	1.0	0.0
asparaginase erwinia chrysanthemi (recombinant)-rywn	**4,055**	**1**	**1**	**1**	**1**	**84**	**1.0**	**1.4**
Female	1,217	1	1	1	1	2	1.0	0.0
Male	2,838	1	1	1	1	84	1.0	1.7

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*NaN: Not a number

		Number of Treatment Episodes by Duration								
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
vericiguat	**25,759**	**12,029**	**100.0%**	**8,129**	**100.0%**	**4,515**	**100.0%**	**866**	**100.0%**	**220**	**100.0%**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	20	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	326	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	4,993	2,410	20.0%	1,649	20.3%	768	17.0%	*****	*****	*****	*****
≥ 65 years	20,420	9,434	78.4%	6,365	78.3%	3,707	82.1%	723	83.5%	191	86.8%
cabotegravir	**67,155**	**53,233**	**100.0%**	**8,641**	**100.0%**	**4,612**	**100.0%**	**564**	**100.0%**	**105**	**100.0%**
0-17 years	23	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
18-24 years	2,108	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	24,473	21,864	41.1%	1,745	20.2%	*****	*****	*****	*****	*****	*****
41-64 years	32,043	24,645	46.3%	4,517	52.3%	2,488	53.9%	334	59.2%	59	56.2%
≥ 65 years	8,508	4,811	9.0%	2,228	25.8%	1,277	27.7%	*****	*****	*****	*****
voclosporin	**3,051**	**1,819**	**100.0%**	**820**	**100.0%**	**370**	**100.0%**	*****	*****	*****	*****
0-17 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	356	187	10.3%	113	13.8%	*****	*****	*****	*****	*****	*****
25-40 years	1,502	932	51.2%	398	48.5%	159	43.0%	*****	*****	*****	*****
41-64 years	1,044	613	33.7%	276	33.7%	134	36.2%	*****	*****	*****	*****
≥ 65 years	*****	*****	*****	*****	*****	27	7.3%	0	0.0%	*****	*****
tepotinib	**1,097**	**622**	**100.0%**	**290**	**100.0%**	**170**	**100.0%**	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
41-64 years	*****	*****	*****	37	12.8%	*****	*****	*****	*****	0	0.0%

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

| | Total Number of Episodes | Number of Treatment Episodes by Duration | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
≥ 65 years	962	547	87.9%	253	87.2%	*****	*****	*****	*****	*****	*****
umbralisib	**134**	**78**	**100.0%**	**36**	**100.0%**	**20**	**100.0%**	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	20	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	114	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
evinacumab-dgnb	**1,737**	**1,691**	**100.0%**	*****	*****	*****	*****	*****	*****	*****	*****
0-17 years	69	69	4.1%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	21	21	1.2%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	183	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
41-64 years	684	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
≥ 65 years	780	769	45.5%	*****	*****	*****	*****	0	0.0%	*****	*****
trilacicilib	**7,087**	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	18	18	0.3%	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	886	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	6,183	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
casimersen	**2,176**	**2,077**	**100.0%**	**49**	**100.0%**	*****	*****	*****	*****	**0**	**NaN**
0-17 years	1,664	1,622	78.1%	*****	*****	*****	*****	*****	*****	0	NaN
18-24 years	450	418	20.1%	17	34.7%	15	31.3%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
41-64 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN

	Total Number of Episodes	Number of Treatment Episodes by Duration								
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
≥ 65 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
fosdenopterin	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
melphalan flufenamide	225	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	37	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
≥ 65 years	188	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
tivozanib	3,372	1,885	100.0%	962	100.0%	500	100.0%	25	100.0%	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
41-64 years	620	341	18.1%	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	2,731	1,531	81.2%	778	80.9%	*****	*****	*****	*****	0	NaN
ponesimod	588	292	100.0%	147	100.0%	114	100.0%	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	11	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	174	98	33.6%	40	27.2%	*****	*****	*****	*****	*****	*****
41-64 years	369	175	59.9%	95	64.6%	78	68.4%	*****	*****	*****	*****

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

| | | Number of Treatment Episodes by Duration | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
≥ 65 years	34	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
dasiglucagon	**2,030**	**1,718**	**100.0%**	**250**	**100.0%**	*****	*****	*****	*****	*****	*****
0-17 years	403	342	19.9%	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	186	149	8.7%	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	309	250	14.6%	45	18.0%	*****	*****	0	0.0%	*****	*****
41-64 years	681	573	33.4%	85	34.0%	*****	*****	*****	*****	0	0.0%
≥ 65 years	451	404	23.5%	*****	*****	*****	*****	0	0.0%	0	0.0%
viloxazine	**78,736**	**49,342**	**100.0%**	**19,702**	**100.0%**	**8,433**	**100.0%**	**1,054**	**100.0%**	**205**	**100.0%**
0-17 years	48,923	30,100	61.0%	12,431	63.1%	5,491	65.1%	732	69.4%	169	82.4%
18-24 years	7,717	5,010	10.2%	1,874	9.5%	739	8.8%	*****	*****	*****	*****
25-40 years	12,289	7,988	16.2%	2,973	15.1%	1,192	14.1%	*****	*****	*****	*****
41-64 years	8,704	5,511	11.2%	2,195	11.1%	883	10.5%	101	9.6%	14	6.8%
≥ 65 years	1,103	733	1.5%	229	1.2%	128	1.5%	13	1.2%	0	0.0%
drospirenone and estetrol	**25,172**	**8,275**	**100.0%**	**9,953**	**100.0%**	**5,992**	**100.0%**	**853**	**100.0%**	**99**	**100.0%**
0-17 years	2,869	*****	*****	*****	*****	*****	*****	*****	*****	15	15.2%
18-24 years	8,068	2,726	32.9%	3,101	31.2%	1,946	32.5%	269	31.5%	26	26.3%
25-40 years	10,565	3,327	40.2%	4,363	43.8%	2,499	41.7%	344	40.3%	32	32.3%
41-64 years	3,658	1,170	14.1%	1,433	14.4%	902	15.1%	127	14.9%	26	26.3%
≥ 65 years	12	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
dostarlimab-gxly	**15,488**	**15,448**	**100.0%**	**28**	**100.0%**	**12**	**100.0%**	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	13	13	0.1%	0	0.0%	0	0.0%	0	NaN	0	NaN

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

| | | Number of Treatment Episodes by Duration | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
25-40 years	195	195	1.3%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	2,539	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
≥ 65 years	12,741	*****	*****	*****	*****	12	100.0%	0	NaN	0	NaN
loncastuximab tesirine-lpyl	**3,367**	*****	*****	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	34	34	1.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
serdexmethylphenidate and dexmethylphenidate	**94,565**	**71,012**	**100.0%**	**17,425**	**100.0%**	**5,617**	**100.0%**	**470**	**100.0%**	**41**	**100.0%**
0-17 years	52,792	40,002	56.3%	9,425	54.1%	3,071	54.7%	267	56.8%	27	65.9%
18-24 years	10,374	8,047	11.3%	1,756	10.1%	538	9.6%	*****	*****	*****	*****
25-40 years	17,431	12,924	18.2%	3,353	19.2%	1,060	18.9%	*****	*****	*****	*****
41-64 years	13,023	9,386	13.2%	2,672	15.3%	*****	*****	*****	*****	*****	*****
≥ 65 years	945	653	0.9%	219	1.3%	*****	*****	*****	*****	*****	*****
pegcetacoplan	**172,157**	**171,809**	**100.0%**	**179**	**100.0%**	**124**	**100.0%**	**33**	**100.0%**	**12**	**100.0%**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	27	12	0.0%	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	83	41	0.0%	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	1,177	1,083	0.6%	40	22.3%	41	33.1%	*****	*****	*****	*****
≥ 65 years	170,870	170,673	99.3%	112	62.6%	62	50.0%	*****	*****	*****	*****

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
amivantamab-vmjw	**13,047**	**13,021**	**100.0%**	**15**	**100.0%**	**11**	**100.0%**	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	68	68	0.5%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	2,178	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	10,801	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
piflufolastat F 18	**193,162**	**193,162**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	13,586	13,586	7.0%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	179,559	179,559	93.0%	0	NaN	0	NaN	0	NaN	0	NaN
sotorasib	**5,637**	**2,962**	**100.0%**	**1,592**	**100.0%**	**958**	**100.0%**	**102**	**100.0%**	**23**	**100.0%**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	13	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	1,154	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	4,470	2,350	79.3%	1,250	78.5%	766	80.0%	*****	*****	*****	*****
infigratinib	**58**	*****	*****	**29**	**100.0%**	*****	*****	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
≥ 65 years	34	*****	*****	18	62.1%	*****	*****	0	NaN	0	NaN
olanzapine and samidorphan	30,475	16,543	100.0%	7,749	100.0%	4,790	100.0%	1,084	100.0%	309	100.0%
0-17 years	175	106	0.6%	45	0.6%	*****	*****	*****	*****	*****	*****
18-24 years	2,111	1,167	7.1%	563	7.3%	*****	*****	*****	*****	*****	*****
25-40 years	10,572	5,773	34.9%	2,685	34.6%	1,628	34.0%	382	35.2%	104	33.7%
41-64 years	14,773	7,866	47.5%	3,780	48.8%	2,404	50.2%	560	51.7%	163	52.8%
≥ 65 years	2,844	1,631	9.9%	676	8.7%	430	9.0%	78	7.2%	29	9.4%
ibrexafungerp	3,992	3,943	100.0%	37	100.0%	12	100.0%	0	NaN	0	NaN
0-17 years	27	27	0.7%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	587	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
25-40 years	1,984	1,966	49.9%	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	1,341	1,317	33.4%	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	53	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
aducanumab-avwa	2,817	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	123	123	4.4%	0	0.0%	0	0.0%	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
asparaginase erwinia chrysanthemi (recombinant)-rywn	4,055	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	3,137	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

| | | Number of Treatment Episodes by Duration | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
18-24 years	442	442	10.9%	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	338	338	8.3%	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*NaN: Not a number

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
vericiguat	**25,759**	**1**	**30**	**51**	**90**	**1,499**	**93.9**	**130.7**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	20	4	30	30	118	289	79.1	76.9
25-40 years	326	2	30	30	90	901	66.1	83.6
41-64 years	4,993	1	30	41	90	1,240	84.8	114.4
≥ 65 years	20,420	1	30	56	90	1,499	96.5	134.9
cabotegravir	**67,155**	**1**	**1**	**1**	**30**	**1,318**	**30.3**	**74.0**
0-17 years	23	1	1	1	1	60	10.1	20.7
18-24 years	2,108	1	1	1	1	722	15.0	45.1
25-40 years	24,473	1	1	1	1	1,119	15.7	46.1
41-64 years	32,043	1	1	1	30	1,318	34.0	79.9
≥ 65 years	8,508	1	1	30	60	1,236	62.4	104.0
voclosporin	**3,051**	**1**	**30**	**30**	**60**	**1,050**	**63.6**	**81.1**
0-17 years	*****	30	30	30	60	313	74.7	105.7
18-24 years	356	1	30	30	88	1,028	72.6	96.1
25-40 years	1,502	1	30	30	60	740	57.8	64.9
41-64 years	1,044	1	30	30	60	1,050	68.1	94.1
≥ 65 years	*****	2	30	30	90	805	69.5	87.2
tepotinib	**1,097**	**1**	**30**	**30**	**79**	**780**	**68.6**	**84.9**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	30	30	30	30	30	30.0	0.0
41-64 years	*****	9	30	30	90	510	76.0	86.8
≥ 65 years	962	1	30	30	79	780	67.8	84.8

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
umbralisib	**134**	**3**	**30**	**30**	**90**	**270**	**59.5**	**48.4**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	20	30	30	30	60	153	53.9	40.0
≥ 65 years	114	3	30	30	90	270	60.5	49.8
evinacumab-dgnb	**1,737**	**1**	**1**	**1**	**1**	**1,323**	**5.2**	**42.2**
0-17 years	69	1	1	1	1	1	1.0	0.0
18-24 years	21	1	1	1	1	1	1.0	0.0
25-40 years	183	1	1	1	1	56	1.9	5.7
41-64 years	684	1	1	1	1	675	7.0	38.5
≥ 65 years	780	1	1	1	1	1,323	4.7	51.6
trilacicilib	**7,087**	**1**	**3**	**3**	**3**	**84**	**2.9**	**1.7**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	18	1	1	1	1	1	1.0	0.0
41-64 years	886	1	3	3	3	42	2.8	1.6
≥ 65 years	6,183	1	3	3	3	84	2.9	1.7
casimersen	**2,176**	**1**	**1**	**1**	**1**	**497**	**7.2**	**31.5**
0-17 years	1,664	1	1	1	1	392	4.2	21.5
18-24 years	450	1	1	1	1	337	10.1	35.3
25-40 years	*****	1	1	14	84	497	65.7	101.0
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	*****	1	1	1	1	1	1.0	NaN

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
fosdenopterin	*****	28	28	33	67	67	42.7	21.2
0-17 years	*****	28	28	33	67	67	42.7	21.2
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
melphalan flufenamide	225	1	1	1	1	140	2.3	10.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	37	1	1	1	1	1	1.0	0.0
≥ 65 years	188	1	1	1	1	140	2.6	11.9
tivozanib	3,372	1	28	28	64	726	59.7	63.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	9	9	33	56	56	32.5	33.2
25-40 years	*****	10	28	28	56	84	36.8	18.4
41-64 years	620	1	28	28	84	616	60.0	59.2
≥ 65 years	2,731	1	28	28	56	726	59.8	65.0
ponesimod	588	1	30	42	102	1,162	105.9	157.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	11	14	14	30	90	484	93.5	138.8
25-40 years	174	10	30	30	90	1,110	86.8	130.6
41-64 years	369	1	30	44	114	1,162	105.7	149.1
≥ 65 years	34	14	30	90	237	1,107	209.3	294.9

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
dasiglucagon	**2,030**	**1**	**1**	**2**	**30**	**791**	**22.9**	**41.3**
0-17 years	403	1	1	2	30	184	19.7	30.9
18-24 years	186	1	1	4	30	270	25.5	38.7
25-40 years	309	1	1	10	30	791	29.7	62.0
41-64 years	681	1	1	2	30	510	23.3	42.3
≥ 65 years	451	1	1	2	30	249	19.5	28.8
viloxazine	**78,736**	**1**	**30**	**30**	**60**	**1,296**	**61.8**	**84.5**
0-17 years	48,923	1	30	30	60	1,296	64.2	90.7
18-24 years	7,717	1	30	30	60	1,225	58.4	74.5
25-40 years	12,289	1	30	30	60	975	56.6	69.6
41-64 years	8,704	1	30	30	60	975	59.2	76.8
≥ 65 years	1,103	1	30	30	60	660	57.8	68.0
drospirenone and estetrol	**25,172**	**1**	**28**	**84**	**112**	**1,188**	**103.3**	**114.4**
0-17 years	2,869	1	28	65	112	1,120	103.4	124.1
18-24 years	8,068	1	28	84	112	1,156	102.0	110.3
25-40 years	10,565	1	28	84	112	1,188	102.4	110.8
41-64 years	3,658	1	28	84	115	1,086	108.7	125.1
≥ 65 years	12	24	28	84	84	560	107.0	148.8
dostarlimab-gxly	**15,488**	**1**	**1**	**1**	**1**	**210**	**1.2**	**4.7**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	13	1	1	1	1	1	1.0	0.0
25-40 years	195	1	1	1	1	1	1.0	0.0
41-64 years	2,539	1	1	1	1	42	1.0	1.2
≥ 65 years	12,741	1	1	1	1	210	1.3	5.2

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
loncastuximab tesirine-lpyl	**3,367**	**1**	**1**	**1**	**1**	**147**	**1.3**	**4.3**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	3	1.1	0.3
41-64 years	288	1	1	1	1	147	2.5	10.6
≥ 65 years	3,036	1	1	1	1	105	1.2	3.1
serdexmethylphenidate and dexmethylphenidate	**94,565**	**1**	**30**	**30**	**30**	**1,156**	**46.4**	**53.3**
0-17 years	52,792	1	30	30	30	1,156	46.3	54.3
18-24 years	10,374	1	30	30	30	736	43.2	44.3
25-40 years	17,431	1	30	30	42	850	46.5	52.8
41-64 years	13,023	1	30	30	60	824	49.0	55.7
≥ 65 years	945	1	30	30	60	792	51.6	60.9
pegcetacoplan	**172,157**	**1**	**1**	**1**	**1**	**1,424**	**1.4**	**12.6**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	27	26	28	56	84	336	81.4	86.0
25-40 years	83	1	28	52	140	868	130.4	200.9
41-64 years	1,177	1	1	1	1	1,093	17.3	75.5
≥ 65 years	170,870	1	1	1	1	1,424	1.2	9.5
amivantamab-vmjw	**13,047**	**1**	**1**	**1**	**1**	**253**	**1.3**	**5.3**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	68	1	1	1	1	2	1.1	0.4
41-64 years	2,178	1	1	1	1	253	1.4	6.9

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	10,801	1	1	1	1	224	1.3	4.9
piflufolastat F 18	**193,162**	**1**	**1**	**1**	**1**	**5**	**1.0**	**0.0**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	13,586	1	1	1	1	5	1.0	0.0
≥ 65 years	179,559	1	1	1	1	2	1.0	0.0
sotorasib	**5,637**	**1**	**30**	**30**	**90**	**1,241**	**77.4**	**102.1**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	13	15	16	30	120	180	63.6	57.5
41-64 years	1,154	3	30	30	84	1,073	73.9	100.2
≥ 65 years	4,470	1	30	30	90	1,241	78.3	102.7
infigratinib	**58**	**10**	**28**	**56**	**84**	**336**	**61.2**	**48.3**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	28	28	70	140	336	112.0	117.5
41-64 years	*****	10	28	56	84	106	53.1	28.6
≥ 65 years	34	18	28	56	77	168	56.5	31.5
olanzapine and samidorphan	**30,475**	**1**	**30**	**30**	**90**	**1,189**	**89.1**	**134.7**
0-17 years	175	2	30	30	60	1,090	65.0	102.9
18-24 years	2,111	1	30	30	86	1,084	79.6	116.7
25-40 years	10,572	1	30	30	90	1,162	88.3	134.6
41-64 years	14,773	1	30	30	90	1,189	92.4	138.6

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	2,844	1	30	30	90	1,140	83.7	127.7
ibrexafungerp	**3,992**	**1**	**1**	**1**	**1**	**356**	**3.0**	**12.5**
0-17 years	27	1	1	1	1	30	2.3	5.6
18-24 years	587	1	1	1	1	114	2.2	6.9
25-40 years	1,984	1	1	1	1	356	2.9	12.2
41-64 years	1,341	1	1	1	1	261	3.5	14.8
≥ 65 years	53	1	1	1	1	84	4.7	13.3
aducanumab-avwa	**2,817**	**1**	**1**	**1**	**1**	**155**	**1.1**	**3.1**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	*****	1	1	1	1	1	1.0	0.0
≥ 65 years	2,693	1	1	1	1	155	1.1	3.2
asparaginase erwinia chrysanthemi (recombinant)-rywn	**4,055**	**1**	**1**	**1**	**1**	**84**	**1.0**	**1.4**
0-17 years	3,137	1	1	1	1	84	1.0	1.6
18-24 years	442	1	1	1	1	1	1.0	0.0
25-40 years	338	1	1	1	1	2	1.0	0.1
41-64 years	50	1	1	1	1	1	1.0	0.0
≥ 65 years	88	1	1	1	1	1	1.0	0.0

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*NaN: Not a number

Table 5a. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
vericiguat	9,873	4,475	45.3%	2,996	30.3%	1,809	18.3%	454	4.6%	139	1.4%
cabotegravir	14,260	10,925	76.6%	2,176	15.3%	954	6.7%	163	1.1%	42	0.3%
voclosporin	945	525	55.6%	259	27.4%	139	14.7%	*****	*****	*****	*****
tepotinib	476	236	49.6%	136	28.6%	*****	*****	*****	*****	*****	*****
umbralisib	79	42	53.2%	22	27.8%	15	19.0%	0	0.0%	0	0.0%
evinacumab-dgnb	139	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
trilacicilib	2,028	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
casimersen	143	109	76.2%	*****	*****	21	14.7%	*****	*****	0	0.0%
fosdenopterin	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
melphalan flufenamide	100	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
tivozanib	1,550	824	53.2%	466	30.1%	247	15.9%	13	0.8%	0	0.0%
ponesimod	181	81	44.8%	39	21.5%	45	24.9%	*****	*****	*****	*****
dasiglucagon	1,399	1,196	85.5%	166	11.9%	*****	*****	*****	*****	*****	*****
viloxazine	37,791	24,574	65.0%	8,727	23.1%	3,766	10.0%	594	1.6%	130	0.3%
drospirenone and estetrol	13,397	3,914	29.2%	5,536	41.3%	3,331	24.9%	546	4.1%	70	0.5%
dostarlimab-gxly	2,701	2,685	99.4%	*****	*****	*****	*****	0	0.0%	0	0.0%
loncastuximab tesirine-lpyl	806	*****	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%
serdexmethylphenidate and dexmethylphenidate	31,666	22,311	70.5%	6,411	20.2%	2,595	8.2%	321	1.0%	28	0.1%
pegcetacoplan	32,242	32,127	99.6%	62	0.2%	35	0.1%	*****	*****	*****	*****
amivantamab-vmjw	1,419	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
piflufolastat F 18	159,348	159,348	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
sotorasib	2,597	1,257	48.4%	759	29.2%	512	19.7%	57	2.2%	12	0.5%

Table 5a. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

		Number of Patients by First Treatment Episode Duration								
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
infigratinib	36	*****	*****	20	55.6%	*****	*****	0	0.0%	0	0.0%
olanzapine and samidorphan	12,692	6,848	54.0%	2,971	23.4%	2,017	15.9%	635	5.0%	221	1.7%
ibrexafungerp	2,617	2,589	98.9%	*****	*****	*****	*****	0	0.0%	0	0.0%
aducanumab-avwa	458	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
asparaginase erwinia chrysanthemi (recombinant)-rywn	280	280	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 5b. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
vericiguat	9,873	1	30	56	90	1,499	106.7	154.8
cabotegravir	14,260	1	1	1	30	1,217	37.3	85.4
voclosporin	945	1	30	30	75	1,050	74.0	105.0
tepotinib	476	6	30	36	90	780	78.0	84.7
umbralisib	79	3	30	30	90	210	65.0	50.4
evinacumab-dgnb	139	1	1	1	1	1,323	26.6	139.1
trilacicilib	2,028	1	3	3	3	84	2.9	2.5
casimersen	143	1	1	1	28	497	38.4	75.2
fosdenopterin	*****	28	28	48	67	67	47.5	27.6
melphalan flufenamide	100	1	1	1	1	140	3.8	16.0
tivozanib	1,550	1	28	28	84	726	61.8	67.6
ponesimod	181	1	30	60	150	1,107	132.8	201.1
dasiglucagon	1,399	1	1	3	30	791	22.9	43.2
viloxazine	37,791	1	30	30	60	1,296	61.2	90.5
drospirenone and estetrol	13,397	1	28	84	126	1,188	111.2	122.5
dostarlimab-gxly	2,701	1	1	1	1	210	1.7	8.4
loncastuximab tesirine-lpyl	806	1	1	1	1	147	1.4	6.5
serdexmethylphenidate and dexmethylphenidate	31,666	1	30	30	60	1,102	53.3	68.3
pegcetacoplan	32,242	1	1	1	1	1,424	1.8	20.3
amivantamab-vmjw	1,419	1	2	2	2	224	2.5	9.4
piflufolastat F 18	159,348	1	1	1	1	5	1.0	0.0
sotorasib	2,597	3	30	45	90	1,241	83.3	107.4
infigratinib	36	10	28	56	84	168	57.9	32.4
olanzapine and samidorphan	12,692	1	30	30	90	1,189	102.6	162.3

Table 5b. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
ibrexafungerp	2,617	1	1	1	1	356	2.8	11.4
aducanumab-avwa	458	1	1	1	1	60	1.1	2.8
asparaginase erwinia chrysanthemi (recombinant)-rywn	280	1	1	1	1	28	1.2	2.3

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

| | | Number of Patients by First Treatment Episode Duration | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
vericiguat	**9,873**	**4,475**	**100.0%**	**2,996**	**100.0%**	**1,809**	**100.0%**	**454**	**100.0%**	**139**	**100.0%**
Female	3,439	1,604	35.8%	1,016	33.9%	617	34.1%	154	33.9%	48	34.5%
Male	6,434	2,871	64.2%	1,980	66.1%	1,192	65.9%	300	66.1%	91	65.5%
cabotegravir	**14,260**	**10,925**	**100.0%**	**2,176**	**100.0%**	**954**	**100.0%**	**163**	**100.0%**	**42**	**100.0%**
Female	2,383	1,680	15.4%	465	21.4%	189	19.8%	*****	*****	*****	*****
Male	11,877	9,245	84.6%	1,711	78.6%	765	80.2%	*****	*****	*****	*****
voclosporin	**945**	**525**	**100.0%**	**259**	**100.0%**	**139**	**100.0%**	*****	*****	*****	*****
Female	810	457	87.0%	225	86.9%	*****	*****	*****	*****	*****	*****
Male	135	68	13.0%	34	13.1%	*****	*****	*****	*****	*****	*****
tepotinib	**476**	**236**	**100.0%**	**136**	**100.0%**	*****	*****	*****	*****	*****	*****
Female	298	145	61.4%	89	65.4%	*****	*****	*****	*****	*****	*****
Male	178	91	38.6%	47	34.6%	*****	*****	*****	*****	0	0.0%
umbralisib	**79**	**42**	**100.0%**	**22**	**100.0%**	**15**	**100.0%**	**0**	**NaN**	**0**	**NaN**
Female	37	18	42.9%	*****	*****	*****	*****	0	NaN	0	NaN
Male	42	24	57.1%	*****	*****	*****	*****	0	NaN	0	NaN
evinacumab-dgnb	**139**	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Female	108	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Male	31	31	23.5%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
trilacicilib	**2,028**	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	1,065	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	963	963	47.5%	0	0.0%	0	NaN	0	NaN	0	NaN
casimersen	**143**	**109**	**100.0%**	*****	*****	**21**	**100.0%**	*****	*****	**0**	**NaN**
Female	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN

Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Patients	Number of Patients (1-30 Days)	Percent of Total Patients (1-30 Days)	Number of Patients (31-90 Days)	Percent of Total Patients (31-90 Days)	Number of Patients (91-365 Days)	Percent of Total Patients (91-365 Days)	Number of Patients (366-730 Days)	Percent of Total Patients (366-730 Days)	Number of Patients (731+ Days)	Percent of Total Patients (731+ Days)
Male	*****	*****	*****	*****	*****	21	100.0%	*****	*****	0	NaN
fosdenopterin	*****	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
Male	*****	0	0.0%	*****	*****	0	NaN	0	NaN	0	NaN
melphalan flufenamide	**100**	*****	*****	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**
Female	53	*****	*****	0	0.0%	*****	*****	0	NaN	0	NaN
Male	47	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
tivozanib	**1,550**	**824**	**100.0%**	**466**	**100.0%**	**247**	**100.0%**	**13**	**100.0%**	**0**	**NaN**
Female	416	226	27.4%	119	25.5%	71	28.7%	0	0.0%	0	NaN
Male	1,134	598	72.6%	347	74.5%	176	71.3%	13	100.0%	0	NaN
ponesimod	**181**	**81**	**100.0%**	**39**	**100.0%**	**45**	**100.0%**	*****	*****	*****	*****
Female	138	60	74.1%	28	71.8%	*****	*****	*****	*****	*****	*****
Male	43	21	25.9%	11	28.2%	*****	*****	*****	*****	*****	*****
dasiglucagon	**1,399**	**1,196**	**100.0%**	**166**	**100.0%**	*****	*****	*****	*****	*****	*****
Female	756	653	54.6%	*****	*****	*****	*****	*****	*****	*****	*****
Male	643	543	45.4%	*****	*****	*****	*****	0	0.0%	0	0.0%
viloxazine	**37,791**	**24,574**	**100.0%**	**8,727**	**100.0%**	**3,766**	**100.0%**	**594**	**100.0%**	**130**	**100.0%**
Female	16,622	11,085	45.1%	3,717	42.6%	1,570	41.7%	220	37.0%	30	23.1%
Male	21,169	13,489	54.9%	5,010	57.4%	2,196	58.3%	374	63.0%	100	76.9%
drospirenone and estetrol	**13,397**	**3,914**	**100.0%**	**5,536**	**100.0%**	**3,331**	**100.0%**	**546**	**100.0%**	**70**	**100.0%**
Female	13,375	3,903	99.7%	*****	*****	*****	*****	*****	*****	70	100.0%
Male	22	11	0.3%	*****	*****	*****	*****	*****	*****	0	0.0%
dostarlimab-gxly	**2,701**	**2,685**	**100.0%**	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**

| | | Number of Patients by First Treatment Episode Duration | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Female	2,534	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	167	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
loncastuximab tesirine-lpyl	**806**	*****	*****	**0**	**NaN**	*****	*****	**0**	**NaN**	**0**	**NaN**
Female	345	*****	*****	0	NaN	*****	*****	0	NaN	0	NaN
Male	461	*****	*****	0	NaN	*****	*****	0	NaN	0	NaN
serdexmethylphenidate and dexmethylphenidate	**31,666**	**22,311**	**100.0%**	**6,411**	**100.0%**	**2,595**	**100.0%**	**321**	**100.0%**	**28**	**100.0%**
Female	14,864	10,600	47.5%	3,013	47.0%	1,116	43.0%	*****	*****	*****	*****
Male	16,802	11,711	52.5%	3,398	53.0%	1,479	57.0%	*****	*****	*****	*****
pegcetacoplan	**32,242**	**32,127**	**100.0%**	**62**	**100.0%**	**35**	**100.0%**	*****	*****	*****	*****
Female	21,919	21,853	68.0%	36	58.1%	*****	*****	*****	*****	*****	*****
Male	10,323	10,274	32.0%	26	41.9%	*****	*****	*****	*****	*****	*****
amivantamab-vmjw	**1,419**	*****	*****	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**
Female	948	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	471	*****	*****	0	0.0%	*****	*****	0	NaN	0	NaN
piflufolastat F 18	**159,348**	**159,348**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	170	170	0.1%	0	NaN	0	NaN	0	NaN	0	NaN
Male	159,178	159,178	99.9%	0	NaN	0	NaN	0	NaN	0	NaN
sotorasib	**2,597**	**1,257**	**100.0%**	**759**	**100.0%**	**512**	**100.0%**	**57**	**100.0%**	**12**	**100.0%**
Female	1,596	781	62.1%	490	64.6%	285	55.7%	*****	*****	*****	*****
Male	1,001	476	37.9%	269	35.4%	227	44.3%	*****	*****	*****	*****
infigratinib	**36**	*****	*****	**20**	**100.0%**	*****	*****	**0**	**NaN**	**0**	**NaN**
Female	22	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN

Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Male	14	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
olanzapine and samidorphan	**12,692**	**6,848**	**100.0%**	**2,971**	**100.0%**	**2,017**	**100.0%**	**635**	**100.0%**	**221**	**100.0%**
Female	7,092	3,947	57.6%	1,648	55.5%	1,086	53.8%	305	48.0%	106	48.0%
Male	5,600	2,901	42.4%	1,323	44.5%	931	46.2%	330	52.0%	115	52.0%
ibrexafungerp	**2,617**	**2,589**	**100.0%**	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**
Female	2,606	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	11	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
aducanumab-avwa	**458**	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	252	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	206	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
asparaginase erwinia chrysanthemi (recombinant)-rywn	**280**	**280**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	94	94	33.6%	0	NaN	0	NaN	0	NaN	0	NaN
Male	186	186	66.4%	0	NaN	0	NaN	0	NaN	0	NaN

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*NaN: Not a number

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
vericiguat	**9,873**	**1**	**30**	**56**	**90**	**1,499**	**106.7**	**154.8**
Female	3,439	1	30	53	90	1,499	104.4	155.0
Male	6,434	1	30	58	90	1,363	107.9	154.7
cabotegravir	**14,260**	**1**	**1**	**1**	**30**	**1,217**	**37.3**	**85.4**
Female	2,383	1	1	28	56	1,094	47.3	96.0
Male	11,877	1	1	1	30	1,217	35.3	82.9
voclosporin	**945**	**1**	**30**	**30**	**75**	**1,050**	**74.0**	**105.0**
Female	810	1	30	30	60	1,016	68.2	88.5
Male	135	12	30	30	90	1,050	109.2	169.8
tepotinib	**476**	**6**	**30**	**36**	**90**	**780**	**78.0**	**84.7**
Female	298	6	30	47	90	780	79.8	88.1
Male	178	6	30	30	90	510	74.9	78.8
umbralisib	**79**	**3**	**30**	**30**	**90**	**210**	**65.0**	**50.4**
Female	37	25	30	47	90	210	73.1	58.4
Male	42	3	30	30	90	180	57.9	41.5
evinacumab-dgnb	**139**	**1**	**1**	**1**	**1**	**1,323**	**26.6**	**139.1**
Female	108	1	1	1	1	1,323	33.5	157.2
Male	31	1	1	1	1	30	2.8	7.0
trilacicilib	**2,028**	**1**	**3**	**3**	**3**	**84**	**2.9**	**2.5**
Female	1,065	1	3	3	3	84	3.0	3.3
Male	963	1	3	3	3	21	2.8	0.9
casimersen	**143**	**1**	**1**	**1**	**28**	**497**	**38.4**	**75.2**
Female	*****	1	1	1	1	1	1.0	NaN
Male	*****	1	1	1	28	497	38.7	75.4
fosdenopterin	*****	**28**	**28**	**48**	**67**	**67**	**47.5**	**27.6**

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Female	*****	28	28	28	28	28	28.0	NaN
Male	*****	67	67	67	67	67	67.0	NaN
melphalan flufenamide	**100**	**1**	**1**	**1**	**1**	**140**	**3.8**	**16.0**
Female	53	1	1	1	1	140	4.1	19.4
Male	47	1	1	1	1	56	3.3	11.2
tivozanib	**1,550**	**1**	**28**	**28**	**84**	**726**	**61.8**	**67.6**
Female	416	1	28	28	84	365	59.2	54.1
Male	1,134	4	28	28	84	726	62.7	71.9
ponesimod	**181**	**1**	**30**	**60**	**150**	**1,107**	**132.8**	**201.1**
Female	138	1	30	60	150	1,107	139.0	207.1
Male	43	12	30	44	114	791	112.8	181.3
dasiglucagon	**1,399**	**1**	**1**	**3**	**30**	**791**	**22.9**	**43.2**
Female	756	1	1	4	30	791	23.8	50.1
Male	643	1	1	3	30	360	21.9	33.3
viloxazine	**37,791**	**1**	**30**	**30**	**60**	**1,296**	**61.2**	**90.5**
Female	16,622	1	30	30	60	1,117	57.6	79.5
Male	21,169	1	30	30	60	1,296	64.1	98.3
drospirenone and estetrol	**13,397**	**1**	**28**	**84**	**126**	**1,188**	**111.2**	**122.5**
Female	13,375	1	28	84	127	1,188	111.2	122.5
Male	22	9	28	43	84	420	78.5	97.1
dostarlimab-gxly	**2,701**	**1**	**1**	**1**	**1**	**210**	**1.7**	**8.4**
Female	2,534	1	1	1	1	210	1.6	8.2
Male	167	1	1	1	1	126	2.2	10.6
loncastuximab tesirine-lpyl	**806**	**1**	**1**	**1**	**1**	**147**	**1.4**	**6.5**
Female	345	1	1	1	1	105	1.4	5.7

Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Male	461	1	1	1	1	147	1.5	7.0
serdexmethylphenidate and dexmethylphenidate	**31,666**	**1**	**30**	**30**	**60**	**1,102**	**53.3**	**68.3**
Female	14,864	1	30	30	60	1,102	50.8	61.9
Male	16,802	1	30	30	60	998	55.5	73.3
pegcetacoplan	**32,242**	**1**	**1**	**1**	**1**	**1,424**	**1.8**	**20.3**
Female	21,919	1	1	1	1	1,424	1.7	19.1
Male	10,323	1	1	1	1	1,232	2.0	22.6
amivantamab-vmjw	**1,419**	**1**	**2**	**2**	**2**	**224**	**2.5**	**9.4**
Female	948	1	2	2	2	168	2.5	8.9
Male	471	1	2	2	2	224	2.4	10.4
piflufolastat F 18	**159,348**	**1**	**1**	**1**	**1**	**5**	**1.0**	**0.0**
Female	170	1	1	1	1	1	1.0	0.0
Male	159,178	1	1	1	1	5	1.0	0.0
sotorasib	**2,597**	**3**	**30**	**45**	**90**	**1,241**	**83.3**	**107.4**
Female	1,596	3	30	41	90	1,073	79.9	102.8
Male	1,001	3	30	53	94	1,241	88.7	114.3
infigratinib	**36**	**10**	**28**	**56**	**84**	**168**	**57.9**	**32.4**
Female	22	10	28	56	84	168	58.5	36.2
Male	14	28	28	56	84	106	57.1	26.6
olanzapine and samidorphan	**12,692**	**1**	**30**	**30**	**90**	**1,189**	**102.6**	**162.3**
Female	7,092	1	30	30	90	1,189	95.0	151.3
Male	5,600	1	30	30	90	1,162	112.1	174.8
ibrexafungerp	**2,617**	**1**	**1**	**1**	**1**	**356**	**2.8**	**11.4**
Female	2,606	1	1	1	1	356	2.7	11.2

Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Male	11	1	1	1	4	94	15.1	31.2
aducanumab-avwa	**458**	**1**	**1**	**1**	**1**	**60**	**1.1**	**2.8**
Female	252	1	1	1	1	60	1.2	3.7
Male	206	1	1	1	1	1	1.0	0.0
asparaginase erwinia chrysanthemi (recombinant)-rywn	**280**	**1**	**1**	**1**	**1**	**28**	**1.2**	**2.3**
Female	94	1	1	1	1	1	1.0	0.0
Male	186	1	1	1	1	28	1.3	2.8

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*NaN: Not a number

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

		Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
vericiguat	**9,873**	**4,475**	**100.0%**	**2,996**	**100.0%**	**1,809**	**100.0%**	**454**	**100.0%**	**139**	**100.0%**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	12	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	123	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	1,819	829	18.5%	564	18.8%	330	18.2%	*****	*****	*****	*****
≥ 65 years	7,919	3,576	79.9%	2,394	79.9%	1,454	80.4%	373	82.2%	122	87.8%
cabotegravir	**14,260**	**10,925**	**100.0%**	**2,176**	**100.0%**	**954**	**100.0%**	**163**	**100.0%**	**42**	**100.0%**
0-17 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
18-24 years	500	420	3.8%	56	2.6%	24	2.5%	0	0.0%	0	0.0%
25-40 years	5,317	4,542	41.6%	*****	*****	204	21.4%	21	12.9%	*****	*****
41-64 years	6,453	4,811	44.0%	1,064	48.9%	458	48.0%	91	55.8%	29	69.0%
≥ 65 years	*****	*****	*****	504	23.2%	268	28.1%	51	31.3%	*****	*****
voclosporin	**945**	**525**	**100.0%**	**259**	**100.0%**	**139**	**100.0%**	*****	*****	*****	*****
0-17 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	39	15.1%	23	16.5%	*****	*****	*****	*****
25-40 years	472	274	52.2%	128	49.4%	*****	*****	*****	*****	0	0.0%
41-64 years	296	164	31.2%	81	31.3%	*****	*****	*****	*****	*****	*****
≥ 65 years	45	24	4.6%	*****	*****	*****	*****	0	0.0%	*****	*****
tepotinib	**476**	**236**	**100.0%**	**136**	**100.0%**	*****	*****	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%

| | | Number of Patients by First Treatment Episode Duration | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
41-64 years	*****	*****	*****	15	11.0%	*****	*****	*****	*****	0	0.0%
≥ 65 years	417	205	86.9%	121	89.0%	*****	*****	*****	*****	*****	*****
umbralisib	**79**	**42**	**100.0%**	**22**	**100.0%**	**15**	**100.0%**	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	13	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	66	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
evinacumab-dgnb	**139**	**132**	**100.0%**	*****	*****	*****	*****	*****	*****	*****	*****
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
41-64 years	49	*****	*****	*****	*****	0	0.0%	*****	*****	0	0.0%
≥ 65 years	68	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****
trilacicilib	**2,028**	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	285	285	14.1%	0	0.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
casimersen	**143**	**109**	**100.0%**	**12**	**100.0%**	*****	*****	*****	*****	**0**	**NaN**
0-17 years	103	84	77.1%	*****	*****	*****	*****	0	0.0%	0	NaN

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

| | | Number of Patients by First Treatment Episode Duration | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
18-24 years	26	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
41-64 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
≥ 65 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
fosdenopterin	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
melphalan flufenamide	100	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	17	17	17.5%	0	0.0%	0	0.0%	0	NaN	0	NaN
≥ 65 years	83	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
tivozanib	1,550	824	100.0%	466	100.0%	247	100.0%	13	100.0%	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
41-64 years	318	*****	*****	*****	*****	55	22.3%	*****	*****	0	NaN
≥ 65 years	1,220	655	79.5%	*****	*****	192	77.7%	*****	*****	0	NaN

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

| | | Number of Patients by First Treatment Episode Duration | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
ponesimod	**181**	**81**	**100.0%**	**39**	**100.0%**	**45**	**100.0%**	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	108	43	53.1%	25	64.1%	29	64.4%	*****	*****	*****	*****
≥ 65 years	16	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
dasiglucagon	**1,399**	**1,196**	**100.0%**	**166**	**100.0%**	*****	*****	*****	*****	*****	*****
0-17 years	200	170	14.2%	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	122	100	8.4%	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	220	180	15.1%	*****	*****	*****	*****	0	0.0%	*****	*****
41-64 years	470	396	33.1%	60	36.1%	*****	*****	*****	*****	0	0.0%
≥ 65 years	387	350	29.3%	*****	*****	*****	*****	0	0.0%	0	0.0%
viloxazine	**37,791**	**24,574**	**100.0%**	**8,727**	**100.0%**	**3,766**	**100.0%**	**594**	**100.0%**	**130**	**100.0%**
0-17 years	21,640	13,777	56.1%	5,065	58.0%	2,292	60.9%	407	68.5%	99	76.2%
18-24 years	3,854	2,573	10.5%	891	10.2%	334	8.9%	*****	*****	*****	*****
25-40 years	6,852	4,626	18.8%	1,521	17.4%	*****	*****	*****	*****	*****	*****
41-64 years	4,824	3,163	12.9%	1,137	13.0%	456	12.1%	56	9.4%	12	9.2%
≥ 65 years	621	435	1.8%	113	1.3%	*****	*****	*****	*****	0	0.0%
drospirenone and estetrol	**13,397**	**3,914**	**100.0%**	**5,536**	**100.0%**	**3,331**	**100.0%**	**546**	**100.0%**	**70**	**100.0%**
0-17 years	1,358	*****	*****	*****	*****	297	8.9%	*****	*****	*****	*****
18-24 years	4,110	1,271	32.5%	1,651	29.8%	*****	*****	167	30.6%	*****	*****
25-40 years	5,877	1,614	41.2%	2,524	45.6%	1,489	44.7%	227	41.6%	23	32.9%

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
41-64 years	2,040	576	14.7%	820	14.8%	539	16.2%	83	15.2%	22	31.4%
≥ 65 years	12	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
dostarlimab-gxly	**2,701**	**2,685**	**100.0%**	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	37	37	1.4%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
≥ 65 years	2,186	2,172	80.9%	*****	*****	*****	*****	0	NaN	0	NaN
loncastuximab tesirine-lpyl	**806**	*****	*****	**0**	**NaN**	*****	*****	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	NaN	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	0.0%	0	NaN	0	NaN
41-64 years	80	79	9.8%	0	NaN	*****	*****	0	NaN	0	NaN
≥ 65 years	714	713	88.7%	0	NaN	*****	*****	0	NaN	0	NaN
serdexmethylphenidate and dexmethylphenidate	**31,666**	**22,311**	**100.0%**	**6,411**	**100.0%**	**2,595**	**100.0%**	**321**	**100.0%**	**28**	**100.0%**
0-17 years	16,119	11,375	51.0%	3,209	50.1%	1,337	51.5%	*****	*****	*****	*****
18-24 years	3,712	2,774	12.4%	675	10.5%	237	9.1%	26	8.1%	0	0.0%
25-40 years	6,718	4,671	20.9%	1,437	22.4%	546	21.0%	*****	*****	*****	*****
41-64 years	4,759	3,261	14.6%	1,006	15.7%	*****	*****	54	16.8%	*****	*****
≥ 65 years	358	230	1.0%	84	1.3%	*****	*****	*****	*****	0	0.0%
pegcetacoplan	**32,242**	**32,127**	**100.0%**	**62**	**100.0%**	**35**	**100.0%**	*****	*****	*****	*****

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

| | | Number of Patients by First Treatment Episode Duration | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	287	260	0.8%	*****	*****	12	34.3%	*****	*****	*****	*****
≥ 65 years	31,913	31,851	99.1%	40	64.5%	*****	*****	*****	*****	*****	*****
amivantamab-vmjw	**1,419**	*****	*****	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	16	16	1.1%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
piflufolastat F 18	**159,348**	**159,348**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	11,728	11,728	7.4%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	147,604	147,604	92.6%	0	NaN	0	NaN	0	NaN	0	NaN
sotorasib	**2,597**	**1,257**	**100.0%**	**759**	**100.0%**	**512**	**100.0%**	**57**	**100.0%**	**12**	**100.0%**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

| | | Number of Patients by First Treatment Episode Duration | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
≥ 65 years	1,994	957	76.1%	582	76.7%	401	78.3%	*****	*****	*****	*****
infigratinib	**36**	**13**	**100.0%**	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	23	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
olanzapine and samidorphan	**12,692**	**6,848**	**100.0%**	**2,971**	**100.0%**	**2,017**	**100.0%**	**635**	**100.0%**	**221**	**100.0%**
0-17 years	86	55	0.8%	18	0.6%	*****	*****	*****	*****	*****	*****
18-24 years	933	500	7.3%	241	8.1%	*****	*****	*****	*****	*****	*****
25-40 years	4,267	2,334	34.1%	1,000	33.7%	646	32.0%	222	35.0%	65	29.4%
41-64 years	6,174	3,265	47.7%	1,430	48.1%	1,027	50.9%	327	51.5%	125	56.6%
≥ 65 years	1,232	694	10.1%	282	9.5%	193	9.6%	44	6.9%	19	8.6%
ibrexafungerp	**2,617**	**2,589**	**100.0%**	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**
0-17 years	19	19	0.7%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	427	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
25-40 years	1,256	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	883	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	32	32	1.2%	0	0.0%	0	0.0%	0	NaN	0	NaN
aducanumab-avwa	**458**	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

| | | Number of Patients by First Treatment Episode Duration | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
25-40 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	21	21	4.6%	0	0.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
asparaginase erwinia chrysanthemi (recombinant)-rywn	**280**	**280**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	203	203	72.5%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	32	32	11.4%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	22	22	7.9%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*NaN: Not a number

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
vericiguat	**9,873**	**1**	**30**	**56**	**90**	**1,499**	**106.7**	**154.8**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	12	30	30	43	118	192	78.7	62.7
25-40 years	123	4	30	30	90	901	72.5	101.8
41-64 years	1,819	1	30	54	90	1,240	99.9	138.9
≥ 65 years	7,919	1	30	57	90	1,499	108.8	158.9
cabotegravir	**14,260**	**1**	**1**	**1**	**30**	**1,217**	**37.3**	**85.4**
0-17 years	*****	1	1	1	56	60	22.0	27.8
18-24 years	*****	1	1	1	30	360	21.5	43.6
25-40 years	5,317	1	1	1	30	1,074	21.1	51.3
41-64 years	6,453	1	1	22	36	1,217	42.2	96.5
≥ 65 years	1,980	1	28	30	60	1,156	68.9	112.8
voclosporin	**945**	**1**	**30**	**30**	**75**	**1,050**	**74.0**	**105.0**
0-17 years	*****	30	30	45	187	313	108.3	137.2
18-24 years	128	11	30	45	90	1,028	93.8	131.6
25-40 years	472	2	30	30	60	630	64.5	75.1
41-64 years	296	1	30	30	84	1,050	79.5	126.9
≥ 65 years	*****	11	30	30	90	805	79.0	119.5
tepotinib	**476**	**6**	**30**	**36**	**90**	**780**	**78.0**	**84.7**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	30	30	30	30	30	30.0	0.0
41-64 years	*****	12	30	30	90	390	90.7	101.9
≥ 65 years	417	6	30	40	90	780	76.5	82.2

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
umbralisib	**79**	**3**	**30**	**30**	**90**	**210**	**65.0**	**50.4**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	13	30	30	30	60	153	59.8	47.9
≥ 65 years	66	3	30	30	90	210	66.0	51.1
evinacumab-dgnb	**139**	**1**	**1**	**1**	**1**	**1,323**	**26.6**	**139.1**
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	30	4.7	9.9
41-64 years	49	1	1	1	1	675	35.9	131.6
≥ 65 years	68	1	1	1	1	1,323	27.4	164.9
trilacicilib	**2,028**	**1**	**3**	**3**	**3**	**84**	**2.9**	**2.5**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	3	3	3	21	2.8	1.3
≥ 65 years	1,741	1	3	3	3	84	2.9	2.6
casimersen	**143**	**1**	**1**	**1**	**28**	**497**	**38.4**	**75.2**
0-17 years	103	1	1	1	28	280	28.5	60.6
18-24 years	26	1	1	28	112	252	55.3	69.1
25-40 years	*****	1	1	14	119	497	85.7	147.8
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	*****	1	1	1	1	1	1.0	NaN

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
fosdenopterin	*****	**28**	**28**	**48**	**67**	**67**	**47.5**	**27.6**
0-17 years	*****	28	28	48	67	67	47.5	27.6
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
melphalan flufenamide	**100**	**1**	**1**	**1**	**1**	**140**	**3.8**	**16.0**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	17	1	1	1	1	1	1.0	0.0
≥ 65 years	83	1	1	1	1	140	4.3	17.5
tivozanib	**1,550**	**1**	**28**	**28**	**84**	**726**	**61.8**	**67.6**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	56	56	56	56	56	56.0	NaN
25-40 years	*****	10	26	28	56	84	38.1	22.1
41-64 years	318	5	28	28	84	616	61.5	60.0
≥ 65 years	1,220	1	28	28	84	726	62.1	69.7
ponesimod	**181**	**1**	**30**	**60**	**150**	**1,107**	**132.8**	**201.1**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	14	14	52	90	90	52.0	43.9
25-40 years	*****	14	30	30	134	710	97.2	125.9
41-64 years	108	1	30	60	150	1,011	134.7	194.2
≥ 65 years	16	14	22	75	389	1,107	257.9	371.5

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
dasiglucagon	**1,399**	**1**	**1**	**3**	**30**	**791**	**22.9**	**43.2**
0-17 years	200	1	2	4	30	180	20.4	28.9
18-24 years	122	1	1	15	30	270	25.8	38.9
25-40 years	220	1	1	13	30	791	30.8	68.9
41-64 years	470	1	1	2	30	510	23.8	45.0
≥ 65 years	387	1	1	2	30	249	17.6	25.1
viloxazine	**37,791**	**1**	**30**	**30**	**60**	**1,296**	**61.2**	**90.5**
0-17 years	21,640	1	30	30	60	1,296	64.5	99.7
18-24 years	3,854	1	30	30	60	896	57.7	78.6
25-40 years	6,852	1	30	30	60	975	55.2	72.4
41-64 years	4,824	1	30	30	60	975	58.5	80.7
≥ 65 years	621	1	30	30	60	630	56.1	70.8
drospirenone and estetrol	**13,397**	**1**	**28**	**84**	**126**	**1,188**	**111.2**	**122.5**
0-17 years	1,358	1	28	84	112	996	111.7	133.5
18-24 years	4,110	1	28	84	121	1,156	108.7	117.9
25-40 years	5,877	1	28	84	127	1,188	110.2	117.4
41-64 years	2,040	1	28	84	145	1,086	118.5	136.9
≥ 65 years	12	24	28	84	84	560	107.0	148.8
dostarlimab-gxly	**2,701**	**1**	**1**	**1**	**1**	**210**	**1.7**	**8.4**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	476	1	1	1	1	42	1.2	2.8
≥ 65 years	2,186	1	1	1	1	210	1.8	9.3

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
loncastuximab tesirine-lpyl	**806**	**1**	**1**	**1**	**1**	**147**	**1.4**	**6.5**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	3	1.2	0.6
41-64 years	80	1	1	1	1	147	2.8	16.3
≥ 65 years	714	1	1	1	1	105	1.3	4.2
serdexmethylphenidate and dexmethylphenidate	**31,666**	**1**	**30**	**30**	**60**	**1,102**	**53.3**	**68.3**
0-17 years	16,119	1	30	30	60	1,102	54.2	71.6
18-24 years	3,712	1	30	30	35	720	47.0	55.3
25-40 years	6,718	1	30	30	60	850	52.2	64.8
41-64 years	4,759	1	30	30	60	824	56.1	70.4
≥ 65 years	358	1	30	30	60	547	59.9	68.6
pegcetacoplan	**32,242**	**1**	**1**	**1**	**1**	**1,424**	**1.8**	**20.3**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	28	28	56	89	336	92.7	110.4
25-40 years	*****	1	28	56	183	868	156.5	225.2
41-64 years	287	1	1	1	1	1,093	24.0	102.1
≥ 65 years	31,913	1	1	1	1	1,424	1.4	15.3
amivantamab-vmjw	**1,419**	**1**	**2**	**2**	**2**	**224**	**2.5**	**9.4**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	16	1	1	2	2	2	1.6	0.5
41-64 years	282	1	1	2	2	28	1.9	2.0

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	1,121	1	2	2	2	224	2.6	10.5
piflufolastat F 18	**159,348**	**1**	**1**	**1**	**1**	**5**	**1.0**	**0.0**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	11,728	1	1	1	1	5	1.0	0.0
≥ 65 years	147,604	1	1	1	1	2	1.0	0.0
sotorasib	**2,597**	**3**	**30**	**45**	**90**	**1,241**	**83.3**	**107.4**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	15	26	45	132	180	75.1	63.8
41-64 years	*****	3	30	33	90	1,073	82.2	118.5
≥ 65 years	1,994	3	30	51	90	1,241	83.6	104.1
infigratinib	**36**	**10**	**28**	**56**	**84**	**168**	**57.9**	**32.4**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	28	28	28	56	56	37.3	16.2
41-64 years	*****	10	28	70	84	106	62.0	31.6
≥ 65 years	23	18	28	56	77	168	58.9	34.3
olanzapine and samidorphan	**12,692**	**1**	**30**	**30**	**90**	**1,189**	**102.6**	**162.3**
0-17 years	86	2	30	30	60	1,090	75.2	139.4
18-24 years	933	1	30	30	90	1,084	92.5	144.6
25-40 years	4,267	1	30	30	90	1,162	99.9	159.9
41-64 years	6,174	1	30	30	90	1,189	108.0	168.8

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	1,232	1	30	30	90	1,140	94.5	149.8
ibrexafungerp	**2,617**	**1**	**1**	**1**	**1**	**356**	**2.8**	**11.4**
0-17 years	19	1	1	1	2	30	2.7	6.6
18-24 years	427	1	1	1	1	114	2.4	7.5
25-40 years	1,256	1	1	1	1	356	2.9	12.9
41-64 years	883	1	1	1	1	200	2.8	10.9
≥ 65 years	32	1	1	1	1	2	1.1	0.3
aducanumab-avwa	**458**	**1**	**1**	**1**	**1**	**60**	**1.1**	**2.8**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	*****	1	1	1	1	1	1.0	0.0
≥ 65 years	436	1	1	1	1	60	1.1	2.8
asparaginase erwinia chrysanthemi (recombinant)-rywn	**280**	**1**	**1**	**1**	**1**	**28**	**1.2**	**2.3**
0-17 years	203	1	1	1	1	28	1.3	2.7
18-24 years	32	1	1	1	1	1	1.0	0.0
25-40 years	22	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	1	1.0	0.0
≥ 65 years	*****	1	1	1	1	1	1.0	0.0

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*NaN: Not a number

Table 6a. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

| | Total Number of Episodes | Number of Treatment Episodes by Duration (Excluding First Treatment Episode) | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
vericiguat	15,886	7,554	47.6%	5,133	32.3%	2,706	17.0%	412	2.6%	81	0.5%
cabotegravir	52,895	42,308	80.0%	6,465	12.2%	3,658	6.9%	401	0.8%	63	0.1%
voclosporin	2,106	1,294	61.4%	561	26.6%	231	11.0%	*****	*****	*****	*****
tepotinib	621	386	62.2%	154	24.8%	*****	*****	*****	*****	*****	*****
umbralisib	55	36	65.5%	*****	*****	*****	*****	0	0.0%	0	0.0%
evinacumab-dgnb	1,598	1,559	97.6%	*****	*****	*****	*****	0	0.0%	0	0.0%
trilacicilib	5,059	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
casimersen	2,033	1,968	96.8%	37	1.8%	*****	*****	*****	*****	0	0.0%
fosdenopterin	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	0.0%
melphalan flufenamide	125	125	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
tivozanib	1,822	1,061	58.2%	496	27.2%	253	13.9%	12	0.7%	0	0.0%
ponesimod	407	211	51.8%	108	26.5%	69	17.0%	*****	*****	*****	*****
dasiglucagon	631	522	82.7%	84	13.3%	25	4.0%	0	0.0%	0	0.0%
viloxazine	40,945	24,768	60.5%	10,975	26.8%	4,667	11.4%	460	1.1%	75	0.2%
drospirenone and estetrol	11,775	4,361	37.0%	4,417	37.5%	2,661	22.6%	307	2.6%	29	0.2%
dostarlimab-gxly	12,787	12,763	99.8%	*****	*****	*****	*****	0	0.0%	0	0.0%
loncastuximab tesirine-lpyl	2,561	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
serdexmethylphenidate and dexmethylphenidate	62,899	48,701	77.4%	11,014	17.5%	3,022	4.8%	149	0.2%	13	0.0%
pegcetacoplan	139,915	139,682	99.8%	117	0.1%	89	0.1%	*****	*****	*****	*****
amivantamab-vmjw	11,628	11,607	99.8%	*****	*****	*****	*****	0	0.0%	0	0.0%
piflufolastat F 18	33,814	33,814	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%

Table 6a. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

| | Total Number of Episodes | Number of Treatment Episodes by Duration (Excluding First Treatment Episode) | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
sotorasib	3,040	1,705	56.1%	833	27.4%	446	14.7%	45	1.5%	11	0.4%
infigratinib	22	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
olanzapine and samidorphan	17,783	9,695	54.5%	4,778	26.9%	2,773	15.6%	449	2.5%	88	0.5%
ibrexafungerp	1,375	1,354	98.5%	*****	*****	*****	*****	0	0.0%	0	0.0%
aducanumab-avwa	2,359	*****	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%
asparaginase erwinia chrysanthemi (recombinant)-rywn	3,775	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 6b. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
vericiguat	15,886	1	30	44	90	1,185	85.9	112.5
cabotegravir	52,895	1	1	1	30	1,318	28.4	70.5
voclosporin	2,106	1	30	30	60	819	59.0	67.3
tepotinib	621	1	30	30	60	750	61.4	84.3
umbralisib	55	17	30	30	60	270	51.7	44.7
evinacumab-dgnb	1,598	1	1	1	1	364	3.3	15.0
trilacicilib	5,059	1	3	3	3	63	2.9	1.3
casimersen	2,033	1	1	1	1	392	5.0	24.4
fosdenopterin	*****	33	33	33	33	33	33.0	NaN
melphalan flufenamide	125	1	1	1	1	28	1.2	2.4
tivozanib	1,822	1	28	28	56	588	57.9	60.4
ponesimod	407	4	30	30	90	1,162	93.9	132.7
dasiglucagon	631	1	1	2	30	247	22.9	36.7
viloxazine	40,945	1	30	30	60	1,225	62.3	78.5
drospirenone and estetrol	11,775	1	28	63	96	1,120	94.4	103.8
dostarlimab-gxly	12,787	1	1	1	1	189	1.2	3.5
loncastuximab tesirine-lpyl	2,561	1	1	1	1	84	1.3	3.3
serdexmethylphenidate and dexmethylphenidate	62,899	1	30	30	30	1,156	43.0	43.4
pegcetacoplan	139,915	1	1	1	1	1,168	1.3	10.1
amivantamab-vmjw	11,628	1	1	1	1	253	1.2	4.5
piflufolastat F 18	33,814	1	1	1	1	2	1.0	0.0
sotorasib	3,040	1	30	30	70	1,191	72.3	97.1
infigratinib	22	28	28	56	84	336	66.5	67.4

Table 6b. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
olanzapine and samidorphan	17,783	1	30	30	90	1,118	79.5	109.9
ibrexafungerp	1,375	1	1	1	1	261	3.6	14.5
aducanumab-avwa	2,359	1	1	1	1	155	1.1	3.2
asparaginase erwinia chrysanthemi (recombinant)-rywn	3,775	1	1	1	1	84	1.0	1.4

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*NaN: Not a number

| | Total Number of Episodes | Number of Treatment Episodes by Duration (Excluding First Treatment Episode) | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
vericiguat	15,886	7,554	100.0%	5,133	100.0%	2,706	100.0%	412	100.0%	81	100.0%
Female	5,680	2,756	36.5%	1,798	35.0%	949	35.1%	149	36.2%	28	34.6%
Male	10,206	4,798	63.5%	3,335	65.0%	1,757	64.9%	263	63.8%	53	65.4%
cabotegravir	52,895	42,308	100.0%	6,465	100.0%	3,658	100.0%	401	100.0%	63	100.0%
Female	7,710	5,512	13.0%	1,389	21.5%	714	19.5%	83	20.7%	12	19.0%
Male	45,185	36,796	87.0%	5,076	78.5%	2,944	80.5%	318	79.3%	51	81.0%
voclosporin	2,106	1,294	100.0%	561	100.0%	231	100.0%	*****	*****	*****	*****
Female	1,715	1,070	82.7%	448	79.9%	*****	*****	*****	*****	0	0.0%
Male	391	224	17.3%	113	20.1%	*****	*****	*****	*****	*****	*****
tepotinib	621	386	100.0%	154	100.0%	*****	*****	*****	*****	*****	*****
Female	421	263	68.1%	102	66.2%	*****	*****	*****	*****	*****	*****
Male	200	123	31.9%	52	33.8%	*****	*****	*****	*****	0	0.0%
umbralisib	55	36	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
Female	27	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	28	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
evinacumab-dgnb	1,598	1,559	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
Female	1,217	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	381	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
trilacicilib	5,059	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Female	2,743	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	2,316	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
casimersen	2,033	1,968	100.0%	37	100.0%	*****	*****	*****	*****	0	NaN
Female	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

| | Total Number of Episodes | Number of Treatment Episodes by Duration (Excluding First Treatment Episode) | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Male	2,033	1,968	100.0%	37	100.0%	*****	*****	*****	*****	0	NaN
fosdenopterin	*****	**0**	**NaN**	*****	*****	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	*****	0	NaN	*****	*****	0	NaN	0	NaN	0	NaN
Male	0	0	NaN	0	0.0%	0	NaN	0	NaN	0	NaN
melphalan flufenamide	**125**	**125**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	62	62	49.6%	0	NaN	0	NaN	0	NaN	0	NaN
Male	63	63	50.4%	0	NaN	0	NaN	0	NaN	0	NaN
tivozanib	**1,822**	**1,061**	**100.0%**	**496**	**100.0%**	**253**	**100.0%**	**12**	**100.0%**	**0**	**NaN**
Female	488	286	27.0%	134	27.0%	*****	*****	*****	*****	0	NaN
Male	1,334	775	73.0%	362	73.0%	*****	*****	*****	*****	0	NaN
ponesimod	**407**	**211**	**100.0%**	**108**	**100.0%**	**69**	**100.0%**	*****	*****	*****	*****
Female	289	154	73.0%	81	75.0%	*****	*****	*****	*****	*****	*****
Male	118	57	27.0%	27	25.0%	*****	*****	*****	*****	0	0.0%
dasiglucagon	**631**	**522**	**100.0%**	**84**	**100.0%**	**25**	**100.0%**	**0**	**NaN**	**0**	**NaN**
Female	386	327	62.6%	*****	*****	*****	*****	0	NaN	0	NaN
Male	245	195	37.4%	*****	*****	*****	*****	0	NaN	0	NaN
viloxazine	**40,945**	**24,768**	**100.0%**	**10,975**	**100.0%**	**4,667**	**100.0%**	**460**	**100.0%**	**75**	**100.0%**
Female	16,994	10,370	41.9%	4,549	41.4%	1,885	40.4%	171	37.2%	19	25.3%
Male	23,951	14,398	58.1%	6,426	58.6%	2,782	59.6%	289	62.8%	56	74.7%
drospirenone and estetrol	**11,775**	**4,361**	**100.0%**	**4,417**	**100.0%**	**2,661**	**100.0%**	**307**	**100.0%**	**29**	**100.0%**
Female	11,752	*****	*****	*****	*****	*****	*****	*****	*****	29	100.0%
Male	23	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
dostarlimab-gxly	**12,787**	**12,763**	**100.0%**	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

| | Total Number of Episodes | Number of Treatment Episodes by Duration (Excluding First Treatment Episode) | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Female	11,911	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	876	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
loncastuximab tesirine-lpyl	**2,561**	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	1,101	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	1,460	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
serdexmethylphenidate and dexmethylphenidate	**62,899**	**48,701**	**100.0%**	**11,014**	**100.0%**	**3,022**	**100.0%**	**149**	**100.0%**	**13**	**100.0%**
Female	27,123	21,148	43.4%	4,672	42.4%	1,239	41.0%	*****	*****	*****	*****
Male	35,776	27,553	56.6%	6,342	57.6%	1,783	59.0%	*****	*****	*****	*****
pegcetacoplan	**139,915**	**139,682**	**100.0%**	**117**	**100.0%**	**89**	**100.0%**	*****	*****	*****	*****
Female	95,281	95,144	68.1%	69	59.0%	55	61.8%	*****	*****	*****	*****
Male	44,634	44,538	31.9%	48	41.0%	34	38.2%	*****	*****	*****	*****
amivantamab-vmjw	**11,628**	**11,607**	**100.0%**	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**
Female	8,368	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	3,260	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
piflufolastat F 18	**33,814**	**33,814**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
sotorasib	**3,040**	**1,705**	**100.0%**	**833**	**100.0%**	**446**	**100.0%**	**45**	**100.0%**	**11**	**100.0%**
Female	1,943	1,090	63.9%	540	64.8%	279	62.6%	*****	*****	*****	*****
Male	1,097	615	36.1%	293	35.2%	167	37.4%	*****	*****	*****	*****
infigratinib	**22**	*****	*****	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**
Female	11	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

| | Total Number of Episodes | Number of Treatment Episodes by Duration (Excluding First Treatment Episode) | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Male	11	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
olanzapine and samidorphan	**17,783**	**9,695**	**100.0%**	**4,778**	**100.0%**	**2,773**	**100.0%**	**449**	**100.0%**	**88**	**100.0%**
Female	9,446	5,269	54.3%	2,525	52.8%	1,392	50.2%	226	50.3%	34	38.6%
Male	8,337	4,426	45.7%	2,253	47.2%	1,381	49.8%	223	49.7%	54	61.4%
ibrexafungerp	**1,375**	*****	*****	**15**	**100.0%**	*****	*****	**0**	**NaN**	**0**	**NaN**
Female	*****	*****	*****	15	100.0%	*****	*****	0	NaN	0	NaN
Male	*****	*****	*****	0	0.0%	*****	*****	0	NaN	0	NaN
aducanumab-avwa	**2,359**	*****	*****	**0**	**NaN**	*****	*****	**0**	**NaN**	**0**	**NaN**
Female	1,188	*****	*****	0	NaN	*****	*****	0	NaN	0	NaN
Male	1,171	*****	*****	0	NaN	0	0.0%	0	NaN	0	NaN
asparaginase erwinia chrysanthemi (recombinant)-rywn	**3,775**	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	1,123	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
Male	2,652	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*NaN: Not a number

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to l April 30, 2025, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
vericiguat	**15,886**	**1**	**30**	**44**	**90**	**1,185**	**85.9**	**112.5**
Female	5,680	1	30	40	90	1,185	84.3	112.6
Male	10,206	1	30	49	90	1,148	86.8	112.5
cabotegravir	**52,895**	**1**	**1**	**1**	**30**	**1,318**	**28.4**	**70.5**
Female	7,710	1	1	1	56	1,119	38.8	80.6
Male	45,185	1	1	1	30	1,318	26.7	68.5
voclosporin	**2,106**	**1**	**30**	**30**	**60**	**819**	**59.0**	**67.3**
Female	1,715	1	30	30	60	690	57.5	63.4
Male	391	9	30	30	60	819	65.6	82.0
tepotinib	**621**	**1**	**30**	**30**	**60**	**750**	**61.4**	**84.3**
Female	421	1	30	30	60	750	64.1	91.6
Male	200	1	30	30	60	649	55.8	66.5
umbralisib	**55**	**17**	**30**	**30**	**60**	**270**	**51.7**	**44.7**
Female	27	17	30	30	60	120	46.2	28.4
Male	28	22	30	30	60	270	57.0	56.2
evinacumab-dgnb	**1,598**	**1**	**1**	**1**	**1**	**364**	**3.3**	**15.0**
Female	1,217	1	1	1	1	364	3.5	16.0
Male	381	1	1	1	1	144	2.5	10.9
trilacicilib	**5,059**	**1**	**3**	**3**	**3**	**63**	**2.9**	**1.3**
Female	2,743	1	3	3	3	42	2.8	1.2
Male	2,316	1	3	3	3	63	2.9	1.5
casimersen	**2,033**	**1**	**1**	**1**	**1**	**392**	**5.0**	**24.4**
Female	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Male	2,033	1	1	1	1	392	5.0	24.4

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to l April 30, 2025, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
fosdenopterin	*********	**33**	**33**	**33**	**33**	**33**	**33.0**	**NaN**
Female	*****	33	33	33	33	33	33.0	NaN
Male	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
melphalan flufenamide	**125**	**1**	**1**	**1**	**1**	**28**	**1.2**	**2.4**
Female	62	1	1	1	1	28	1.4	3.4
Male	63	1	1	1	1	1	1.0	0.0
tivozanib	**1,822**	**1**	**28**	**28**	**56**	**588**	**57.9**	**60.4**
Female	488	1	28	28	56	588	56.9	61.9
Male	1,334	1	28	28	56	476	58.3	59.8
ponesimod	**407**	**4**	**30**	**30**	**90**	**1,162**	**93.9**	**132.7**
Female	289	4	30	30	90	1,162	88.8	135.5
Male	118	5	30	43	120	570	106.4	125.4
dasiglucagon	**631**	**1**	**1**	**2**	**30**	**247**	**22.9**	**36.7**
Female	386	1	1	2	30	247	21.2	36.1
Male	245	1	1	4	30	229	25.6	37.6
viloxazine	**40,945**	**1**	**30**	**30**	**60**	**1,225**	**62.3**	**78.5**
Female	16,994	1	30	30	60	1,225	60.7	73.7
Male	23,951	1	30	30	60	1,204	63.4	81.7
drospirenone and estetrol	**11,775**	**1**	**28**	**63**	**96**	**1,120**	**94.4**	**103.8**
Female	11,752	1	28	63	96	1,120	94.4	103.8
Male	23	8	28	66	84	420	96.0	106.9
dostarlimab-gxly	**12,787**	**1**	**1**	**1**	**1**	**189**	**1.2**	**3.5**
Female	11,911	1	1	1	1	189	1.2	3.5
Male	876	1	1	1	1	84	1.2	3.8

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to l April 30, 2025, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
loncastuximab tesirine-lpyl	**2,561**	**1**	**1**	**1**	**1**	**84**	**1.3**	**3.3**
Female	1,101	1	1	1	1	84	1.3	3.2
Male	1,460	1	1	1	1	84	1.3	3.4
serdexmethylphenidate and dexmethylphenidate	**62,899**	**1**	**30**	**30**	**30**	**1,156**	**43.0**	**43.4**
Female	27,123	1	30	30	30	1,119	42.3	41.2
Male	35,776	1	30	30	30	1,156	43.5	45.1
pegcetacoplan	**139,915**	**1**	**1**	**1**	**1**	**1,168**	**1.3**	**10.1**
Female	95,281	1	1	1	1	1,012	1.3	8.4
Male	44,634	1	1	1	1	1,168	1.4	12.9
amivantamab-vmjw	**11,628**	**1**	**1**	**1**	**1**	**253**	**1.2**	**4.5**
Female	8,368	1	1	1	1	253	1.2	4.6
Male	3,260	1	1	1	1	168	1.2	4.2
piflufolastat F 18	**33,814**	**1**	**1**	**1**	**1**	**2**	**1.0**	**0.0**
Female	*****	1	1	1	1	1	1.0	0.0
Male	*****	1	1	1	1	2	1.0	0.0
sotorasib	**3,040**	**1**	**30**	**30**	**70**	**1,191**	**72.3**	**97.1**
Female	1,943	1	30	30	60	1,191	71.4	96.6
Male	1,097	1	30	30	86	994	73.9	98.0
infigratinib	**22**	**28**	**28**	**56**	**84**	**336**	**66.5**	**67.4**
Female	11	28	28	28	84	140	51.6	38.0
Male	11	28	28	56	84	336	81.5	87.2
olanzapine and samidorphan	**17,783**	**1**	**30**	**30**	**90**	**1,118**	**79.5**	**109.9**
Female	9,446	1	30	30	85	986	75.7	102.0

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to l April 30, 2025, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Male	8,337	1	30	30	90	1,118	83.9	118.1
ibrexafungerp	**1,375**	**1**	**1**	**1**	**1**	**261**	**3.6**	**14.5**
Female	*****	1	1	1	1	240	3.4	12.7
Male	*****	1	1	1	131	261	66.0	130.0
aducanumab-avwa	**2,359**	**1**	**1**	**1**	**1**	**155**	**1.1**	**3.2**
Female	1,188	1	1	1	1	155	1.1	4.5
Male	1,171	1	1	1	1	1	1.0	0.0
asparaginase erwinia chrysanthemi (recombinant)-rywn	**3,775**	**1**	**1**	**1**	**1**	**84**	**1.0**	**1.4**
Female	1,123	1	1	1	1	2	1.0	0.0
Male	2,652	1	1	1	1	84	1.0	1.6

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*NaN: Not a number

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

| | | Number of Treatment Episodes by Duration (Excluding First Treatment Episode) | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
vericiguat	**15,886**	**7,554**	**100.0%**	**5,133**	**100.0%**	**2,706**	**100.0%**	**412**	**100.0%**	**81**	**100.0%**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	13	0.5%	*****	*****	0	0.0%
41-64 years	3,174	1,581	20.9%	1,085	21.1%	*****	*****	*****	*****	12	14.8%
≥ 65 years	12,501	5,858	77.5%	3,971	77.4%	2,253	83.3%	350	85.0%	69	85.2%
cabotegravir	**52,895**	**42,308**	**100.0%**	**6,465**	**100.0%**	**3,658**	**100.0%**	**401**	**100.0%**	**63**	**100.0%**
0-17 years	13	13	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	1,608	1,474	3.5%	91	1.4%	*****	*****	*****	*****	0	0.0%
25-40 years	19,156	17,322	40.9%	1,197	18.5%	*****	*****	*****	*****	*****	*****
41-64 years	25,590	19,834	46.9%	3,453	53.4%	2,030	55.5%	*****	*****	*****	*****
≥ 65 years	6,528	3,665	8.7%	1,724	26.7%	1,009	27.6%	104	25.9%	26	41.3%
voclosporin	**2,106**	**1,294**	**100.0%**	**561**	**100.0%**	**231**	**100.0%**	*****	*****	*****	*****
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	74	13.2%	*****	*****	*****	*****	0	0.0%
25-40 years	1,030	658	50.9%	270	48.1%	*****	*****	*****	*****	*****	*****
41-64 years	748	449	34.7%	195	34.8%	*****	*****	*****	*****	*****	*****
≥ 65 years	97	58	4.5%	22	3.9%	17	7.4%	0	0.0%	0	0.0%
tepotinib	**621**	**386**	**100.0%**	**154**	**100.0%**	*****	*****	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

| | | Number of Treatment Episodes by Duration (Excluding First Treatment Episode) | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
41-64 years	*****	*****	*****	22	14.3%	*****	*****	*****	*****	0	0.0%
≥ 65 years	545	342	88.6%	132	85.7%	*****	*****	*****	*****	*****	*****
umbralisib	**55**	**36**	**100.0%**	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
evinacumab-dgnb	**1,598**	**1,559**	**100.0%**	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**
0-17 years	64	64	4.1%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	19	19	1.2%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	168	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	635	605	38.8%	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	712	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
trilacicilib	**5,059**	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	16	16	0.3%	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	601	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	4,442	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
casimersen	**2,033**	**1,968**	**100.0%**	**37**	**100.0%**	*****	*****	*****	*****	**0**	**NaN**
0-17 years	1,561	1,538	78.2%	*****	*****	*****	*****	*****	*****	0	NaN

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

| | | Number of Treatment Episodes by Duration (Excluding First Treatment Episode) | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
18-24 years	424	402	20.4%	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	48	28	1.4%	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
fosdenopterin	*****	**0**	**NaN**	*****	*****	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	*****	0	NaN	*****	*****	0	NaN	0	NaN	0	NaN
18-24 years	0	0	NaN	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	0	0	NaN	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	0	0	NaN	0	0.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	0	0	NaN	0	0.0%	0	NaN	0	NaN	0	NaN
melphalan flufenamide	**125**	**125**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	20	20	16.0%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	105	105	84.0%	0	NaN	0	NaN	0	NaN	0	NaN
tivozanib	**1,822**	**1,061**	**100.0%**	**496**	**100.0%**	**253**	**100.0%**	**12**	**100.0%**	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
41-64 years	*****	*****	*****	*****	*****	46	18.2%	0	0.0%	0	NaN
≥ 65 years	1,511	876	82.6%	416	83.9%	207	81.8%	12	100.0%	0	NaN

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

| | | Number of Treatment Episodes by Duration (Excluding First Treatment Episode) | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
ponesimod	**407**	**211**	**100.0%**	**108**	**100.0%**	**69**	**100.0%**	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	*****	*****	*****	*****	*****	16	23.2%	*****	*****	*****	*****
41-64 years	261	132	62.6%	70	64.8%	*****	*****	*****	*****	*****	*****
≥ 65 years	18	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
dasiglucagon	**631**	**522**	**100.0%**	**84**	**100.0%**	**25**	**100.0%**	**0**	**NaN**	**0**	**NaN**
0-17 years	203	172	33.0%	*****	*****	*****	*****	0	NaN	0	NaN
18-24 years	64	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
25-40 years	89	70	13.4%	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	211	177	33.9%	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	64	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
viloxazine	**40,945**	**24,768**	**100.0%**	**10,975**	**100.0%**	**4,667**	**100.0%**	**460**	**100.0%**	**75**	**100.0%**
0-17 years	27,283	16,323	65.9%	7,366	67.1%	3,199	68.5%	*****	*****	*****	*****
18-24 years	3,863	2,437	9.8%	983	9.0%	*****	*****	*****	*****	*****	*****
25-40 years	5,437	3,362	13.6%	1,452	13.2%	571	12.2%	*****	*****	*****	*****
41-64 years	3,880	2,348	9.5%	1,058	9.6%	427	9.1%	*****	*****	*****	*****
≥ 65 years	482	298	1.2%	116	1.1%	*****	*****	*****	*****	0	0.0%
drospirenone and estetrol	**11,775**	**4,361**	**100.0%**	**4,417**	**100.0%**	**2,661**	**100.0%**	**307**	**100.0%**	**29**	**100.0%**
0-17 years	1,511	599	13.7%	515	11.7%	347	13.0%	*****	*****	*****	*****
18-24 years	3,958	1,455	33.4%	1,450	32.8%	941	35.4%	*****	*****	*****	*****
25-40 years	4,688	1,713	39.3%	1,839	41.6%	1,010	38.0%	*****	*****	*****	*****

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

| | Total Number of Episodes | Number of Treatment Episodes by Duration (Excluding First Treatment Episode) | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
41-64 years	1,618	594	13.6%	613	13.9%	363	13.6%	*****	*****	*****	*****
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
dostarlimab-gxly	**12,787**	**12,763**	**100.0%**	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	11	11	0.1%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	158	158	1.2%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	2,063	2,063	16.2%	0	0.0%	0	0.0%	0	NaN	0	NaN
≥ 65 years	10,555	10,531	82.5%	*****	*****	*****	*****	0	NaN	0	NaN
loncastuximab tesirine-lpyl	**2,561**	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	208	206	8.1%	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	2,322	2,320	90.7%	*****	*****	0	NaN	0	NaN	0	NaN
serdexmethylphenidate and dexmethylphenidate	**62,899**	**48,701**	**100.0%**	**11,014**	**100.0%**	**3,022**	**100.0%**	**149**	**100.0%**	**13**	**100.0%**
0-17 years	36,673	28,627	58.8%	6,216	56.4%	1,734	57.4%	*****	*****	*****	*****
18-24 years	6,662	5,273	10.8%	1,081	9.8%	*****	*****	*****	*****	*****	*****
25-40 years	10,713	8,253	16.9%	1,916	17.4%	514	17.0%	*****	*****	*****	*****
41-64 years	8,264	6,125	12.6%	1,666	15.1%	447	14.8%	*****	*****	*****	*****
≥ 65 years	587	423	0.9%	135	1.2%	*****	*****	*****	*****	*****	*****
pegcetacoplan	**139,915**	**139,682**	**100.0%**	**117**	**100.0%**	**89**	**100.0%**	*****	*****	*****	*****

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

| | | Number of Treatment Episodes by Duration (Excluding First Treatment Episode) | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	20	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	48	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	890	823	0.6%	30	25.6%	*****	*****	*****	*****	*****	*****
≥ 65 years	138,957	138,822	99.4%	72	61.5%	48	53.9%	*****	*****	*****	*****
amivantamab-vmjw	**11,628**	**11,607**	**100.0%**	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	52	52	0.4%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	1,896	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	9,680	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
piflufolastat F 18	**33,814**	**33,814**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	31,955	31,955	94.5%	0	NaN	0	NaN	0	NaN	0	NaN
sotorasib	**3,040**	**1,705**	**100.0%**	**833**	**100.0%**	**446**	**100.0%**	**45**	**100.0%**	**11**	**100.0%**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

| | | Number of Treatment Episodes by Duration (Excluding First Treatment Episode) | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
≥ 65 years	2,476	1,393	81.7%	668	80.2%	365	81.8%	*****	*****	*****	*****
infigratinib	**22**	**10**	**100.0%**	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	0	0.0%	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
≥ 65 years	11	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
olanzapine and samidorphan	**17,783**	**9,695**	**100.0%**	**4,778**	**100.0%**	**2,773**	**100.0%**	**449**	**100.0%**	**88**	**100.0%**
0-17 years	89	51	0.5%	27	0.6%	11	0.4%	0	0.0%	0	0.0%
18-24 years	1,178	667	6.9%	322	6.7%	166	6.0%	*****	*****	*****	*****
25-40 years	6,305	3,439	35.5%	1,685	35.3%	982	35.4%	160	35.6%	39	44.3%
41-64 years	8,599	4,601	47.5%	2,350	49.2%	1,377	49.7%	233	51.9%	38	43.2%
≥ 65 years	1,612	937	9.7%	394	8.2%	237	8.5%	*****	*****	*****	*****
ibrexafungerp	**1,375**	**1,354**	**100.0%**	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	160	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
25-40 years	728	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	458	445	32.9%	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
aducanumab-avwa	**2,359**	*****	*****	**0**	**NaN**	*****	*****	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	NaN	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	0.0%	0	NaN	0	NaN

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

| | | Number of Treatment Episodes by Duration (Excluding First Treatment Episode) | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
25-40 years	0	0	0.0%	0	NaN	0	0.0%	0	NaN	0	NaN
41-64 years	102	102	4.3%	0	NaN	0	0.0%	0	NaN	0	NaN
≥ 65 years	2,257	*****	*****	0	NaN	*****	*****	0	NaN	0	NaN
asparaginase erwinia chrysanthemi (recombinant)-rywn	**3,775**	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	2,934	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
18-24 years	410	410	10.9%	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	316	316	8.4%	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	42	42	1.1%	0	0.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	73	73	1.9%	0	0.0%	0	NaN	0	NaN	0	NaN

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*NaN: Not a number

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
vericiguat	**15,886**	**1**	**30**	**44**	**90**	**1,185**	**85.9**	**112.5**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	4	30	30	113	289	79.8	99.4
25-40 years	*****	2	30	30	87	450	62.3	70.2
41-64 years	3,174	1	30	33	90	1,130	76.2	96.6
≥ 65 years	12,501	1	30	50	90	1,185	88.8	116.6
cabotegravir	**52,895**	**1**	**1**	**1**	**30**	**1,318**	**28.4**	**70.5**
0-17 years	13	1	1	1	1	1	1.0	0.0
18-24 years	1,608	1	1	1	1	722	13.0	45.3
25-40 years	19,156	1	1	1	1	1,119	14.2	44.4
41-64 years	25,590	1	1	1	30	1,318	31.9	75.0
≥ 65 years	6,528	1	1	30	60	1,236	60.5	101.1
voclosporin	**2,106**	**1**	**30**	**30**	**60**	**819**	**59.0**	**67.3**
0-17 years	*****	30	30	30	30	30	30.0	0.0
18-24 years	228	1	30	30	60	570	60.7	66.0
25-40 years	1,030	1	30	30	60	740	54.8	59.5
41-64 years	748	2	30	30	60	819	63.5	77.0
≥ 65 years	*****	2	30	30	71	357	65.1	67.6
tepotinib	**621**	**1**	**30**	**30**	**60**	**750**	**61.4**	**84.3**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	30	30	30	30	30	30.0	0.0
41-64 years	*****	9	30	30	60	510	64.6	71.5
≥ 65 years	545	1	30	30	60	750	61.2	86.2

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
umbralisib	**55**	**17**	**30**	**30**	**60**	**270**	**51.7**	**44.7**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	*****	30	30	30	60	60	42.9	16.0
≥ 65 years	*****	17	30	30	60	270	53.0	47.4
evinacumab-dgnb	**1,598**	**1**	**1**	**1**	**1**	**364**	**3.3**	**15.0**
0-17 years	64	1	1	1	1	1	1.0	0.0
18-24 years	19	1	1	1	1	1	1.0	0.0
25-40 years	168	1	1	1	1	56	1.7	5.2
41-64 years	635	1	1	1	1	144	4.8	14.8
≥ 65 years	712	1	1	1	1	364	2.6	17.3
trilacicilib	**5,059**	**1**	**3**	**3**	**3**	**63**	**2.9**	**1.3**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	16	1	1	1	1	1	1.0	0.0
41-64 years	601	1	3	3	3	42	2.8	1.8
≥ 65 years	4,442	1	3	3	3	63	2.9	1.2
casimersen	**2,033**	**1**	**1**	**1**	**1**	**392**	**5.0**	**24.4**
0-17 years	1,561	1	1	1	1	392	2.6	14.5
18-24 years	424	1	1	1	1	337	7.4	30.1
25-40 years	48	1	1	15	84	329	60.3	85.4
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
fosdenopterin	*****	**33**	**33**	**33**	**33**	**33**	**33.0**	**NaN**
0-17 years	*****	33	33	33	33	33	33.0	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
melphalan flufenamide	**125**	**1**	**1**	**1**	**1**	**28**	**1.2**	**2.4**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	20	1	1	1	1	1	1.0	0.0
≥ 65 years	105	1	1	1	1	28	1.3	2.6
tivozanib	**1,822**	**1**	**28**	**28**	**56**	**588**	**57.9**	**60.4**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	9	9	9	9	9	9.0	NaN
25-40 years	*****	28	28	28	42	56	35.0	13.0
41-64 years	*****	1	28	28	79	364	58.5	58.4
≥ 65 years	1,511	1	28	28	56	588	57.9	60.9
ponesimod	**407**	**4**	**30**	**30**	**90**	**1,162**	**93.9**	**132.7**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	14	30	30	180	484	117.3	171.3
25-40 years	121	10	30	30	90	1,110	82.2	132.9
41-64 years	261	4	30	30	90	1,162	93.7	124.3
≥ 65 years	*****	30	30	90	120	720	166.1	207.0

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
dasiglucagon	**631**	**1**	**1**	**2**	**30**	**247**	**22.9**	**36.7**
0-17 years	203	1	1	2	30	184	18.9	32.7
18-24 years	64	1	1	2	30	210	24.8	38.4
25-40 years	89	1	1	4	30	210	26.9	40.0
41-64 years	211	1	1	2	30	229	22.1	35.8
≥ 65 years	64	1	2	30	30	247	30.7	43.9
viloxazine	**40,945**	**1**	**30**	**30**	**60**	**1,225**	**62.3**	**78.5**
0-17 years	27,283	1	30	30	60	1,204	63.9	82.9
18-24 years	3,863	1	30	30	60	1,225	59.0	70.1
25-40 years	5,437	1	30	30	60	840	58.2	66.0
41-64 years	3,880	1	30	30	60	870	60.2	71.7
≥ 65 years	482	1	30	30	60	660	59.9	64.3
drospirenone and estetrol	**11,775**	**1**	**28**	**63**	**96**	**1,120**	**94.4**	**103.8**
0-17 years	1,511	1	28	56	112	1,120	96.1	114.5
18-24 years	3,958	1	28	70	112	964	95.0	101.3
25-40 years	4,688	1	28	63	84	1,066	92.6	101.0
41-64 years	1,618	1	28	60	99	850	96.3	107.2
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
dostarlimab-gxly	**12,787**	**1**	**1**	**1**	**1**	**189**	**1.2**	**3.5**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	11	1	1	1	1	1	1.0	0.0
25-40 years	158	1	1	1	1	1	1.0	0.0
41-64 years	2,063	1	1	1	1	2	1.0	0.0
≥ 65 years	10,555	1	1	1	1	189	1.2	3.8

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
loncastuximab tesirine-lpyl	**2,561**	**1**	**1**	**1**	**1**	**84**	**1.3**	**3.3**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	208	1	1	1	1	84	2.4	7.4
≥ 65 years	2,322	1	1	1	1	84	1.2	2.7
serdexmethylphenidate and dexmethylphenidate	**62,899**	**1**	**30**	**30**	**30**	**1,156**	**43.0**	**43.4**
0-17 years	36,673	1	30	30	30	1,156	42.9	44.1
18-24 years	6,662	1	30	30	30	736	41.1	36.6
25-40 years	10,713	1	30	30	30	775	43.0	43.2
41-64 years	8,264	1	30	30	42	817	44.9	44.6
≥ 65 years	587	1	30	30	50	792	46.6	55.1
pegcetacoplan	**139,915**	**1**	**1**	**1**	**1**	**1,168**	**1.3**	**10.1**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	20	26	28	56	84	318	77.5	78.7
25-40 years	48	1	2	30	98	787	111.4	181.3
41-64 years	890	1	1	1	1	1,012	15.1	64.5
≥ 65 years	138,957	1	1	1	1	1,168	1.2	7.6
amivantamab-vmjw	**11,628**	**1**	**1**	**1**	**1**	**253**	**1.2**	**4.5**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	52	1	1	1	1	1	1.0	0.0
41-64 years	1,896	1	1	1	1	253	1.4	7.3

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	9,680	1	1	1	1	168	1.2	3.7
piflufolastat F 18	**33,814**	**1**	**1**	**1**	**1**	**2**	**1.0**	**0.0**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	NaN
41-64 years	*****	1	1	1	1	1	1.0	0.0
≥ 65 years	31,955	1	1	1	1	2	1.0	0.0
sotorasib	**3,040**	**1**	**30**	**30**	**70**	**1,191**	**72.3**	**97.1**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	15	15	16	60	120	45.2	46.1
41-64 years	*****	3	30	30	60	780	65.1	75.0
≥ 65 years	2,476	1	30	30	75	1,191	74.0	101.4
infigratinib	**22**	**28**	**28**	**56**	**84**	**336**	**66.5**	**67.4**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	84	84	140	336	336	186.7	132.3
41-64 years	*****	28	28	28	56	84	42.0	21.2
≥ 65 years	11	28	28	56	84	92	51.6	25.6
olanzapine and samidorphan	**17,783**	**1**	**30**	**30**	**90**	**1,118**	**79.5**	**109.9**
0-17 years	89	2	30	30	60	222	55.0	44.3
18-24 years	1,178	1	30	30	68	1,058	69.4	87.3
25-40 years	6,305	1	30	30	90	1,108	80.5	113.7
41-64 years	8,599	1	30	30	90	1,118	81.1	110.8

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	1,612	1	30	30	79	945	75.5	107.1
ibrexafungerp	**1,375**	**1**	**1**	**1**	**1**	**261**	**3.6**	**14.5**
0-17 years	*****	1	1	1	1	2	1.1	0.4
18-24 years	160	1	1	1	1	33	1.9	4.7
25-40 years	728	1	1	1	1	208	2.8	10.9
41-64 years	458	1	1	1	1	261	5.0	20.3
≥ 65 years	*****	1	1	1	1	84	10.2	20.2
aducanumab-avwa	**2,359**	**1**	**1**	**1**	**1**	**155**	**1.1**	**3.2**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	102	1	1	1	1	1	1.0	0.0
≥ 65 years	2,257	1	1	1	1	155	1.1	3.2
asparaginase erwinia chrysanthemi (recombinant)-rywn	**3,775**	**1**	**1**	**1**	**1**	**84**	**1.0**	**1.4**
0-17 years	2,934	1	1	1	1	84	1.0	1.5
18-24 years	410	1	1	1	1	1	1.0	0.0
25-40 years	316	1	1	1	1	2	1.0	0.1
41-64 years	42	1	1	1	1	1	1.0	0.0
≥ 65 years	73	1	1	1	1	1	1.0	0.0

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*NaN: Not a number

Table 7a. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
vericiguat	15,886	1	3	8	23	1,247	25.3	58.3
cabotegravir	52,895	1	17	39	57	1,116	40.2	36.3
voclosporin	2,106	1	3	7	18	739	20.1	49.0
tepotinib	621	1	3	7	20	425	19.0	35.9
umbralisib	55	1	2	5	11	116	12.0	19.3
evinacumab-dgnb	1,598	1	27	27	29	485	29.8	19.6
trilacicilib	5,059	1	18	18	20	522	23.0	31.6
casimersen	2,033	1	6	6	13	230	10.6	11.7
fosdenopterin	*****	7	7	7	7	7	7.0	NaN
melphalan flufenamide	125	10	27	28	41	91	34.0	11.6
tivozanib	1,822	1	3	6	14	426	14.9	30.5
ponesimod	407	1	3	6	12	430	13.4	31.9
dasiglucagon	631	1	8	35	118	879	105.2	157.1
viloxazine	40,945	1	3	8	21	1,000	21.9	47.8
drospirenone and estetrol	11,775	1	3	7	24	867	25.5	56.5
dostarlimab-gxly	12,787	1	20	20	41	418	29.2	16.0
loncastuximab tesirine-lpyl	2,561	1	20	20	23	407	24.7	16.9
serdexmethylphenidate and dexmethylphenidate	62,899	1	3	9	22	1,052	20.2	38.7
pegcetacoplan	139,915	1	34	51	60	658	48.8	25.4
amivantamab-vmjw	11,628	1	7	13	14	910	14.1	14.5
piflufolastat F 18	33,814	1	152	236	380	1,202	288.7	182.8
sotorasib	3,040	1	3	6	17	718	18.2	43.5
infigratinib	22	1	3	6	21	62	12.8	14.3

Table 7a. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
olanzapine and samidorphan	17,783	1	3	6	17	996	20.6	53.4
ibrexafungerp	1,375	1	7	26	60	1,031	53.2	83.5
aducanumab-avwa	2,359	1	27	27	32	959	43.1	63.5
asparaginase erwinia chrysanthemi (recombinant)-rywn	3,775	1	1	1	2	928	5.6	21.8

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*NaN: Not a number

Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
vericiguat	**15,886**	**1**	**3**	**8**	**23**	**1,247**	**25.3**	**58.3**
Female	5,680	1	3	8	22	1,247	24.8	56.7
Male	10,206	1	3	8	23	1,062	25.6	59.2
cabotegravir	**52,895**	**1**	**17**	**39**	**57**	**1,116**	**40.2**	**36.3**
Female	7,710	1	9	29	55	810	36.3	40.0
Male	45,185	1	19	42	58	1,116	40.9	35.7
voclosporin	**2,106**	**1**	**3**	**7**	**18**	**739**	**20.1**	**49.0**
Female	1,715	1	3	8	18	739	20.1	47.5
Male	391	1	3	6	16	640	20.5	55.2
tepotinib	**621**	**1**	**3**	**7**	**20**	**425**	**19.0**	**35.9**
Female	421	1	3	6	18	290	18.3	31.5
Male	200	1	3	8	23	425	20.4	43.8
umbralisib	**55**	**1**	**2**	**5**	**11**	**116**	**12.0**	**19.3**
Female	27	1	2	4	21	116	16.5	26.0
Male	28	1	2	6	10	27	7.7	7.4
evinacumab-dgnb	**1,598**	**1**	**27**	**27**	**29**	**485**	**29.8**	**19.6**
Female	1,217	1	27	27	29	485	29.8	21.0
Male	381	1	27	27	28	240	29.5	14.3
trilacicilib	**5,059**	**1**	**18**	**18**	**20**	**522**	**23.0**	**31.6**
Female	2,743	1	18	18	20	522	23.4	35.1
Male	2,316	1	18	18	20	459	22.5	27.0
casimersen	**2,033**	**1**	**6**	**6**	**13**	**230**	**10.6**	**11.7**
Female	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Male	2,033	1	6	6	13	230	10.6	11.7

Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
fosdenopterin	*********	**7**	**7**	**7**	**7**	**7**	**7.0**	**NaN**
Female	*****	7	7	7	7	7	7.0	NaN
Male	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
melphalan flufenamide	**125**	**10**	**27**	**28**	**41**	**91**	**34.0**	**11.6**
Female	62	21	27	27	38	75	33.1	10.9
Male	63	10	27	30	41	91	34.8	12.3
tivozanib	**1,822**	**1**	**3**	**6**	**14**	**426**	**14.9**	**30.5**
Female	488	1	3	7	17	371	17.2	38.1
Male	1,334	1	3	6	13	426	14.0	27.2
ponesimod	**407**	**1**	**3**	**6**	**12**	**430**	**13.4**	**31.9**
Female	289	1	3	6	11	248	12.4	26.1
Male	118	1	4	7	14	430	16.1	43.0
dasiglucagon	**631**	**1**	**8**	**35**	**118**	**879**	**105.2**	**157.1**
Female	386	1	7	33	100	879	99.5	159.0
Male	245	1	11	42	152	727	114.2	153.9
viloxazine	**40,945**	**1**	**3**	**8**	**21**	**1,000**	**21.9**	**47.8**
Female	16,994	1	4	9	23	1,000	23.2	49.9
Male	23,951	1	3	8	20	996	20.9	46.3
drospirenone and estetrol	**11,775**	**1**	**3**	**7**	**24**	**867**	**25.5**	**56.5**
Female	11,752	1	3	7	24	867	25.5	56.6
Male	23	1	5	12	43	87	24.3	25.0
dostarlimab-gxly	**12,787**	**1**	**20**	**20**	**41**	**418**	**29.2**	**16.0**
Female	11,911	1	20	20	41	418	29.3	16.1
Male	876	1	20	20	41	209	27.0	14.2

Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
loncastuximab tesirine-lpyl	**2,561**	**1**	**20**	**20**	**23**	**407**	**24.7**	**16.9**
Female	1,101	3	20	20	26	407	25.9	22.3
Male	1,460	1	20	20	22	171	23.9	11.1
serdexmethylphenidate and dexmethylphenidate	**62,899**	**1**	**3**	**9**	**22**	**1,052**	**20.2**	**38.7**
Female	27,123	1	4	9	22	1,018	20.6	39.3
Male	35,776	1	3	9	22	1,052	20.0	38.3
pegcetacoplan	**139,915**	**1**	**34**	**51**	**60**	**658**	**48.8**	**25.4**
Female	95,281	1	34	50	60	575	48.8	25.6
Male	44,634	1	34	52	60	658	48.9	25.0
amivantamab-vmjw	**11,628**	**1**	**7**	**13**	**14**	**910**	**14.1**	**14.5**
Female	8,368	1	8	13	14	910	14.0	15.0
Male	3,260	1	6	13	14	323	14.1	13.2
piflufolastat F 18	**33,814**	**1**	**152**	**236**	**380**	**1,202**	**288.7**	**182.8**
Female	*****	140	146	237	419	517	282.5	176.8
Male	*****	1	152	236	380	1,202	288.7	182.8
sotorasib	**3,040**	**1**	**3**	**6**	**17**	**718**	**18.2**	**43.5**
Female	1,943	1	3	6	17	718	18.5	45.0
Male	1,097	1	2	5	16	543	17.8	40.8
infigratinib	**22**	**1**	**3**	**6**	**21**	**62**	**12.8**	**14.3**
Female	11	1	2	5	9	27	7.9	8.5
Male	11	1	5	18	24	62	17.6	17.5
olanzapine and samidorphan	**17,783**	**1**	**3**	**6**	**17**	**996**	**20.6**	**53.4**
Female	9,446	1	3	7	18	938	22.6	57.8

Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

| | Total Number of Gaps | Distribution of Treatment Episode Gap Durations, days | | | | | | |
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Male	8,337	1	3	6	16	996	18.4	47.7
ibrexafungerp	**1,375**	**1**	**7**	**26**	**60**	**1,031**	**53.2**	**83.5**
Female	*****	1	7	26	60	1,031	53.3	83.5
Male	*****	3	3	10	27	37	14.8	16.0
aducanumab-avwa	**2,359**	**1**	**27**	**27**	**32**	**959**	**43.1**	**63.5**
Female	1,188	1	27	27	32	693	40.4	53.6
Male	1,171	5	27	27	31	959	45.8	72.1
asparaginase erwinia chrysanthemi (recombinant)-rywn	**3,775**	**1**	**1**	**1**	**2**	**928**	**5.6**	**21.8**
Female	1,123	1	1	1	2	160	5.4	15.5
Male	2,652	1	1	1	2	928	5.7	24.0

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*NaN: Not a number

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
vericiguat	**15,886**	**1**	**3**	**8**	**23**	**1,247**	**25.3**	**58.3**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	4	12	21	160	29.1	53.5
25-40 years	*****	1	4	14	33	575	40.1	82.2
41-64 years	3,174	1	3	9	25	693	25.9	51.2
≥ 65 years	12,501	1	3	8	22	1,247	24.9	59.5
cabotegravir	**52,895**	**1**	**17**	**39**	**57**	**1,116**	**40.2**	**36.3**
0-17 years	13	27	46	56	62	113	54.8	22.4
18-24 years	1,608	1	26	52	59	670	44.9	34.7
25-40 years	19,156	1	27	53	60	967	44.9	34.1
41-64 years	25,590	1	14	34	56	1,116	39.1	38.2
≥ 65 years	6,528	1	6	26	53	500	29.6	32.9
voclosporin	**2,106**	**1**	**3**	**7**	**18**	**739**	**20.1**	**49.0**
0-17 years	*****	2	2	2	4	4	2.7	1.2
18-24 years	228	1	3	7	18	640	21.7	54.4
25-40 years	1,030	1	3	8	17	739	20.3	50.0
41-64 years	748	1	3	7	18	509	19.7	47.8
≥ 65 years	*****	1	2	5	21	215	18.5	32.8
tepotinib	**621**	**1**	**3**	**7**	**20**	**425**	**19.0**	**35.9**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	2	4	10	76	9.8	14.8
≥ 65 years	545	1	3	7	23	425	20.3	37.7

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
umbralisib	**55**	**1**	**2**	**5**	**11**	**116**	**12.0**	**19.3**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	*****	3	7	8	11	116	23.4	40.9
≥ 65 years	*****	1	2	5	13	60	10.4	13.9
evinacumab-dgnb	**1,598**	**1**	**27**	**27**	**29**	**485**	**29.8**	**19.6**
0-17 years	64	22	27	27	27	55	28.4	5.5
18-24 years	19	26	27	27	28	240	41.8	49.2
25-40 years	168	1	27	27	28	48	28.1	5.8
41-64 years	635	1	27	27	28	368	28.7	17.4
≥ 65 years	712	1	27	27	30	485	30.9	22.6
trilacicilib	**5,059**	**1**	**18**	**18**	**20**	**522**	**23.0**	**31.6**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	16	6	6	13	13	71	14.9	15.7
41-64 years	601	1	18	18	21	376	22.7	27.1
≥ 65 years	4,442	1	18	18	20	522	23.1	32.2
casimersen	**2,033**	**1**	**6**	**6**	**13**	**230**	**10.6**	**11.7**
0-17 years	1,561	1	6	6	13	230	11.1	11.5
18-24 years	424	1	6	6	8	160	8.5	9.5
25-40 years	48	1	2	6	7	146	12.5	25.7
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
fosdenopterin	*****	7	7	7	7	7	7.0	NaN
0-17 years	*****	7	7	7	7	7	7.0	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
melphalan flufenamide	125	10	27	28	41	91	34.0	11.6
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	20	19	27	27	37	55	32.3	9.3
≥ 65 years	105	10	27	28	41	91	34.3	12.0
tivozanib	1,822	1	3	6	14	426	14.9	30.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	17	17	17	17	17	17.0	NaN
25-40 years	*****	1	2	3	11	36	8.5	12.2
41-64 years	*****	1	3	6	13	204	11.3	19.2
≥ 65 years	1,511	1	3	7	14	426	15.6	32.4
ponesimod	407	1	3	6	12	430	13.4	31.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	15	40	180	248	80.3	94.9
25-40 years	121	1	3	6	12	67	9.5	10.3
41-64 years	261	1	3	6	11	430	13.6	34.3
≥ 65 years	*****	1	1	6	13	97	12.2	22.3

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
dasiglucagon	**631**	**1**	**8**	**35**	**118**	**879**	**105.2**	**157.1**
0-17 years	203	1	8	36	149	737	113.9	163.4
18-24 years	64	1	13	41	183	624	112.8	141.8
25-40 years	89	1	7	41	141	879	128.2	195.2
41-64 years	211	1	7	27	85	727	80.4	135.2
≥ 65 years	64	4	16	48	166	791	119.7	153.9
viloxazine	**40,945**	**1**	**3**	**8**	**21**	**1,000**	**21.9**	**47.8**
0-17 years	27,283	1	3	8	20	985	21.1	47.5
18-24 years	3,863	1	4	9	25	1,000	24.3	49.8
25-40 years	5,437	1	4	9	23	872	22.7	47.0
41-64 years	3,880	1	4	9	23	996	23.3	49.8
≥ 65 years	482	1	4	9	29	325	24.5	41.0
drospirenone and estetrol	**11,775**	**1**	**3**	**7**	**24**	**867**	**25.5**	**56.5**
0-17 years	1,511	1	2	7	27	867	28.5	62.1
18-24 years	3,958	1	3	7	26	818	26.9	58.9
25-40 years	4,688	1	3	7	22	784	23.9	52.5
41-64 years	1,618	1	2	7	21	779	23.8	56.4
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
dostarlimab-gxly	**12,787**	**1**	**20**	**20**	**41**	**418**	**29.2**	**16.0**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	11	19	20	20	20	27	20.5	2.2
25-40 years	158	19	20	20	39	90	26.8	11.8
41-64 years	2,063	1	20	20	41	216	29.0	16.0
≥ 65 years	10,555	1	20	20	41	418	29.2	16.0

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
loncastuximab tesirine-lpyl	**2,561**	**1**	**20**	**20**	**23**	**407**	**24.7**	**16.9**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	20	20	22	41	42	27.1	10.0
25-40 years	*****	17	20	22	29	69	28.4	14.8
41-64 years	208	2	20	20	27	235	25.6	21.9
≥ 65 years	2,322	1	20	20	23	407	24.6	16.4
serdexmethylphenidate and dexmethylphenidate	**62,899**	**1**	**3**	**9**	**22**	**1,052**	**20.2**	**38.7**
0-17 years	36,673	1	4	10	24	1,052	21.4	39.5
18-24 years	6,662	1	4	10	26	677	23.2	41.7
25-40 years	10,713	1	3	7	19	712	17.8	34.6
41-64 years	8,264	1	3	6	16	1,018	15.9	36.6
≥ 65 years	587	1	3	6	15	488	18.9	43.0
pegcetacoplan	**139,915**	**1**	**34**	**51**	**60**	**658**	**48.8**	**25.4**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	20	1	2	3	9	402	27.1	88.8
25-40 years	48	1	3	8	35	104	21.8	28.6
41-64 years	890	1	27	39	55	433	42.3	36.2
≥ 65 years	138,957	1	34	51	60	658	48.9	25.3
amivantamab-vmjw	**11,628**	**1**	**7**	**13**	**14**	**910**	**14.1**	**14.5**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	52	1	6	6	14	53	11.1	9.9
41-64 years	1,896	1	6	13	15	431	14.0	15.7

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	9,680	1	7	13	14	910	14.1	14.3
piflufolastat F 18	**33,814**	**1**	**152**	**236**	**380**	**1,202**	**288.7**	**182.8**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	68	68	68	68	68	68.0	NaN
41-64 years	*****	8	139	209	343	963	261.1	168.4
≥ 65 years	31,955	1	153	237	383	1,202	290.3	183.5
sotorasib	**3,040**	**1**	**3**	**6**	**17**	**718**	**18.2**	**43.5**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	4	4	11	130	30.0	56.0
41-64 years	*****	1	2	6	15	298	15.8	29.8
≥ 65 years	2,476	1	3	6	17	718	18.8	46.0
infigratinib	**22**	**1**	**3**	**6**	**21**	**62**	**12.8**	**14.3**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	5	5	6	18	18	9.7	7.2
41-64 years	*****	1	2	5	23	27	10.8	11.4
≥ 65 years	11	1	3	8	21	62	15.1	17.8
olanzapine and samidorphan	**17,783**	**1**	**3**	**6**	**17**	**996**	**20.6**	**53.4**
0-17 years	89	1	3	6	19	276	21.8	41.2
18-24 years	1,178	1	3	7	19	646	21.0	46.5
25-40 years	6,305	1	3	6	17	938	19.8	53.3
41-64 years	8,599	1	3	6	17	996	20.9	55.6

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	1,612	1	3	8	22	601	21.9	46.4
ibrexafungerp	**1,375**	**1**	**7**	**26**	**60**	**1,031**	**53.2**	**83.5**
0-17 years	*****	1	2	7	20	25	10.3	9.7
18-24 years	160	1	13	30	63	822	56.8	99.8
25-40 years	728	1	6	24	52	531	48.0	70.5
41-64 years	458	1	7	29	76	1,031	61.6	95.8
≥ 65 years	*****	1	12	21	31	336	37.0	70.5
aducanumab-avwa	**2,359**	**1**	**27**	**27**	**32**	**959**	**43.1**	**63.5**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	102	22	27	28	32	83	32.0	10.9
≥ 65 years	2,257	1	27	27	32	959	43.6	64.9
asparaginase erwinia chrysanthemi (recombinant)-rywn	**3,775**	**1**	**1**	**1**	**2**	**928**	**5.6**	**21.8**
0-17 years	2,934	1	1	1	2	928	5.5	22.7
18-24 years	410	1	1	1	2	320	7.9	24.7
25-40 years	316	1	1	1	2	67	4.0	8.1
41-64 years	42	1	1	1	4	37	3.8	6.5
≥ 65 years	73	1	1	1	4	29	4.4	6.5

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*NaN: Not a number

Table 8a. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
vericiguat	5,335	1	4	11	29	1,247	32.3	71.8
cabotegravir	11,174	1	11	27	37	1,116	32.6	43.6
voclosporin	580	1	3	8	20	739	23.0	57.5
tepotinib	230	1	3	6	17	425	19.9	46.9
umbralisib	32	1	2	5	13	116	12.4	22.2
evinacumab-dgnb	123	1	27	27	31	86	29.2	11.2
trilacicilib	1,657	1	18	18	19	366	20.0	12.2
casimersen	117	1	6	6	13	103	13.0	15.2
fosdenopterin	*****	7	7	7	7	7	7.0	NaN
melphalan flufenamide	52	10	27	27	41	91	34.0	13.9
tivozanib	778	1	3	6	15	371	17.0	35.2
ponesimod	116	1	3	6	15	430	15.2	42.8
dasiglucagon	313	1	9	45	205	879	134.5	184.2
viloxazine	16,102	1	4	9	21	1,000	23.0	54.1
drospirenone and estetrol	5,565	1	3	10	32	867	31.2	61.9
dostarlimab-gxly	2,308	1	20	20	21	418	24.2	16.3
loncastuximab tesirine-lpyl	604	1	20	20	21	145	23.0	10.1
dexmethylphenidate	17,480	1	3	8	22	1,052	22.9	51.5
pegcetacoplan	27,568	1	35	55	62	658	53.1	32.6
amivantamab-vmjw	1,242	1	5	5	6	910	8.9	27.5
piflufolastat F 18	24,087	1	175	279	424	1,202	322.5	192.4
sotorasib	1,221	1	2	6	19	718	21.7	50.8
infigratinib	15	1	2	5	8	22	7.5	7.5
olanzapine and samidorphan	5,837	1	3	7	19	996	26.6	70.4
ibrexafungerp	686	1	6	29	73	1,031	61.6	96.0

Table 8a. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
aducanumab-avwa	357	1	27	27	32	566	49.4	71.9
asparaginase erwinia chrysanthemi (recombinant)-rywn	251	1	1	1	2	139	3.8	12.8

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*NaN: Not a number

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
vericiguat	**5,335**	**1**	**4**	**11**	**29**	**1,247**	**32.3**	**71.8**
Female	1,886	1	4	11	29	1,247	31.2	65.8
Male	3,449	1	4	11	29	1,062	33.0	74.9
cabotegravir	**11,174**	**1**	**11**	**27**	**37**	**1,116**	**32.6**	**43.6**
Female	1,755	1	7	26	33	809	31.0	47.0
Male	9,419	1	12	27	38	1,116	32.9	42.9
voclosporin	**580**	**1**	**3**	**8**	**20**	**739**	**23.0**	**57.5**
Female	492	1	3	8	19	739	22.1	55.9
Male	88	1	3	8	22	455	28.2	65.5
tepotinib	**230**	**1**	**3**	**6**	**17**	**425**	**19.9**	**46.9**
Female	148	1	3	6	13	290	14.5	32.0
Male	82	1	3	8	27	425	29.6	64.9
umbralisib	**32**	**1**	**2**	**5**	**13**	**116**	**12.4**	**22.2**
Female	16	1	3	6	20	116	18.1	30.2
Male	16	1	2	5	10	25	6.8	6.5
evinacumab-dgnb	**123**	**1**	**27**	**27**	**31**	**86**	**29.2**	**11.2**
Female	96	1	27	27	32	86	29.3	11.7
Male	27	1	27	27	27	58	28.7	9.3
trilacicilib	**1,657**	**1**	**18**	**18**	**19**	**366**	**20.0**	**12.2**
Female	888	1	18	18	20	74	19.7	7.6
Male	769	1	18	18	19	366	20.2	16.0
casimersen	**117**	**1**	**6**	**6**	**13**	**103**	**13.0**	**15.2**

Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Female	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Male	117	1	6	6	13	103	13.0	15.2
fosdenopterin	*****	**7**	**7**	**7**	**7**	**7**	**7.0**	**NaN**
Female	*****	7	7	7	7	7	7.0	NaN
Male	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
melphalan flufenamide	**52**	**10**	**27**	**27**	**41**	**91**	**34.0**	**13.9**
Female	25	21	27	27	41	75	34.0	13.0
Male	27	10	27	27	41	91	34.0	14.8
tivozanib	**778**	**1**	**3**	**6**	**15**	**371**	**17.0**	**35.2**
Female	206	1	3	8	20	371	22.4	49.9
Male	572	1	3	6	14	294	15.0	27.9
ponesimod	**116**	**1**	**3**	**6**	**15**	**430**	**15.2**	**42.8**
Female	82	1	3	6	12	141	11.4	20.6
Male	34	1	5	9	20	430	24.4	72.3
dasiglucagon	**313**	**1**	**9**	**45**	**205**	**879**	**134.5**	**184.2**
Female	198	1	7	42	178	879	132.8	194.0
Male	115	1	14	49	221	727	137.6	166.7
viloxazine	**16,102**	**1**	**4**	**9**	**21**	**1,000**	**23.0**	**54.1**
Female	6,775	1	4	9	23	1,000	24.5	54.7
Male	9,327	1	3	8	20	996	22.0	53.7
drospirenone and estetrol	**5,565**	**1**	**3**	**10**	**32**	**867**	**31.2**	**61.9**
Female	5,553	1	3	10	32	867	31.2	61.9

Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Male	12	3	6	22	46	62	25.8	21.3
dostarlimab-gxly	**2,308**	**1**	**20**	**20**	**21**	**418**	**24.2**	**16.3**
Female	2,166	1	20	20	21	418	24.2	16.4
Male	142	1	20	20	20	135	24.3	15.0
loncastuximab tesirine-lpyl	**604**	**1**	**20**	**20**	**21**	**145**	**23.0**	**10.1**
Female	262	3	20	20	22	145	23.7	11.3
Male	342	1	20	20	21	86	22.5	9.1
serdexmethylphenidate and dexmethylphenidate	**17,480**	**1**	**3**	**8**	**22**	**1,052**	**22.9**	**51.5**
Female	7,894	1	3	9	23	1,018	23.3	51.5
Male	9,586	1	3	8	21	1,052	22.6	51.5
pegcetacoplan	**27,568**	**1**	**35**	**55**	**62**	**658**	**53.1**	**32.6**
Female	18,773	1	35	55	62	575	53.4	33.2
Male	8,795	1	35	55	62	658	52.5	31.2
amivantamab-vmjw	**1,242**	**1**	**5**	**5**	**6**	**910**	**8.9**	**27.5**
Female	842	1	5	5	7	910	9.1	32.6
Male	400	1	5	5	6	121	8.5	11.0
piflufolastat F 18	**24,087**	**1**	**175**	**279**	**424**	**1,202**	**322.5**	**192.4**
Female	*****	140	146	237	419	517	282.5	176.8
Male	*****	1	175	279	424	1,202	322.5	192.4
sotorasib	**1,221**	**1**	**2**	**6**	**19**	**718**	**21.7**	**50.8**
Female	748	1	3	7	21	718	21.9	50.8
Male	473	1	2	5	17	543	21.4	50.9

Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
infigratinib	**15**	**1**	**2**	**5**	**8**	**22**	**7.5**	**7.5**
Female	*****	1	2	5	7	21	6.1	6.5
Male	*****	1	2	6	21	22	9.0	8.8
olanzapine and samidorphan	**5,837**	**1**	**3**	**7**	**19**	**996**	**26.6**	**70.4**
Female	3,157	1	3	7	21	938	28.9	75.5
Male	2,680	1	3	7	18	996	23.8	63.7
ibrexafungerp	**686**	**1**	**6**	**29**	**73**	**1,031**	**61.6**	**96.0**
Female	*****	1	6	29	74	1,031	61.8	96.1
Male	*****	3	3	10	16	16	9.5	9.2
aducanumab-avwa	**357**	**1**	**27**	**27**	**32**	**566**	**49.4**	**71.9**
Female	200	1	27	27	32	566	44.0	66.1
Male	157	20	27	27	32	472	56.2	78.4
asparaginase erwinia chrysanthemi (recombinant)-rywn	**251**	**1**	**1**	**1**	**2**	**139**	**3.8**	**12.8**
Female	82	1	1	1	2	54	3.4	7.7
Male	169	1	1	1	2	139	3.9	14.6

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*NaN: Not a number

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
vericiguat	**5,335**	**1**	**4**	**11**	**29**	**1,247**	**32.3**	**71.8**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	3	12	19	160	34.3	62.0
25-40 years	*****	1	6	20	46	575	64.9	121.5
41-64 years	997	1	4	12	32	693	31.9	57.9
≥ 65 years	4,260	1	4	11	28	1,247	31.9	73.5
cabotegravir	**11,174**	**1**	**11**	**27**	**37**	**1,116**	**32.6**	**43.6**
0-17 years	*****	27	27	50	61	113	54.5	31.8
18-24 years	*****	1	20	27	41	670	38.5	53.1
25-40 years	4,188	1	21	28	51	967	36.2	39.3
41-64 years	5,098	1	9	27	35	1,116	31.3	45.6
≥ 65 years	1,500	1	5	17	29	500	25.5	43.9
voclosporin	**580**	**1**	**3**	**8**	**20**	**739**	**23.0**	**57.5**
0-17 years	*****	4	4	4	4	4	4.0	NaN
18-24 years	*****	1	2	6	15	188	17.9	32.9
25-40 years	285	1	3	8	20	739	22.7	60.7
41-64 years	190	1	3	9	21	455	26.5	63.5
≥ 65 years	32	1	3	7	23	129	17.1	26.5
tepotinib	**230**	**1**	**3**	**6**	**17**	**425**	**19.9**	**46.9**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	NaN
41-64 years	*****	1	2	5	11	76	10.4	15.7
≥ 65 years	201	1	3	6	18	425	21.4	49.7

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
umbralisib	**32**	**1**	**2**	**5**	**13**	**116**	**12.4**	**22.2**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	*****	3	8	8	11	116	29.2	48.6
≥ 65 years	*****	1	2	4	15	60	9.3	12.7
evinacumab-dgnb	**123**	**1**	**27**	**27**	**31**	**86**	**29.2**	**11.2**
0-17 years	*****	27	27	27	27	27	27.0	0.0
18-24 years	*****	26	26	27	27	27	26.5	0.7
25-40 years	*****	1	27	27	30	48	27.9	10.9
41-64 years	42	1	27	27	34	86	31.2	14.5
≥ 65 years	62	1	27	27	32	62	28.3	9.2
trilaciclib	**1,657**	**1**	**18**	**18**	**19**	**366**	**20.0**	**12.2**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	6	6	39	71	71	38.5	46.0
41-64 years	*****	1	18	18	20	74	20.1	9.1
≥ 65 years	1,423	1	18	18	19	366	19.9	12.6
casimersen	**117**	**1**	**6**	**6**	**13**	**103**	**13.0**	**15.2**
0-17 years	88	1	6	6	15	103	13.9	16.2
18-24 years	*****	1	5	6	13	56	11.4	12.3
25-40 years	*****	1	1	6	7	33	7.8	9.6
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
fosdenopterin	*****	7	7	7	7	7	7.0	NaN
0-17 years	*****	7	7	7	7	7	7.0	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
melphalan flufenamide	52	10	27	27	41	91	34.0	13.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	12	19	27	27	44	55	33.9	11.4
≥ 65 years	40	10	27	27	41	91	34.1	14.6
tivozanib	778	1	3	6	15	371	17.0	35.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	17	17	17	17	17	17.0	NaN
25-40 years	*****	3	3	4	36	36	14.3	18.8
41-64 years	*****	1	2	5	12	204	11.8	22.7
≥ 65 years	641	1	3	7	16	371	18.1	37.3
ponesimod	116	1	3	6	15	430	15.2	42.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	15	25	25	13.7	12.1
25-40 years	*****	1	3	6	13	33	9.3	8.3
41-64 years	67	1	3	6	14	430	17.9	54.9
≥ 65 years	*****	3	5	8	26	97	23.3	33.5

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
dasiglucagon	**313**	**1**	**9**	**45**	**205**	**879**	**134.5**	**184.2**
0-17 years	80	1	11	66	301	737	164.8	199.1
18-24 years	30	1	16	102	261	624	153.8	166.4
25-40 years	51	1	5	52	318	879	175.0	236.4
41-64 years	111	1	7	27	99	727	94.2	148.2
≥ 65 years	41	4	16	47	138	791	120.3	164.5
viloxazine	**16,102**	**1**	**4**	**9**	**21**	**1,000**	**23.0**	**54.1**
0-17 years	10,182	1	3	8	19	985	21.4	52.7
18-24 years	1,594	1	4	10	26	1,000	26.4	57.7
25-40 years	2,423	1	4	9	24	872	24.8	54.9
41-64 years	1,712	1	4	10	24	996	26.4	57.6
≥ 65 years	191	1	4	11	34	325	30.5	52.7
drospirenone and estetrol	**5,565**	**1**	**3**	**10**	**32**	**867**	**31.2**	**61.9**
0-17 years	651	1	4	12	42	867	36.4	72.5
18-24 years	1,837	1	3	11	33	629	32.7	61.9
25-40 years	2,298	1	3	10	30	670	29.8	60.1
41-64 years	779	1	3	9	29	715	27.5	56.7
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
dostarlimab-gxly	**2,308**	**1**	**20**	**20**	**21**	**418**	**24.2**	**16.3**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	20	20	20	20	20	20.0	0.0
25-40 years	*****	19	20	20	21	41	22.3	5.5
41-64 years	402	3	20	20	21	216	25.5	18.5
≥ 65 years	1,875	1	20	20	21	418	23.9	15.9

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
loncastuximab tesirine-lpyl	**604**	**1**	**20**	**20**	**21**	**145**	**23.0**	**10.1**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	20	20	31	42	42	31.0	15.6
25-40 years	*****	19	21	24	27	56	28.5	13.8
41-64 years	*****	2	20	20	23	83	22.7	10.7
≥ 65 years	541	1	20	20	21	145	23.0	10.0
serdexmethylphenidate and dexmethylphenidate	**17,480**	**1**	**3**	**8**	**22**	**1,052**	**22.9**	**51.5**
0-17 years	9,622	1	3	9	24	1,052	23.9	53.9
18-24 years	1,965	1	4	10	28	677	27.0	52.8
25-40 years	3,318	1	3	7	19	712	20.0	44.5
41-64 years	2,410	1	3	6	16	1,018	18.9	48.1
≥ 65 years	165	1	3	7	27	488	29.8	66.0
pegcetacoplan	**27,568**	**1**	**35**	**55**	**62**	**658**	**53.1**	**32.6**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	3	6	14	402	85.2	177.2
25-40 years	*****	1	5	9	30	104	20.9	25.7
41-64 years	206	1	27	48	62	391	49.0	46.6
≥ 65 years	27,339	1	35	55	62	658	53.2	32.3
amivantamab-vmjw	**1,242**	**1**	**5**	**5**	**6**	**910**	**8.9**	**27.5**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	13	1	5	5	6	48	9.9	12.4
41-64 years	242	1	5	5	7	69	8.0	6.8

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	987	1	5	5	6	910	9.1	30.7
piflufolastat F 18	**24,087**	**1**	**175**	**279**	**424**	**1,202**	**322.5**	**192.4**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	68	68	68	68	68	68.0	NaN
41-64 years	*****	8	148	228	363	963	277.7	175.0
≥ 65 years	22,674	1	177	282	426	1,202	325.3	193.0
sotorasib	**1,221**	**1**	**2**	**6**	**19**	**718**	**21.7**	**50.8**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	3	4	67	130	34.8	63.5
41-64 years	*****	1	2	7	15	298	17.9	36.1
≥ 65 years	950	1	3	6	20	718	22.7	54.2
infigratinib	**15**	**1**	**2**	**5**	**8**	**22**	**7.5**	**7.5**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	5	5	6	6	6	5.5	0.7
41-64 years	*****	1	1	4	5	22	6.6	8.8
≥ 65 years	*****	1	3	6	15	21	8.5	8.1
olanzapine and samidorphan	**5,837**	**1**	**3**	**7**	**19**	**996**	**26.6**	**70.4**
0-17 years	35	1	2	5	11	276	21.5	51.3
18-24 years	416	1	3	7	19	337	21.6	43.3
25-40 years	2,056	1	3	7	19	938	25.7	72.5
41-64 years	2,816	1	3	7	20	996	28.2	74.9

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	514	1	3	8	24	511	25.2	52.8
ibrexafungerp	**686**	**1**	**6**	**29**	**73**	**1,031**	**61.6**	**96.0**
0-17 years	*****	1	2	9	22	25	11.8	11.2
18-24 years	81	1	12	32	68	822	63.6	109.6
25-40 years	350	1	5	25	72	531	56.5	82.3
41-64 years	243	1	7	34	82	1,031	68.7	109.0
≥ 65 years	*****	20	21	33	67	336	80.6	114.0
aducanumab-avwa	**357**	**1**	**27**	**27**	**32**	**566**	**49.4**	**71.9**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	15	26	27	27	32	80	33.5	14.7
≥ 65 years	342	1	27	27	32	566	50.1	73.3
asparaginase erwinia chrysanthemi (recombinant)-rywn	**251**	**1**	**1**	**1**	**2**	**139**	**3.8**	**12.8**
0-17 years	191	1	1	1	2	139	3.7	13.9
18-24 years	28	1	1	1	2	54	4.0	10.8
25-40 years	19	1	1	1	2	29	3.9	7.5
41-64 years	*****	1	1	1	4	13	4.0	5.2
≥ 65 years	*****	1	1	3	6	6	3.3	2.5

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*NaN: Not a number

		Censoring Reason							
		End of Exposure Episode[3]		**Occurrence of User-Defined Censoring Criteria[4]**		**Disenrollment[5]**		**End of Data[6]**	
	Total Number of Episodes	**Number of Episodes**	**Percent of Total Episodes**	**Number of Episodes**	**Percent of Total Episodes**	**Number of Episodes**	**Percent of Total Episodes**	**Number of Episodes**	**Percent of Total Episodes**
vericiguat	25,759	24,953	96.9%	0	0.0%	4,419	17.2%	3,361	13.0%
cabotegravir	67,155	67,094	99.9%	0	0.0%	4,607	6.9%	3,220	4.8%
voclosporin	3,051	3,047	99.9%	0	0.0%	442	14.5%	289	9.5%
tepotinib	1,097	1,044	95.2%	0	0.0%	145	13.2%	116	10.6%
umbralisib	134	*****	*****	0	0.0%	*****	*****	0	0.0%
evinacumab-dgnb	1,737	1,737	100.0%	0	0.0%	14	0.8%	14	0.8%
trilacicilib	7,087	7,087	100.0%	0	0.0%	49	0.7%	45	0.6%
casimersen	2,176	2,176	100.0%	0	0.0%	61	2.8%	53	2.4%
fosdenopterin	*****	*****	*****	0	0.0%	*****	*****	*****	*****
melphalan flufenamide	225	225	100.0%	0	0.0%	0	0.0%	0	0.0%
tivozanib	3,372	3,232	95.8%	0	0.0%	307	9.1%	238	7.1%
ponesimod	588	584	99.3%	0	0.0%	93	15.8%	50	8.5%
dasiglucagon	2,030	2,028	99.9%	0	0.0%	108	5.3%	56	2.8%
viloxazine	78,736	78,728	100.0%	0	0.0%	14,302	18.2%	9,982	12.7%
drospirenone and estetrol	25,172	25,172	100.0%	0	0.0%	6,501	25.8%	2,685	10.7%
dostarlimab-gxly	15,488	15,485	100.0%	0	0.0%	72	0.5%	78	0.5%
loncastuximab tesirine-lpyl	3,367	*****	*****	0	0.0%	*****	*****	*****	*****
serdexmethylphenidate and dexmethylphenidate	94,565	94,564	100.0%	0	0.0%	10,612	11.2%	6,710	7.1%
pegcetacoplan	172,157	172,152	100.0%	0	0.0%	441	0.3%	424	0.2%
amivantamab-vmjw	13,047	13,045	100.0%	0	0.0%	53	0.4%	58	0.4%
piflufolastat F 18	193,162	193,162	100.0%	0	0.0%	275	0.1%	286	0.1%

Table 9. Summary of Reasons Treatment Episodes Ended for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025[1,2]

		Censoring Reason							
		End of Exposure Episode[3]		Occurrence of User-Defined Censoring Criteria[4]		Disenrollment[5]		End of Data[6]	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
sotorasib	5,637	5,332	94.6%	0	0.0%	635	11.3%	430	7.6%
infigratinib	58	*****	*****	0	0.0%	*****	*****	*****	*****
olanzapine and samidorphan	30,475	30,412	99.8%	0	0.0%	5,912	19.4%	4,312	14.1%
ibrexafungerp	3,992	3,992	100.0%	0	0.0%	*****	*****	*****	*****
aducanumab-avwa	2,817	*****	*****	0	0.0%	*****	*****	0	0.0%
asparaginase erwinia chrysanthemi (recombinant)-rywn	4,055	*****	*****	0	0.0%	0	0.0%	*****	*****

[1]An episode may be censored due to more than one reason if they occur on the same date. Therefore, the sum of the reasons for censoring may be greater than the total number of episodes.

[2]All reasons for censoring may not be displayed to prevent publication of small cells.

[3]Represents episodes censored due to end of the exposure episode. In as-treated analyses, exposure episodes are defined using days supplied as recorded in outpatient pharmacy dispensing records, and episodes end after days supplied are exhausted or a pre-determined maximum episode duration is met. In point exposure analyses, exposure episodes end when a pre-determined maximum episode duration is met.

[4]Represents episodes censored due to occurrence of additional user-defined criteria using drug, procedure, diagnosis, and/or laboratory codes.

[5]Represents episodes censored due to disenrollment from health plan. Data Partners often artificially assign a "disenrollment" date equal to data end date for members still enrolled on that date. Therefore, a patient may have dual reasons for censoring as "disenrollment" and "end of data" on the same day - this can be interpreted as right-censoring in most cases.

[6]Represents episodes censored due to Data Partner data end date. This end date represents the last day of the most recent year-month in which all of a Data Partner's data tables in the Sentinel Common Data Model have at least 80% of the record count relative to the prior month.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	vericiguat		cabotegravir		voclosporin		tepotinib	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	263,378,654	N/A	263,378,654	N/A	263,378,654	N/A	263,378,654	N/A
Had required coverage type (medical and/or drug coverage)	196,528,773	66,849,881	196,528,773	66,849,881	196,528,773	66,849,881	196,528,773	66,849,881
Enrolled during specified age range	196,523,101	5,672	196,523,101	5,672	196,523,101	5,672	196,523,101	5,672
Had requestable medical charts	196,523,101	0	196,523,101	0	196,523,101	0	196,523,101	0
Met demographic requirements (sex, race, and Hispanic origin)	196,440,467	82,634	196,440,467	82,634	196,440,467	82,634	196,440,467	82,634
Members with a valid index event								
Had any cohort-defining claim during the query period	11,418	196,429,049	17,249	196,423,218	1,119	196,439,348	524	196,439,943
Claim recorded during specified age range	11,418	0	17,249	0	1,119	0	524	0
Episode defining index claim recorded during the query period	11,418	0	17,249	0	1,119	0	524	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	9,873	1,545	14,260	2,989	945	174	476	48
Met inclusion and exclusion criteria	9,873	0	14,260	0	945	0	476	0
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	9,873	0	14,260	0	945	0	476	0
Final cohort								
Number of members	9,873	N/A	14,260	N/A	945	N/A	476	N/A

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	umbralisib		evinacumab-dgnb		trilacicilib		casimersen	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	263,378,654	N/A	263,378,654	N/A	263,378,654	N/A	263,378,654	N/A
Had required coverage type (medical and/or drug coverage)	196,528,773	66,849,881	196,528,773	66,849,881	196,528,773	66,849,881	196,528,773	66,849,881
Enrolled during specified age range	196,523,101	5,672	196,523,101	5,672	196,523,101	5,672	196,523,101	5,672
Had requestable medical charts	196,523,101	0	196,523,101	0	196,523,101	0	196,523,101	0
Met demographic requirements (sex, race, and Hispanic origin)	196,440,467	82,634	196,440,467	82,634	196,440,467	82,634	196,440,467	82,634
Members with a valid index event								
Had any cohort-defining claim during the query period	*****	*****	*****	*****	2,290	196,438,177	*****	*****
Claim recorded during specified age range	*****	0	*****	0	2,290	0	*****	0
Episode defining index claim recorded during the query period	*****	0	*****	0	2,290	0	*****	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	79	*****	139	*****	2,028	262	143	*****
Met inclusion and exclusion criteria	79	0	139	0	2,028	0	143	0
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	79	0	139	0	2,028	0	143	0
Final cohort								
Number of members	79	N/A	139	N/A	2,028	N/A	143	N/A

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	fosdenopterin		melphalan flufenamide		tivozanib		ponesimod	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	263,378,654	N/A	263,378,654	N/A	263,378,654	N/A	263,378,654	N/A
Had required coverage type (medical and/or drug coverage)	196,528,773	66,849,881	196,528,773	66,849,881	196,528,773	66,849,881	196,528,773	66,849,881
Enrolled during specified age range	196,523,101	5,672	196,523,101	5,672	196,523,101	5,672	196,523,101	5,672
Had requestable medical charts	196,523,101	0	196,523,101	0	196,523,101	0	196,523,101	0
Met demographic requirements (sex, race, and Hispanic origin)	196,440,467	82,634	196,440,467	82,634	196,440,467	82,634	196,440,467	82,634
Members with a valid index event								
Had any cohort-defining claim during the query period	*****	*****	*****	*****	1,706	196,438,761	229	196,440,238
Claim recorded during specified age range	*****	0	*****	0	1,706	0	229	0
Episode defining index claim recorded during the query period	*****	0	*****	0	1,706	0	229	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	*****	0	100	*****	1,550	156	181	48
Met inclusion and exclusion criteria	*****	0	100	0	1,550	0	181	0
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	*****	0	100	0	1,550	0	181	0
Final cohort								
Number of members	*****	N/A	100	N/A	1,550	N/A	181	N/A

	dasiglucagon		viloxazine		drospirenone and estetrol		dostarlimab-gxly	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	263,378,654	N/A	263,378,654	N/A	263,378,654	N/A	263,378,654	N/A
Had required coverage type (medical and/or drug coverage)	196,528,773	66,849,881	196,528,773	66,849,881	196,528,773	66,849,881	196,528,773	66,849,881
Enrolled during specified age range	196,523,101	5,672	196,523,101	5,672	196,523,101	5,672	196,523,101	5,672
Had requestable medical charts	196,523,101	0	196,523,101	0	196,523,101	0	196,523,101	0
Met demographic requirements (sex, race, and Hispanic origin)	196,440,467	82,634	196,440,467	82,634	196,440,467	82,634	196,440,467	82,634
Members with a valid index event								
Had any cohort-defining claim during the query period	1,627	196,438,840	43,678	196,396,789	16,737	196,423,730	2,962	196,437,505
Claim recorded during specified age range	1,627	0	43,678	0	16,737	0	2,962	0
Episode defining index claim recorded during the query period	1,627	0	43,678	0	16,737	0	2,962	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	1,399	228	37,791	5,887	13,397	3,340	2,701	261
Met inclusion and exclusion criteria	1,399	0	37,791	0	13,397	0	2,701	0
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	1,399	0	37,791	0	13,397	0	2,701	0
Final cohort								
Number of members	1,399	N/A	37,791	N/A	13,397	N/A	2,701	N/A

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	loncastuximab tesirine-lpyl		serdexmethylphenidate and dexmethylphenidate		pegcetacoplan		amivantamab-vmjw	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	263,378,654	N/A	263,378,654	N/A	263,378,654	N/A	263,378,654	N/A
Had required coverage type (medical and/or drug coverage)	196,528,773	66,849,881	196,528,773	66,849,881	196,528,773	66,849,881	196,528,773	66,849,881
Enrolled during specified age range	196,523,101	5,672	196,523,101	5,672	196,523,101	5,672	196,523,101	5,672
Had requestable medical charts	196,523,101	0	196,523,101	0	196,523,101	0	196,523,101	0
Met demographic requirements (sex, race, and Hispanic origin)	196,440,467	82,634	196,440,467	82,634	196,440,467	82,634	196,440,467	82,634
Members with a valid index event								
Had any cohort-defining claim during the query period	866	196,439,601	36,380	196,404,087	33,164	196,407,303	1,539	196,438,928
Claim recorded during specified age range	866	0	36,380	0	33,164	0	1,539	0
Episode defining index claim recorded during the query period	866	0	36,380	0	33,164	0	1,539	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	806	60	31,666	4,714	32,242	922	1,419	120
Met inclusion and exclusion criteria	806	0	31,666	0	32,242	0	1,419	0
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	806	0	31,666	0	32,242	0	1,419	0
Final cohort								
Number of members	806	N/A	31,666	N/A	32,242	N/A	1,419	N/A

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	piflufolastat F 18		sotorasib		infigratinib		olanzapine and samidorphan	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	263,378,654	N/A	263,378,654	N/A	263,378,654	N/A	263,378,654	N/A
Had required coverage type (medical and/or drug coverage)	196,528,773	66,849,881	196,528,773	66,849,881	196,528,773	66,849,881	196,528,773	66,849,881
Enrolled during specified age range	196,523,101	5,672	196,523,101	5,672	196,523,101	5,672	196,523,101	5,672
Had requestable medical charts	196,523,101	0	196,523,101	0	196,523,101	0	196,523,101	0
Met demographic requirements (sex, race, and Hispanic origin)	196,440,467	82,634	196,440,467	82,634	196,440,467	82,634	196,440,467	82,634
Members with a valid index event								
Had any cohort-defining claim during the query period	172,371	196,268,096	2,976	196,437,491	*****	*****	15,310	196,425,157
Claim recorded during specified age range	172,371	0	2,976	0	*****	0	15,310	0
Episode defining index claim recorded during the query period	172,371	0	2,976	0	*****	0	15,310	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	159,348	13,023	2,597	379	36	*****	12,692	2,618
Met inclusion and exclusion criteria	159,348	0	2,597	0	36	0	12,692	0
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	159,348	0	2,597	0	36	0	12,692	0
Final cohort								
Number of members	159,348	N/A	2,597	N/A	36	N/A	12,692	N/A

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	ibrexafungerp		aducanumab-avwa		asparaginase erwinia chrysanthemi (recombinant)-rywn	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements						
Enrolled at any point during the query period	263,378,654	N/A	263,378,654	N/A	263,378,654	N/A
Had required coverage type (medical and/or drug coverage)	196,528,773	66,849,881	196,528,773	66,849,881	196,528,773	66,849,881
Enrolled during specified age range	196,523,101	5,672	196,523,101	5,672	196,523,101	5,672
Had requestable medical charts	196,523,101	0	196,523,101	0	196,523,101	0
Met demographic requirements (sex, race, and Hispanic origin)	196,440,467	82,634	196,440,467	82,634	196,440,467	82,634
Members with a valid index event						
Had any cohort-defining claim during the query period	3,041	196,437,426	482	196,439,985	306	196,440,161
Claim recorded during specified age range	3,041	0	482	0	306	0
Episode defining index claim recorded during the query period	3,041	0	482	0	306	0
Members with required pre-index history						
Had sufficient pre-index continuous enrollment	2,617	424	458	24	280	26
Met inclusion and exclusion criteria	2,617	0	458	0	280	0
Members with required post-index follow-up						
Had sufficient post-index continuous enrollment	2,617	0	458	0	280	0
Final cohort						
Number of members	2,617	N/A	458	N/A	280	N/A

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Figure 1a. Patient Entry into Study by Month for vericiguat in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

*The FDA approval date for this drug was on January 19, 2021, as listed on the FDA website:

https://web.archive.org/web/20240430031329/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021

Figure 1b. Patient Entry into Study by Month for cabotegravir in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

*The FDA approval date for this drug was on January 21, 2021, as listed on the FDA website:

https://web.archive.org/web/20240430031329/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021

Figure 1c. Patient Entry into Study by Month for voclosporin in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

*The FDA approval date for this drug was on January 22, 2021, as listed on the FDA website:
https://web.archive.org/web/20240430031329/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021

Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1d. Patient Entry into Study by Month for tepotinib in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

*The FDA approval date for this drug was on February 3, 2021, as listed on the FDA website:

https://web.archive.org/web/20240430031329/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021

Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1e. Patient Entry into Study by Month for umbralisib in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

*The FDA approval date for this drug was on February 5, 2021, as listed on the FDA website:

https://web.archive.org/web/20240430031329/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021

Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1f. Patient Entry into Study by Month for evinacumab-dgnb in the Sentinel Distributed Database from January 1, 2021 to April 30,2025

*The FDA approval date for this drug was on February 11, 2021, as listed on the FDA website:
https://web.archive.org/web/20240430031329/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021
Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1g. Patient Entry into Study by Month for trilacicilib in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

*The FDA approval date for this drug was on February 12, 2021, as listed on the FDA website:
https://web.archive.org/web/20240430031329/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021
Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1h. Patient Entry into Study by Month for casimersen in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

*The FDA approval date for this drug was on February 25, 2021, as listed on the FDA website:
https://web.archive.org/web/20240430031329/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021
Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1i. Patient Entry into Study by Month for fosdenopterin in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

*The FDA approval date for this drug was on February 26, 2021, as listed on the FDA website:

https://web.archive.org/web/20240430031329/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021

Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1j. Patient Entry into Study by Month for melphalan flufenamide in the Sentinel Distributed Database from January 1, 2021 to April30, 2025

*The FDA approval date for this drug was on February 26, 2021, as listed on the FDA website:

https://web.archive.org/web/20240430031329/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021

Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1k. Patient Entry into Study by Month for tivozanib in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

*The FDA approval date for this drug was on March 10, 2021, as listed on the FDA website:
https://web.archive.org/web/20240430031329/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021

Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1l. Patient Entry into Study by Month for ponesimod in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

*The FDA approval date for this drug was on March 18, 2021, as listed on the FDA website:
https://web.archive.org/web/20240430031329/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021
Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1m. Patient Entry into Study by Month for dasiglucagon in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

*The FDA approval date for this drug was on March 22, 2021, as listed on the FDA website:

https://web.archive.org/web/20240430031329/https:/www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-

Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1n. Patient Entry into Study by Month for viloxazine in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

*The FDA approval date for this drug was on April 2, 2021, as listed on the FDA website:
https://web.archive.org/web/20240430031329/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021

Figure 1o. Patient Entry into Study by Month for drospirenone and estetrol in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

*The FDA approval date for this drug was on April 15, 2021, as listed on the FDA website:
https://web.archive.org/web/20240430031329/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021

Figure 1p. Patient Entry into Study by Month for dostarlimab-gxly in the Sentinel Distributed Database from January 1, 2021 to April 30,2025

*The FDA approval date for this drug was on April 22, 2021, as listed on the FDA website:

https://web.archive.org/web/20240430031329/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-

Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1q. Patient Entry into Study by Month for loncastuximab tesirine-lpyl in the Sentinel Distributed Database from January 1, 2021 toApril 30, 2025

*The FDA approval date for this drug was on April 23, 2021, as listed on the FDA website:
https://web.archive.org/web/20240430031329/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021
Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1r. Patient Entry into Study by Month for serdexmethylphenidate and dexmethylphenidate in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

*The FDA approval date for this drug was on May 7, 2021, as listed on the FDA website: https://web.archive.org/web/20240430031329/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021

Figure 1s. Patient Entry into Study by Month for pegcetacoplan in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

*The FDA approval date for this drug was on May 14, 2021, as listed on the FDA website:
https://web.archive.org/web/20240430031329/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021

Figure 1t. Patient Entry into Study by Month for amivantamab-vmjw in the Sentinel Distributed Database from January 1, 2021 to April 30,2025

*The FDA approval date for this drug was on May 21, 2021, as listed on the FDA website:

https://web.archive.org/web/20240430031329/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-

Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1u. Patient Entry into Study by Month for piflufolastat F 18 in the Sentinel Distributed Database from January 1, 2021 to April 30,2025

*The FDA approval date for this drug was on May 26, 2021, as listed on the FDA website:

https://web.archive.org/web/20240430031329/https:/www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021

Figure 1v. Patient Entry into Study by Month for sotorasib in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

*The FDA approval date for this drug was on May 28, 2021, as listed on the FDA website:

https://web.archive.org/web/20240430031329/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021

Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1w. Patient Entry into Study by Month for infigratinib in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

*The FDA approval date for this drug was on May 28, 2021, as listed on the FDA website:
https://web.archive.org/web/20240430031329/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021
Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1x. Patient Entry into Study by Month for olanzapine and samidorphan in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

*The FDA approval date for this drug was on May 28, 2021, as listed on the FDA website:
https://web.archive.org/web/20240430031329/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021

Figure 1y. Patient Entry into Study by Month for ibrexafungerp in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

*The FDA approval date for this drug was on June 1, 2021, as listed on the FDA website:

https://web.archive.org/web/20240430031329/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021

Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1z. Patient Entry into Study by Month for aducanumab-avwa in the Sentinel Distributed Database from January 1, 2021 to April 30,2025

*The FDA approval date for this drug was on June 7, 2021, as listed on the FDA website:
https://web.archive.org/web/20240430031329/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021
Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1aa. Patient Entry into Study by Month for asparaginase erwinia chrysanthemi (recombinant)-rywn in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

*The FDA approval date for this drug was on June 30, 2021, as listed on the FDA website:
https://web.archive.org/web/20240430031329/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021
Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Appendix A. Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date

Masked DP ID	DP Start Date	DP End Date[1]
DP01	01/01/2000	01/31/2024
DP02	01/01/2000	01/31/2024
DP03	01/01/2008	12/31/2024
DP04	01/01/2006	10/31/2024
DP05	01/01/2005	07/31/2022
DP06	01/01/2000	04/30/2025
DP07	01/01/2004	03/31/2024
DP08	01/01/2000	04/30/2024
DP09	01/01/2007	10/31/2024
DP10	01/01/2000	04/30/2024
DP11	01/01/2014	12/31/2021
DP12	01/01/2008	03/31/2025
DP13	01/01/2010	12/31/2024

[1]End Date represents the earliest of: (1) query end date, or (2) last day of the most recent month for which all of a Data Partner's data tables (enrollment, dispensing, etc.) have at least 80% of the record count relative to the prior month.

Appendix B. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exposures in this Request

Non-Proprietary Name	Proprietary Name
vericiguat	
vericiguat	Verquvo
cabotegravir	
cabotegravir sodium	Vocabria
cabotegravir	cabotegravir
cabotegravir	Apretude
cabotegravir/rilpivirine	Cabenuva
voclosporin	
voclosporin	Lupkynis
tepotinib	
tepotinib HCl	Tepmetko
umbralisib	
umbralisib tosylate	Ukoniq
evinacumab-dgnb	
evinacumab-dgnb	Evkeeza
trilacicilib	
trilaciclib dihydrochloride	Cosela
casimersen	
casimersen	Amondys-45
fosdenopterin	
fosdenopterin hydrobromide	Nulibry
melphalan flufenamide	
melphalan flufenamide hydrochloride	Pepaxto
tivozanib	
tivozanib HCl	Fotivda
ponesimod	
ponesimod	Ponvory 14-Day Starter Pack
ponesimod	Ponvory
dasiglucagon	
dasiglucagon HCl	Zegalogue Autoinjector
dasiglucagon HCl	Zegalogue Syringe
viloxazine	
viloxazine HCl	Qelbree
drospirenone and estetrol	
drospirenone/estetrol	Nextstellis
drospirenone/estetrol	Vestura (28)
drospirenone/estetrol	Gianvi (28)

Non-Proprietary Name	Proprietary Name
drospirenone/estetrol	drospirenone-ethinyl estradiol
drospirenone/estetrol	Ocella
drospirenone/estetrol	Slynd
drospirenone/estetrol	
drospirenone/estetrol	drospirenone-e.estradiol-lm.FA
drospirenone/estetrol	Jasmiel (28)
drospirenone/estetrol	Yasmin (28)
drospirenone/estetrol	Safyral
drospirenone/estetrol	YAZ (28)
drospirenone/estetrol	Beyaz
drospirenone/estetrol	Angeliq
drospirenone/estetrol	Zarah
drospirenone/estetrol	Ocella
drospirenone/estetrol	Lo-Zumandimine (28)
drospirenone/estetrol	Zumandimine (28)
drospirenone/estetrol	Nikki (28)
drospirenone/estetrol	Loryna (28)
drospirenone/estetrol	Tydemy
drospirenone/estetrol	Syeda
dostarlimab-gxly	
dostarlimab-gxly	Jemperli
loncastuximab tesirine-lpyl	
loncastuximab tesirine-lpyl	Zynlonta
serdexmethylphenidate and dexmethylphenidate	
serdexmethylphenidate chloride/dexmethylphenidate HCl	Azstarys
pegcetacoplan	
pegcetacoplan	Empaveli
pegcetacoplan	Syfovre
pegcetacoplan/PF	Syfovre (PF)
amivantamab-vmjw	
amivantamab-vmjw	Rybrevant
piflufolastat F 18	
piflufolastat F 18	Pylarify
sotorasib	
sotorasib	Lumakras

Appendix B. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exposures in this Request

Non-Proprietary Name	Proprietary Name
infigratinib	
infigratinib phosphate	Truseltiq
olanzapine and samidorphan	
olanzapine/samidorphan malate	Lybalvi
ibrexafungerp	
ibrexafungerp citrate	Brexafemme
aducanumab-avwa	
aducanumab-avwa	Aduhelm
asparaginase erwinia chrysanthemi (recombinant)-rywn	
asparaginase Erwinia chrysanthemi (recombinant)-rywn	Rylaze

Appendix C. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS), and National Drug Code (NDC) Codes Used to Define Exposures in this Request

Code	Description	Code Category	Code Type
cabotegravir			
C9077	Injection, cabotegravir and rilpivirine, 2 mg/3 mg	Procedure	HCPCS
J0739	Injection, cabotegravir, 1 mg, FDA-approved prescription, only for use as HIV pre-exposure prophylaxis (not for use as treatment for HIV)	Procedure	HCPCS
J0741	Injection, cabotegravir and rilpivirine, 2 mg/3 mg	Procedure	HCPCS
evinacumab-dgnb			
C9079	Injection, evinacumab-dgnb, 5 mg	Procedure	HCPCS
J1305	Injection, evinacumab-dgnb, 5 mg	Procedure	HCPCS
trilacicilib			
C9078	Injection, trilaciclib, 1 mg	Procedure	HCPCS
J1448	Injection, trilaciclib, 1 mg	Procedure	HCPCS
casimersen			
C9075	Injection, casimersen, 10 mg	Procedure	HCPCS
J1426	Injection, casimersen, 10 mg	Procedure	HCPCS
melphalan flufenamide			
C9080	Injection, melphalan flufenamide HCl, 1 mg	Procedure	HCPCS
J9247	Injection, melphalan flufenamide, 1 mg	Procedure	HCPCS
dasiglucagon			
XW0136A	Approach, New Technology	Procedure	ICD-10-PCS
dostarlimab-gxly			
C9082	Injection, dostarlimab-gxly, 100 mg	Procedure	HCPCS
J9272	Injection, dostarlimab-gxly, 10 mg	Procedure	HCPCS
loncastuximab tesirine-lpyl			
C9084	Injection, loncastuximab tesirine-lpyl, 0.1 mg	Procedure	HCPCS
J9359	Injection, loncastuximab tesirine-lpyl, 0.075 mg	Procedure	HCPCS
pegcetacoplan			
C9151	Injection, pegcetacoplan, 1 mg	Procedure	HCPCS
J2781	Injection, pegcetacoplan, intravitreal, 1 mg	Procedure	HCPCS
amivantamab-vmjw			
C9083	Injection, amivantamab-vmjw, 10 mg	Procedure	HCPCS
J9061	Injection, amivantamab-vmjw, 2 mg	Procedure	HCPCS
piflufolastat F 18			
A9595	Piflufolastat F-18, diagnostic, 1 mCi	Procedure	HCPCS
aducanumab-avwa			
J0172	Injection, aducanumab-avwa, 2 mg	Procedure	HCPCS
asparaginase erwinia chrysanthemi (recombinant)-rywn			
J9021	Injection, asparaginase, recombinant, (Rylaze), 0.1 mg	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
Acquired Hypothyroidism			
E00.0	Congenital iodine-deficiency syndrome, neurological type	Diagnosis	ICD-10-CM
E00.1	Congenital iodine-deficiency syndrome, myxedematous type	Diagnosis	ICD-10-CM
E00.2	Congenital iodine-deficiency syndrome, mixed type	Diagnosis	ICD-10-CM
E00.9	Congenital iodine-deficiency syndrome, unspecified	Diagnosis	ICD-10-CM
E01.8	Other iodine-deficiency related thyroid disorders and allied conditions	Diagnosis	ICD-10-CM
E02	Subclinical iodine-deficiency hypothyroidism	Diagnosis	ICD-10-CM
E03.0	Congenital hypothyroidism with diffuse goiter	Diagnosis	ICD-10-CM
E03.1	Congenital hypothyroidism without goiter	Diagnosis	ICD-10-CM
E03.2	Hypothyroidism due to medicaments and other exogenous substances	Diagnosis	ICD-10-CM
E03.3	Postinfectious hypothyroidism	Diagnosis	ICD-10-CM
E03.4	Atrophy of thyroid (acquired)	Diagnosis	ICD-10-CM
E03.8	Other specified hypothyroidism	Diagnosis	ICD-10-CM
E03.9	Hypothyroidism, unspecified	Diagnosis	ICD-10-CM
E89.0	Postprocedural hypothyroidism	Diagnosis	ICD-10-CM
Alcohol Abuse			
F10.10	Alcohol abuse, uncomplicated	Diagnosis	ICD-10-CM
F10.11	Alcohol abuse, in remission	Diagnosis	ICD-10-CM
F10.120	Alcohol abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.121	Alcohol abuse with intoxication delirium	Diagnosis	ICD-10-CM
F10.129	Alcohol abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.130	Alcohol abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.131	Alcohol abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F10.132	Alcohol abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.139	Alcohol abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.14	Alcohol abuse with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.150	Alcohol abuse with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.151	Alcohol abuse with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.159	Alcohol abuse with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.180	Alcohol abuse with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.181	Alcohol abuse with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.182	Alcohol abuse with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.188	Alcohol abuse with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.19	Alcohol abuse with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.20	Alcohol dependence, uncomplicated	Diagnosis	ICD-10-CM
F10.21	Alcohol dependence, in remission	Diagnosis	ICD-10-CM
F10.220	Alcohol dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.221	Alcohol dependence with intoxication delirium	Diagnosis	ICD-10-CM
F10.229	Alcohol dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.230	Alcohol dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.231	Alcohol dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F10.232	Alcohol dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.239	Alcohol dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
F10.24	Alcohol dependence with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.250	Alcohol dependence with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.251	Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.259	Alcohol dependence with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.26	Alcohol dependence with alcohol-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F10.27	Alcohol dependence with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.280	Alcohol dependence with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.281	Alcohol dependence with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.282	Alcohol dependence with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.288	Alcohol dependence with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.29	Alcohol dependence with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.920	Alcohol use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.921	Alcohol use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F10.929	Alcohol use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.930	Alcohol use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.931	Alcohol use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F10.932	Alcohol use, unspecified with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.939	Alcohol use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.94	Alcohol use, unspecified with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.950	Alcohol use, unspecified with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.951	Alcohol use, unspecified with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.959	Alcohol use, unspecified with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.96	Alcohol use, unspecified with alcohol-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F10.97	Alcohol use, unspecified with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.980	Alcohol use, unspecified with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.981	Alcohol use, unspecified with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.982	Alcohol use, unspecified with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.988	Alcohol use, unspecified with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.99	Alcohol use, unspecified with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
G62.1	Alcoholic polyneuropathy	Diagnosis	ICD-10-CM
HZ2ZZZZ	Detoxification Services for Substance Abuse Treatment	Procedure	ICD-10-PCS
HZ30ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ31ZZZ	Individual Counseling for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ32ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ33ZZZ	Individual Counseling for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ34ZZZ	Individual Counseling for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS

Code	Description	Code Category	Code Type
HZ35ZZZ	Individual Counseling for Substance Abuse Treatment, Vocational	Procedure	ICD-10-PCS
HZ36ZZZ	Individual Counseling for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ37ZZZ	Individual Counseling for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ38ZZZ	Individual Counseling for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ39ZZZ	Individual Counseling for Substance Abuse Treatment, Continuing Care	Procedure	ICD-10-PCS
HZ3BZZZ	Individual Counseling for Substance Abuse Treatment, Spiritual	Procedure	ICD-10-PCS
HZ40ZZZ	Group Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ93ZZZ	Pharmacotherapy for Substance Abuse Treatment, Antabuse	Procedure	ICD-10-PCS
HZ96ZZZ	Pharmacotherapy for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
I42.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
K29.20	Alcoholic gastritis without bleeding	Diagnosis	ICD-10-CM
K29.21	Alcoholic gastritis with bleeding	Diagnosis	ICD-10-CM
K70.0	Alcoholic fatty liver	Diagnosis	ICD-10-CM
K70.10	Alcoholic hepatitis without ascites	Diagnosis	ICD-10-CM
K70.11	Alcoholic hepatitis with ascites	Diagnosis	ICD-10-CM
K70.2	Alcoholic fibrosis and sclerosis of liver	Diagnosis	ICD-10-CM
K70.30	Alcoholic cirrhosis of liver without ascites	Diagnosis	ICD-10-CM
K70.31	Alcoholic cirrhosis of liver with ascites	Diagnosis	ICD-10-CM
K70.40	Alcoholic hepatic failure without coma	Diagnosis	ICD-10-CM
K70.41	Alcoholic hepatic failure with coma	Diagnosis	ICD-10-CM
K70.9	Alcoholic liver disease, unspecified	Diagnosis	ICD-10-CM
R78.0	Finding of alcohol in blood	Diagnosis	ICD-10-CM
T51.0X1A	Toxic effect of ethanol, accidental (unintentional), initial encounter	Procedure	ICD-10-PCS
T51.0X2A	Toxic effect of ethanol, intentional self-harm, initial encounter	Procedure	ICD-10-PCS
T51.0X3A	Toxic effect of ethanol, assault, initial encounter	Procedure	ICD-10-PCS
T51.0X4A	Toxic effect of ethanol, undetermined, initial encounter	Procedure	ICD-10-PCS
Z65.8	Other specified problems related to psychosocial circumstances	Diagnosis	ICD-10-CM
Z71.41	Alcohol abuse counseling and surveillance of alcoholic	Diagnosis	ICD-10-CM
Alzheimers			
G30.0	Alzheimer's disease with early onset	Diagnosis	ICD-10-CM
G30.1	Alzheimer's disease with late onset	Diagnosis	ICD-10-CM
G30.8	Other Alzheimer's disease	Diagnosis	ICD-10-CM
G30.9	Alzheimer's disease, unspecified	Diagnosis	ICD-10-CM
Acute Myocardial Infraction			
I21.01	ST elevation (STEMI) myocardial infarction involving left main coronary artery	Diagnosis	ICD-10-CM
I21.02	ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery	Diagnosis	ICD-10-CM
I21.09	ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall	Diagnosis	ICD-10-CM
I21.11	ST elevation (STEMI) myocardial infarction involving right coronary artery	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
I21.19	ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall	Diagnosis	ICD-10-CM
I21.21	ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery	Diagnosis	ICD-10-CM
I21.29	ST elevation (STEMI) myocardial infarction involving other sites	Diagnosis	ICD-10-CM
I21.3	ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I21.4	Non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I21.9	Acute myocardial infarction, unspecified	Diagnosis	ICD-10-CM
I21.A1	Myocardial infarction type 2	Diagnosis	ICD-10-CM
I21.A9	Other myocardial infarction type	Diagnosis	ICD-10-CM
I21.B	Myocardial infarction with coronary microvascular dysfunction	Diagnosis	ICD-10-CM
I22.0	Subsequent ST elevation (STEMI) myocardial infarction of anterior wall	Diagnosis	ICD-10-CM
I22.1	Subsequent ST elevation (STEMI) myocardial infarction of inferior wall	Diagnosis	ICD-10-CM
I22.2	Subsequent non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I22.8	Subsequent ST elevation (STEMI) myocardial infarction of other sites	Diagnosis	ICD-10-CM
I22.9	Subsequent ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I23.0	Hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.1	Atrial septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.2	Ventricular septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.3	Rupture of cardiac wall without hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.4	Rupture of chordae tendineae as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.5	Rupture of papillary muscle as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.6	Thrombosis of atrium, auricular appendage, and ventricle as current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.7	Postinfarction angina	Diagnosis	ICD-10-CM
I23.8	Other current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
Anemia			
C94.6	Myelodysplastic disease, not elsewhere classified	Diagnosis	ICD-10-CM
D46.0	Refractory anemia without ring sideroblasts, so stated	Diagnosis	ICD-10-CM
D46.1	Refractory anemia with ring sideroblasts	Diagnosis	ICD-10-CM
D46.20	Refractory anemia with excess of blasts, unspecified	Diagnosis	ICD-10-CM
D46.21	Refractory anemia with excess of blasts 1	Diagnosis	ICD-10-CM
D46.22	Refractory anemia with excess of blasts 2	Diagnosis	ICD-10-CM
D46.4	Refractory anemia, unspecified	Diagnosis	ICD-10-CM
D46.9	Myelodysplastic syndrome, unspecified	Diagnosis	ICD-10-CM
D46.A	Refractory cytopenia with multilineage dysplasia	Diagnosis	ICD-10-CM
D46.B	Refractory cytopenia with multilineage dysplasia and ring sideroblasts	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
D46.C	Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality	Diagnosis	ICD-10-CM
D46.Z	Other myelodysplastic syndromes	Diagnosis	ICD-10-CM
D47.4	Osteomyelofibrosis	Diagnosis	ICD-10-CM
D50.0	Iron deficiency anemia secondary to blood loss (chronic)	Diagnosis	ICD-10-CM
D50.1	Sideropenic dysphagia	Diagnosis	ICD-10-CM
D50.8	Other iron deficiency anemias	Diagnosis	ICD-10-CM
D50.9	Iron deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D51.0	Vitamin B12 deficiency anemia due to intrinsic factor deficiency	Diagnosis	ICD-10-CM
D51.1	Vitamin B12 deficiency anemia due to selective vitamin B12 malabsorption with proteinuria	Diagnosis	ICD-10-CM
D51.2	Transcobalamin II deficiency	Diagnosis	ICD-10-CM
D51.3	Other dietary vitamin B12 deficiency anemia	Diagnosis	ICD-10-CM
D51.8	Other vitamin B12 deficiency anemias	Diagnosis	ICD-10-CM
D51.9	Vitamin B12 deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D52.0	Dietary folate deficiency anemia	Diagnosis	ICD-10-CM
D52.1	Drug-induced folate deficiency anemia	Diagnosis	ICD-10-CM
D52.8	Other folate deficiency anemias	Diagnosis	ICD-10-CM
D52.9	Folate deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D53.0	Protein deficiency anemia	Diagnosis	ICD-10-CM
D53.1	Other megaloblastic anemias, not elsewhere classified	Diagnosis	ICD-10-CM
D53.2	Scorbutic anemia	Diagnosis	ICD-10-CM
D53.8	Other specified nutritional anemias	Diagnosis	ICD-10-CM
D53.9	Nutritional anemia, unspecified	Diagnosis	ICD-10-CM
D55.0	Anemia due to glucose-6-phosphate dehydrogenase [G6PD] deficiency	Diagnosis	ICD-10-CM
D55.1	Anemia due to other disorders of glutathione metabolism	Diagnosis	ICD-10-CM
D55.2	Anemia due to disorders of glycolytic enzymes	Diagnosis	ICD-10-CM
D55.21	Anemia due to pyruvate kinase deficiency	Diagnosis	ICD-10-CM
D55.29	Anemia due to other disorders of glycolytic enzymes	Diagnosis	ICD-10-CM
D55.3	Anemia due to disorders of nucleotide metabolism	Diagnosis	ICD-10-CM
D55.8	Other anemias due to enzyme disorders	Diagnosis	ICD-10-CM
D55.9	Anemia due to enzyme disorder, unspecified	Diagnosis	ICD-10-CM
D56.0	Alpha thalassemia	Diagnosis	ICD-10-CM
D56.1	Beta thalassemia	Diagnosis	ICD-10-CM
D56.2	Delta-beta thalassemia	Diagnosis	ICD-10-CM
D56.3	Thalassemia minor	Diagnosis	ICD-10-CM
D56.4	Hereditary persistence of fetal hemoglobin [HPFH]	Diagnosis	ICD-10-CM
D56.5	Hemoglobin E-beta thalassemia	Diagnosis	ICD-10-CM
D56.8	Other thalassemias	Diagnosis	ICD-10-CM
D56.9	Thalassemia, unspecified	Diagnosis	ICD-10-CM
D57.00	Hb-SS disease with crisis, unspecified	Diagnosis	ICD-10-CM
D57.01	Hb-SS disease with acute chest syndrome	Diagnosis	ICD-10-CM
D57.02	Hb-SS disease with splenic sequestration	Diagnosis	ICD-10-CM
D57.03	Hb-SS disease with cerebral vascular involvement	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
D57.04	Hb-SS disease with dactylitis	Diagnosis	ICD-10-CM
D57.09	Hb-SS disease with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.1	Sickle-cell disease without crisis	Diagnosis	ICD-10-CM
D57.20	Sickle-cell/Hb-C disease without crisis	Diagnosis	ICD-10-CM
D57.211	Sickle-cell/Hb-C disease with acute chest syndrome	Diagnosis	ICD-10-CM
D57.212	Sickle-cell/Hb-C disease with splenic sequestration	Diagnosis	ICD-10-CM
D57.213	Sickle-cell/Hb-C disease with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.214	Sickle-cell/Hb-C disease with dactylitis	Diagnosis	ICD-10-CM
D57.218	Sickle-cell/Hb-C disease with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.219	Sickle-cell/Hb-C disease with crisis, unspecified	Diagnosis	ICD-10-CM
D57.3	Sickle-cell trait	Diagnosis	ICD-10-CM
D57.40	Sickle-cell thalassemia without crisis	Diagnosis	ICD-10-CM
D57.411	Sickle-cell thalassemia, unspecified, with acute chest syndrome	Diagnosis	ICD-10-CM
D57.412	Sickle-cell thalassemia, unspecified, with splenic sequestration	Diagnosis	ICD-10-CM
D57.413	Sickle-cell thalassemia, unspecified, with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.414	Sickle-cell thalassemia, unspecified, with dactylitis	Diagnosis	ICD-10-CM
D57.418	Sickle-cell thalassemia, unspecified, with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.419	Sickle-cell thalassemia, unspecified, with crisis	Diagnosis	ICD-10-CM
D57.42	Sickle-cell thalassemia beta zero without crisis	Diagnosis	ICD-10-CM
D57.431	Sickle-cell thalassemia beta zero with acute chest syndrome	Diagnosis	ICD-10-CM
D57.432	Sickle-cell thalassemia beta zero with splenic sequestration	Diagnosis	ICD-10-CM
D57.433	Sickle-cell thalassemia beta zero with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.434	Sickle-cell thalassemia beta zero with dactylitis	Diagnosis	ICD-10-CM
D57.438	Sickle-cell thalassemia beta zero with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.439	Sickle-cell thalassemia beta zero with crisis, unspecified	Diagnosis	ICD-10-CM
D57.44	Sickle-cell thalassemia beta plus without crisis	Diagnosis	ICD-10-CM
D57.451	Sickle-cell thalassemia beta plus with acute chest syndrome	Diagnosis	ICD-10-CM
D57.452	Sickle-cell thalassemia beta plus with splenic sequestration	Diagnosis	ICD-10-CM
D57.453	Sickle-cell thalassemia beta plus with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.454	Sickle-cell thalassemia beta plus with dactylitis	Diagnosis	ICD-10-CM
D57.458	Sickle-cell thalassemia beta plus with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.459	Sickle-cell thalassemia beta plus with crisis, unspecified	Diagnosis	ICD-10-CM
D57.80	Other sickle-cell disorders without crisis	Diagnosis	ICD-10-CM
D57.811	Other sickle-cell disorders with acute chest syndrome	Diagnosis	ICD-10-CM
D57.812	Other sickle-cell disorders with splenic sequestration	Diagnosis	ICD-10-CM
D57.813	Other sickle-cell disorders with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.814	Other sickle-cell disorders with dactylitis	Diagnosis	ICD-10-CM
D57.818	Other sickle-cell disorders with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.819	Other sickle-cell disorders with crisis, unspecified	Diagnosis	ICD-10-CM
D58.0	Hereditary spherocytosis	Diagnosis	ICD-10-CM
D58.1	Hereditary elliptocytosis	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
D58.2	Other hemoglobinopathies	Diagnosis	ICD-10-CM
D58.8	Other specified hereditary hemolytic anemias	Diagnosis	ICD-10-CM
D58.9	Hereditary hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D59.0	Drug-induced autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.1	Other autoimmune hemolytic anemias	Diagnosis	ICD-10-CM
D59.10	Autoimmune hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D59.11	Warm autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.12	Cold autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.13	Mixed type autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.19	Other autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.2	Drug-induced nonautoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.3	Hemolytic-uremic syndrome	Diagnosis	ICD-10-CM
D59.30	Hemolytic-uremic syndrome, unspecified	Diagnosis	ICD-10-CM
D59.31	Infection-associated hemolytic-uremic syndrome	Diagnosis	ICD-10-CM
D59.32	Hereditary hemolytic-uremic syndrome	Diagnosis	ICD-10-CM
D59.39	Other hemolytic-uremic syndrome	Diagnosis	ICD-10-CM
D59.4	Other nonautoimmune hemolytic anemias	Diagnosis	ICD-10-CM
D59.5	Paroxysmal nocturnal hemoglobinuria [Marchiafava-Micheli]	Diagnosis	ICD-10-CM
D59.6	Hemoglobinuria due to hemolysis from other external causes	Diagnosis	ICD-10-CM
D59.8	Other acquired hemolytic anemias	Diagnosis	ICD-10-CM
D59.9	Acquired hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D60.0	Chronic acquired pure red cell aplasia	Diagnosis	ICD-10-CM
D60.1	Transient acquired pure red cell aplasia	Diagnosis	ICD-10-CM
D60.8	Other acquired pure red cell aplasias	Diagnosis	ICD-10-CM
D60.9	Acquired pure red cell aplasia, unspecified	Diagnosis	ICD-10-CM
D61.01	Constitutional (pure) red blood cell aplasia	Diagnosis	ICD-10-CM
D61.02	Shwachman-Diamond syndrome	Diagnosis	ICD-10-CM
D61.09	Other constitutional aplastic anemia	Diagnosis	ICD-10-CM
D61.1	Drug-induced aplastic anemia	Diagnosis	ICD-10-CM
D61.2	Aplastic anemia due to other external agents	Diagnosis	ICD-10-CM
D61.3	Idiopathic aplastic anemia	Diagnosis	ICD-10-CM
D61.810	Antineoplastic chemotherapy induced pancytopenia	Diagnosis	ICD-10-CM
D61.811	Other drug-induced pancytopenia	Diagnosis	ICD-10-CM
D61.818	Other pancytopenia	Diagnosis	ICD-10-CM
D61.82	Myelophthisis	Diagnosis	ICD-10-CM
D61.89	Other specified aplastic anemias and other bone marrow failure syndromes	Diagnosis	ICD-10-CM
D61.9	Aplastic anemia, unspecified	Diagnosis	ICD-10-CM
D63.0	Anemia in neoplastic disease	Diagnosis	ICD-10-CM
D63.1	Anemia in chronic kidney disease	Diagnosis	ICD-10-CM
D63.8	Anemia in other chronic diseases classified elsewhere	Diagnosis	ICD-10-CM
D64.0	Hereditary sideroblastic anemia	Diagnosis	ICD-10-CM
D64.1	Secondary sideroblastic anemia due to disease	Diagnosis	ICD-10-CM
D64.2	Secondary sideroblastic anemia due to drugs and toxins	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
D64.3	Other sideroblastic anemias	Diagnosis	ICD-10-CM
D64.4	Congenital dyserythropoietic anemia	Diagnosis	ICD-10-CM
D64.81	Anemia due to antineoplastic chemotherapy	Diagnosis	ICD-10-CM
D64.89	Other specified anemias	Diagnosis	ICD-10-CM
D64.9	Anemia, unspecified	Diagnosis	ICD-10-CM
D75.81	Myelofibrosis	Diagnosis	ICD-10-CM
Asthma			
J45.20	Mild intermittent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.21	Mild intermittent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.22	Mild intermittent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.30	Mild persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.31	Mild persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.32	Mild persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.40	Moderate persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.41	Moderate persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.42	Moderate persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.50	Severe persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.51	Severe persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.52	Severe persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.901	Unspecified asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.902	Unspecified asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.909	Unspecified asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.990	Exercise induced bronchospasm	Diagnosis	ICD-10-CM
J45.991	Cough variant asthma	Diagnosis	ICD-10-CM
J45.998	Other asthma	Diagnosis	ICD-10-CM
Atrial Fibrillation			
I48.0	Paroxysmal atrial fibrillation	Diagnosis	ICD-10-CM
I48.1	Persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.11	Longstanding persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.19	Other persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.2	Chronic atrial fibrillation	Diagnosis	ICD-10-CM
I48.20	Chronic atrial fibrillation, unspecified	Diagnosis	ICD-10-CM
I48.21	Permanent atrial fibrillation	Diagnosis	ICD-10-CM
I48.3	Typical atrial flutter	Diagnosis	ICD-10-CM
I48.4	Atypical atrial flutter	Diagnosis	ICD-10-CM
I48.91	Unspecified atrial fibrillation	Diagnosis	ICD-10-CM
Benign Prostatic Hyperplasia			
N40.0	Benign prostatic hyperplasia without lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.1	Benign prostatic hyperplasia with lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.2	Nodular prostate without lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.3	Nodular prostate with lower urinary tract symptoms	Diagnosis	ICD-10-CM
Breast Cancer			
C50.011	Malignant neoplasm of nipple and areola, right female breast	Diagnosis	ICD-10-CM
C50.012	Malignant neoplasm of nipple and areola, left female breast	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
C50.019	Malignant neoplasm of nipple and areola, unspecified female breast	Diagnosis	ICD-10-CM
C50.021	Malignant neoplasm of nipple and areola, right male breast	Diagnosis	ICD-10-CM
C50.022	Malignant neoplasm of nipple and areola, left male breast	Diagnosis	ICD-10-CM
C50.029	Malignant neoplasm of nipple and areola, unspecified male breast	Diagnosis	ICD-10-CM
C50.111	Malignant neoplasm of central portion of right female breast	Diagnosis	ICD-10-CM
C50.112	Malignant neoplasm of central portion of left female breast	Diagnosis	ICD-10-CM
C50.119	Malignant neoplasm of central portion of unspecified female breast	Diagnosis	ICD-10-CM
C50.121	Malignant neoplasm of central portion of right male breast	Diagnosis	ICD-10-CM
C50.122	Malignant neoplasm of central portion of left male breast	Diagnosis	ICD-10-CM
C50.129	Malignant neoplasm of central portion of unspecified male breast	Diagnosis	ICD-10-CM
C50.211	Malignant neoplasm of upper-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.212	Malignant neoplasm of upper-inner quadrant of left female breast	Diagnosis	ICD-10-CM
C50.219	Malignant neoplasm of upper-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.221	Malignant neoplasm of upper-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.222	Malignant neoplasm of upper-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.229	Malignant neoplasm of upper-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.311	Malignant neoplasm of lower-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.312	Malignant neoplasm of lower-inner quadrant of left female breast	Diagnosis	ICD-10-CM
C50.319	Malignant neoplasm of lower-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.321	Malignant neoplasm of lower-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.322	Malignant neoplasm of lower-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.329	Malignant neoplasm of lower-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.411	Malignant neoplasm of upper-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.412	Malignant neoplasm of upper-outer quadrant of left female breast	Diagnosis	ICD-10-CM
C50.419	Malignant neoplasm of upper-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.421	Malignant neoplasm of upper-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.422	Malignant neoplasm of upper-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.429	Malignant neoplasm of upper-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.511	Malignant neoplasm of lower-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.512	Malignant neoplasm of lower-outer quadrant of left female breast	Diagnosis	ICD-10-CM
C50.519	Malignant neoplasm of lower-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.521	Malignant neoplasm of lower-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.522	Malignant neoplasm of lower-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.529	Malignant neoplasm of lower-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.611	Malignant neoplasm of axillary tail of right female breast	Diagnosis	ICD-10-CM
C50.612	Malignant neoplasm of axillary tail of left female breast	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
C50.619	Malignant neoplasm of axillary tail of unspecified female breast	Diagnosis	ICD-10-CM
C50.621	Malignant neoplasm of axillary tail of right male breast	Diagnosis	ICD-10-CM
C50.622	Malignant neoplasm of axillary tail of left male breast	Diagnosis	ICD-10-CM
C50.629	Malignant neoplasm of axillary tail of unspecified male breast	Diagnosis	ICD-10-CM
C50.811	Malignant neoplasm of overlapping sites of right female breast	Diagnosis	ICD-10-CM
C50.812	Malignant neoplasm of overlapping sites of left female breast	Diagnosis	ICD-10-CM
C50.819	Malignant neoplasm of overlapping sites of unspecified female breast	Diagnosis	ICD-10-CM
C50.821	Malignant neoplasm of overlapping sites of right male breast	Diagnosis	ICD-10-CM
C50.822	Malignant neoplasm of overlapping sites of left male breast	Diagnosis	ICD-10-CM
C50.829	Malignant neoplasm of overlapping sites of unspecified male breast	Diagnosis	ICD-10-CM
C50.911	Malignant neoplasm of unspecified site of right female breast	Diagnosis	ICD-10-CM
C50.912	Malignant neoplasm of unspecified site of left female breast	Diagnosis	ICD-10-CM
C50.919	Malignant neoplasm of unspecified site of unspecified female breast	Diagnosis	ICD-10-CM
C50.921	Malignant neoplasm of unspecified site of right male breast	Diagnosis	ICD-10-CM
C50.922	Malignant neoplasm of unspecified site of left male breast	Diagnosis	ICD-10-CM
C50.929	Malignant neoplasm of unspecified site of unspecified male breast	Diagnosis	ICD-10-CM
D05.00	Lobular carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.01	Lobular carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.02	Lobular carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.10	Intraductal carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.11	Intraductal carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.12	Intraductal carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.80	Other specified type of carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.81	Other specified type of carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.82	Other specified type of carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.90	Unspecified type of carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.91	Unspecified type of carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.92	Unspecified type of carcinoma in situ of left breast	Diagnosis	ICD-10-CM
Z17.0	Estrogen receptor positive status [ER+]	Diagnosis	ICD-10-CM
Z17.1	Estrogen receptor negative status [ER-]	Diagnosis	ICD-10-CM
Z19.1	Hormone sensitive malignancy status	Diagnosis	ICD-10-CM
Z19.2	Hormone resistant malignancy status	Diagnosis	ICD-10-CM
Z85.3	Personal history of malignant neoplasm of breast	Diagnosis	ICD-10-CM
Z86.000	Personal history of in-situ neoplasm of breast	Diagnosis	ICD-10-CM
Cardiac Arrest			
I46.2	Cardiac arrest due to underlying cardiac condition	Diagnosis	ICD-10-CM
I46.8	Cardiac arrest due to other underlying condition	Diagnosis	ICD-10-CM
I46.9	Cardiac arrest, cause unspecified	Diagnosis	ICD-10-CM
I97.120	Postprocedural cardiac arrest following cardiac surgery	Diagnosis	ICD-10-CM
I97.121	Postprocedural cardiac arrest following other surgery	Diagnosis	ICD-10-CM
I97.710	Intraoperative cardiac arrest during cardiac surgery	Diagnosis	ICD-10-CM
I97.711	Intraoperative cardiac arrest during other surgery	Diagnosis	ICD-10-CM
Z86.74	Personal history of sudden cardiac arrest	Diagnosis	ICD-10-CM
Chronic Kidney Disease			

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
A18.11	Tuberculosis of kidney and ureter	Diagnosis	ICD-10-CM
A52.75	Syphilis of kidney and ureter	Diagnosis	ICD-10-CM
B52.0	Plasmodium malariae malaria with nephropathy	Diagnosis	ICD-10-CM
E08.21	Diabetes mellitus due to underlying condition with diabetic nephropathy	Diagnosis	ICD-10-CM
E08.22	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E08.29	Diabetes mellitus due to underlying condition with other diabetic kidney complication	Diagnosis	ICD-10-CM
E09.21	Drug or chemical induced diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E09.22	Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E09.29	Drug or chemical induced diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E11.21	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E13.21	Other specified diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.29	Other specified diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
I12.0	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease	Diagnosis	ICD-10-CM
I12.9	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.11	Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
K76.7	Hepatorenal syndrome	Diagnosis	ICD-10-CM
M10.30	Gout due to renal impairment, unspecified site	Diagnosis	ICD-10-CM
M10.311	Gout due to renal impairment, right shoulder	Diagnosis	ICD-10-CM
M10.312	Gout due to renal impairment, left shoulder	Diagnosis	ICD-10-CM
M10.319	Gout due to renal impairment, unspecified shoulder	Diagnosis	ICD-10-CM
M10.321	Gout due to renal impairment, right elbow	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M10.322	Gout due to renal impairment, left elbow	Diagnosis	ICD-10-CM
M10.329	Gout due to renal impairment, unspecified elbow	Diagnosis	ICD-10-CM
M10.331	Gout due to renal impairment, right wrist	Diagnosis	ICD-10-CM
M10.332	Gout due to renal impairment, left wrist	Diagnosis	ICD-10-CM
M10.339	Gout due to renal impairment, unspecified wrist	Diagnosis	ICD-10-CM
M10.341	Gout due to renal impairment, right hand	Diagnosis	ICD-10-CM
M10.342	Gout due to renal impairment, left hand	Diagnosis	ICD-10-CM
M10.349	Gout due to renal impairment, unspecified hand	Diagnosis	ICD-10-CM
M10.351	Gout due to renal impairment, right hip	Diagnosis	ICD-10-CM
M10.352	Gout due to renal impairment, left hip	Diagnosis	ICD-10-CM
M10.359	Gout due to renal impairment, unspecified hip	Diagnosis	ICD-10-CM
M10.361	Gout due to renal impairment, right knee	Diagnosis	ICD-10-CM
M10.362	Gout due to renal impairment, left knee	Diagnosis	ICD-10-CM
M10.369	Gout due to renal impairment, unspecified knee	Diagnosis	ICD-10-CM
M10.371	Gout due to renal impairment, right ankle and foot	Diagnosis	ICD-10-CM
M10.372	Gout due to renal impairment, left ankle and foot	Diagnosis	ICD-10-CM
M10.379	Gout due to renal impairment, unspecified ankle and foot	Diagnosis	ICD-10-CM
M10.38	Gout due to renal impairment, vertebrae	Diagnosis	ICD-10-CM
M10.39	Gout due to renal impairment, multiple sites	Diagnosis	ICD-10-CM
M32.14	Glomerular disease in systemic lupus erythematosus	Diagnosis	ICD-10-CM
M32.15	Tubulo-interstitial nephropathy in systemic lupus erythematosus	Diagnosis	ICD-10-CM
M35.04	Sjogren syndrome with tubulo-interstitial nephropathy	Diagnosis	ICD-10-CM
M35.0A	Sjogren syndrome with glomerular disease	Diagnosis	ICD-10-CM
N01.0	Rapidly progressive nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N01.1	Rapidly progressive nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N01.2	Rapidly progressive nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N01.3	Rapidly progressive nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N01.4	Rapidly progressive nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N01.5	Rapidly progressive nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N01.6	Rapidly progressive nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N01.7	Rapidly progressive nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N01.8	Rapidly progressive nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N01.9	Rapidly progressive nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N01.A	Rapidly progressive nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N02.0	Recurrent and persistent hematuria with minor glomerular abnormality	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
N02.1	Recurrent and persistent hematuria with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N02.2	Recurrent and persistent hematuria with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N02.3	Recurrent and persistent hematuria with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N02.4	Recurrent and persistent hematuria with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N02.5	Recurrent and persistent hematuria with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N02.6	Recurrent and persistent hematuria with dense deposit disease	Diagnosis	ICD-10-CM
N02.7	Recurrent and persistent hematuria with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N02.8	Recurrent and persistent hematuria with other morphologic changes	Diagnosis	ICD-10-CM
N02.9	Recurrent and persistent hematuria with unspecified morphologic changes	Diagnosis	ICD-10-CM
N02.A	Recurrent and persistent hematuria with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N02.B1	Recurrent and persistent immunoglobulin A nephropathy with glomerular lesion	Diagnosis	ICD-10-CM
N02.B2	Recurrent and persistent immunoglobulin A nephropathy with focal and segmental glomerular lesion	Diagnosis	ICD-10-CM
N02.B3	Recurrent and persistent immunoglobulin A nephropathy with diffuse membranoproliferative glomerulonephritis	Diagnosis	ICD-10-CM
N02.B4	Recurrent and persistent immunoglobulin A nephropathy with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N02.B5	Recurrent and persistent immunoglobulin A nephropathy with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N02.B6	Recurrent and persistent immunoglobulin A nephropathy with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N02.B9	Other recurrent and persistent immunoglobulin A nephropathy	Diagnosis	ICD-10-CM
N03.0	Chronic nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N03.1	Chronic nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N03.2	Chronic nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N03.3	Chronic nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N03.4	Chronic nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N03.5	Chronic nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N03.6	Chronic nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N03.7	Chronic nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N03.8	Chronic nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
N03.9	Chronic nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N03.A	Chronic nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N04.0	Nephrotic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N04.1	Nephrotic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N04.2	Nephrotic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N04.20	Nephrotic syndrome with diffuse membranous glomerulonephritis, unspecified	Diagnosis	ICD-10-CM
N04.21	Primary membranous nephropathy with nephrotic syndrome	Diagnosis	ICD-10-CM
N04.22	Secondary membranous nephropathy with nephrotic syndrome	Diagnosis	ICD-10-CM
N04.29	Other nephrotic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N04.3	Nephrotic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N04.4	Nephrotic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N04.5	Nephrotic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N04.6	Nephrotic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N04.7	Nephrotic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N04.8	Nephrotic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N04.9	Nephrotic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N04.A	Nephrotic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N05.0	Unspecified nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N05.1	Unspecified nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N05.2	Unspecified nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N05.3	Unspecified nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N05.4	Unspecified nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N05.5	Unspecified nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N05.6	Unspecified nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N05.7	Unspecified nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N05.8	Unspecified nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N05.9	Unspecified nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N05.A	Unspecified nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N06.0	Isolated proteinuria with minor glomerular abnormality	Diagnosis	ICD-10-CM
N06.1	Isolated proteinuria with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N06.2	Isolated proteinuria with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N06.20	Isolated proteinuria with diffuse membranous glomerulonephritis, unspecified	Diagnosis	ICD-10-CM
N06.21	Primary membranous nephropathy with isolated proteinuria	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
N06.22	Secondary membranous nephropathy with isolated proteinuria	Diagnosis	ICD-10-CM
N06.29	Other isolated proteinuria with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N06.3	Isolated proteinuria with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N06.4	Isolated proteinuria with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N06.5	Isolated proteinuria with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N06.6	Isolated proteinuria with dense deposit disease	Diagnosis	ICD-10-CM
N06.7	Isolated proteinuria with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N06.8	Isolated proteinuria with other morphologic lesion	Diagnosis	ICD-10-CM
N06.9	Isolated proteinuria with unspecified morphologic lesion	Diagnosis	ICD-10-CM
N06.A	Isolated proteinuria with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N07.0	Hereditary nephropathy, not elsewhere classified with minor glomerular abnormality	Diagnosis	ICD-10-CM
N07.1	Hereditary nephropathy, not elsewhere classified with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N07.2	Hereditary nephropathy, not elsewhere classified with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N07.3	Hereditary nephropathy, not elsewhere classified with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N07.4	Hereditary nephropathy, not elsewhere classified with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N07.5	Hereditary nephropathy, not elsewhere classified with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N07.6	Hereditary nephropathy, not elsewhere classified with dense deposit disease	Diagnosis	ICD-10-CM
N07.7	Hereditary nephropathy, not elsewhere classified with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N07.8	Hereditary nephropathy, not elsewhere classified with other morphologic lesions	Diagnosis	ICD-10-CM
N07.9	Hereditary nephropathy, not elsewhere classified with unspecified morphologic lesions	Diagnosis	ICD-10-CM
N07.A	Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N08	Glomerular disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
N14.0	Analgesic nephropathy	Diagnosis	ICD-10-CM
N14.1	Nephropathy induced by other drugs, medicaments and biological substances	Diagnosis	ICD-10-CM
N14.11	Contrast-induced nephropathy	Diagnosis	ICD-10-CM
N14.19	Nephropathy induced by other drugs, medicaments and biological substances	Diagnosis	ICD-10-CM
N14.2	Nephropathy induced by unspecified drug, medicament or biological substance	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
N14.3	Nephropathy induced by heavy metals	Diagnosis	ICD-10-CM
N14.4	Toxic nephropathy, not elsewhere classified	Diagnosis	ICD-10-CM
N15.0	Balkan nephropathy	Diagnosis	ICD-10-CM
N15.8	Other specified renal tubulo-interstitial diseases	Diagnosis	ICD-10-CM
N15.9	Renal tubulo-interstitial disease, unspecified	Diagnosis	ICD-10-CM
N16	Renal tubulo-interstitial disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
N18.1	Chronic kidney disease, stage 1	Diagnosis	ICD-10-CM
N18.2	Chronic kidney disease, stage 2 (mild)	Diagnosis	ICD-10-CM
N18.3	Chronic kidney disease, stage 3 (moderate)	Diagnosis	ICD-10-CM
N18.30	Chronic kidney disease, stage 3 unspecified	Diagnosis	ICD-10-CM
N18.31	Chronic kidney disease, stage 3a	Diagnosis	ICD-10-CM
N18.32	Chronic kidney disease, stage 3b	Diagnosis	ICD-10-CM
N18.4	Chronic kidney disease, stage 4 (severe)	Diagnosis	ICD-10-CM
N18.5	Chronic kidney disease, stage 5	Diagnosis	ICD-10-CM
N18.6	End stage renal disease	Diagnosis	ICD-10-CM
N18.9	Chronic kidney disease, unspecified	Diagnosis	ICD-10-CM
N25.1	Nephrogenic diabetes insipidus	Diagnosis	ICD-10-CM
N25.89	Other disorders resulting from impaired renal tubular function	Diagnosis	ICD-10-CM
N25.9	Disorder resulting from impaired renal tubular function, unspecified	Diagnosis	ICD-10-CM
N26.1	Atrophy of kidney (terminal)	Diagnosis	ICD-10-CM
N26.9	Renal sclerosis, unspecified	Diagnosis	ICD-10-CM
N99.0	Postprocedural (acute) (chronic) kidney failure	Diagnosis	ICD-10-CM
Q61.02	Congenital multiple renal cysts	Diagnosis	ICD-10-CM
Q61.11	Cystic dilatation of collecting ducts	Diagnosis	ICD-10-CM
Q61.19	Other polycystic kidney, infantile type	Diagnosis	ICD-10-CM
Q61.2	Polycystic kidney, adult type	Diagnosis	ICD-10-CM
Q61.3	Polycystic kidney, unspecified	Diagnosis	ICD-10-CM
Q61.4	Renal dysplasia	Diagnosis	ICD-10-CM
Q61.5	Medullary cystic kidney	Diagnosis	ICD-10-CM
Q61.8	Other cystic kidney diseases	Diagnosis	ICD-10-CM
Colorectal Cancer			
C18.0	Malignant neoplasm of cecum	Diagnosis	ICD-10-CM
C18.1	Malignant neoplasm of appendix	Diagnosis	ICD-10-CM
C18.2	Malignant neoplasm of ascending colon	Diagnosis	ICD-10-CM
C18.3	Malignant neoplasm of hepatic flexure	Diagnosis	ICD-10-CM
C18.4	Malignant neoplasm of transverse colon	Diagnosis	ICD-10-CM
C18.5	Malignant neoplasm of splenic flexure	Diagnosis	ICD-10-CM
C18.6	Malignant neoplasm of descending colon	Diagnosis	ICD-10-CM
C18.7	Malignant neoplasm of sigmoid colon	Diagnosis	ICD-10-CM
C18.8	Malignant neoplasm of overlapping sites of colon	Diagnosis	ICD-10-CM
C18.9	Malignant neoplasm of colon, unspecified	Diagnosis	ICD-10-CM
C19	Malignant neoplasm of rectosigmoid junction	Diagnosis	ICD-10-CM
C20	Malignant neoplasm of rectum	Diagnosis	ICD-10-CM
C49.A4	Gastrointestinal stromal tumor of large intestine	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
C49.A5	Gastrointestinal stromal tumor of rectum	Diagnosis	ICD-10-CM
D01.0	Carcinoma in situ of colon	Diagnosis	ICD-10-CM
D01.1	Carcinoma in situ of rectosigmoid junction	Diagnosis	ICD-10-CM
D01.2	Carcinoma in situ of rectum	Diagnosis	ICD-10-CM
Z85.030	Personal history of malignant carcinoid tumor of large intestine	Diagnosis	ICD-10-CM
Z85.038	Personal history of other malignant neoplasm of large intestine	Diagnosis	ICD-10-CM
Z85.040	Personal history of malignant carcinoid tumor of rectum	Diagnosis	ICD-10-CM
Z85.048	Personal history of other malignant neoplasm of rectum, rectosigmoid junction, and anus	Diagnosis	ICD-10-CM
Chronic Obstructive Pulmonary Disease			
J40	Bronchitis, not specified as acute or chronic	Diagnosis	ICD-10-CM
J41.0	Simple chronic bronchitis	Diagnosis	ICD-10-CM
J41.1	Mucopurulent chronic bronchitis	Diagnosis	ICD-10-CM
J41.8	Mixed simple and mucopurulent chronic bronchitis	Diagnosis	ICD-10-CM
J42	Unspecified chronic bronchitis	Diagnosis	ICD-10-CM
J43.0	Unilateral pulmonary emphysema [MacLeod's syndrome]	Diagnosis	ICD-10-CM
J43.1	Panlobular emphysema	Diagnosis	ICD-10-CM
J43.2	Centrilobular emphysema	Diagnosis	ICD-10-CM
J43.9	Emphysema, unspecified	Diagnosis	ICD-10-CM
J44.0	Chronic obstructive pulmonary disease with (acute) lower respiratory infection	Diagnosis	ICD-10-CM
J44.1	Chronic obstructive pulmonary disease with (acute) exacerbation	Diagnosis	ICD-10-CM
J44.81	Bronchiolitis obliterans and bronchiolitis obliterans syndrome	Diagnosis	ICD-10-CM
J44.89	Other specified chronic obstructive pulmonary disease	Diagnosis	ICD-10-CM
J44.9	Chronic obstructive pulmonary disease, unspecified	Diagnosis	ICD-10-CM
J47.0	Bronchiectasis with acute lower respiratory infection	Diagnosis	ICD-10-CM
J47.1	Bronchiectasis with (acute) exacerbation	Diagnosis	ICD-10-CM
J47.9	Bronchiectasis, uncomplicated	Diagnosis	ICD-10-CM
J98.2	Interstitial emphysema	Diagnosis	ICD-10-CM
J98.3	Compensatory emphysema	Diagnosis	ICD-10-CM
Coronary Angioplasty Bypass			
00566	Anesthesia for direct coronary artery bypass grafting; without pump oxygenator	Procedure	CPT-4
00567	Anesthesia for direct coronary artery bypass grafting; with pump oxygenator	Procedure	CPT-4
02104Z3	Bypass Coronary Artery, One Artery from Coronary Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114Z3	Bypass Coronary Artery, Two Arteries from Coronary Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124Z3	Bypass Coronary Artery, Three Arteries from Coronary Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134Z3	Bypass Coronary Artery, Four or More Arteries from Coronary Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
0270346	Dilation of Coronary Artery, One Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
027034Z	Dilation of Coronary Artery, One Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0270356	Dilation of Coronary Artery, One Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027035Z	Dilation of Coronary Artery, One Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0270366	Dilation of Coronary Artery, One Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027036Z	Dilation of Coronary Artery, One Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0270376	Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027037Z	Dilation of Coronary Artery, One Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703D6	Dilation of Coronary Artery, One Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02703DZ	Dilation of Coronary Artery, One Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02703E6	Dilation of Coronary Artery, One Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703EZ	Dilation of Coronary Artery, One Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703F6	Dilation of Coronary Artery, One Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703FZ	Dilation of Coronary Artery, One Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703G6	Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703GZ	Dilation of Coronary Artery, One Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703T6	Dilation of Coronary Artery, One Artery, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02703TZ	Dilation of Coronary Artery, One Artery with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02703Z6	Dilation of Coronary Artery, One Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
02703ZZ	Dilation of Coronary Artery, One Artery, Percutaneous Approach	Procedure	ICD-10-PCS
0270446	Dilation of Coronary Artery, One Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027044Z	Dilation of Coronary Artery, One Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Code	Description	Code Category	Code Type
0270456	Dilation of Coronary Artery, One Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027045Z	Dilation of Coronary Artery, One Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0270466	Dilation of Coronary Artery, One Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027046Z	Dilation of Coronary Artery, One Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0270476	Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027047Z	Dilation of Coronary Artery, One Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704D6	Dilation of Coronary Artery, One Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704DZ	Dilation of Coronary Artery, One Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704E6	Dilation of Coronary Artery, One Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704EZ	Dilation of Coronary Artery, One Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704F6	Dilation of Coronary Artery, One Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704FZ	Dilation of Coronary Artery, One Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704G6	Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704GZ	Dilation of Coronary Artery, One Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704T6	Dilation of Coronary Artery, One Artery, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704TZ	Dilation of Coronary Artery, One Artery with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704Z6	Dilation of Coronary Artery, One Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704ZZ	Dilation of Coronary Artery, One Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0271346	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
027134Z	Dilation of Coronary Artery, Two Arteries with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0271356	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027135Z	Dilation of Coronary Artery, Two Arteries with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

Code	Description	Code Category	Code Type
0271366	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027136Z	Dilation of Coronary Artery, Two Arteries with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0271376	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027137Z	Dilation of Coronary Artery, Two Arteries with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713D6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02713DZ	Dilation of Coronary Artery, Two Arteries with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02713E6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713EZ	Dilation of Coronary Artery, Two Arteries with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713F6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713FZ	Dilation of Coronary Artery, Two Arteries with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713G6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713GZ	Dilation of Coronary Artery, Two Arteries with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713T6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02713TZ	Dilation of Coronary Artery, Two Arteries with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02713Z6	Dilation of Coronary Artery, Two Arteries, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
02713ZZ	Dilation of Coronary Artery, Two Arteries, Percutaneous Approach	Procedure	ICD-10-PCS
0271446	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027144Z	Dilation of Coronary Artery, Two Arteries with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0271456	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027145Z	Dilation of Coronary Artery, Two Arteries with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0271466	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027146Z	Dilation of Coronary Artery, Two Arteries with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
0271476	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027147Z	Dilation of Coronary Artery, Two Arteries with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714D6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714DZ	Dilation of Coronary Artery, Two Arteries with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714E6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714EZ	Dilation of Coronary Artery, Two Arteries with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714F6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714FZ	Dilation of Coronary Artery, Two Arteries with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714G6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714GZ	Dilation of Coronary Artery, Two Arteries with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714T6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714TZ	Dilation of Coronary Artery, Two Arteries with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714Z6	Dilation of Coronary Artery, Two Arteries, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714ZZ	Dilation of Coronary Artery, Two Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0272346	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
027234Z	Dilation of Coronary Artery, Three Arteries with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0272356	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027235Z	Dilation of Coronary Artery, Three Arteries with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0272366	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027236Z	Dilation of Coronary Artery, Three Arteries with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0272376	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

Code	Description	Code Category	Code Type
027237Z	Dilation of Coronary Artery, Three Arteries with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02723D6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02723DZ	Dilation of Coronary Artery, Three Arteries with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02723E6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02723EZ	Dilation of Coronary Artery, Three Arteries with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02723F6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02723FZ	Dilation of Coronary Artery, Three Arteries with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02723G6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02723GZ	Dilation of Coronary Artery, Three Arteries with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02723T6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02723TZ	Dilation of Coronary Artery, Three Arteries with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02723Z6	Dilation of Coronary Artery, Three Arteries, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
02723ZZ	Dilation of Coronary Artery, Three Arteries, Percutaneous Approach	Procedure	ICD-10-PCS
0272446	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027244Z	Dilation of Coronary Artery, Three Arteries with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0272456	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027245Z	Dilation of Coronary Artery, Three Arteries with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0272466	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027246Z	Dilation of Coronary Artery, Three Arteries with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0272476	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027247Z	Dilation of Coronary Artery, Three Arteries with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724D6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Code	Description	Code Category	Code Type
02724DZ	Dilation of Coronary Artery, Three Arteries with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724E6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724EZ	Dilation of Coronary Artery, Three Arteries with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724F6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724FZ	Dilation of Coronary Artery, Three Arteries with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724G6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724GZ	Dilation of Coronary Artery, Three Arteries with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724T6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724TZ	Dilation of Coronary Artery, Three Arteries with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724Z6	Dilation of Coronary Artery, Three Arteries, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724ZZ	Dilation of Coronary Artery, Three Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0273346	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
027334Z	Dilation of Coronary Artery, Four or More Arteries with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0273356	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027335Z	Dilation of Coronary Artery, Four or More Arteries with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0273366	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027336Z	Dilation of Coronary Artery, Four or More Arteries with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0273376	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027337Z	Dilation of Coronary Artery, Four or More Arteries with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02733D6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02733DZ	Dilation of Coronary Artery, Four or More Arteries with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS

Code	Description	Code Category	Code Type
02733E6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02733EZ	Dilation of Coronary Artery, Four or More Arteries with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02733F6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02733FZ	Dilation of Coronary Artery, Four or More Arteries with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02733G6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02733GZ	Dilation of Coronary Artery, Four or More Arteries with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02733T6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02733TZ	Dilation of Coronary Artery, Four or More Arteries with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02733Z6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
02733ZZ	Dilation of Coronary Artery, Four or More Arteries, Percutaneous Approach	Procedure	ICD-10-PCS
0273446	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027344Z	Dilation of Coronary Artery, Four or More Arteries with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0273456	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027345Z	Dilation of Coronary Artery, Four or More Arteries with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0273466	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027346Z	Dilation of Coronary Artery, Four or More Arteries with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0273476	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027347Z	Dilation of Coronary Artery, Four or More Arteries with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734D6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734DZ	Dilation of Coronary Artery, Four or More Arteries with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
02734E6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734EZ	Dilation of Coronary Artery, Four or More Arteries with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734F6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734FZ	Dilation of Coronary Artery, Four or More Arteries with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734G6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734GZ	Dilation of Coronary Artery, Four or More Arteries with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734T6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734TZ	Dilation of Coronary Artery, Four or More Arteries with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734Z6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734ZZ	Dilation of Coronary Artery, Four or More Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0644T	Transcatheter removal or debulking of intracardiac mass (eg, vegetations, thrombus) via suction (eg, vacuum, aspiration) device, percutaneous approach, with intraoperative reinfusion of aspirated blood, including imaging guidance, when performed	Procedure	CPT-3
33508	Endoscopy, surgical, including video-assisted harvest of vein(s) for coronary artery bypass procedure (List separately in addition to code for primary procedure)	Procedure	CPT-4
33509	Harvest of upper extremity artery, 1 segment, for coronary artery bypass procedure, endoscopic	Procedure	CPT-4
33510	Coronary artery bypass, vein only; single coronary venous graft	Procedure	CPT-4
33511	Coronary artery bypass, vein only; 2 coronary venous grafts	Procedure	CPT-4
33512	Coronary artery bypass, vein only; 3 coronary venous grafts	Procedure	CPT-4
33513	Coronary artery bypass, vein only; 4 coronary venous grafts	Procedure	CPT-4
33514	Coronary artery bypass, vein only; 5 coronary venous grafts	Procedure	CPT-4
33516	Coronary artery bypass, vein only; 6 or more coronary venous grafts	Procedure	CPT-4
33517	Coronary artery bypass, using venous graft(s) and arterial graft(s); single vein graft (List separately in addition to code for primary procedure)	Procedure	CPT-4
33518	Coronary artery bypass, using venous graft(s) and arterial graft(s); 2 venous grafts (List separately in addition to code for primary procedure)	Procedure	CPT-4
33519	Coronary artery bypass, using venous graft(s) and arterial graft(s); 3 venous grafts (List separately in addition to code for primary procedure)	Procedure	CPT-4

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
33520	Coronary Artery Bypass, Nonautogenous Graft (eg, Synthetic Or Cadaver); Single Graft	Procedure	CPT-4
33521	Coronary artery bypass, using venous graft(s) and arterial graft(s); 4 venous grafts (List separately in addition to code for primary procedure)	Procedure	CPT-4
33522	Coronary artery bypass, using venous graft(s) and arterial graft(s); 5 venous grafts (List separately in addition to code for primary procedure)	Procedure	CPT-4
33523	Coronary artery bypass, using venous graft(s) and arterial graft(s); 6 or more venous grafts (List separately in addition to code for primary procedure)	Procedure	CPT-4
33525	Coronary Artery Bypass, Nonautogenous Graft (eg, Synthetic Or Cadaver); Two Coronary Grafts	Procedure	CPT-4
33528	Coronary Artery Bypass, Nonautogenous Graft (eg, Synthetic Or Cadaver); Three Or More Coronary Grafts	Procedure	CPT-4
33530	Reoperation, coronary artery bypass procedure or valve procedure, more than 1 month after original operation (List separately in addition to code for primary procedure)	Procedure	CPT-4
33533	Coronary artery bypass, using arterial graft(s); single arterial graft	Procedure	CPT-4
33534	Coronary artery bypass, using arterial graft(s); 2 coronary arterial grafts	Procedure	CPT-4
33535	Coronary artery bypass, using arterial graft(s); 3 coronary arterial grafts	Procedure	CPT-4
33536	Coronary artery bypass, using arterial graft(s); 4 or more coronary arterial grafts	Procedure	CPT-4
33572	Coronary endarterectomy, open, any method, of left anterior descending, circumflex, or right coronary artery performed in conjunction with coronary artery bypass graft procedure, each vessel (List separately in addition to primary procedure)	Procedure	CPT-4
35500	Harvest of upper extremity vein, 1 segment, for lower extremity or coronary artery bypass procedure (List separately in addition to code for primary procedure)	Procedure	CPT-4
35600	Harvest of upper extremity artery, 1 segment, for coronary artery bypass procedure, open	Procedure	CPT-4
4110F	Internal mammary artery graft performed for primary, isolated coronary artery bypass graft procedure (CABG)	Procedure	CPT-2
92920	Percutaneous transluminal coronary angioplasty; single major coronary artery or branch	Procedure	CPT-4
92921	Percutaneous transluminal coronary angioplasty; each additional branch of a major coronary artery (List separately in addition to code for primary procedure)	Procedure	CPT-4
92924	Percutaneous transluminal coronary atherectomy, with coronary angioplasty when performed; single major coronary artery or branch	Procedure	CPT-4

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
92925	Percutaneous transluminal coronary atherectomy, with coronary angioplasty when performed; each additional branch of a major coronary artery (List separately in addition to code for primary procedure)	Procedure	CPT-4
92928	Percutaneous transcatheter placement of intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch	Procedure	CPT-4
92929	Percutaneous transcatheter placement of intracoronary stent(s), with coronary angioplasty when performed; each additional branch of a major coronary artery (List separately in addition to code for primary procedure)	Procedure	CPT-4
92933	Percutaneous transluminal coronary atherectomy, with intracoronary stent, with coronary angioplasty when performed; single major coronary artery or branch	Procedure	CPT-4
92934	Percutaneous transluminal coronary atherectomy, with intracoronary stent, with coronary angioplasty when performed; each additional branch of a major coronary artery (List separately in addition to code for primary procedure)	Procedure	CPT-4
92937	Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of intracoronary stent, atherectomy and angioplasty, including distal protection when performed; single	Procedure	CPT-4
92938	Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of intracoronary stent, atherectomy and angioplasty, including distal protection when performed; each ad	Procedure	CPT-4
92941	Percutaneous transluminal revascularization of acute total/subtotal occlusion during acute myocardial infarction, coronary artery or coronary artery bypass graft, any combination of intracoronary stent, atherectomy and angioplasty, including aspirati	Procedure	CPT-4
92943	Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of intracoronary stent, atherectomy and angioplasty; single vessel	Procedure	CPT-4
92944	Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of intracoronary stent, atherectomy and angioplasty; each additional coronary artery, co	Procedure	CPT-4
C9600	Percutaneous transcatheter placement of drug eluting intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
C9601	Percutaneous transcatheter placement of drug-eluting intracoronary stent(s), with coronary angioplasty when performed; each additional branch of a major coronary artery (list separately in addition to code for primary procedure)	Procedure	HCPCS
C9602	Percutaneous transluminal coronary atherectomy, with drug eluting intracoronary stent, with coronary angioplasty when performed; single major coronary artery or branch	Procedure	HCPCS
C9603	Percutaneous transluminal coronary atherectomy, with drug-eluting intracoronary stent, with coronary angioplasty when performed; each additional branch of a major coronary artery (list separately in addition to code for primary procedure)	Procedure	HCPCS
C9604	Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of drug-eluting intracoronary stent, atherectomy and angioplasty, including distal protection when perfo	Procedure	HCPCS
C9605	Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of drug-eluting intracoronary stent, atherectomy and angioplasty, including distal protection when perfo	Procedure	HCPCS
C9606	Percutaneous transluminal revascularization of acute total/subtotal occlusion during acute myocardial infarction, coronary artery or coronary artery bypass graft, any combination of drug-eluting intracoronary stent, atherectomy and angioplasty, inclu	Procedure	HCPCS
C9607	Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of drug-eluting intracoronary stent, atherectomy and angioplasty; single vessel	Procedure	HCPCS
C9608	Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of drug-eluting intracoronary stent, atherectomy and angioplasty; each additional corona	Procedure	HCPCS
S2205	Minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using arterial graft(s), single coronary arterial graft	Procedure	HCPCS
S2206	Minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using arterial graft(s), two coronary arterial grafts	Procedure	HCPCS
S2207	Minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using venous graft only, single coronary venous graft	Procedure	HCPCS
S2208	Minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using single arterial and venous graft(s), single venous graft	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
S2209	Minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using two arterial grafts and single venous graft	Procedure	HCPCS
T82.2	Mechanical complication of coronary artery bypass graft and biological heart valve graft	Diagnosis	ICD-10-CM
T82.21	Mechanical complication of coronary artery bypass graft	Diagnosis	ICD-10-CM
T82.211	Breakdown (mechanical) of coronary artery bypass graft	Diagnosis	ICD-10-CM
T82.211A	Breakdown (mechanical) of coronary artery bypass graft, initial encounter	Diagnosis	ICD-10-CM
T82.211D	Breakdown (mechanical) of coronary artery bypass graft, subsequent encounter	Diagnosis	ICD-10-CM
T82.211S	Breakdown (mechanical) of coronary artery bypass graft, sequela	Diagnosis	ICD-10-CM
T82.212	Displacement of coronary artery bypass graft	Diagnosis	ICD-10-CM
T82.212A	Displacement of coronary artery bypass graft, initial encounter	Diagnosis	ICD-10-CM
T82.212D	Displacement of coronary artery bypass graft, subsequent encounter	Diagnosis	ICD-10-CM
T82.212S	Displacement of coronary artery bypass graft, sequela	Diagnosis	ICD-10-CM
T82.213	Leakage of coronary artery bypass graft	Diagnosis	ICD-10-CM
T82.213A	Leakage of coronary artery bypass graft, initial encounter	Diagnosis	ICD-10-CM
T82.213D	Leakage of coronary artery bypass graft, subsequent encounter	Diagnosis	ICD-10-CM
T82.213S	Leakage of coronary artery bypass graft, sequela	Diagnosis	ICD-10-CM
T82.218	Other mechanical complication of coronary artery bypass graft	Diagnosis	ICD-10-CM
T82.218A	Other mechanical complication of coronary artery bypass graft, initial encounter	Diagnosis	ICD-10-CM
T82.218D	Other mechanical complication of coronary artery bypass graft, subsequent encounter	Diagnosis	ICD-10-CM
T82.218S	Other mechanical complication of coronary artery bypass graft, sequela	Diagnosis	ICD-10-CM
Z95.1	Presence of aortocoronary bypass graft	Diagnosis	ICD-10-CM
Z95.5	Presence of coronary angioplasty implant and graft	Diagnosis	ICD-10-CM
Z98.61	Coronary angioplasty status	Diagnosis	ICD-10-CM
Dementia			
F01.50	Vascular dementia, unspecified severity, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F01.51	Vascular dementia, unspecified severity, with behavioral disturbance	Diagnosis	ICD-10-CM
F01.511	Vascular dementia, unspecified severity, with agitation	Diagnosis	ICD-10-CM
F01.518	Vascular dementia, unspecified severity, with other behavioral disturbance	Diagnosis	ICD-10-CM
F01.52	Vascular dementia, unspecified severity, with psychotic disturbance	Diagnosis	ICD-10-CM
F01.53	Vascular dementia, unspecified severity, with mood disturbance	Diagnosis	ICD-10-CM
F01.54	Vascular dementia, unspecified severity, with anxiety	Diagnosis	ICD-10-CM
F01.A0	Vascular dementia, mild, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F01.A11	Vascular dementia, mild, with agitation	Diagnosis	ICD-10-CM
F01.A18	Vascular dementia, mild, with other behavioral disturbance	Diagnosis	ICD-10-CM
F01.A2	Vascular dementia, mild, with psychotic disturbance	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
F01.A3	Vascular dementia, mild, with mood disturbance	Diagnosis	ICD-10-CM
F01.A4	Vascular dementia, mild, with anxiety	Diagnosis	ICD-10-CM
F01.B0	Vascular dementia, moderate, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F01.B11	Vascular dementia, moderate, with agitation	Diagnosis	ICD-10-CM
F01.B18	Vascular dementia, moderate, with other behavioral disturbance	Diagnosis	ICD-10-CM
F01.B2	Vascular dementia, moderate, with psychotic disturbance	Diagnosis	ICD-10-CM
F01.B3	Vascular dementia, moderate, with mood disturbance	Diagnosis	ICD-10-CM
F01.B4	Vascular dementia, moderate, with anxiety	Diagnosis	ICD-10-CM
F01.C0	Vascular dementia, severe, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F01.C11	Vascular dementia, severe, with agitation	Diagnosis	ICD-10-CM
F01.C18	Vascular dementia, severe, with other behavioral disturbance	Diagnosis	ICD-10-CM
F01.C2	Vascular dementia, severe, with psychotic disturbance	Diagnosis	ICD-10-CM
F01.C3	Vascular dementia, severe, with mood disturbance	Diagnosis	ICD-10-CM
F01.C4	Vascular dementia, severe, with anxiety	Diagnosis	ICD-10-CM
F02.80	Dementia in other diseases classified elsewhere, unspecified severity, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F02.81	Dementia in other diseases classified elsewhere, unspecified severity, with behavioral disturbance	Diagnosis	ICD-10-CM
F02.811	Dementia in other diseases classified elsewhere, unspecified severity, with agitation	Diagnosis	ICD-10-CM
F02.818	Dementia in other diseases classified elsewhere, unspecified severity, with other behavioral disturbance	Diagnosis	ICD-10-CM
F02.82	Dementia in other diseases classified elsewhere, unspecified severity, with psychotic disturbance	Diagnosis	ICD-10-CM
F02.83	Dementia in other diseases classified elsewhere, unspecified severity, with mood disturbance	Diagnosis	ICD-10-CM
F02.84	Dementia in other diseases classified elsewhere, unspecified severity, with anxiety	Diagnosis	ICD-10-CM
F02.A0	Dementia in other diseases classified elsewhere, mild, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F02.A11	Dementia in other diseases classified elsewhere, mild, with agitation	Diagnosis	ICD-10-CM
F02.A18	Dementia in other diseases classified elsewhere, mild, with other behavioral disturbance	Diagnosis	ICD-10-CM
F02.A2	Dementia in other diseases classified elsewhere, mild, with psychotic disturbance	Diagnosis	ICD-10-CM
F02.A3	Dementia in other diseases classified elsewhere, mild, with mood disturbance	Diagnosis	ICD-10-CM
F02.A4	Dementia in other diseases classified elsewhere, mild, with anxiety	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
F02.B0	Dementia in other diseases classified elsewhere, moderate, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F02.B11	Dementia in other diseases classified elsewhere, moderate, with agitation	Diagnosis	ICD-10-CM
F02.B18	Dementia in other diseases classified elsewhere, moderate, with other behavioral disturbance	Diagnosis	ICD-10-CM
F02.B2	Dementia in other diseases classified elsewhere, moderate, with psychotic disturbance	Diagnosis	ICD-10-CM
F02.B3	Dementia in other diseases classified elsewhere, moderate, with mood disturbance	Diagnosis	ICD-10-CM
F02.B4	Dementia in other diseases classified elsewhere, moderate, with anxiety	Diagnosis	ICD-10-CM
F02.C0	Dementia in other diseases classified elsewhere, severe, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F02.C11	Dementia in other diseases classified elsewhere, severe, with agitation	Diagnosis	ICD-10-CM
F02.C18	Dementia in other diseases classified elsewhere, severe, with other behavioral disturbance	Diagnosis	ICD-10-CM
F02.C2	Dementia in other diseases classified elsewhere, severe, with psychotic disturbance	Diagnosis	ICD-10-CM
F02.C3	Dementia in other diseases classified elsewhere, severe, with mood disturbance	Diagnosis	ICD-10-CM
F02.C4	Dementia in other diseases classified elsewhere, severe, with anxiety	Diagnosis	ICD-10-CM
F03.90	Unspecified dementia, unspecified severity, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F03.91	Unspecified dementia, unspecified severity, with behavioral disturbance	Diagnosis	ICD-10-CM
F03.911	Unspecified dementia, unspecified severity, with agitation	Diagnosis	ICD-10-CM
F03.918	Unspecified dementia, unspecified severity, with other behavioral disturbance	Diagnosis	ICD-10-CM
F03.92	Unspecified dementia, unspecified severity, with psychotic disturbance	Diagnosis	ICD-10-CM
F03.93	Unspecified dementia, unspecified severity, with mood disturbance	Diagnosis	ICD-10-CM
F03.94	Unspecified dementia, unspecified severity, with anxiety	Diagnosis	ICD-10-CM
F03.A0	Unspecified dementia, mild, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F03.A11	Unspecified dementia, mild, with agitation	Diagnosis	ICD-10-CM
F03.A18	Unspecified dementia, mild, with other behavioral disturbance	Diagnosis	ICD-10-CM
F03.A2	Unspecified dementia, mild, with psychotic disturbance	Diagnosis	ICD-10-CM
F03.A3	Unspecified dementia, mild, with mood disturbance	Diagnosis	ICD-10-CM
F03.A4	Unspecified dementia, mild, with anxiety	Diagnosis	ICD-10-CM
F03.B0	Unspecified dementia, moderate, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F03.B11	Unspecified dementia, moderate, with agitation	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
F03.B18	Unspecified dementia, moderate, with other behavioral disturbance	Diagnosis	ICD-10-CM
F03.B2	Unspecified dementia, moderate, with psychotic disturbance	Diagnosis	ICD-10-CM
F03.B3	Unspecified dementia, moderate, with mood disturbance	Diagnosis	ICD-10-CM
F03.B4	Unspecified dementia, moderate, with anxiety	Diagnosis	ICD-10-CM
F03.C0	Unspecified dementia, severe, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F03.C11	Unspecified dementia, severe, with agitation	Diagnosis	ICD-10-CM
F03.C18	Unspecified dementia, severe, with other behavioral disturbance	Diagnosis	ICD-10-CM
F03.C2	Unspecified dementia, severe, with psychotic disturbance	Diagnosis	ICD-10-CM
F03.C3	Unspecified dementia, severe, with mood disturbance	Diagnosis	ICD-10-CM
F03.C4	Unspecified dementia, severe, with anxiety	Diagnosis	ICD-10-CM
F05	Delirium due to known physiological condition	Diagnosis	ICD-10-CM
G13.8	Systemic atrophy primarily affecting central nervous system in other diseases classified elsewhere	Diagnosis	ICD-10-CM
G31.01	Pick's disease	Diagnosis	ICD-10-CM
G31.09	Other frontotemporal neurocognitive disorder	Diagnosis	ICD-10-CM
G31.1	Senile degeneration of brain, not elsewhere classified	Diagnosis	ICD-10-CM
G31.2	Degeneration of nervous system due to alcohol	Diagnosis	ICD-10-CM
G31.83	Neurocognitive disorder with Lewy bodies	Diagnosis	ICD-10-CM
G94	Other disorders of brain in diseases classified elsewhere	Diagnosis	ICD-10-CM
R41.81	Age-related cognitive decline	Diagnosis	ICD-10-CM
Depression			
F06.31	Mood disorder due to known physiological condition with depressive features	Diagnosis	ICD-10-CM
F06.32	Mood disorder due to known physiological condition with major depressive-like episode	Diagnosis	ICD-10-CM
F31.0	Bipolar disorder, current episode hypomanic	Diagnosis	ICD-10-CM
F31.10	Bipolar disorder, current episode manic without psychotic features, unspecified	Diagnosis	ICD-10-CM
F31.11	Bipolar disorder, current episode manic without psychotic features, mild	Diagnosis	ICD-10-CM
F31.12	Bipolar disorder, current episode manic without psychotic features, moderate	Diagnosis	ICD-10-CM
F31.13	Bipolar disorder, current episode manic without psychotic features, severe	Diagnosis	ICD-10-CM
F31.2	Bipolar disorder, current episode manic severe with psychotic features	Diagnosis	ICD-10-CM
F31.30	Bipolar disorder, current episode depressed, mild or moderate severity, unspecified	Diagnosis	ICD-10-CM
F31.31	Bipolar disorder, current episode depressed, mild	Diagnosis	ICD-10-CM
F31.32	Bipolar disorder, current episode depressed, moderate	Diagnosis	ICD-10-CM
F31.4	Bipolar disorder, current episode depressed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.5	Bipolar disorder, current episode depressed, severe, with psychotic features	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
F31.60	Bipolar disorder, current episode mixed, unspecified	Diagnosis	ICD-10-CM
F31.61	Bipolar disorder, current episode mixed, mild	Diagnosis	ICD-10-CM
F31.62	Bipolar disorder, current episode mixed, moderate	Diagnosis	ICD-10-CM
F31.63	Bipolar disorder, current episode mixed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.64	Bipolar disorder, current episode mixed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.71	Bipolar disorder, in partial remission, most recent episode hypomanic	Diagnosis	ICD-10-CM
F31.73	Bipolar disorder, in partial remission, most recent episode manic	Diagnosis	ICD-10-CM
F31.75	Bipolar disorder, in partial remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.76	Bipolar disorder, in full remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.77	Bipolar disorder, in partial remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.78	Bipolar disorder, in full remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.81	Bipolar II disorder	Diagnosis	ICD-10-CM
F31.89	Other bipolar disorder	Diagnosis	ICD-10-CM
F31.9	Bipolar disorder, unspecified	Diagnosis	ICD-10-CM
F32.0	Major depressive disorder, single episode, mild	Diagnosis	ICD-10-CM
F32.1	Major depressive disorder, single episode, moderate	Diagnosis	ICD-10-CM
F32.2	Major depressive disorder, single episode, severe without psychotic features	Diagnosis	ICD-10-CM
F32.3	Major depressive disorder, single episode, severe with psychotic features	Diagnosis	ICD-10-CM
F32.4	Major depressive disorder, single episode, in partial remission	Diagnosis	ICD-10-CM
F32.5	Major depressive disorder, single episode, in full remission	Diagnosis	ICD-10-CM
F32.8	Other depressive episodes	Diagnosis	ICD-10-CM
F32.89	Other specified depressive episodes	Diagnosis	ICD-10-CM
F32.9	Major depressive disorder, single episode, unspecified	Diagnosis	ICD-10-CM
F32.A	Depression, unspecified	Diagnosis	ICD-10-CM
F33.0	Major depressive disorder, recurrent, mild	Diagnosis	ICD-10-CM
F33.1	Major depressive disorder, recurrent, moderate	Diagnosis	ICD-10-CM
F33.2	Major depressive disorder, recurrent severe without psychotic features	Diagnosis	ICD-10-CM
F33.3	Major depressive disorder, recurrent, severe with psychotic symptoms	Diagnosis	ICD-10-CM
F33.40	Major depressive disorder, recurrent, in remission, unspecified	Diagnosis	ICD-10-CM
F33.41	Major depressive disorder, recurrent, in partial remission	Diagnosis	ICD-10-CM
F33.42	Major depressive disorder, recurrent, in full remission	Diagnosis	ICD-10-CM
F33.8	Other recurrent depressive disorders	Diagnosis	ICD-10-CM
F33.9	Major depressive disorder, recurrent, unspecified	Diagnosis	ICD-10-CM
F34.0	Cyclothymic disorder	Diagnosis	ICD-10-CM
F34.1	Dysthymic disorder	Diagnosis	ICD-10-CM
F43.21	Adjustment disorder with depressed mood	Diagnosis	ICD-10-CM
F43.23	Adjustment disorder with mixed anxiety and depressed mood	Diagnosis	ICD-10-CM
Diabetes			
E08.00	Diabetes mellitus due to underlying condition with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
E08.01	Diabetes mellitus due to underlying condition with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E08.10	Diabetes mellitus due to underlying condition with ketoacidosis without coma	Diagnosis	ICD-10-CM
E08.11	Diabetes mellitus due to underlying condition with ketoacidosis with coma	Diagnosis	ICD-10-CM
E08.21	Diabetes mellitus due to underlying condition with diabetic nephropathy	Diagnosis	ICD-10-CM
E08.22	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E08.29	Diabetes mellitus due to underlying condition with other diabetic kidney complication	Diagnosis	ICD-10-CM
E08.311	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.319	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.321	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3211	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3212	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3213	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3219	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.329	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3291	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3292	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3293	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3299	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.331	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3311	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3312	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E08.3313	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3319	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.339	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3391	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3392	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3393	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3399	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.341	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3411	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3412	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3413	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3419	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.349	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3491	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3492	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3493	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3499	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.351	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3511	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3512	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E08.3513	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3519	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.3521	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E08.3522	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E08.3523	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E08.3529	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E08.3531	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E08.3532	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E08.3533	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E08.3539	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E08.3541	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E08.3542	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E08.3543	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E08.3549	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E08.3551	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E08.3552	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E08.3553	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E08.3559	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E08.359	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3591	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3592	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3593	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3599	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.36	Diabetes mellitus due to underlying condition with diabetic cataract	Diagnosis	ICD-10-CM
E08.37X1	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E08.37X2	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E08.37X3	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E08.37X9	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E08.39	Diabetes mellitus due to underlying condition with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E08.40	Diabetes mellitus due to underlying condition with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E08.41	Diabetes mellitus due to underlying condition with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E08.42	Diabetes mellitus due to underlying condition with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E08.43	Diabetes mellitus due to underlying condition with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E08.44	Diabetes mellitus due to underlying condition with diabetic amyotrophy	Diagnosis	ICD-10-CM
E08.49	Diabetes mellitus due to underlying condition with other diabetic neurological complication	Diagnosis	ICD-10-CM
E08.51	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E08.52	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E08.59	Diabetes mellitus due to underlying condition with other circulatory complications	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E08.610	Diabetes mellitus due to underlying condition with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E08.618	Diabetes mellitus due to underlying condition with other diabetic arthropathy	Diagnosis	ICD-10-CM
E08.620	Diabetes mellitus due to underlying condition with diabetic dermatitis	Diagnosis	ICD-10-CM
E08.621	Diabetes mellitus due to underlying condition with foot ulcer	Diagnosis	ICD-10-CM
E08.622	Diabetes mellitus due to underlying condition with other skin ulcer	Diagnosis	ICD-10-CM
E08.628	Diabetes mellitus due to underlying condition with other skin complications	Diagnosis	ICD-10-CM
E08.630	Diabetes mellitus due to underlying condition with periodontal disease	Diagnosis	ICD-10-CM
E08.638	Diabetes mellitus due to underlying condition with other oral complications	Diagnosis	ICD-10-CM
E08.641	Diabetes mellitus due to underlying condition with hypoglycemia with coma	Diagnosis	ICD-10-CM
E08.649	Diabetes mellitus due to underlying condition with hypoglycemia without coma	Diagnosis	ICD-10-CM
E08.65	Diabetes mellitus due to underlying condition with hyperglycemia	Diagnosis	ICD-10-CM
E08.69	Diabetes mellitus due to underlying condition with other specified complication	Diagnosis	ICD-10-CM
E08.8	Diabetes mellitus due to underlying condition with unspecified complications	Diagnosis	ICD-10-CM
E08.9	Diabetes mellitus due to underlying condition without complications	Diagnosis	ICD-10-CM
E09.00	Drug or chemical induced diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E09.01	Drug or chemical induced diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E09.10	Drug or chemical induced diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E09.11	Drug or chemical induced diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E09.21	Drug or chemical induced diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E09.22	Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E09.29	Drug or chemical induced diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E09.311	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.319	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.321	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3211	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
E09.3212	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3213	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3219	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.329	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3291	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3292	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3293	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3299	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.331	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3311	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3312	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3313	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3319	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.339	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3391	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3392	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3393	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3399	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.341	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3411	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3412	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
E09.3413	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3419	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.349	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3491	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3492	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3493	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3499	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.351	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3511	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3512	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3513	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3519	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.3521	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E09.3522	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E09.3523	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E09.3529	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E09.3531	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E09.3532	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E09.3533	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E09.3539	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E09.3541	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E09.3542	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E09.3543	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E09.3549	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E09.3551	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E09.3552	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E09.3553	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E09.3559	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E09.359	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3591	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3592	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3593	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3599	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.36	Drug or chemical induced diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E09.37X1	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E09.37X2	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E09.37X3	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
E09.37X9	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E09.39	Drug or chemical induced diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E09.40	Drug or chemical induced diabetes mellitus with neurological complications with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E09.41	Drug or chemical induced diabetes mellitus with neurological complications with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E09.42	Drug or chemical induced diabetes mellitus with neurological complications with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E09.43	Drug or chemical induced diabetes mellitus with neurological complications with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E09.44	Drug or chemical induced diabetes mellitus with neurological complications with diabetic amyotrophy	Diagnosis	ICD-10-CM
E09.49	Drug or chemical induced diabetes mellitus with neurological complications with other diabetic neurological complication	Diagnosis	ICD-10-CM
E09.51	Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E09.52	Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E09.59	Drug or chemical induced diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E09.610	Drug or chemical induced diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E09.618	Drug or chemical induced diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E09.620	Drug or chemical induced diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E09.621	Drug or chemical induced diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E09.622	Drug or chemical induced diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E09.628	Drug or chemical induced diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E09.630	Drug or chemical induced diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E09.638	Drug or chemical induced diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E09.641	Drug or chemical induced diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E09.649	Drug or chemical induced diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E09.65	Drug or chemical induced diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E09.69	Drug or chemical induced diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E09.8	Drug or chemical induced diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E09.9	Drug or chemical induced diabetes mellitus without complications	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E10.10	Type 1 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E10.11	Type 1 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E10.311	Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.319	Type 1 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.321	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3211	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3212	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3213	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3219	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.329	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3291	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3292	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3293	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3299	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.331	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3311	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3312	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3313	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3319	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.339	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3391	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
E10.3392	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3393	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3399	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.341	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3411	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3412	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3413	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3419	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.349	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3491	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3492	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3493	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3499	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.351	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3511	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3512	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3513	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3519	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.3521	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E10.3522	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E10.3523	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E10.3529	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
E10.3531	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E10.3532	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E10.3533	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E10.3539	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E10.3541	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E10.3542	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E10.3543	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E10.3549	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E10.3551	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E10.3552	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E10.3553	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E10.3559	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E10.359	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3591	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3592	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3593	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3599	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.36	Type 1 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E10.37X1	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E10.37X2	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
E10.37X3	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E10.37X9	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E10.39	Type 1 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E10.40	Type 1 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E10.41	Type 1 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E10.42	Type 1 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E10.43	Type 1 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E10.44	Type 1 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E10.49	Type 1 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E10.51	Type 1 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E10.52	Type 1 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E10.59	Type 1 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E10.610	Type 1 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E10.618	Type 1 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E10.620	Type 1 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E10.621	Type 1 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E10.622	Type 1 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E10.628	Type 1 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E10.630	Type 1 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E10.638	Type 1 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E10.641	Type 1 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E10.649	Type 1 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E10.65	Type 1 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E10.69	Type 1 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E10.8	Type 1 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E10.9	Type 1 diabetes mellitus without complications	Diagnosis	ICD-10-CM
E11.00	Type 2 diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E11.01	Type 2 diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E11.10	Type 2 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E11.11	Type 2 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E11.21	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E11.311	Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.319	Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.321	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E11.3211	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3212	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3213	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3219	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.329	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3291	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3292	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3293	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3299	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.331	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3311	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3312	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3313	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3319	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.339	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3391	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3392	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3393	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3399	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.341	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3411	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3412	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
E11.3413	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3419	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.349	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3491	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3492	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3493	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3499	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.351	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3511	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3512	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3513	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3519	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.3521	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3522	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3523	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3529	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.3531	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3532	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3533	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3539	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.3541	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E11.3542	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E11.3543	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E11.3549	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E11.3551	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E11.3552	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E11.3553	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E11.3559	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E11.359	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3591	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3592	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3593	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3599	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.36	Type 2 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E11.37X1	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E11.37X2	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E11.37X3	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E11.37X9	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E11.39	Type 2 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E11.40	Type 2 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E11.41	Type 2 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E11.42	Type 2 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E11.43	Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E11.44	Type 2 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E11.49	Type 2 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
E11.51	Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E11.52	Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E11.59	Type 2 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E11.610	Type 2 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E11.618	Type 2 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E11.620	Type 2 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E11.621	Type 2 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E11.622	Type 2 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E11.628	Type 2 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E11.630	Type 2 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E11.638	Type 2 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E11.641	Type 2 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E11.649	Type 2 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E11.65	Type 2 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E11.69	Type 2 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E11.8	Type 2 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E11.9	Type 2 diabetes mellitus without complications	Diagnosis	ICD-10-CM
E13.00	Other specified diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E13.01	Other specified diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E13.10	Other specified diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E13.11	Other specified diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E13.21	Other specified diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.29	Other specified diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E13.311	Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.319	Other specified diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.321	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3211	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3212	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3213	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3219	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.329	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E13.3291	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3292	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3293	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3299	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.331	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3311	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3312	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3313	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3319	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.339	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3391	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3392	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3393	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3399	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.341	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3411	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3412	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3413	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3419	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.349	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3491	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3492	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E13.3493	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3499	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.351	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3511	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3512	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3513	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3519	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.3521	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3522	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E13.3523	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3529	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E13.3531	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3532	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E13.3533	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3539	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E13.3541	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E13.3542	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E13.3543	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E13.3549	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E13.3551	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E13.3552	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E13.3553	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E13.3559	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E13.359	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3591	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3592	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3593	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3599	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.36	Other specified diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E13.39	Other specified diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E13.40	Other specified diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E13.41	Other specified diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E13.42	Other specified diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E13.43	Other specified diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E13.44	Other specified diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E13.49	Other specified diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E13.51	Other specified diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E13.52	Other specified diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E13.59	Other specified diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E13.610	Other specified diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E13.618	Other specified diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E13.620	Other specified diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
E13.621	Other specified diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E13.622	Other specified diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E13.628	Other specified diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E13.630	Other specified diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E13.638	Other specified diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E13.641	Other specified diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E13.649	Other specified diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E13.65	Other specified diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E13.69	Other specified diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E13.8	Other specified diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E13.9	Other specified diabetes mellitus without complications	Diagnosis	ICD-10-CM
Drug Abuse			
F11.10	Opioid abuse, uncomplicated	Diagnosis	ICD-10-CM
F11.11	Opioid abuse, in remission	Diagnosis	ICD-10-CM
F11.120	Opioid abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.121	Opioid abuse with intoxication delirium	Diagnosis	ICD-10-CM
F11.122	Opioid abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.129	Opioid abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.13	Opioid abuse with withdrawal	Diagnosis	ICD-10-CM
F11.14	Opioid abuse with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.150	Opioid abuse with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.151	Opioid abuse with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.159	Opioid abuse with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.181	Opioid abuse with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.182	Opioid abuse with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.188	Opioid abuse with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.19	Opioid abuse with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.20	Opioid dependence, uncomplicated	Diagnosis	ICD-10-CM
F11.220	Opioid dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.221	Opioid dependence with intoxication delirium	Diagnosis	ICD-10-CM
F11.222	Opioid dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.229	Opioid dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.23	Opioid dependence with withdrawal	Diagnosis	ICD-10-CM
F11.24	Opioid dependence with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.250	Opioid dependence with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.251	Opioid dependence with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.259	Opioid dependence with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.281	Opioid dependence with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.282	Opioid dependence with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.288	Opioid dependence with other opioid-induced disorder	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
F11.29	Opioid dependence with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.90	Opioid use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F11.920	Opioid use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.921	Opioid use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F11.922	Opioid use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.929	Opioid use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.93	Opioid use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F11.94	Opioid use, unspecified with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.950	Opioid use, unspecified with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.951	Opioid use, unspecified with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.959	Opioid use, unspecified with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.981	Opioid use, unspecified with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.982	Opioid use, unspecified with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.988	Opioid use, unspecified with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.99	Opioid use, unspecified with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F12.10	Cannabis abuse, uncomplicated	Diagnosis	ICD-10-CM
F12.11	Cannabis abuse, in remission	Diagnosis	ICD-10-CM
F12.120	Cannabis abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.121	Cannabis abuse with intoxication delirium	Diagnosis	ICD-10-CM
F12.122	Cannabis abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.129	Cannabis abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.13	Cannabis abuse with withdrawal	Diagnosis	ICD-10-CM
F12.150	Cannabis abuse with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.151	Cannabis abuse with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.159	Cannabis abuse with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.180	Cannabis abuse with cannabis-induced anxiety disorder	Diagnosis	ICD-10-CM
F12.188	Cannabis abuse with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.19	Cannabis abuse with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.20	Cannabis dependence, uncomplicated	Diagnosis	ICD-10-CM
F12.220	Cannabis dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.221	Cannabis dependence with intoxication delirium	Diagnosis	ICD-10-CM
F12.222	Cannabis dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.229	Cannabis dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.250	Cannabis dependence with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.251	Cannabis dependence with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.259	Cannabis dependence with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.280	Cannabis dependence with cannabis-induced anxiety disorder	Diagnosis	ICD-10-CM
F12.288	Cannabis dependence with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.29	Cannabis dependence with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.90	Cannabis use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F12.920	Cannabis use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
F12.921	Cannabis use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F12.922	Cannabis use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.929	Cannabis use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.950	Cannabis use, unspecified with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.951	Cannabis use, unspecified with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.959	Cannabis use, unspecified with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.980	Cannabis use, unspecified with anxiety disorder	Diagnosis	ICD-10-CM
F12.988	Cannabis use, unspecified with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.99	Cannabis use, unspecified with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F13.10	Sedative, hypnotic or anxiolytic abuse, uncomplicated	Diagnosis	ICD-10-CM
F13.11	Sedative, hypnotic or anxiolytic abuse, in remission	Diagnosis	ICD-10-CM
F13.120	Sedative, hypnotic or anxiolytic abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.121	Sedative, hypnotic or anxiolytic abuse with intoxication delirium	Diagnosis	ICD-10-CM
F13.129	Sedative, hypnotic or anxiolytic abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.130	Sedative, hypnotic or anxiolytic abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.131	Sedative, hypnotic or anxiolytic abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F13.132	Sedative, hypnotic or anxiolytic abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F13.139	Sedative, hypnotic or anxiolytic abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.14	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.150	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.151	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.159	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.180	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.181	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.182	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.188	Sedative, hypnotic or anxiolytic abuse with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.19	Sedative, hypnotic or anxiolytic abuse with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.20	Sedative, hypnotic or anxiolytic dependence, uncomplicated	Diagnosis	ICD-10-CM
F13.220	Sedative, hypnotic or anxiolytic dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.221	Sedative, hypnotic or anxiolytic dependence with intoxication delirium	Diagnosis	ICD-10-CM
F13.229	Sedative, hypnotic or anxiolytic dependence with intoxication, unspecified	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
F13.230	Sedative, hypnotic or anxiolytic dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.231	Sedative, hypnotic or anxiolytic dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F13.232	Sedative, hypnotic or anxiolytic dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F13.239	Sedative, hypnotic or anxiolytic dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.24	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.250	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.251	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.259	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.26	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F13.27	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting dementia	Diagnosis	ICD-10-CM
F13.280	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.281	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.282	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.288	Sedative, hypnotic or anxiolytic dependence with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.29	Sedative, hypnotic or anxiolytic dependence with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.90	Sedative, hypnotic, or anxiolytic use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F13.920	Sedative, hypnotic or anxiolytic use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.921	Sedative, hypnotic or anxiolytic use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F13.929	Sedative, hypnotic or anxiolytic use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.930	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.931	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F13.932	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal with perceptual disturbances	Diagnosis	ICD-10-CM
F13.939	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
F13.94	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.950	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.951	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.959	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.96	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F13.97	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting dementia	Diagnosis	ICD-10-CM
F13.980	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.981	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.982	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.988	Sedative, hypnotic or anxiolytic use, unspecified with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.99	Sedative, hypnotic or anxiolytic use, unspecified with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F14.10	Cocaine abuse, uncomplicated	Diagnosis	ICD-10-CM
F14.11	Cocaine abuse, in remission	Diagnosis	ICD-10-CM
F14.120	Cocaine abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.121	Cocaine abuse with intoxication with delirium	Diagnosis	ICD-10-CM
F14.122	Cocaine abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.129	Cocaine abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.13	Cocaine abuse, unspecified with withdrawal	Diagnosis	ICD-10-CM
F14.14	Cocaine abuse with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.150	Cocaine abuse with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.151	Cocaine abuse with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.159	Cocaine abuse with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.180	Cocaine abuse with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.181	Cocaine abuse with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.182	Cocaine abuse with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.188	Cocaine abuse with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.19	Cocaine abuse with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.20	Cocaine dependence, uncomplicated	Diagnosis	ICD-10-CM
F14.220	Cocaine dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.221	Cocaine dependence with intoxication delirium	Diagnosis	ICD-10-CM
F14.222	Cocaine dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.229	Cocaine dependence with intoxication, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
F14.23	Cocaine dependence with withdrawal	Diagnosis	ICD-10-CM
F14.24	Cocaine dependence with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.250	Cocaine dependence with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.251	Cocaine dependence with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.259	Cocaine dependence with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.280	Cocaine dependence with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.281	Cocaine dependence with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.282	Cocaine dependence with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.288	Cocaine dependence with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.29	Cocaine dependence with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.90	Cocaine use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F14.920	Cocaine use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.921	Cocaine use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F14.922	Cocaine use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.929	Cocaine use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.93	Cocaine use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F14.94	Cocaine use, unspecified with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.950	Cocaine use, unspecified with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.951	Cocaine use, unspecified with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.959	Cocaine use, unspecified with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.980	Cocaine use, unspecified with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.981	Cocaine use, unspecified with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.982	Cocaine use, unspecified with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.988	Cocaine use, unspecified with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.99	Cocaine use, unspecified with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F15.10	Other stimulant abuse, uncomplicated	Diagnosis	ICD-10-CM
F15.11	Other stimulant abuse, in remission	Diagnosis	ICD-10-CM
F15.120	Other stimulant abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.121	Other stimulant abuse with intoxication delirium	Diagnosis	ICD-10-CM
F15.122	Other stimulant abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.129	Other stimulant abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.13	Other stimulant abuse with withdrawal	Diagnosis	ICD-10-CM
F15.14	Other stimulant abuse with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.150	Other stimulant abuse with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.151	Other stimulant abuse with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
F15.159	Other stimulant abuse with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.180	Other stimulant abuse with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.181	Other stimulant abuse with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.182	Other stimulant abuse with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.188	Other stimulant abuse with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.19	Other stimulant abuse with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.20	Other stimulant dependence, uncomplicated	Diagnosis	ICD-10-CM
F15.220	Other stimulant dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.221	Other stimulant dependence with intoxication delirium	Diagnosis	ICD-10-CM
F15.222	Other stimulant dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.229	Other stimulant dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.23	Other stimulant dependence with withdrawal	Diagnosis	ICD-10-CM
F15.24	Other stimulant dependence with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.250	Other stimulant dependence with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.251	Other stimulant dependence with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.259	Other stimulant dependence with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.280	Other stimulant dependence with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.281	Other stimulant dependence with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.282	Other stimulant dependence with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.288	Other stimulant dependence with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.29	Other stimulant dependence with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.90	Other stimulant use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F15.920	Other stimulant use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.921	Other stimulant use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F15.922	Other stimulant use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.929	Other stimulant use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.93	Other stimulant use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F15.94	Other stimulant use, unspecified with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.950	Other stimulant use, unspecified with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.951	Other stimulant use, unspecified with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.959	Other stimulant use, unspecified with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
F15.980	Other stimulant use, unspecified with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.981	Other stimulant use, unspecified with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.982	Other stimulant use, unspecified with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.988	Other stimulant use, unspecified with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.99	Other stimulant use, unspecified with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F16.10	Hallucinogen abuse, uncomplicated	Diagnosis	ICD-10-CM
F16.11	Hallucinogen abuse, in remission	Diagnosis	ICD-10-CM
F16.120	Hallucinogen abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.121	Hallucinogen abuse with intoxication with delirium	Diagnosis	ICD-10-CM
F16.122	Hallucinogen abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F16.129	Hallucinogen abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.14	Hallucinogen abuse with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.150	Hallucinogen abuse with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.151	Hallucinogen abuse with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.159	Hallucinogen abuse with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.180	Hallucinogen abuse with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.183	Hallucinogen abuse with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.188	Hallucinogen abuse with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.19	Hallucinogen abuse with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.20	Hallucinogen dependence, uncomplicated	Diagnosis	ICD-10-CM
F16.220	Hallucinogen dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.221	Hallucinogen dependence with intoxication with delirium	Diagnosis	ICD-10-CM
F16.229	Hallucinogen dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.24	Hallucinogen dependence with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.250	Hallucinogen dependence with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.251	Hallucinogen dependence with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.259	Hallucinogen dependence with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.280	Hallucinogen dependence with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.283	Hallucinogen dependence with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.288	Hallucinogen dependence with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.29	Hallucinogen dependence with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.90	Hallucinogen use, unspecified, uncomplicated	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
F16.920	Hallucinogen use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.921	Hallucinogen use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F16.929	Hallucinogen use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.94	Hallucinogen use, unspecified with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.950	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.951	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.959	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.980	Hallucinogen use, unspecified with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.983	Hallucinogen use, unspecified with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.988	Hallucinogen use, unspecified with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.99	Hallucinogen use, unspecified with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F18.10	Inhalant abuse, uncomplicated	Diagnosis	ICD-10-CM
F18.11	Inhalant abuse, in remission	Diagnosis	ICD-10-CM
F18.120	Inhalant abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.121	Inhalant abuse with intoxication delirium	Diagnosis	ICD-10-CM
F18.129	Inhalant abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.14	Inhalant abuse with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.150	Inhalant abuse with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.151	Inhalant abuse with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.159	Inhalant abuse with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.17	Inhalant abuse with inhalant-induced dementia	Diagnosis	ICD-10-CM
F18.180	Inhalant abuse with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.188	Inhalant abuse with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.19	Inhalant abuse with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.20	Inhalant dependence, uncomplicated	Diagnosis	ICD-10-CM
F18.220	Inhalant dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.221	Inhalant dependence with intoxication delirium	Diagnosis	ICD-10-CM
F18.229	Inhalant dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.24	Inhalant dependence with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.250	Inhalant dependence with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.251	Inhalant dependence with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.259	Inhalant dependence with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.27	Inhalant dependence with inhalant-induced dementia	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
F18.280	Inhalant dependence with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.288	Inhalant dependence with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.29	Inhalant dependence with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.90	Inhalant use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F18.920	Inhalant use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.921	Inhalant use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F18.929	Inhalant use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.94	Inhalant use, unspecified with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.950	Inhalant use, unspecified with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.951	Inhalant use, unspecified with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.959	Inhalant use, unspecified with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.97	Inhalant use, unspecified with inhalant-induced persisting dementia	Diagnosis	ICD-10-CM
F18.980	Inhalant use, unspecified with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.988	Inhalant use, unspecified with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.99	Inhalant use, unspecified with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F19.10	Other psychoactive substance abuse, uncomplicated	Diagnosis	ICD-10-CM
F19.11	Other psychoactive substance abuse, in remission	Diagnosis	ICD-10-CM
F19.120	Other psychoactive substance abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.121	Other psychoactive substance abuse with intoxication delirium	Diagnosis	ICD-10-CM
F19.122	Other psychoactive substance abuse with intoxication with perceptual disturbances	Diagnosis	ICD-10-CM
F19.129	Other psychoactive substance abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.130	Other psychoactive substance abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.131	Other psychoactive substance abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F19.132	Other psychoactive substance abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.139	Other psychoactive substance abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.14	Other psychoactive substance abuse with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.150	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.151	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.159	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.16	Other psychoactive substance abuse with psychoactive substance-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F19.17	Other psychoactive substance abuse with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.180	Other psychoactive substance abuse with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
F19.181	Other psychoactive substance abuse with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.182	Other psychoactive substance abuse with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.188	Other psychoactive substance abuse with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.19	Other psychoactive substance abuse with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.20	Other psychoactive substance dependence, uncomplicated	Diagnosis	ICD-10-CM
F19.21	Other psychoactive substance dependence, in remission	Diagnosis	ICD-10-CM
F19.220	Other psychoactive substance dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.221	Other psychoactive substance dependence with intoxication delirium	Diagnosis	ICD-10-CM
F19.222	Other psychoactive substance dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F19.229	Other psychoactive substance dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.230	Other psychoactive substance dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.231	Other psychoactive substance dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F19.232	Other psychoactive substance dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.239	Other psychoactive substance dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.24	Other psychoactive substance dependence with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.250	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.251	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.259	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.26	Other psychoactive substance dependence with psychoactive substance-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F19.27	Other psychoactive substance dependence with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.280	Other psychoactive substance dependence with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.281	Other psychoactive substance dependence with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.282	Other psychoactive substance dependence with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.288	Other psychoactive substance dependence with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
F19.29	Other psychoactive substance dependence with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.90	Other psychoactive substance use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F19.920	Other psychoactive substance use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.921	Other psychoactive substance use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F19.922	Other psychoactive substance use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F19.929	Other psychoactive substance use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.930	Other psychoactive substance use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.931	Other psychoactive substance use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F19.932	Other psychoactive substance use, unspecified with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.939	Other psychoactive substance use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.94	Other psychoactive substance use, unspecified with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.950	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.951	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.959	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.96	Other psychoactive substance use, unspecified with psychoactive substance-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F19.97	Other psychoactive substance use, unspecified with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.980	Other psychoactive substance use, unspecified with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.981	Other psychoactive substance use, unspecified with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.982	Other psychoactive substance use, unspecified with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.988	Other psychoactive substance use, unspecified with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.99	Other psychoactive substance use, unspecified with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
HZ2ZZZZ	Detoxification Services for Substance Abuse Treatment	Procedure	ICD-10-PCS
HZ30ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ31ZZZ	Individual Counseling for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
HZ32ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ33ZZZ	Individual Counseling for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ34ZZZ	Individual Counseling for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ35ZZZ	Individual Counseling for Substance Abuse Treatment, Vocational	Procedure	ICD-10-PCS
HZ36ZZZ	Individual Counseling for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ37ZZZ	Individual Counseling for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ38ZZZ	Individual Counseling for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ39ZZZ	Individual Counseling for Substance Abuse Treatment, Continuing Care	Procedure	ICD-10-PCS
HZ3BZZZ	Individual Counseling for Substance Abuse Treatment, Spiritual	Procedure	ICD-10-PCS
HZ40ZZZ	Group Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ41ZZZ	Group Counseling for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ42ZZZ	Group Counseling for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ43ZZZ	Group Counseling for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ44ZZZ	Group Counseling for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ45ZZZ	Group Counseling for Substance Abuse Treatment, Vocational	Procedure	ICD-10-PCS
HZ46ZZZ	Group Counseling for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ47ZZZ	Group Counseling for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ48ZZZ	Group Counseling for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ49ZZZ	Group Counseling for Substance Abuse Treatment, Continuing Care	Procedure	ICD-10-PCS
HZ4BZZZ	Group Counseling for Substance Abuse Treatment, Spiritual	Procedure	ICD-10-PCS
HZ50ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ51ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ52ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ53ZZZ	Individual Psychotherapy for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ54ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ55ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Interactive	Procedure	ICD-10-PCS
HZ56ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ57ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ58ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ59ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Supportive	Procedure	ICD-10-PCS
HZ5BZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychoanalysis	Procedure	ICD-10-PCS
HZ5CZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychodynamic	Procedure	ICD-10-PCS

Code	Description	Code Category	Code Type
HZ5DZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychophysiological	Procedure	ICD-10-PCS
HZ63ZZZ	Family Counseling for Substance Abuse Treatment	Procedure	ICD-10-PCS
HZ83ZZZ	Medication Management for Substance Abuse Treatment, Antabuse	Procedure	ICD-10-PCS
HZ86ZZZ	Medication Management for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
HZ88ZZZ	Medication Management for Substance Abuse Treatment, Psychiatric Medication	Procedure	ICD-10-PCS
HZ89ZZZ	Medication Management for Substance Abuse Treatment, Other Replacement Medication	Procedure	ICD-10-PCS
HZ93ZZZ	Pharmacotherapy for Substance Abuse Treatment, Antabuse	Procedure	ICD-10-PCS
HZ96ZZZ	Pharmacotherapy for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
HZ98ZZZ	Pharmacotherapy for Substance Abuse Treatment, Psychiatric Medication	Procedure	ICD-10-PCS
HZ99ZZZ	Pharmacotherapy for Substance Abuse Treatment, Other Replacement Medication	Procedure	ICD-10-PCS
O35.5XX0	Maternal care for (suspected) damage to fetus by drugs, not applicable or unspecified	Diagnosis	ICD-10-CM
O35.5XX1	Maternal care for (suspected) damage to fetus by drugs, fetus 1	Diagnosis	ICD-10-CM
O35.5XX2	Maternal care for (suspected) damage to fetus by drugs, fetus 2	Diagnosis	ICD-10-CM
O35.5XX3	Maternal care for (suspected) damage to fetus by drugs, fetus 3	Diagnosis	ICD-10-CM
O35.5XX4	Maternal care for (suspected) damage to fetus by drugs, fetus 4	Diagnosis	ICD-10-CM
O35.5XX5	Maternal care for (suspected) damage to fetus by drugs, fetus 5	Diagnosis	ICD-10-CM
O35.5XX9	Maternal care for (suspected) damage to fetus by drugs, other fetus	Diagnosis	ICD-10-CM
T40.0X1A	Poisoning by opium, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.0X2A	Poisoning by opium, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.0X3A	Poisoning by opium, assault, initial encounter	Diagnosis	ICD-10-CM
T40.0X4A	Poisoning by opium, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.0X5A	Adverse effect of opium, initial encounter	Diagnosis	ICD-10-CM
T40.0X5S	Adverse effect of opium, sequela	Diagnosis	ICD-10-CM
T40.1X1A	Poisoning by heroin, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.1X2A	Poisoning by heroin, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.1X3A	Poisoning by heroin, assault, initial encounter	Diagnosis	ICD-10-CM
T40.1X4A	Poisoning by heroin, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.2X1A	Poisoning by other opioids, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.2X2A	Poisoning by other opioids, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.2X3A	Poisoning by other opioids, assault, initial encounter	Diagnosis	ICD-10-CM
T40.2X4A	Poisoning by other opioids, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.3X1A	Poisoning by methadone, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.3X2A	Poisoning by methadone, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.3X3A	Poisoning by methadone, assault, initial encounter	Diagnosis	ICD-10-CM
T40.3X4A	Poisoning by methadone, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.3X5A	Adverse effect of methadone, initial encounter	Diagnosis	ICD-10-CM
T40.3X5S	Adverse effect of methadone, sequela	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
T40.411A	Poisoning by fentanyl or fentanyl analogs, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.412A	Poisoning by fentanyl or fentanyl analogs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.413A	Poisoning by fentanyl or fentanyl analogs, assault, initial encounter	Diagnosis	ICD-10-CM
T40.414A	Poisoning by fentanyl or fentanyl analogs, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.415A	Adverse effect of fentanyl or fentanyl analogs, initial encounter	Diagnosis	ICD-10-CM
T40.421A	Poisoning by tramadol, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.422A	Poisoning by tramadol, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.423A	Poisoning by tramadol, assault, initial encounter	Diagnosis	ICD-10-CM
T40.424A	Poisoning by tramadol, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.425A	Adverse effect of tramadol, initial encounter	Diagnosis	ICD-10-CM
T40.491A	Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.492A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.493A	Poisoning by other synthetic narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.494A	Poisoning by other synthetic narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.495A	Adverse effect of other synthetic narcotics, initial encounter	Diagnosis	ICD-10-CM
T40.4X1A	Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.4X2A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.4X3A	Poisoning by other synthetic narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.4X4A	Poisoning by other synthetic narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.601A	Poisoning by unspecified narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.602A	Poisoning by unspecified narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.603A	Poisoning by unspecified narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.604A	Poisoning by unspecified narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.691A	Poisoning by other narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.692A	Poisoning by other narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.693A	Poisoning by other narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.694A	Poisoning by other narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.711A	Poisoning by cannabis, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.721A	Poisoning by synthetic cannabinoids, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.7X1A	Poisoning by cannabis (derivatives), accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.8X1A	Poisoning by lysergide [LSD], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
T40.901A	Poisoning by unspecified psychodysleptics [hallucinogens], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.991A	Poisoning by other psychodysleptics [hallucinogens], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
Z71.51	Drug abuse counseling and surveillance of drug abuser	Diagnosis	ICD-10-CM
Endometrial Cancer			
C54.0	Malignant neoplasm of isthmus uteri	Diagnosis	ICD-10-CM
C54.1	Malignant neoplasm of endometrium	Diagnosis	ICD-10-CM
C54.2	Malignant neoplasm of myometrium	Diagnosis	ICD-10-CM
C54.3	Malignant neoplasm of fundus uteri	Diagnosis	ICD-10-CM
C54.8	Malignant neoplasm of overlapping sites of corpus uteri	Diagnosis	ICD-10-CM
C54.9	Malignant neoplasm of corpus uteri, unspecified	Diagnosis	ICD-10-CM
D07.0	Carcinoma in situ of endometrium	Diagnosis	ICD-10-CM
Z85.42	Personal history of malignant neoplasm of other parts of uterus	Diagnosis	ICD-10-CM
Glaucoma			
H40.011	Open angle with borderline findings, low risk, right eye	Diagnosis	ICD-10-CM
H40.012	Open angle with borderline findings, low risk, left eye	Diagnosis	ICD-10-CM
H40.013	Open angle with borderline findings, low risk, bilateral	Diagnosis	ICD-10-CM
H40.019	Open angle with borderline findings, low risk, unspecified eye	Diagnosis	ICD-10-CM
H40.021	Open angle with borderline findings, high risk, right eye	Diagnosis	ICD-10-CM
H40.022	Open angle with borderline findings, high risk, left eye	Diagnosis	ICD-10-CM
H40.023	Open angle with borderline findings, high risk, bilateral	Diagnosis	ICD-10-CM
H40.029	Open angle with borderline findings, high risk, unspecified eye	Diagnosis	ICD-10-CM
H40.041	Steroid responder, right eye	Diagnosis	ICD-10-CM
H40.042	Steroid responder, left eye	Diagnosis	ICD-10-CM
H40.043	Steroid responder, bilateral	Diagnosis	ICD-10-CM
H40.049	Steroid responder, unspecified eye	Diagnosis	ICD-10-CM
H40.051	Ocular hypertension, right eye	Diagnosis	ICD-10-CM
H40.052	Ocular hypertension, left eye	Diagnosis	ICD-10-CM
H40.053	Ocular hypertension, bilateral	Diagnosis	ICD-10-CM
H40.059	Ocular hypertension, unspecified eye	Diagnosis	ICD-10-CM
H40.10X0	Unspecified open-angle glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.10X1	Unspecified open-angle glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.10X2	Unspecified open-angle glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.10X3	Unspecified open-angle glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.10X4	Unspecified open-angle glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.1110	Primary open-angle glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1111	Primary open-angle glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1112	Primary open-angle glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1113	Primary open-angle glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1114	Primary open-angle glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1120	Primary open-angle glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1121	Primary open-angle glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1122	Primary open-angle glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
H40.1123	Primary open-angle glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1124	Primary open-angle glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1130	Primary open-angle glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1131	Primary open-angle glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1132	Primary open-angle glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1133	Primary open-angle glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1134	Primary open-angle glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1190	Primary open-angle glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1191	Primary open-angle glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1192	Primary open-angle glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1193	Primary open-angle glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1194	Primary open-angle glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.11X0	Primary open-angle glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.11X1	Primary open-angle glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.11X2	Primary open-angle glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.11X3	Primary open-angle glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.11X4	Primary open-angle glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.1210	Low-tension glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1211	Low-tension glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1212	Low-tension glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1213	Low-tension glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1214	Low-tension glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1220	Low-tension glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1221	Low-tension glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1222	Low-tension glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1223	Low-tension glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1224	Low-tension glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1230	Low-tension glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1231	Low-tension glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1232	Low-tension glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1233	Low-tension glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1234	Low-tension glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1290	Low-tension glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1291	Low-tension glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1292	Low-tension glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1293	Low-tension glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1294	Low-tension glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1310	Pigmentary glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1311	Pigmentary glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1312	Pigmentary glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1313	Pigmentary glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1314	Pigmentary glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1320	Pigmentary glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1321	Pigmentary glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
H40.1322	Pigmentary glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1323	Pigmentary glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1324	Pigmentary glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1330	Pigmentary glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1331	Pigmentary glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1332	Pigmentary glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1333	Pigmentary glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1334	Pigmentary glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1390	Pigmentary glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1391	Pigmentary glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1392	Pigmentary glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1393	Pigmentary glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1394	Pigmentary glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1410	Capsular glaucoma with pseudoexfoliation of lens, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1411	Capsular glaucoma with pseudoexfoliation of lens, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1412	Capsular glaucoma with pseudoexfoliation of lens, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1413	Capsular glaucoma with pseudoexfoliation of lens, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1414	Capsular glaucoma with pseudoexfoliation of lens, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1420	Capsular glaucoma with pseudoexfoliation of lens, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1421	Capsular glaucoma with pseudoexfoliation of lens, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1422	Capsular glaucoma with pseudoexfoliation of lens, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1423	Capsular glaucoma with pseudoexfoliation of lens, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1424	Capsular glaucoma with pseudoexfoliation of lens, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1430	Capsular glaucoma with pseudoexfoliation of lens, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1431	Capsular glaucoma with pseudoexfoliation of lens, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1432	Capsular glaucoma with pseudoexfoliation of lens, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1433	Capsular glaucoma with pseudoexfoliation of lens, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1434	Capsular glaucoma with pseudoexfoliation of lens, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1490	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1491	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, mild stage	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
H40.1492	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1493	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1494	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.151	Residual stage of open-angle glaucoma, right eye	Diagnosis	ICD-10-CM
H40.152	Residual stage of open-angle glaucoma, left eye	Diagnosis	ICD-10-CM
H40.153	Residual stage of open-angle glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.159	Residual stage of open-angle glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.20X0	Unspecified primary angle-closure glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.20X1	Unspecified primary angle-closure glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.20X2	Unspecified primary angle-closure glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.20X3	Unspecified primary angle-closure glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.20X4	Unspecified primary angle-closure glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.211	Acute angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.212	Acute angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.213	Acute angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.219	Acute angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.2210	Chronic angle-closure glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2211	Chronic angle-closure glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.2212	Chronic angle-closure glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.2213	Chronic angle-closure glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.2214	Chronic angle-closure glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.2220	Chronic angle-closure glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2221	Chronic angle-closure glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.2222	Chronic angle-closure glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.2223	Chronic angle-closure glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.2224	Chronic angle-closure glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.2230	Chronic angle-closure glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.2231	Chronic angle-closure glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.2232	Chronic angle-closure glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.2233	Chronic angle-closure glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.2234	Chronic angle-closure glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.2290	Chronic angle-closure glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2291	Chronic angle-closure glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.2292	Chronic angle-closure glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.2293	Chronic angle-closure glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.2294	Chronic angle-closure glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.231	Intermittent angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.232	Intermittent angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.233	Intermittent angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.239	Intermittent angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.241	Residual stage of angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
H40.242	Residual stage of angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.243	Residual stage of angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.249	Residual stage of angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.30X0	Glaucoma secondary to eye trauma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.30X1	Glaucoma secondary to eye trauma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.30X2	Glaucoma secondary to eye trauma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.30X3	Glaucoma secondary to eye trauma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.30X4	Glaucoma secondary to eye trauma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.31X0	Glaucoma secondary to eye trauma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.31X1	Glaucoma secondary to eye trauma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.31X2	Glaucoma secondary to eye trauma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.31X3	Glaucoma secondary to eye trauma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.31X4	Glaucoma secondary to eye trauma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.32X0	Glaucoma secondary to eye trauma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.32X1	Glaucoma secondary to eye trauma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.32X2	Glaucoma secondary to eye trauma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.32X3	Glaucoma secondary to eye trauma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.32X4	Glaucoma secondary to eye trauma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.33X0	Glaucoma secondary to eye trauma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.33X1	Glaucoma secondary to eye trauma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.33X2	Glaucoma secondary to eye trauma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.33X3	Glaucoma secondary to eye trauma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.33X4	Glaucoma secondary to eye trauma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.40X0	Glaucoma secondary to eye inflammation, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.40X1	Glaucoma secondary to eye inflammation, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.40X2	Glaucoma secondary to eye inflammation, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.40X3	Glaucoma secondary to eye inflammation, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.40X4	Glaucoma secondary to eye inflammation, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.41X0	Glaucoma secondary to eye inflammation, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.41X1	Glaucoma secondary to eye inflammation, right eye, mild stage	Diagnosis	ICD-10-CM
H40.41X2	Glaucoma secondary to eye inflammation, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.41X3	Glaucoma secondary to eye inflammation, right eye, severe stage	Diagnosis	ICD-10-CM
H40.41X4	Glaucoma secondary to eye inflammation, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.42X0	Glaucoma secondary to eye inflammation, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.42X1	Glaucoma secondary to eye inflammation, left eye, mild stage	Diagnosis	ICD-10-CM
H40.42X2	Glaucoma secondary to eye inflammation, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.42X3	Glaucoma secondary to eye inflammation, left eye, severe stage	Diagnosis	ICD-10-CM
H40.42X4	Glaucoma secondary to eye inflammation, left eye, indeterminate stage	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
H40.43X0	Glaucoma secondary to eye inflammation, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.43X1	Glaucoma secondary to eye inflammation, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.43X2	Glaucoma secondary to eye inflammation, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.43X3	Glaucoma secondary to eye inflammation, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.43X4	Glaucoma secondary to eye inflammation, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.50X0	Glaucoma secondary to other eye disorders, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.50X1	Glaucoma secondary to other eye disorders, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.50X2	Glaucoma secondary to other eye disorders, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.50X3	Glaucoma secondary to other eye disorders, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.50X4	Glaucoma secondary to other eye disorders, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.51X0	Glaucoma secondary to other eye disorders, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.51X1	Glaucoma secondary to other eye disorders, right eye, mild stage	Diagnosis	ICD-10-CM
H40.51X2	Glaucoma secondary to other eye disorders, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.51X3	Glaucoma secondary to other eye disorders, right eye, severe stage	Diagnosis	ICD-10-CM
H40.51X4	Glaucoma secondary to other eye disorders, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.52X0	Glaucoma secondary to other eye disorders, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.52X1	Glaucoma secondary to other eye disorders, left eye, mild stage	Diagnosis	ICD-10-CM
H40.52X2	Glaucoma secondary to other eye disorders, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.52X3	Glaucoma secondary to other eye disorders, left eye, severe stage	Diagnosis	ICD-10-CM
H40.52X4	Glaucoma secondary to other eye disorders, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.53X0	Glaucoma secondary to other eye disorders, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.53X1	Glaucoma secondary to other eye disorders, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.53X2	Glaucoma secondary to other eye disorders, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.53X3	Glaucoma secondary to other eye disorders, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.53X4	Glaucoma secondary to other eye disorders, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.60X0	Glaucoma secondary to drugs, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.60X1	Glaucoma secondary to drugs, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.60X2	Glaucoma secondary to drugs, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.60X3	Glaucoma secondary to drugs, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.60X4	Glaucoma secondary to drugs, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.61X0	Glaucoma secondary to drugs, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.61X1	Glaucoma secondary to drugs, right eye, mild stage	Diagnosis	ICD-10-CM
H40.61X2	Glaucoma secondary to drugs, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.61X3	Glaucoma secondary to drugs, right eye, severe stage	Diagnosis	ICD-10-CM
H40.61X4	Glaucoma secondary to drugs, right eye, indeterminate stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
H40.62X0	Glaucoma secondary to drugs, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.62X1	Glaucoma secondary to drugs, left eye, mild stage	Diagnosis	ICD-10-CM
H40.62X2	Glaucoma secondary to drugs, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.62X3	Glaucoma secondary to drugs, left eye, severe stage	Diagnosis	ICD-10-CM
H40.62X4	Glaucoma secondary to drugs, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.63X0	Glaucoma secondary to drugs, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.63X1	Glaucoma secondary to drugs, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.63X2	Glaucoma secondary to drugs, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.63X3	Glaucoma secondary to drugs, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.63X4	Glaucoma secondary to drugs, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.811	Glaucoma with increased episcleral venous pressure, right eye	Diagnosis	ICD-10-CM
H40.812	Glaucoma with increased episcleral venous pressure, left eye	Diagnosis	ICD-10-CM
H40.813	Glaucoma with increased episcleral venous pressure, bilateral	Diagnosis	ICD-10-CM
H40.819	Glaucoma with increased episcleral venous pressure, unspecified eye	Diagnosis	ICD-10-CM
H40.821	Hypersecretion glaucoma, right eye	Diagnosis	ICD-10-CM
H40.822	Hypersecretion glaucoma, left eye	Diagnosis	ICD-10-CM
H40.823	Hypersecretion glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.829	Hypersecretion glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.831	Aqueous misdirection, right eye	Diagnosis	ICD-10-CM
H40.832	Aqueous misdirection, left eye	Diagnosis	ICD-10-CM
H40.833	Aqueous misdirection, bilateral	Diagnosis	ICD-10-CM
H40.839	Aqueous misdirection, unspecified eye	Diagnosis	ICD-10-CM
H40.89	Other specified glaucoma	Diagnosis	ICD-10-CM
H40.9	Unspecified glaucoma	Diagnosis	ICD-10-CM
H42	Glaucoma in diseases classified elsewhere	Diagnosis	ICD-10-CM
H44.511	Absolute glaucoma, right eye	Diagnosis	ICD-10-CM
H44.512	Absolute glaucoma, left eye	Diagnosis	ICD-10-CM
H44.513	Absolute glaucoma, bilateral	Diagnosis	ICD-10-CM
H44.519	Absolute glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H47.231	Glaucomatous optic atrophy, right eye	Diagnosis	ICD-10-CM
H47.232	Glaucomatous optic atrophy, left eye	Diagnosis	ICD-10-CM
H47.233	Glaucomatous optic atrophy, bilateral	Diagnosis	ICD-10-CM
H47.239	Glaucomatous optic atrophy, unspecified eye	Diagnosis	ICD-10-CM
Q15.0	Congenital glaucoma	Diagnosis	ICD-10-CM
Heart Failure			
I09.81	Rheumatic heart failure	Diagnosis	ICD-10-CM
I11.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I42.0	Dilated cardiomyopathy	Diagnosis	ICD-10-CM
I42.5	Other restrictive cardiomyopathy	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I42.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
I42.7	Cardiomyopathy due to drug and external agent	Diagnosis	ICD-10-CM
I42.8	Other cardiomyopathies	Diagnosis	ICD-10-CM
I43	Cardiomyopathy in diseases classified elsewhere	Diagnosis	ICD-10-CM
I50.1	Left ventricular failure, unspecified	Diagnosis	ICD-10-CM
I50.20	Unspecified systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.21	Acute systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.22	Chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.23	Acute on chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.30	Unspecified diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.31	Acute diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.32	Chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.33	Acute on chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.40	Unspecified combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.41	Acute combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.42	Chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.43	Acute on chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.810	Right heart failure, unspecified	Diagnosis	ICD-10-CM
I50.811	Acute right heart failure	Diagnosis	ICD-10-CM
I50.812	Chronic right heart failure	Diagnosis	ICD-10-CM
I50.813	Acute on chronic right heart failure	Diagnosis	ICD-10-CM
I50.814	Right heart failure due to left heart failure	Diagnosis	ICD-10-CM
I50.82	Biventricular heart failure	Diagnosis	ICD-10-CM
I50.83	High output heart failure	Diagnosis	ICD-10-CM
I50.84	End stage heart failure	Diagnosis	ICD-10-CM
I50.89	Other heart failure	Diagnosis	ICD-10-CM
I50.9	Heart failure, unspecified	Diagnosis	ICD-10-CM
P29.0	Neonatal cardiac failure	Diagnosis	ICD-10-CM
Hyperlipidemia			
E78.0	Pure hypercholesterolemia	Diagnosis	ICD-10-CM
E78.00	Pure hypercholesterolemia, unspecified	Diagnosis	ICD-10-CM
E78.01	Familial hypercholesterolemia	Diagnosis	ICD-10-CM
E78.1	Pure hyperglyceridemia	Diagnosis	ICD-10-CM
E78.2	Mixed hyperlipidemia	Diagnosis	ICD-10-CM
E78.3	Hyperchylomicronemia	Diagnosis	ICD-10-CM
E78.4	Other hyperlipidemia	Diagnosis	ICD-10-CM
E78.41	Elevated Lipoprotein(a)	Diagnosis	ICD-10-CM
E78.49	Other hyperlipidemia	Diagnosis	ICD-10-CM
E78.5	Hyperlipidemia, unspecified	Diagnosis	ICD-10-CM
Hypertension			

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
H35.031	Hypertensive retinopathy, right eye	Diagnosis	ICD-10-CM
H35.032	Hypertensive retinopathy, left eye	Diagnosis	ICD-10-CM
H35.033	Hypertensive retinopathy, bilateral	Diagnosis	ICD-10-CM
H35.039	Hypertensive retinopathy, unspecified eye	Diagnosis	ICD-10-CM
I10	Essential (primary) hypertension	Diagnosis	ICD-10-CM
I11.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
I11.9	Hypertensive heart disease without heart failure	Diagnosis	ICD-10-CM
I12.0	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease	Diagnosis	ICD-10-CM
I12.9	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.11	Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I15.0	Renovascular hypertension	Diagnosis	ICD-10-CM
I15.1	Hypertension secondary to other renal disorders	Diagnosis	ICD-10-CM
I15.2	Hypertension secondary to endocrine disorders	Diagnosis	ICD-10-CM
I15.8	Other secondary hypertension	Diagnosis	ICD-10-CM
I15.9	Secondary hypertension, unspecified	Diagnosis	ICD-10-CM
I1A.0	Resistant hypertension	Diagnosis	ICD-10-CM
I67.4	Hypertensive encephalopathy	Diagnosis	ICD-10-CM
N26.2	Page kidney	Diagnosis	ICD-10-CM
Ischemic Heart Disease			
I20.0	Unstable angina	Diagnosis	ICD-10-CM
I20.1	Angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I20.2	Refractory angina pectoris	Diagnosis	ICD-10-CM
I20.8	Other forms of angina pectoris	Diagnosis	ICD-10-CM
I20.81	Angina pectoris with coronary microvascular dysfunction	Diagnosis	ICD-10-CM
I20.89	Other forms of angina pectoris	Diagnosis	ICD-10-CM
I24.0	Acute coronary thrombosis not resulting in myocardial infarction	Diagnosis	ICD-10-CM
I24.1	Dressler's syndrome	Diagnosis	ICD-10-CM
I24.8	Other forms of acute ischemic heart disease	Diagnosis	ICD-10-CM
I24.81	Acute coronary microvascular dysfunction	Diagnosis	ICD-10-CM
I24.89	Other forms of acute ischemic heart disease	Diagnosis	ICD-10-CM
I25.10	Atherosclerotic heart disease of native coronary artery without angina pectoris	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I25.110	Atherosclerotic heart disease of native coronary artery with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.111	Atherosclerotic heart disease of native coronary artery with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.112	Atherosclerotic heart disease of native coronary artery with refractory angina pectoris	Diagnosis	ICD-10-CM
I25.118	Atherosclerotic heart disease of native coronary artery with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.119	Atherosclerotic heart disease of native coronary artery with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.3	Aneurysm of heart	Diagnosis	ICD-10-CM
I25.41	Coronary artery aneurysm	Diagnosis	ICD-10-CM
I25.42	Coronary artery dissection	Diagnosis	ICD-10-CM
I25.5	Ischemic cardiomyopathy	Diagnosis	ICD-10-CM
I25.6	Silent myocardial ischemia	Diagnosis	ICD-10-CM
I25.700	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.701	Atherosclerosis of coronary artery bypass graft(s), unspecified, with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.702	Atherosclerosis of coronary artery bypass graft(s), unspecified, with refractory angina pectoris	Diagnosis	ICD-10-CM
I25.708	Atherosclerosis of coronary artery bypass graft(s), unspecified, with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.710	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.711	Atherosclerosis of autologous vein coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.712	Atherosclerosis of autologous vein coronary artery bypass graft(s) with refractory angina pectoris	Diagnosis	ICD-10-CM
I25.718	Atherosclerosis of autologous vein coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.719	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.720	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.721	Atherosclerosis of autologous artery coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.722	Atherosclerosis of autologous artery coronary artery bypass graft(s) with refractory angina pectoris	Diagnosis	ICD-10-CM
I25.728	Atherosclerosis of autologous artery coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.729	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
I25.730	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.731	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.732	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with refractory angina pectoris	Diagnosis	ICD-10-CM
I25.738	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.739	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.750	Atherosclerosis of native coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
I25.751	Atherosclerosis of native coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.752	Atherosclerosis of native coronary artery of transplanted heart with refractory angina pectoris	Diagnosis	ICD-10-CM
I25.758	Atherosclerosis of native coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.759	Atherosclerosis of native coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.760	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
I25.761	Atherosclerosis of bypass graft of coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.762	Atherosclerosis of bypass graft of coronary artery of transplanted heart with refractory angina pectoris	Diagnosis	ICD-10-CM
I25.768	Atherosclerosis of bypass graft of coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.769	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.790	Atherosclerosis of other coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.791	Atherosclerosis of other coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.792	Atherosclerosis of other coronary artery bypass graft(s) with refractory angina pectoris	Diagnosis	ICD-10-CM
I25.798	Atherosclerosis of other coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.799	Atherosclerosis of other coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.810	Atherosclerosis of coronary artery bypass graft(s) without angina pectoris	Diagnosis	ICD-10-CM
I25.811	Atherosclerosis of native coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
I25.812	Atherosclerosis of bypass graft of coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM
I25.82	Chronic total occlusion of coronary artery	Diagnosis	ICD-10-CM
I25.83	Coronary atherosclerosis due to lipid rich plaque	Diagnosis	ICD-10-CM
I25.84	Coronary atherosclerosis due to calcified coronary lesion	Diagnosis	ICD-10-CM
I25.85	Chronic coronary microvascular dysfunction	Diagnosis	ICD-10-CM
I25.89	Other forms of chronic ischemic heart disease	Diagnosis	ICD-10-CM
I25.9	Chronic ischemic heart disease, unspecified	Diagnosis	ICD-10-CM
Liver Disease CCW			
K70	Alcoholic liver disease	Diagnosis	ICD-10-CM
K70.0	Alcoholic fatty liver	Diagnosis	ICD-10-CM
K70.1	Alcoholic hepatitis	Diagnosis	ICD-10-CM
K70.10	Alcoholic hepatitis without ascites	Diagnosis	ICD-10-CM
K70.11	Alcoholic hepatitis with ascites	Diagnosis	ICD-10-CM
K70.2	Alcoholic fibrosis and sclerosis of liver	Diagnosis	ICD-10-CM
K70.3	Alcoholic cirrhosis of liver	Diagnosis	ICD-10-CM
K70.30	Alcoholic cirrhosis of liver without ascites	Diagnosis	ICD-10-CM
K70.31	Alcoholic cirrhosis of liver with ascites	Diagnosis	ICD-10-CM
K70.4	Alcoholic hepatic failure	Diagnosis	ICD-10-CM
K70.40	Alcoholic hepatic failure without coma	Diagnosis	ICD-10-CM
K70.41	Alcoholic hepatic failure with coma	Diagnosis	ICD-10-CM
K70.9	Alcoholic liver disease, unspecified	Diagnosis	ICD-10-CM
K71.0	Toxic liver disease with cholestasis	Diagnosis	ICD-10-CM
K71.11	Toxic liver disease with hepatic necrosis, with coma	Diagnosis	ICD-10-CM
K71.7	Toxic liver disease with fibrosis and cirrhosis of liver	Diagnosis	ICD-10-CM
K71.8	Toxic liver disease with other disorders of liver	Diagnosis	ICD-10-CM
K71.9	Toxic liver disease, unspecified	Diagnosis	ICD-10-CM
K72	Hepatic failure, not elsewhere classified	Diagnosis	ICD-10-CM
K72.0	Acute and subacute hepatic failure	Diagnosis	ICD-10-CM
K72.00	Acute and subacute hepatic failure without coma	Diagnosis	ICD-10-CM
K72.01	Acute and subacute hepatic failure with coma	Diagnosis	ICD-10-CM
K72.1	Chronic hepatic failure	Diagnosis	ICD-10-CM
K72.10	Chronic hepatic failure without coma	Diagnosis	ICD-10-CM
K72.11	Chronic hepatic failure with coma	Diagnosis	ICD-10-CM
K72.9	Hepatic failure, unspecified	Diagnosis	ICD-10-CM
K72.90	Hepatic failure, unspecified without coma	Diagnosis	ICD-10-CM
K72.91	Hepatic failure, unspecified with coma	Diagnosis	ICD-10-CM
K74	Fibrosis and cirrhosis of liver	Diagnosis	ICD-10-CM
K74.0	Hepatic fibrosis	Diagnosis	ICD-10-CM
K74.00	Hepatic fibrosis, unspecified	Diagnosis	ICD-10-CM
K74.01	Hepatic fibrosis, early fibrosis	Diagnosis	ICD-10-CM
K74.02	Hepatic fibrosis, advanced fibrosis	Diagnosis	ICD-10-CM
K74.1	Hepatic sclerosis	Diagnosis	ICD-10-CM
K74.2	Hepatic fibrosis with hepatic sclerosis	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
K74.3	Primary biliary cirrhosis	Diagnosis	ICD-10-CM
K74.4	Secondary biliary cirrhosis	Diagnosis	ICD-10-CM
K74.5	Biliary cirrhosis, unspecified	Diagnosis	ICD-10-CM
K74.6	Other and unspecified cirrhosis of liver	Diagnosis	ICD-10-CM
K74.60	Unspecified cirrhosis of liver	Diagnosis	ICD-10-CM
K74.69	Other cirrhosis of liver	Diagnosis	ICD-10-CM
K75.0	Abscess of liver	Diagnosis	ICD-10-CM
K75.1	Phlebitis of portal vein	Diagnosis	ICD-10-CM
K75.8	Other specified inflammatory liver diseases	Diagnosis	ICD-10-CM
K75.81	Nonalcoholic steatohepatitis (NASH)	Diagnosis	ICD-10-CM
K75.89	Other specified inflammatory liver diseases	Diagnosis	ICD-10-CM
K75.9	Inflammatory liver disease, unspecified	Diagnosis	ICD-10-CM
K76.0	Fatty (change of) liver, not elsewhere classified	Diagnosis	ICD-10-CM
K76.1	Chronic passive congestion of liver	Diagnosis	ICD-10-CM
K76.2	Central hemorrhagic necrosis of liver	Diagnosis	ICD-10-CM
K76.3	Infarction of liver	Diagnosis	ICD-10-CM
K76.5	Hepatic veno-occlusive disease	Diagnosis	ICD-10-CM
K76.6	Portal hypertension	Diagnosis	ICD-10-CM
K76.7	Hepatorenal syndrome	Diagnosis	ICD-10-CM
K76.8	Other specified diseases of liver	Diagnosis	ICD-10-CM
K76.81	Hepatopulmonary syndrome	Diagnosis	ICD-10-CM
K76.82	Hepatic encephalopathy	Diagnosis	ICD-10-CM
K76.89	Other specified diseases of liver	Diagnosis	ICD-10-CM
K76.9	Liver disease, unspecified	Diagnosis	ICD-10-CM
K77	Liver disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
K80.30	Calculus of bile duct with cholangitis, unspecified, without obstruction	Diagnosis	ICD-10-CM
K80.31	Calculus of bile duct with cholangitis, unspecified, with obstruction	Diagnosis	ICD-10-CM
K80.32	Calculus of bile duct with acute cholangitis without obstruction	Diagnosis	ICD-10-CM
K80.33	Calculus of bile duct with acute cholangitis with obstruction	Diagnosis	ICD-10-CM
K80.34	Calculus of bile duct with chronic cholangitis without obstruction	Diagnosis	ICD-10-CM
K80.35	Calculus of bile duct with chronic cholangitis with obstruction	Diagnosis	ICD-10-CM
K80.36	Calculus of bile duct with acute and chronic cholangitis without obstruction	Diagnosis	ICD-10-CM
K80.37	Calculus of bile duct with acute and chronic cholangitis with obstruction	Diagnosis	ICD-10-CM
K83.0	Cholangitis	Diagnosis	ICD-10-CM
R16.0	Hepatomegaly, not elsewhere classified	Diagnosis	ICD-10-CM
R16.2	Hepatomegaly with splenomegaly, not elsewhere classified	Diagnosis	ICD-10-CM
Z48.23	Encounter for aftercare following liver transplant	Diagnosis	ICD-10-CM
Z94.4	Liver transplant status	Diagnosis	ICD-10-CM
Liver Disease Extended DX List			
K70	Alcoholic liver disease	Diagnosis	ICD-10-CM
K70.0	Alcoholic fatty liver	Diagnosis	ICD-10-CM
K70.1	Alcoholic hepatitis	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
K70.10	Alcoholic hepatitis without ascites	Diagnosis	ICD-10-CM
K70.11	Alcoholic hepatitis with ascites	Diagnosis	ICD-10-CM
K70.2	Alcoholic fibrosis and sclerosis of liver	Diagnosis	ICD-10-CM
K70.3	Alcoholic cirrhosis of liver	Diagnosis	ICD-10-CM
K70.30	Alcoholic cirrhosis of liver without ascites	Diagnosis	ICD-10-CM
K70.31	Alcoholic cirrhosis of liver with ascites	Diagnosis	ICD-10-CM
K70.4	Alcoholic hepatic failure	Diagnosis	ICD-10-CM
K70.40	Alcoholic hepatic failure without coma	Diagnosis	ICD-10-CM
K70.41	Alcoholic hepatic failure with coma	Diagnosis	ICD-10-CM
K70.9	Alcoholic liver disease, unspecified	Diagnosis	ICD-10-CM
K71	Toxic liver disease	Diagnosis	ICD-10-CM
K71.0	Toxic liver disease with cholestasis	Diagnosis	ICD-10-CM
K71.1	Toxic liver disease with hepatic necrosis	Diagnosis	ICD-10-CM
K71.10	Toxic liver disease with hepatic necrosis, without coma	Diagnosis	ICD-10-CM
K71.11	Toxic liver disease with hepatic necrosis, with coma	Diagnosis	ICD-10-CM
K71.2	Toxic liver disease with acute hepatitis	Diagnosis	ICD-10-CM
K71.3	Toxic liver disease with chronic persistent hepatitis	Diagnosis	ICD-10-CM
K71.4	Toxic liver disease with chronic lobular hepatitis	Diagnosis	ICD-10-CM
K71.5	Toxic liver disease with chronic active hepatitis	Diagnosis	ICD-10-CM
K71.50	Toxic liver disease with chronic active hepatitis without ascites	Diagnosis	ICD-10-CM
K71.51	Toxic liver disease with chronic active hepatitis with ascites	Diagnosis	ICD-10-CM
K71.6	Toxic liver disease with hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K71.7	Toxic liver disease with fibrosis and cirrhosis of liver	Diagnosis	ICD-10-CM
K71.8	Toxic liver disease with other disorders of liver	Diagnosis	ICD-10-CM
K71.9	Toxic liver disease, unspecified	Diagnosis	ICD-10-CM
K72	Hepatic failure, not elsewhere classified	Diagnosis	ICD-10-CM
K72.0	Acute and subacute hepatic failure	Diagnosis	ICD-10-CM
K72.00	Acute and subacute hepatic failure without coma	Diagnosis	ICD-10-CM
K72.01	Acute and subacute hepatic failure with coma	Diagnosis	ICD-10-CM
K72.1	Chronic hepatic failure	Diagnosis	ICD-10-CM
K72.10	Chronic hepatic failure without coma	Diagnosis	ICD-10-CM
K72.11	Chronic hepatic failure with coma	Diagnosis	ICD-10-CM
K72.9	Hepatic failure, unspecified	Diagnosis	ICD-10-CM
K72.90	Hepatic failure, unspecified without coma	Diagnosis	ICD-10-CM
K72.91	Hepatic failure, unspecified with coma	Diagnosis	ICD-10-CM
K73	Chronic hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K73.0	Chronic persistent hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K73.1	Chronic lobular hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K73.2	Chronic active hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K73.8	Other chronic hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K73.9	Chronic hepatitis, unspecified	Diagnosis	ICD-10-CM
K74	Fibrosis and cirrhosis of liver	Diagnosis	ICD-10-CM
K74.0	Hepatic fibrosis	Diagnosis	ICD-10-CM
K74.00	Hepatic fibrosis, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
K74.01	Hepatic fibrosis, early fibrosis	Diagnosis	ICD-10-CM
K74.02	Hepatic fibrosis, advanced fibrosis	Diagnosis	ICD-10-CM
K74.1	Hepatic sclerosis	Diagnosis	ICD-10-CM
K74.2	Hepatic fibrosis with hepatic sclerosis	Diagnosis	ICD-10-CM
K74.3	Primary biliary cirrhosis	Diagnosis	ICD-10-CM
K74.4	Secondary biliary cirrhosis	Diagnosis	ICD-10-CM
K74.5	Biliary cirrhosis, unspecified	Diagnosis	ICD-10-CM
K74.6	Other and unspecified cirrhosis of liver	Diagnosis	ICD-10-CM
K74.60	Unspecified cirrhosis of liver	Diagnosis	ICD-10-CM
K74.69	Other cirrhosis of liver	Diagnosis	ICD-10-CM
K75	Other inflammatory liver diseases	Diagnosis	ICD-10-CM
K75.0	Abscess of liver	Diagnosis	ICD-10-CM
K75.1	Phlebitis of portal vein	Diagnosis	ICD-10-CM
K75.2	Nonspecific reactive hepatitis	Diagnosis	ICD-10-CM
K75.3	Granulomatous hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K75.4	Autoimmune hepatitis	Diagnosis	ICD-10-CM
K75.8	Other specified inflammatory liver diseases	Diagnosis	ICD-10-CM
K75.81	Nonalcoholic steatohepatitis (NASH)	Diagnosis	ICD-10-CM
K75.89	Other specified inflammatory liver diseases	Diagnosis	ICD-10-CM
K75.9	Inflammatory liver disease, unspecified	Diagnosis	ICD-10-CM
K76	Other diseases of liver	Diagnosis	ICD-10-CM
K76.0	Fatty (change of) liver, not elsewhere classified	Diagnosis	ICD-10-CM
K76.1	Chronic passive congestion of liver	Diagnosis	ICD-10-CM
K76.2	Central hemorrhagic necrosis of liver	Diagnosis	ICD-10-CM
K76.3	Infarction of liver	Diagnosis	ICD-10-CM
K76.4	Peliosis hepatis	Diagnosis	ICD-10-CM
K76.5	Hepatic veno-occlusive disease	Diagnosis	ICD-10-CM
K76.6	Portal hypertension	Diagnosis	ICD-10-CM
K76.7	Hepatorenal syndrome	Diagnosis	ICD-10-CM
K76.8	Other specified diseases of liver	Diagnosis	ICD-10-CM
K76.81	Hepatopulmonary syndrome	Diagnosis	ICD-10-CM
K76.82	Hepatic encephalopathy	Diagnosis	ICD-10-CM
K76.89	Other specified diseases of liver	Diagnosis	ICD-10-CM
K76.9	Liver disease, unspecified	Diagnosis	ICD-10-CM
K77	Liver disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
K80.30	Calculus of bile duct with cholangitis, unspecified, without obstruction	Diagnosis	ICD-10-CM
K80.31	Calculus of bile duct with cholangitis, unspecified, with obstruction	Diagnosis	ICD-10-CM
K80.32	Calculus of bile duct with acute cholangitis without obstruction	Diagnosis	ICD-10-CM
K80.33	Calculus of bile duct with acute cholangitis with obstruction	Diagnosis	ICD-10-CM
K80.34	Calculus of bile duct with chronic cholangitis without obstruction	Diagnosis	ICD-10-CM
K80.35	Calculus of bile duct with chronic cholangitis with obstruction	Diagnosis	ICD-10-CM
K80.36	Calculus of bile duct with acute and chronic cholangitis without obstruction	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
K80.37	Calculus of bile duct with acute and chronic cholangitis with obstruction	Diagnosis	ICD-10-CM
K83.0	Cholangitis	Diagnosis	ICD-10-CM
R16.0	Hepatomegaly, not elsewhere classified	Diagnosis	ICD-10-CM
R16.2	Hepatomegaly with splenomegaly, not elsewhere classified	Diagnosis	ICD-10-CM
Z48.23	Encounter for aftercare following liver transplant	Diagnosis	ICD-10-CM
Z94.4	Liver transplant status	Diagnosis	ICD-10-CM
Liver Disease Procedures			
06L20ZZ	Occlusion of Gastric Vein, Open Approach	Procedure	ICD-10-PCS
06L23ZZ	Occlusion of Gastric Vein, Percutaneous Approach	Procedure	ICD-10-PCS
06L24ZZ	Occlusion of Gastric Vein, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
06L30ZZ	Occlusion of Esophageal Vein, Open Approach	Procedure	ICD-10-PCS
06L33ZZ	Occlusion of Esophageal Vein, Percutaneous Approach	Procedure	ICD-10-PCS
06L34ZZ	Occlusion of Esophageal Vein, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D9S30Z	Drainage of Greater Omentum with Drainage Device, Percutaneous Approach	Procedure	ICD-10-PCS
0D9S3ZZ	Drainage of Greater Omentum, Percutaneous Approach	Procedure	ICD-10-PCS
0D9S40Z	Drainage of Greater Omentum with Drainage Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D9S4ZZ	Drainage of Greater Omentum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D9T30Z	Drainage of Lesser Omentum with Drainage Device, Percutaneous Approach	Procedure	ICD-10-PCS
0D9T3ZZ	Drainage of Lesser Omentum, Percutaneous Approach	Procedure	ICD-10-PCS
0D9T40Z	Drainage of Lesser Omentum with Drainage Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D9T4ZZ	Drainage of Lesser Omentum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D9V30Z	Drainage of Mesentery with Drainage Device, Percutaneous Approach	Procedure	ICD-10-PCS
0D9V3ZZ	Drainage of Mesentery, Percutaneous Approach	Procedure	ICD-10-PCS
0D9V40Z	Drainage of Mesentery with Drainage Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D9V4ZZ	Drainage of Mesentery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D9W30Z	Drainage of Peritoneum with Drainage Device, Percutaneous Approach	Procedure	ICD-10-PCS
0D9W3ZZ	Drainage of Peritoneum, Percutaneous Approach	Procedure	ICD-10-PCS
0D9W40Z	Drainage of Peritoneum with Drainage Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D9W4ZZ	Drainage of Peritoneum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DL57DZ	Occlusion of Esophagus with Intraluminal Device, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DL58DZ	Occlusion of Esophagus with Intraluminal Device, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0W9F30Z	Drainage of Abdominal Wall with Drainage Device, Percutaneous Approach	Procedure	ICD-10-PCS
0W9F3ZZ	Drainage of Abdominal Wall, Percutaneous Approach	Procedure	ICD-10-PCS

Code	Description	Code Category	Code Type
0W9F40Z	Drainage of Abdominal Wall with Drainage Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0W9F4ZZ	Drainage of Abdominal Wall, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0W9G30Z	Drainage of Peritoneal Cavity with Drainage Device, Percutaneous Approach	Procedure	ICD-10-PCS
0W9G3ZZ	Drainage of Peritoneal Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
0W9G40Z	Drainage of Peritoneal Cavity with Drainage Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0W9G4ZZ	Drainage of Peritoneal Cavity, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0W9J30Z	Drainage of Pelvic Cavity with Drainage Device, Percutaneous Approach	Procedure	ICD-10-PCS
0W9J3ZZ	Drainage of Pelvic Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
Lung Cancer			
C34.00	Malignant neoplasm of unspecified main bronchus	Diagnosis	ICD-10-CM
C34.01	Malignant neoplasm of right main bronchus	Diagnosis	ICD-10-CM
C34.02	Malignant neoplasm of left main bronchus	Diagnosis	ICD-10-CM
C34.10	Malignant neoplasm of upper lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.11	Malignant neoplasm of upper lobe, right bronchus or lung	Diagnosis	ICD-10-CM
C34.12	Malignant neoplasm of upper lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.2	Malignant neoplasm of middle lobe, bronchus or lung	Diagnosis	ICD-10-CM
C34.30	Malignant neoplasm of lower lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.31	Malignant neoplasm of lower lobe, right bronchus or lung	Diagnosis	ICD-10-CM
C34.32	Malignant neoplasm of lower lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.80	Malignant neoplasm of overlapping sites of unspecified bronchus and lung	Diagnosis	ICD-10-CM
C34.81	Malignant neoplasm of overlapping sites of right bronchus and lung	Diagnosis	ICD-10-CM
C34.82	Malignant neoplasm of overlapping sites of left bronchus and lung	Diagnosis	ICD-10-CM
C34.90	Malignant neoplasm of unspecified part of unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.91	Malignant neoplasm of unspecified part of right bronchus or lung	Diagnosis	ICD-10-CM
C34.92	Malignant neoplasm of unspecified part of left bronchus or lung	Diagnosis	ICD-10-CM
D02.20	Carcinoma in situ of unspecified bronchus and lung	Diagnosis	ICD-10-CM
D02.21	Carcinoma in situ of right bronchus and lung	Diagnosis	ICD-10-CM
D02.22	Carcinoma in situ of left bronchus and lung	Diagnosis	ICD-10-CM
Z85.110	Personal history of malignant carcinoid tumor of bronchus and lung	Diagnosis	ICD-10-CM
Z85.118	Personal history of other malignant neoplasm of bronchus and lung	Diagnosis	ICD-10-CM
Obesity			
0D16079	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS

Code	Description	Code Category	Code Type
0D160J9	Bypass Stomach to Duodenum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JA	Bypass Stomach to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JB	Bypass Stomach to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160Z9	Bypass Stomach to Duodenum, Open Approach	Procedure	ICD-10-PCS
0D160ZA	Bypass Stomach to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D160ZB	Bypass Stomach to Ileum, Open Approach	Procedure	ICD-10-PCS
0D160ZL	Bypass Stomach to Transverse Colon, Open Approach	Procedure	ICD-10-PCS
0D16479	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164J9	Bypass Stomach to Duodenum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JA	Bypass Stomach to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JB	Bypass Stomach to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164Z9	Bypass Stomach to Duodenum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZA	Bypass Stomach to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Code	Description	Code Category	Code Type
0D164ZB	Bypass Stomach to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZL	Bypass Stomach to Transverse Colon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D16879	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168J9	Bypass Stomach to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JA	Bypass Stomach to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JB	Bypass Stomach to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168Z9	Bypass Stomach to Duodenum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZA	Bypass Stomach to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZB	Bypass Stomach to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZL	Bypass Stomach to Transverse Colon, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D19079	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1907A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1907B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS

Code	Description	Code Category	Code Type
0D190JB	Bypass Duodenum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190Z9	Bypass Duodenum to Duodenum, Open Approach	Procedure	ICD-10-PCS
0D190ZA	Bypass Duodenum to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D190ZB	Bypass Duodenum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D19479	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1947A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1947B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194JB	Bypass Duodenum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194Z9	Bypass Duodenum to Duodenum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194ZA	Bypass Duodenum to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194ZB	Bypass Duodenum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D19879	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1987A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1987B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198JB	Bypass Duodenum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
0D198K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198Z9	Bypass Duodenum to Duodenum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198ZA	Bypass Duodenum to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198ZB	Bypass Duodenum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A07A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A07B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0JB	Bypass Jejunum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0ZA	Bypass Jejunum to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D1A0ZB	Bypass Jejunum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D1A47A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A47B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4JB	Bypass Jejunum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4ZA	Bypass Jejunum to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4ZB	Bypass Jejunum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A87A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A87B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS

Code	Description	Code Category	Code Type
0D1A8JB	Bypass Jejunum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZA	Bypass Jejunum to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZB	Bypass Jejunum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZH	Bypass Jejunum to Cecum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B07B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0JB	Bypass Ileum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0ZB	Bypass Ileum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D1B47B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4JB	Bypass Ileum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4ZB	Bypass Ileum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B87B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8JB	Bypass Ileum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8ZB	Bypass Ileum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8ZH	Bypass Ileum to Cecum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DB60Z3	Excision of Stomach, Open Approach, Vertical	Procedure	ICD-10-PCS
0DB60ZZ	Excision of Stomach, Open Approach	Procedure	ICD-10-PCS
0DB63Z3	Excision of Stomach, Percutaneous Approach, Vertical	Procedure	ICD-10-PCS
0DB63ZZ	Excision of Stomach, Percutaneous Approach	Procedure	ICD-10-PCS
0DB67Z3	Excision of Stomach, Via Natural or Artificial Opening, Vertical	Procedure	ICD-10-PCS
0DB67ZZ	Excision of Stomach, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DB68Z3	Excision of Stomach, Via Natural or Artificial Opening Endoscopic, Vertical	Procedure	ICD-10-PCS
0DB80ZZ	Excision of Small Intestine, Open Approach	Procedure	ICD-10-PCS
0DB90ZZ	Excision of Duodenum, Open Approach	Procedure	ICD-10-PCS
0DBB0ZZ	Excision of Ileum, Open Approach	Procedure	ICD-10-PCS
0DQ64ZZ	Repair Stomach, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Code	Description	Code Category	Code Type
0DV64CZ	Restriction of Stomach with Extraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0F190Z3	Bypass Common Bile Duct to Duodenum, Open Approach	Procedure	ICD-10-PCS
0TRB07Z	Replacement of Bladder with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
43644	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and Roux-en-Y gastroenterostomy (roux limb 150 cm or less)	Procedure	CPT-4
43645	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and small intestine reconstruction to limit absorption	Procedure	CPT-4
43770	Laparoscopy, surgical, gastric restrictive procedure; placement of adjustable gastric restrictive device (eg, gastric band and subcutaneous port components)	Procedure	CPT-4
43842	Gastric restrictive procedure, without gastric bypass, for morbid obesity; vertical-banded gastroplasty	Procedure	CPT-4
43843	Gastric restrictive procedure, without gastric bypass, for morbid obesity; other than vertical-banded gastroplasty	Procedure	CPT-4
43845	Gastric restrictive procedure with partial gastrectomy, pylorus-preserving duodenoileostomy and ileoileostomy (50 to 100 cm common channel) to limit absorption (biliopancreatic diversion with duodenal switch)	Procedure	CPT-4
43846	Gastric restrictive procedure, with gastric bypass for morbid obesity; with short limb (150 cm or less) Roux-en-Y gastroenterostomy	Procedure	CPT-4
43847	Gastric restrictive procedure, with gastric bypass for morbid obesity; with small intestine reconstruction to limit absorption	Procedure	CPT-4
E66.01	Morbid (severe) obesity due to excess calories	Diagnosis	ICD-10-CM
E66.09	Other obesity due to excess calories	Diagnosis	ICD-10-CM
E66.1	Drug-induced obesity	Diagnosis	ICD-10-CM
E66.2	Morbid (severe) obesity with alveolar hypoventilation	Diagnosis	ICD-10-CM
E66.8	Other obesity	Diagnosis	ICD-10-CM
E66.9	Obesity, unspecified	Diagnosis	ICD-10-CM
K95.01	Infection due to gastric band procedure	Diagnosis	ICD-10-CM
K95.09	Other complications of gastric band procedure	Diagnosis	ICD-10-CM
K95.81	Infection due to other bariatric procedure	Diagnosis	ICD-10-CM
K95.89	Other complications of other bariatric procedure	Diagnosis	ICD-10-CM
O99.210	Obesity complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.211	Obesity complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.212	Obesity complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.213	Obesity complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.214	Obesity complicating childbirth	Diagnosis	ICD-10-CM
O99.215	Obesity complicating the puerperium	Diagnosis	ICD-10-CM
O99.840	Bariatric surgery status complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.841	Bariatric surgery status complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.842	Bariatric surgery status complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.843	Bariatric surgery status complicating pregnancy, third trimester	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
O99.844	Bariatric surgery status complicating childbirth	Diagnosis	ICD-10-CM
O99.845	Bariatric surgery status complicating the puerperium	Diagnosis	ICD-10-CM
Z68.30	Body mass index (BMI) 30.0-30.9, adult	Diagnosis	ICD-10-CM
Z68.31	Body mass index (BMI) 31.0-31.9, adult	Diagnosis	ICD-10-CM
Z68.32	Body mass index (BMI) 32.0-32.9, adult	Diagnosis	ICD-10-CM
Z68.33	Body mass index (BMI) 33.0-33.9, adult	Diagnosis	ICD-10-CM
Z68.34	Body mass index (BMI) 34.0-34.9, adult	Diagnosis	ICD-10-CM
Z68.35	Body mass index (BMI) 35.0-35.9, adult	Diagnosis	ICD-10-CM
Z68.36	Body mass index (BMI) 36.0-36.9, adult	Diagnosis	ICD-10-CM
Z68.37	Body mass index (BMI) 37.0-37.9, adult	Diagnosis	ICD-10-CM
Z68.38	Body mass index (BMI) 38.0-38.9, adult	Diagnosis	ICD-10-CM
Z68.39	Body mass index (BMI) 39.0-39.9, adult	Diagnosis	ICD-10-CM
Z68.41	Body mass index (BMI) 40.0-44.9, adult	Diagnosis	ICD-10-CM
Z68.42	Body mass index (BMI) 45.0-49.9, adult	Diagnosis	ICD-10-CM
Z68.43	Body mass index (BMI) 50-59.9, adult	Diagnosis	ICD-10-CM
Z68.44	Body mass index (BMI) 60.0-69.9, adult	Diagnosis	ICD-10-CM
Z68.45	Body mass index (BMI) 70 or greater, adult	Diagnosis	ICD-10-CM
Osteoporosis			
M80.00XA	Age-related osteoporosis with current pathological fracture, unspecified site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.011A	Age-related osteoporosis with current pathological fracture, right shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.012A	Age-related osteoporosis with current pathological fracture, left shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.019A	Age-related osteoporosis with current pathological fracture, unspecified shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.021A	Age-related osteoporosis with current pathological fracture, right humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.022A	Age-related osteoporosis with current pathological fracture, left humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.029A	Age-related osteoporosis with current pathological fracture, unspecified humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.031A	Age-related osteoporosis with current pathological fracture, right forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.032A	Age-related osteoporosis with current pathological fracture, left forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.039A	Age-related osteoporosis with current pathological fracture, unspecified forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.041A	Age-related osteoporosis with current pathological fracture, right hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.042A	Age-related osteoporosis with current pathological fracture, left hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.049A	Age-related osteoporosis with current pathological fracture, unspecified hand, initial encounter for fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M80.051A	Age-related osteoporosis with current pathological fracture, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.052A	Age-related osteoporosis with current pathological fracture, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.059A	Age-related osteoporosis with current pathological fracture, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.061A	Age-related osteoporosis with current pathological fracture, right lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.062A	Age-related osteoporosis with current pathological fracture, left lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.069A	Age-related osteoporosis with current pathological fracture, unspecified lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.071A	Age-related osteoporosis with current pathological fracture, right ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.072A	Age-related osteoporosis with current pathological fracture, left ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.079A	Age-related osteoporosis with current pathological fracture, unspecified ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.08XA	Age-related osteoporosis with current pathological fracture, vertebra(e), initial encounter for fracture	Diagnosis	ICD-10-CM
M80.0AXA	Age-related osteoporosis with current pathological fracture, other site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.0B1A	Age-related osteoporosis with current pathological fracture, right pelvis, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.0B2A	Age-related osteoporosis with current pathological fracture, left pelvis, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.0B9A	Age-related osteoporosis with current pathological fracture, unspecified pelvis, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.80XA	Other osteoporosis with current pathological fracture, unspecified site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.811A	Other osteoporosis with current pathological fracture, right shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.812A	Other osteoporosis with current pathological fracture, left shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.819A	Other osteoporosis with current pathological fracture, unspecified shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.821A	Other osteoporosis with current pathological fracture, right humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.822A	Other osteoporosis with current pathological fracture, left humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.829A	Other osteoporosis with current pathological fracture, unspecified humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.831A	Other osteoporosis with current pathological fracture, right forearm, initial encounter for fracture	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
M80.832A	Other osteoporosis with current pathological fracture, left forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.839A	Other osteoporosis with current pathological fracture, unspecified forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.841A	Other osteoporosis with current pathological fracture, right hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.842A	Other osteoporosis with current pathological fracture, left hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.849A	Other osteoporosis with current pathological fracture, unspecified hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.851A	Other osteoporosis with current pathological fracture, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.852A	Other osteoporosis with current pathological fracture, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.859A	Other osteoporosis with current pathological fracture, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.861A	Other osteoporosis with current pathological fracture, right lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.862A	Other osteoporosis with current pathological fracture, left lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.869A	Other osteoporosis with current pathological fracture, unspecified lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.871A	Other osteoporosis with current pathological fracture, right ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.872A	Other osteoporosis with current pathological fracture, left ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.879A	Other osteoporosis with current pathological fracture, unspecified ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.88XA	Other osteoporosis with current pathological fracture, vertebra(e), initial encounter for fracture	Diagnosis	ICD-10-CM
M80.8AXA	Other osteoporosis with current pathological fracture, other site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.8B1A	Other osteoporosis with current pathological fracture, right pelvis, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.8B2A	Other osteoporosis with current pathological fracture, left pelvis, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.8B9A	Other osteoporosis with current pathological fracture, unspecified pelvis, initial encounter for fracture	Diagnosis	ICD-10-CM
M81.0	Age-related osteoporosis without current pathological fracture	Diagnosis	ICD-10-CM
M81.6	Localized osteoporosis [Lequesne]	Diagnosis	ICD-10-CM
M81.8	Other osteoporosis without current pathological fracture	Diagnosis	ICD-10-CM
Overweight			
E66.3	Overweight	Diagnosis	ICD-10-CM
Z68.25	Body mass index (BMI) 25.0-25.9, adult	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
Z68.26	Body mass index (BMI) 26.0-26.9, adult	Diagnosis	ICD-10-CM
Z68.27	Body mass index (BMI) 27.0-27.9, adult	Diagnosis	ICD-10-CM
Z68.28	Body mass index (BMI) 28.0-28.9, adult	Diagnosis	ICD-10-CM
Z68.29	Body mass index (BMI) 29.0-29.9, adult	Diagnosis	ICD-10-CM
Prostate			
C61	Malignant neoplasm of prostate	Diagnosis	ICD-10-CM
D07.5	Carcinoma in situ of prostate	Diagnosis	ICD-10-CM
Z85.46	Personal history of malignant neoplasm of prostate	Diagnosis	ICD-10-CM
Rheumatoid Arthritis			
L40.50	Arthropathic psoriasis, unspecified	Diagnosis	ICD-10-CM
L40.51	Distal interphalangeal psoriatic arthropathy	Diagnosis	ICD-10-CM
L40.54	Psoriatic juvenile arthropathy	Diagnosis	ICD-10-CM
L40.59	Other psoriatic arthropathy	Diagnosis	ICD-10-CM
M05.00	Felty's syndrome, unspecified site	Diagnosis	ICD-10-CM
M05.011	Felty's syndrome, right shoulder	Diagnosis	ICD-10-CM
M05.012	Felty's syndrome, left shoulder	Diagnosis	ICD-10-CM
M05.019	Felty's syndrome, unspecified shoulder	Diagnosis	ICD-10-CM
M05.021	Felty's syndrome, right elbow	Diagnosis	ICD-10-CM
M05.022	Felty's syndrome, left elbow	Diagnosis	ICD-10-CM
M05.029	Felty's syndrome, unspecified elbow	Diagnosis	ICD-10-CM
M05.031	Felty's syndrome, right wrist	Diagnosis	ICD-10-CM
M05.032	Felty's syndrome, left wrist	Diagnosis	ICD-10-CM
M05.039	Felty's syndrome, unspecified wrist	Diagnosis	ICD-10-CM
M05.041	Felty's syndrome, right hand	Diagnosis	ICD-10-CM
M05.042	Felty's syndrome, left hand	Diagnosis	ICD-10-CM
M05.049	Felty's syndrome, unspecified hand	Diagnosis	ICD-10-CM
M05.051	Felty's syndrome, right hip	Diagnosis	ICD-10-CM
M05.052	Felty's syndrome, left hip	Diagnosis	ICD-10-CM
M05.059	Felty's syndrome, unspecified hip	Diagnosis	ICD-10-CM
M05.061	Felty's syndrome, right knee	Diagnosis	ICD-10-CM
M05.062	Felty's syndrome, left knee	Diagnosis	ICD-10-CM
M05.069	Felty's syndrome, unspecified knee	Diagnosis	ICD-10-CM
M05.071	Felty's syndrome, right ankle and foot	Diagnosis	ICD-10-CM
M05.072	Felty's syndrome, left ankle and foot	Diagnosis	ICD-10-CM
M05.079	Felty's syndrome, unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.09	Felty's syndrome, multiple sites	Diagnosis	ICD-10-CM
M05.10	Rheumatoid lung disease with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.111	Rheumatoid lung disease with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.112	Rheumatoid lung disease with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.119	Rheumatoid lung disease with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.121	Rheumatoid lung disease with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.122	Rheumatoid lung disease with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
M05.129	Rheumatoid lung disease with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.131	Rheumatoid lung disease with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.132	Rheumatoid lung disease with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.139	Rheumatoid lung disease with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.141	Rheumatoid lung disease with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.142	Rheumatoid lung disease with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.149	Rheumatoid lung disease with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.151	Rheumatoid lung disease with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.152	Rheumatoid lung disease with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.159	Rheumatoid lung disease with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.161	Rheumatoid lung disease with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.162	Rheumatoid lung disease with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.169	Rheumatoid lung disease with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.171	Rheumatoid lung disease with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.172	Rheumatoid lung disease with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.179	Rheumatoid lung disease with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.19	Rheumatoid lung disease with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.20	Rheumatoid vasculitis with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.211	Rheumatoid vasculitis with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.212	Rheumatoid vasculitis with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.219	Rheumatoid vasculitis with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.221	Rheumatoid vasculitis with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.222	Rheumatoid vasculitis with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.229	Rheumatoid vasculitis with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.231	Rheumatoid vasculitis with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.232	Rheumatoid vasculitis with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.239	Rheumatoid vasculitis with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.241	Rheumatoid vasculitis with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.242	Rheumatoid vasculitis with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.249	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.251	Rheumatoid vasculitis with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.252	Rheumatoid vasculitis with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.259	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.261	Rheumatoid vasculitis with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.262	Rheumatoid vasculitis with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.269	Rheumatoid vasculitis with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.271	Rheumatoid vasculitis with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.272	Rheumatoid vasculitis with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M05.279	Rheumatoid vasculitis with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.29	Rheumatoid vasculitis with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.30	Rheumatoid heart disease with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.311	Rheumatoid heart disease with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.312	Rheumatoid heart disease with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.319	Rheumatoid heart disease with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.321	Rheumatoid heart disease with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.322	Rheumatoid heart disease with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.329	Rheumatoid heart disease with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.331	Rheumatoid heart disease with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.332	Rheumatoid heart disease with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.339	Rheumatoid heart disease with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.341	Rheumatoid heart disease with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.342	Rheumatoid heart disease with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.349	Rheumatoid heart disease with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.351	Rheumatoid heart disease with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.352	Rheumatoid heart disease with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.359	Rheumatoid heart disease with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.361	Rheumatoid heart disease with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.362	Rheumatoid heart disease with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.369	Rheumatoid heart disease with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.371	Rheumatoid heart disease with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.372	Rheumatoid heart disease with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.379	Rheumatoid heart disease with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.39	Rheumatoid heart disease with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.40	Rheumatoid myopathy with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.411	Rheumatoid myopathy with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.412	Rheumatoid myopathy with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.419	Rheumatoid myopathy with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.421	Rheumatoid myopathy with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.422	Rheumatoid myopathy with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.429	Rheumatoid myopathy with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.431	Rheumatoid myopathy with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.432	Rheumatoid myopathy with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
M05.439	Rheumatoid myopathy with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.441	Rheumatoid myopathy with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.442	Rheumatoid myopathy with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.449	Rheumatoid myopathy with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.451	Rheumatoid myopathy with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.452	Rheumatoid myopathy with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.459	Rheumatoid myopathy with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.461	Rheumatoid myopathy with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.462	Rheumatoid myopathy with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.469	Rheumatoid myopathy with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.471	Rheumatoid myopathy with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.472	Rheumatoid myopathy with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.479	Rheumatoid myopathy with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.49	Rheumatoid myopathy with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.50	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.511	Rheumatoid polyneuropathy with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.512	Rheumatoid polyneuropathy with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.519	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.521	Rheumatoid polyneuropathy with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.522	Rheumatoid polyneuropathy with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.529	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.531	Rheumatoid polyneuropathy with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.532	Rheumatoid polyneuropathy with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.539	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.541	Rheumatoid polyneuropathy with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.542	Rheumatoid polyneuropathy with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.549	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.551	Rheumatoid polyneuropathy with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.552	Rheumatoid polyneuropathy with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.559	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.561	Rheumatoid polyneuropathy with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.562	Rheumatoid polyneuropathy with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.569	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M05.571	Rheumatoid polyneuropathy with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.572	Rheumatoid polyneuropathy with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.579	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.59	Rheumatoid polyneuropathy with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.60	Rheumatoid arthritis of unspecified site with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.611	Rheumatoid arthritis of right shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.612	Rheumatoid arthritis of left shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.619	Rheumatoid arthritis of unspecified shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.621	Rheumatoid arthritis of right elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.622	Rheumatoid arthritis of left elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.629	Rheumatoid arthritis of unspecified elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.631	Rheumatoid arthritis of right wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.632	Rheumatoid arthritis of left wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.639	Rheumatoid arthritis of unspecified wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.641	Rheumatoid arthritis of right hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.642	Rheumatoid arthritis of left hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.649	Rheumatoid arthritis of unspecified hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.651	Rheumatoid arthritis of right hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.652	Rheumatoid arthritis of left hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.659	Rheumatoid arthritis of unspecified hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.661	Rheumatoid arthritis of right knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.662	Rheumatoid arthritis of left knee with involvement of other organs and systems	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
M05.669	Rheumatoid arthritis of unspecified knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.671	Rheumatoid arthritis of right ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.672	Rheumatoid arthritis of left ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.679	Rheumatoid arthritis of unspecified ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.69	Rheumatoid arthritis of multiple sites with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.70	Rheumatoid arthritis with rheumatoid factor of unspecified site without organ or systems involvement	Diagnosis	ICD-10-CM
M05.711	Rheumatoid arthritis with rheumatoid factor of right shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.712	Rheumatoid arthritis with rheumatoid factor of left shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.719	Rheumatoid arthritis with rheumatoid factor of unspecified shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.721	Rheumatoid arthritis with rheumatoid factor of right elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.722	Rheumatoid arthritis with rheumatoid factor of left elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.729	Rheumatoid arthritis with rheumatoid factor of unspecified elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.731	Rheumatoid arthritis with rheumatoid factor of right wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.732	Rheumatoid arthritis with rheumatoid factor of left wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.739	Rheumatoid arthritis with rheumatoid factor of unspecified wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.741	Rheumatoid arthritis with rheumatoid factor of right hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.742	Rheumatoid arthritis with rheumatoid factor of left hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.749	Rheumatoid arthritis with rheumatoid factor of unspecified hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.751	Rheumatoid arthritis with rheumatoid factor of right hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.752	Rheumatoid arthritis with rheumatoid factor of left hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.759	Rheumatoid arthritis with rheumatoid factor of unspecified hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.761	Rheumatoid arthritis with rheumatoid factor of right knee without organ or systems involvement	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M05.762	Rheumatoid arthritis with rheumatoid factor of left knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.769	Rheumatoid arthritis with rheumatoid factor of unspecified knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.771	Rheumatoid arthritis with rheumatoid factor of right ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.772	Rheumatoid arthritis with rheumatoid factor of left ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.779	Rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.79	Rheumatoid arthritis with rheumatoid factor of multiple sites without organ or systems involvement	Diagnosis	ICD-10-CM
M05.7A	Rheumatoid arthritis with rheumatoid factor of other specified site without organ or systems involvement	Diagnosis	ICD-10-CM
M05.80	Other rheumatoid arthritis with rheumatoid factor of unspecified site	Diagnosis	ICD-10-CM
M05.811	Other rheumatoid arthritis with rheumatoid factor of right shoulder	Diagnosis	ICD-10-CM
M05.812	Other rheumatoid arthritis with rheumatoid factor of left shoulder	Diagnosis	ICD-10-CM
M05.819	Other rheumatoid arthritis with rheumatoid factor of unspecified shoulder	Diagnosis	ICD-10-CM
M05.821	Other rheumatoid arthritis with rheumatoid factor of right elbow	Diagnosis	ICD-10-CM
M05.822	Other rheumatoid arthritis with rheumatoid factor of left elbow	Diagnosis	ICD-10-CM
M05.829	Other rheumatoid arthritis with rheumatoid factor of unspecified elbow	Diagnosis	ICD-10-CM
M05.831	Other rheumatoid arthritis with rheumatoid factor of right wrist	Diagnosis	ICD-10-CM
M05.832	Other rheumatoid arthritis with rheumatoid factor of left wrist	Diagnosis	ICD-10-CM
M05.839	Other rheumatoid arthritis with rheumatoid factor of unspecified wrist	Diagnosis	ICD-10-CM
M05.841	Other rheumatoid arthritis with rheumatoid factor of right hand	Diagnosis	ICD-10-CM
M05.842	Other rheumatoid arthritis with rheumatoid factor of left hand	Diagnosis	ICD-10-CM
M05.849	Other rheumatoid arthritis with rheumatoid factor of unspecified hand	Diagnosis	ICD-10-CM
M05.851	Other rheumatoid arthritis with rheumatoid factor of right hip	Diagnosis	ICD-10-CM
M05.852	Other rheumatoid arthritis with rheumatoid factor of left hip	Diagnosis	ICD-10-CM
M05.859	Other rheumatoid arthritis with rheumatoid factor of unspecified hip	Diagnosis	ICD-10-CM
M05.861	Other rheumatoid arthritis with rheumatoid factor of right knee	Diagnosis	ICD-10-CM
M05.862	Other rheumatoid arthritis with rheumatoid factor of left knee	Diagnosis	ICD-10-CM
M05.869	Other rheumatoid arthritis with rheumatoid factor of unspecified knee	Diagnosis	ICD-10-CM
M05.871	Other rheumatoid arthritis with rheumatoid factor of right ankle and foot	Diagnosis	ICD-10-CM
M05.872	Other rheumatoid arthritis with rheumatoid factor of left ankle and foot	Diagnosis	ICD-10-CM
M05.879	Other rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.89	Other rheumatoid arthritis with rheumatoid factor of multiple sites	Diagnosis	ICD-10-CM
M05.8A	Other rheumatoid arthritis with rheumatoid factor of other specified site	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M05.9	Rheumatoid arthritis with rheumatoid factor, unspecified	Diagnosis	ICD-10-CM
M06.00	Rheumatoid arthritis without rheumatoid factor, unspecified site	Diagnosis	ICD-10-CM
M06.011	Rheumatoid arthritis without rheumatoid factor, right shoulder	Diagnosis	ICD-10-CM
M06.012	Rheumatoid arthritis without rheumatoid factor, left shoulder	Diagnosis	ICD-10-CM
M06.019	Rheumatoid arthritis without rheumatoid factor, unspecified shoulder	Diagnosis	ICD-10-CM
M06.021	Rheumatoid arthritis without rheumatoid factor, right elbow	Diagnosis	ICD-10-CM
M06.022	Rheumatoid arthritis without rheumatoid factor, left elbow	Diagnosis	ICD-10-CM
M06.029	Rheumatoid arthritis without rheumatoid factor, unspecified elbow	Diagnosis	ICD-10-CM
M06.031	Rheumatoid arthritis without rheumatoid factor, right wrist	Diagnosis	ICD-10-CM
M06.032	Rheumatoid arthritis without rheumatoid factor, left wrist	Diagnosis	ICD-10-CM
M06.039	Rheumatoid arthritis without rheumatoid factor, unspecified wrist	Diagnosis	ICD-10-CM
M06.041	Rheumatoid arthritis without rheumatoid factor, right hand	Diagnosis	ICD-10-CM
M06.042	Rheumatoid arthritis without rheumatoid factor, left hand	Diagnosis	ICD-10-CM
M06.049	Rheumatoid arthritis without rheumatoid factor, unspecified hand	Diagnosis	ICD-10-CM
M06.051	Rheumatoid arthritis without rheumatoid factor, right hip	Diagnosis	ICD-10-CM
M06.052	Rheumatoid arthritis without rheumatoid factor, left hip	Diagnosis	ICD-10-CM
M06.059	Rheumatoid arthritis without rheumatoid factor, unspecified hip	Diagnosis	ICD-10-CM
M06.061	Rheumatoid arthritis without rheumatoid factor, right knee	Diagnosis	ICD-10-CM
M06.062	Rheumatoid arthritis without rheumatoid factor, left knee	Diagnosis	ICD-10-CM
M06.069	Rheumatoid arthritis without rheumatoid factor, unspecified knee	Diagnosis	ICD-10-CM
M06.071	Rheumatoid arthritis without rheumatoid factor, right ankle and foot	Diagnosis	ICD-10-CM
M06.072	Rheumatoid arthritis without rheumatoid factor, left ankle and foot	Diagnosis	ICD-10-CM
M06.079	Rheumatoid arthritis without rheumatoid factor, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.08	Rheumatoid arthritis without rheumatoid factor, vertebrae	Diagnosis	ICD-10-CM
M06.09	Rheumatoid arthritis without rheumatoid factor, multiple sites	Diagnosis	ICD-10-CM
M06.0A	Rheumatoid arthritis without rheumatoid factor, other specified site	Diagnosis	ICD-10-CM
M06.1	Adult-onset Still's disease	Diagnosis	ICD-10-CM
M06.20	Rheumatoid bursitis, unspecified site	Diagnosis	ICD-10-CM
M06.211	Rheumatoid bursitis, right shoulder	Diagnosis	ICD-10-CM
M06.212	Rheumatoid bursitis, left shoulder	Diagnosis	ICD-10-CM
M06.219	Rheumatoid bursitis, unspecified shoulder	Diagnosis	ICD-10-CM
M06.221	Rheumatoid bursitis, right elbow	Diagnosis	ICD-10-CM
M06.222	Rheumatoid bursitis, left elbow	Diagnosis	ICD-10-CM
M06.229	Rheumatoid bursitis, unspecified elbow	Diagnosis	ICD-10-CM
M06.231	Rheumatoid bursitis, right wrist	Diagnosis	ICD-10-CM
M06.232	Rheumatoid bursitis, left wrist	Diagnosis	ICD-10-CM
M06.239	Rheumatoid bursitis, unspecified wrist	Diagnosis	ICD-10-CM
M06.241	Rheumatoid bursitis, right hand	Diagnosis	ICD-10-CM
M06.242	Rheumatoid bursitis, left hand	Diagnosis	ICD-10-CM
M06.249	Rheumatoid bursitis, unspecified hand	Diagnosis	ICD-10-CM
M06.251	Rheumatoid bursitis, right hip	Diagnosis	ICD-10-CM
M06.252	Rheumatoid bursitis, left hip	Diagnosis	ICD-10-CM
M06.259	Rheumatoid bursitis, unspecified hip	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M06.261	Rheumatoid bursitis, right knee	Diagnosis	ICD-10-CM
M06.262	Rheumatoid bursitis, left knee	Diagnosis	ICD-10-CM
M06.269	Rheumatoid bursitis, unspecified knee	Diagnosis	ICD-10-CM
M06.271	Rheumatoid bursitis, right ankle and foot	Diagnosis	ICD-10-CM
M06.272	Rheumatoid bursitis, left ankle and foot	Diagnosis	ICD-10-CM
M06.279	Rheumatoid bursitis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.28	Rheumatoid bursitis, vertebrae	Diagnosis	ICD-10-CM
M06.29	Rheumatoid bursitis, multiple sites	Diagnosis	ICD-10-CM
M06.30	Rheumatoid nodule, unspecified site	Diagnosis	ICD-10-CM
M06.311	Rheumatoid nodule, right shoulder	Diagnosis	ICD-10-CM
M06.312	Rheumatoid nodule, left shoulder	Diagnosis	ICD-10-CM
M06.319	Rheumatoid nodule, unspecified shoulder	Diagnosis	ICD-10-CM
M06.321	Rheumatoid nodule, right elbow	Diagnosis	ICD-10-CM
M06.322	Rheumatoid nodule, left elbow	Diagnosis	ICD-10-CM
M06.329	Rheumatoid nodule, unspecified elbow	Diagnosis	ICD-10-CM
M06.331	Rheumatoid nodule, right wrist	Diagnosis	ICD-10-CM
M06.332	Rheumatoid nodule, left wrist	Diagnosis	ICD-10-CM
M06.339	Rheumatoid nodule, unspecified wrist	Diagnosis	ICD-10-CM
M06.341	Rheumatoid nodule, right hand	Diagnosis	ICD-10-CM
M06.342	Rheumatoid nodule, left hand	Diagnosis	ICD-10-CM
M06.349	Rheumatoid nodule, unspecified hand	Diagnosis	ICD-10-CM
M06.351	Rheumatoid nodule, right hip	Diagnosis	ICD-10-CM
M06.352	Rheumatoid nodule, left hip	Diagnosis	ICD-10-CM
M06.359	Rheumatoid nodule, unspecified hip	Diagnosis	ICD-10-CM
M06.361	Rheumatoid nodule, right knee	Diagnosis	ICD-10-CM
M06.362	Rheumatoid nodule, left knee	Diagnosis	ICD-10-CM
M06.369	Rheumatoid nodule, unspecified knee	Diagnosis	ICD-10-CM
M06.371	Rheumatoid nodule, right ankle and foot	Diagnosis	ICD-10-CM
M06.372	Rheumatoid nodule, left ankle and foot	Diagnosis	ICD-10-CM
M06.379	Rheumatoid nodule, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.38	Rheumatoid nodule, vertebrae	Diagnosis	ICD-10-CM
M06.39	Rheumatoid nodule, multiple sites	Diagnosis	ICD-10-CM
M06.80	Other specified rheumatoid arthritis, unspecified site	Diagnosis	ICD-10-CM
M06.811	Other specified rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M06.812	Other specified rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M06.819	Other specified rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M06.821	Other specified rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M06.822	Other specified rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M06.829	Other specified rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M06.831	Other specified rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M06.832	Other specified rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M06.839	Other specified rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M06.841	Other specified rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M06.842	Other specified rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
M06.849	Other specified rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M06.851	Other specified rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M06.852	Other specified rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M06.859	Other specified rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M06.861	Other specified rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M06.862	Other specified rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M06.869	Other specified rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M06.871	Other specified rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M06.872	Other specified rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M06.879	Other specified rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.88	Other specified rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M06.89	Other specified rheumatoid arthritis, multiple sites	Diagnosis	ICD-10-CM
M06.8A	Other specified rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M06.9	Rheumatoid arthritis, unspecified	Diagnosis	ICD-10-CM
M08.00	Unspecified juvenile rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M08.011	Unspecified juvenile rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.012	Unspecified juvenile rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.019	Unspecified juvenile rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.021	Unspecified juvenile rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M08.022	Unspecified juvenile rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M08.029	Unspecified juvenile rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.031	Unspecified juvenile rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M08.032	Unspecified juvenile rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M08.039	Unspecified juvenile rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.041	Unspecified juvenile rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M08.042	Unspecified juvenile rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M08.049	Unspecified juvenile rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.051	Unspecified juvenile rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M08.052	Unspecified juvenile rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M08.059	Unspecified juvenile rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.061	Unspecified juvenile rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M08.062	Unspecified juvenile rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M08.069	Unspecified juvenile rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.071	Unspecified juvenile rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.072	Unspecified juvenile rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.079	Unspecified juvenile rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.08	Unspecified juvenile rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M08.09	Unspecified juvenile rheumatoid arthritis, multiple sites	Diagnosis	ICD-10-CM
M08.0A	Unspecified juvenile rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M08.1	Juvenile ankylosing spondylitis	Diagnosis	ICD-10-CM
M08.20	Juvenile rheumatoid arthritis with systemic onset, unspecified site	Diagnosis	ICD-10-CM
M08.211	Juvenile rheumatoid arthritis with systemic onset, right shoulder	Diagnosis	ICD-10-CM
M08.212	Juvenile rheumatoid arthritis with systemic onset, left shoulder	Diagnosis	ICD-10-CM
M08.219	Juvenile rheumatoid arthritis with systemic onset, unspecified shoulder	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
M08.221	Juvenile rheumatoid arthritis with systemic onset, right elbow	Diagnosis	ICD-10-CM
M08.222	Juvenile rheumatoid arthritis with systemic onset, left elbow	Diagnosis	ICD-10-CM
M08.229	Juvenile rheumatoid arthritis with systemic onset, unspecified elbow	Diagnosis	ICD-10-CM
M08.231	Juvenile rheumatoid arthritis with systemic onset, right wrist	Diagnosis	ICD-10-CM
M08.232	Juvenile rheumatoid arthritis with systemic onset, left wrist	Diagnosis	ICD-10-CM
M08.239	Juvenile rheumatoid arthritis with systemic onset, unspecified wrist	Diagnosis	ICD-10-CM
M08.241	Juvenile rheumatoid arthritis with systemic onset, right hand	Diagnosis	ICD-10-CM
M08.242	Juvenile rheumatoid arthritis with systemic onset, left hand	Diagnosis	ICD-10-CM
M08.249	Juvenile rheumatoid arthritis with systemic onset, unspecified hand	Diagnosis	ICD-10-CM
M08.251	Juvenile rheumatoid arthritis with systemic onset, right hip	Diagnosis	ICD-10-CM
M08.252	Juvenile rheumatoid arthritis with systemic onset, left hip	Diagnosis	ICD-10-CM
M08.259	Juvenile rheumatoid arthritis with systemic onset, unspecified hip	Diagnosis	ICD-10-CM
M08.261	Juvenile rheumatoid arthritis with systemic onset, right knee	Diagnosis	ICD-10-CM
M08.262	Juvenile rheumatoid arthritis with systemic onset, left knee	Diagnosis	ICD-10-CM
M08.269	Juvenile rheumatoid arthritis with systemic onset, unspecified knee	Diagnosis	ICD-10-CM
M08.271	Juvenile rheumatoid arthritis with systemic onset, right ankle and foot	Diagnosis	ICD-10-CM
M08.272	Juvenile rheumatoid arthritis with systemic onset, left ankle and foot	Diagnosis	ICD-10-CM
M08.279	Juvenile rheumatoid arthritis with systemic onset, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.28	Juvenile rheumatoid arthritis with systemic onset, vertebrae	Diagnosis	ICD-10-CM
M08.29	Juvenile rheumatoid arthritis with systemic onset, multiple sites	Diagnosis	ICD-10-CM
M08.2A	Juvenile rheumatoid arthritis with systemic onset, other specified site	Diagnosis	ICD-10-CM
M08.3	Juvenile rheumatoid polyarthritis (seronegative)	Diagnosis	ICD-10-CM
M08.40	Pauciarticular juvenile rheumatoid arthritis, unspecified site	Diagnosis	ICD-10-CM
M08.411	Pauciarticular juvenile rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.412	Pauciarticular juvenile rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.419	Pauciarticular juvenile rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.421	Pauciarticular juvenile rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M08.422	Pauciarticular juvenile rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M08.429	Pauciarticular juvenile rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.431	Pauciarticular juvenile rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M08.432	Pauciarticular juvenile rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M08.439	Pauciarticular juvenile rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.441	Pauciarticular juvenile rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M08.442	Pauciarticular juvenile rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M08.449	Pauciarticular juvenile rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.451	Pauciarticular juvenile rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M08.452	Pauciarticular juvenile rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M08.459	Pauciarticular juvenile rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.461	Pauciarticular juvenile rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M08.462	Pauciarticular juvenile rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M08.469	Pauciarticular juvenile rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.471	Pauciarticular juvenile rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.472	Pauciarticular juvenile rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
M08.479	Pauciarticular juvenile rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.48	Pauciarticular juvenile rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M08.4A	Pauciarticular juvenile rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M08.80	Other juvenile arthritis, unspecified site	Diagnosis	ICD-10-CM
M08.811	Other juvenile arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.812	Other juvenile arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.819	Other juvenile arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.821	Other juvenile arthritis, right elbow	Diagnosis	ICD-10-CM
M08.822	Other juvenile arthritis, left elbow	Diagnosis	ICD-10-CM
M08.829	Other juvenile arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.831	Other juvenile arthritis, right wrist	Diagnosis	ICD-10-CM
M08.832	Other juvenile arthritis, left wrist	Diagnosis	ICD-10-CM
M08.839	Other juvenile arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.841	Other juvenile arthritis, right hand	Diagnosis	ICD-10-CM
M08.842	Other juvenile arthritis, left hand	Diagnosis	ICD-10-CM
M08.849	Other juvenile arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.851	Other juvenile arthritis, right hip	Diagnosis	ICD-10-CM
M08.852	Other juvenile arthritis, left hip	Diagnosis	ICD-10-CM
M08.859	Other juvenile arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.861	Other juvenile arthritis, right knee	Diagnosis	ICD-10-CM
M08.862	Other juvenile arthritis, left knee	Diagnosis	ICD-10-CM
M08.869	Other juvenile arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.871	Other juvenile arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.872	Other juvenile arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.879	Other juvenile arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.88	Other juvenile arthritis, other specified site	Diagnosis	ICD-10-CM
M08.89	Other juvenile arthritis, multiple sites	Diagnosis	ICD-10-CM
M08.90	Juvenile arthritis, unspecified, unspecified site	Diagnosis	ICD-10-CM
M08.911	Juvenile arthritis, unspecified, right shoulder	Diagnosis	ICD-10-CM
M08.912	Juvenile arthritis, unspecified, left shoulder	Diagnosis	ICD-10-CM
M08.919	Juvenile arthritis, unspecified, unspecified shoulder	Diagnosis	ICD-10-CM
M08.921	Juvenile arthritis, unspecified, right elbow	Diagnosis	ICD-10-CM
M08.922	Juvenile arthritis, unspecified, left elbow	Diagnosis	ICD-10-CM
M08.929	Juvenile arthritis, unspecified, unspecified elbow	Diagnosis	ICD-10-CM
M08.931	Juvenile arthritis, unspecified, right wrist	Diagnosis	ICD-10-CM
M08.932	Juvenile arthritis, unspecified, left wrist	Diagnosis	ICD-10-CM
M08.939	Juvenile arthritis, unspecified, unspecified wrist	Diagnosis	ICD-10-CM
M08.941	Juvenile arthritis, unspecified, right hand	Diagnosis	ICD-10-CM
M08.942	Juvenile arthritis, unspecified, left hand	Diagnosis	ICD-10-CM
M08.949	Juvenile arthritis, unspecified, unspecified hand	Diagnosis	ICD-10-CM
M08.951	Juvenile arthritis, unspecified, right hip	Diagnosis	ICD-10-CM
M08.952	Juvenile arthritis, unspecified, left hip	Diagnosis	ICD-10-CM
M08.959	Juvenile arthritis, unspecified, unspecified hip	Diagnosis	ICD-10-CM
M08.961	Juvenile arthritis, unspecified, right knee	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
M08.962	Juvenile arthritis, unspecified, left knee	Diagnosis	ICD-10-CM
M08.969	Juvenile arthritis, unspecified, unspecified knee	Diagnosis	ICD-10-CM
M08.971	Juvenile arthritis, unspecified, right ankle and foot	Diagnosis	ICD-10-CM
M08.972	Juvenile arthritis, unspecified, left ankle and foot	Diagnosis	ICD-10-CM
M08.979	Juvenile arthritis, unspecified, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.98	Juvenile arthritis, unspecified, vertebrae	Diagnosis	ICD-10-CM
M08.99	Juvenile arthritis, unspecified, multiple sites	Diagnosis	ICD-10-CM
M08.9A	Juvenile arthritis, unspecified, other specified site	Diagnosis	ICD-10-CM
M15.0	Primary generalized (osteo)arthritis	Diagnosis	ICD-10-CM
M15.1	Heberden's nodes (with arthropathy)	Diagnosis	ICD-10-CM
M15.2	Bouchard's nodes (with arthropathy)	Diagnosis	ICD-10-CM
M15.3	Secondary multiple arthritis	Diagnosis	ICD-10-CM
M15.4	Erosive (osteo)arthritis	Diagnosis	ICD-10-CM
M15.8	Other polyosteoarthritis	Diagnosis	ICD-10-CM
M15.9	Polyosteoarthritis, unspecified	Diagnosis	ICD-10-CM
M16.0	Bilateral primary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.10	Unilateral primary osteoarthritis, unspecified hip	Diagnosis	ICD-10-CM
M16.11	Unilateral primary osteoarthritis, right hip	Diagnosis	ICD-10-CM
M16.12	Unilateral primary osteoarthritis, left hip	Diagnosis	ICD-10-CM
M16.2	Bilateral osteoarthritis resulting from hip dysplasia	Diagnosis	ICD-10-CM
M16.30	Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip	Diagnosis	ICD-10-CM
M16.31	Unilateral osteoarthritis resulting from hip dysplasia, right hip	Diagnosis	ICD-10-CM
M16.32	Unilateral osteoarthritis resulting from hip dysplasia, left hip	Diagnosis	ICD-10-CM
M16.4	Bilateral post-traumatic osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.50	Unilateral post-traumatic osteoarthritis, unspecified hip	Diagnosis	ICD-10-CM
M16.51	Unilateral post-traumatic osteoarthritis, right hip	Diagnosis	ICD-10-CM
M16.52	Unilateral post-traumatic osteoarthritis, left hip	Diagnosis	ICD-10-CM
M16.6	Other bilateral secondary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.7	Other unilateral secondary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.9	Osteoarthritis of hip, unspecified	Diagnosis	ICD-10-CM
M17.0	Bilateral primary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.10	Unilateral primary osteoarthritis, unspecified knee	Diagnosis	ICD-10-CM
M17.11	Unilateral primary osteoarthritis, right knee	Diagnosis	ICD-10-CM
M17.12	Unilateral primary osteoarthritis, left knee	Diagnosis	ICD-10-CM
M17.2	Bilateral post-traumatic osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.30	Unilateral post-traumatic osteoarthritis, unspecified knee	Diagnosis	ICD-10-CM
M17.31	Unilateral post-traumatic osteoarthritis, right knee	Diagnosis	ICD-10-CM
M17.32	Unilateral post-traumatic osteoarthritis, left knee	Diagnosis	ICD-10-CM
M17.4	Other bilateral secondary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.5	Other unilateral secondary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.9	Osteoarthritis of knee, unspecified	Diagnosis	ICD-10-CM
M18.0	Bilateral primary osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.10	Unilateral primary osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
M18.11	Unilateral primary osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.12	Unilateral primary osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.2	Bilateral post-traumatic osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.30	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.31	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.32	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.4	Other bilateral secondary osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.50	Other unilateral secondary osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.51	Other unilateral secondary osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.52	Other unilateral secondary osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.9	Osteoarthritis of first carpometacarpal joint, unspecified	Diagnosis	ICD-10-CM
M19.011	Primary osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.012	Primary osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.019	Primary osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.021	Primary osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.022	Primary osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.029	Primary osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.031	Primary osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.032	Primary osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.039	Primary osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.041	Primary osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.042	Primary osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.049	Primary osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.071	Primary osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.072	Primary osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.079	Primary osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.09	Primary osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.111	Post-traumatic osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.112	Post-traumatic osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.119	Post-traumatic osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.121	Post-traumatic osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.122	Post-traumatic osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.129	Post-traumatic osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.131	Post-traumatic osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.132	Post-traumatic osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.139	Post-traumatic osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M19.141	Post-traumatic osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.142	Post-traumatic osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.149	Post-traumatic osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.171	Post-traumatic osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.172	Post-traumatic osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.179	Post-traumatic osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.19	Post-traumatic osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.211	Secondary osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.212	Secondary osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.219	Secondary osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.221	Secondary osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.222	Secondary osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.229	Secondary osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.231	Secondary osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.232	Secondary osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.239	Secondary osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.241	Secondary osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.242	Secondary osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.249	Secondary osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.271	Secondary osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.272	Secondary osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.279	Secondary osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.29	Secondary osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.90	Unspecified osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.91	Primary osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.92	Post-traumatic osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.93	Secondary osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M45.0	Ankylosing spondylitis of multiple sites in spine	Diagnosis	ICD-10-CM
M45.1	Ankylosing spondylitis of occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M45.2	Ankylosing spondylitis of cervical region	Diagnosis	ICD-10-CM
M45.3	Ankylosing spondylitis of cervicothoracic region	Diagnosis	ICD-10-CM
M45.4	Ankylosing spondylitis of thoracic region	Diagnosis	ICD-10-CM
M45.5	Ankylosing spondylitis of thoracolumbar region	Diagnosis	ICD-10-CM
M45.6	Ankylosing spondylitis lumbar region	Diagnosis	ICD-10-CM
M45.7	Ankylosing spondylitis of lumbosacral region	Diagnosis	ICD-10-CM
M45.8	Ankylosing spondylitis sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M45.9	Ankylosing spondylitis of unspecified sites in spine	Diagnosis	ICD-10-CM
M45.A0	Non-radiographic axial spondyloarthritis of unspecified sites in spine	Diagnosis	ICD-10-CM
M45.A1	Non-radiographic axial spondyloarthritis of occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M45.A2	Non-radiographic axial spondyloarthritis of cervical region	Diagnosis	ICD-10-CM
M45.A3	Non-radiographic axial spondyloarthritis of cervicothoracic region	Diagnosis	ICD-10-CM
M45.A4	Non-radiographic axial spondyloarthritis of thoracic region	Diagnosis	ICD-10-CM
M45.A5	Non-radiographic axial spondyloarthritis of thoracolumbar region	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
M45.A6	Non-radiographic axial spondyloarthritis of lumbar region	Diagnosis	ICD-10-CM
M45.A7	Non-radiographic axial spondyloarthritis of lumbosacral region	Diagnosis	ICD-10-CM
M45.A8	Non-radiographic axial spondyloarthritis of sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M45.AB	Non-radiographic axial spondyloarthritis of multiple sites in spine	Diagnosis	ICD-10-CM
M46.80	Other specified inflammatory spondylopathies, site unspecified	Diagnosis	ICD-10-CM
M46.81	Other specified inflammatory spondylopathies, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M46.82	Other specified inflammatory spondylopathies, cervical region	Diagnosis	ICD-10-CM
M46.83	Other specified inflammatory spondylopathies, cervicothoracic region	Diagnosis	ICD-10-CM
M46.84	Other specified inflammatory spondylopathies, thoracic region	Diagnosis	ICD-10-CM
M46.85	Other specified inflammatory spondylopathies, thoracolumbar region	Diagnosis	ICD-10-CM
M46.86	Other specified inflammatory spondylopathies, lumbar region	Diagnosis	ICD-10-CM
M46.87	Other specified inflammatory spondylopathies, lumbosacral region	Diagnosis	ICD-10-CM
M46.88	Other specified inflammatory spondylopathies, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M46.89	Other specified inflammatory spondylopathies, multiple sites in spine	Diagnosis	ICD-10-CM
M46.90	Unspecified inflammatory spondylopathy, site unspecified	Diagnosis	ICD-10-CM
M46.91	Unspecified inflammatory spondylopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M46.92	Unspecified inflammatory spondylopathy, cervical region	Diagnosis	ICD-10-CM
M46.93	Unspecified inflammatory spondylopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M46.94	Unspecified inflammatory spondylopathy, thoracic region	Diagnosis	ICD-10-CM
M46.95	Unspecified inflammatory spondylopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M46.96	Unspecified inflammatory spondylopathy, lumbar region	Diagnosis	ICD-10-CM
M46.97	Unspecified inflammatory spondylopathy, lumbosacral region	Diagnosis	ICD-10-CM
M46.98	Unspecified inflammatory spondylopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M46.99	Unspecified inflammatory spondylopathy, multiple sites in spine	Diagnosis	ICD-10-CM
M47.011	Anterior spinal artery compression syndromes, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.012	Anterior spinal artery compression syndromes, cervical region	Diagnosis	ICD-10-CM
M47.013	Anterior spinal artery compression syndromes, cervicothoracic region	Diagnosis	ICD-10-CM
M47.014	Anterior spinal artery compression syndromes, thoracic region	Diagnosis	ICD-10-CM
M47.015	Anterior spinal artery compression syndromes, thoracolumbar region	Diagnosis	ICD-10-CM
M47.016	Anterior spinal artery compression syndromes, lumbar region	Diagnosis	ICD-10-CM
M47.019	Anterior spinal artery compression syndromes, site unspecified	Diagnosis	ICD-10-CM
M47.021	Vertebral artery compression syndromes, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.022	Vertebral artery compression syndromes, cervical region	Diagnosis	ICD-10-CM
M47.029	Vertebral artery compression syndromes, site unspecified	Diagnosis	ICD-10-CM
M47.10	Other spondylosis with myelopathy, site unspecified	Diagnosis	ICD-10-CM
M47.11	Other spondylosis with myelopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.12	Other spondylosis with myelopathy, cervical region	Diagnosis	ICD-10-CM
M47.13	Other spondylosis with myelopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.14	Other spondylosis with myelopathy, thoracic region	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
M47.15	Other spondylosis with myelopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.16	Other spondylosis with myelopathy, lumbar region	Diagnosis	ICD-10-CM
M47.20	Other spondylosis with radiculopathy, site unspecified	Diagnosis	ICD-10-CM
M47.21	Other spondylosis with radiculopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.22	Other spondylosis with radiculopathy, cervical region	Diagnosis	ICD-10-CM
M47.23	Other spondylosis with radiculopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.24	Other spondylosis with radiculopathy, thoracic region	Diagnosis	ICD-10-CM
M47.25	Other spondylosis with radiculopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.26	Other spondylosis with radiculopathy, lumbar region	Diagnosis	ICD-10-CM
M47.27	Other spondylosis with radiculopathy, lumbosacral region	Diagnosis	ICD-10-CM
M47.28	Other spondylosis with radiculopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.811	Spondylosis without myelopathy or radiculopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.812	Spondylosis without myelopathy or radiculopathy, cervical region	Diagnosis	ICD-10-CM
M47.813	Spondylosis without myelopathy or radiculopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.814	Spondylosis without myelopathy or radiculopathy, thoracic region	Diagnosis	ICD-10-CM
M47.815	Spondylosis without myelopathy or radiculopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.816	Spondylosis without myelopathy or radiculopathy, lumbar region	Diagnosis	ICD-10-CM
M47.817	Spondylosis without myelopathy or radiculopathy, lumbosacral region	Diagnosis	ICD-10-CM
M47.818	Spondylosis without myelopathy or radiculopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.819	Spondylosis without myelopathy or radiculopathy, site unspecified	Diagnosis	ICD-10-CM
M47.891	Other spondylosis, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.892	Other spondylosis, cervical region	Diagnosis	ICD-10-CM
M47.893	Other spondylosis, cervicothoracic region	Diagnosis	ICD-10-CM
M47.894	Other spondylosis, thoracic region	Diagnosis	ICD-10-CM
M47.895	Other spondylosis, thoracolumbar region	Diagnosis	ICD-10-CM
M47.896	Other spondylosis, lumbar region	Diagnosis	ICD-10-CM
M47.897	Other spondylosis, lumbosacral region	Diagnosis	ICD-10-CM
M47.898	Other spondylosis, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.899	Other spondylosis, site unspecified	Diagnosis	ICD-10-CM
M47.9	Spondylosis, unspecified	Diagnosis	ICD-10-CM
M48.8X1	Other specified spondylopathies, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M48.8X2	Other specified spondylopathies, cervical region	Diagnosis	ICD-10-CM
M48.8X3	Other specified spondylopathies, cervicothoracic region	Diagnosis	ICD-10-CM
M48.8X4	Other specified spondylopathies, thoracic region	Diagnosis	ICD-10-CM
M48.8X5	Other specified spondylopathies, thoracolumbar region	Diagnosis	ICD-10-CM
M48.8X6	Other specified spondylopathies, lumbar region	Diagnosis	ICD-10-CM
M48.8X7	Other specified spondylopathies, lumbosacral region	Diagnosis	ICD-10-CM
M48.8X8	Other specified spondylopathies, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M48.8X9	Other specified spondylopathies, site unspecified	Diagnosis	ICD-10-CM
Smoking			

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
1034F	Current tobacco smoker (CAD, CAP, COPD, PV) (DM)	Procedure	CPT-2
4001F	Tobacco use cessation intervention, pharmacologic therapy (COPD, CAD, CAP, PV, Asthma) (DM) (PV)	Procedure	CPT-2
4004F	Patient screened for tobacco use and received tobacco cessation intervention (counseling, pharmacotherapy, or both), if identified as a tobacco user (PV, CAD)	Procedure	CPT-2
99406	Smoking and tobacco use cessation counseling visit; intermediate, greater than 3 minutes up to 10 minutes	Procedure	CPT-4
99407	Smoking and tobacco use cessation counseling visit; intensive, greater than 10 minutes	Procedure	CPT-4
F17.200	Nicotine dependence, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F17.201	Nicotine dependence, unspecified, in remission	Diagnosis	ICD-10-CM
F17.203	Nicotine dependence unspecified, with withdrawal	Diagnosis	ICD-10-CM
F17.208	Nicotine dependence, unspecified, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.209	Nicotine dependence, unspecified, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.210	Nicotine dependence, cigarettes, uncomplicated	Diagnosis	ICD-10-CM
F17.211	Nicotine dependence, cigarettes, in remission	Diagnosis	ICD-10-CM
F17.213	Nicotine dependence, cigarettes, with withdrawal	Diagnosis	ICD-10-CM
F17.218	Nicotine dependence, cigarettes, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.219	Nicotine dependence, cigarettes, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.223	Nicotine dependence, chewing tobacco, with withdrawal	Diagnosis	ICD-10-CM
F17.228	Nicotine dependence, chewing tobacco, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.229	Nicotine dependence, chewing tobacco, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.290	Nicotine dependence, other tobacco product, uncomplicated	Diagnosis	ICD-10-CM
F17.291	Nicotine dependence, other tobacco product, in remission	Diagnosis	ICD-10-CM
F17.293	Nicotine dependence, other tobacco product, with withdrawal	Diagnosis	ICD-10-CM
F17.298	Nicotine dependence, other tobacco product, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.299	Nicotine dependence, other tobacco product, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
G0436	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intermediate, greater than 3 minutes, up to 10 minutes	Procedure	HCPCS
G0437	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intensive, greater than 10 minutes	Procedure	HCPCS
G9016	Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [demo project code only]	Procedure	HCPCS
G9276	Documentation that patient is a current tobacco user	Procedure	HCPCS

Code	Description	Code Category	Code Type
G9458	Patient documented as tobacco user and received tobacco cessation intervention (must include at least one of the following: advice given to quit smoking or tobacco use, counseling on the benefits of quitting smoking or tobacco use, assistance with or	Procedure	HCPCS
O99.330	Smoking (tobacco) complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.331	Smoking (tobacco) complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.332	Smoking (tobacco) complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.333	Smoking (tobacco) complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.334	Smoking (tobacco) complicating childbirth	Diagnosis	ICD-10-CM
O99.335	Smoking (tobacco) complicating the puerperium	Diagnosis	ICD-10-CM
S4995	Smoking cessation gum	Procedure	HCPCS
S9075	Smoking cessation treatment	Procedure	HCPCS
S9453	Smoking cessation classes, nonphysician provider, per session	Procedure	HCPCS
T65.221A	Toxic effect of tobacco cigarettes, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T65.222A	Toxic effect of tobacco cigarettes, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.223A	Toxic effect of tobacco cigarettes, assault, initial encounter	Diagnosis	ICD-10-CM
T65.224A	Toxic effect of tobacco cigarettes, undetermined, initial encounter	Diagnosis	ICD-10-CM
Z71.6	Tobacco abuse counseling	Diagnosis	ICD-10-CM
Z87.891	Personal history of nicotine dependence	Diagnosis	ICD-10-CM
Transient Ischemic Attack			
G45.0	Vertebro-basilar artery syndrome	Diagnosis	ICD-10-CM
G45.1	Carotid artery syndrome (hemispheric)	Diagnosis	ICD-10-CM
G45.2	Multiple and bilateral precerebral artery syndromes	Diagnosis	ICD-10-CM
G45.3	Amaurosis fugax	Diagnosis	ICD-10-CM
G45.8	Other transient cerebral ischemic attacks and related syndromes	Diagnosis	ICD-10-CM
G45.9	Transient cerebral ischemic attack, unspecified	Diagnosis	ICD-10-CM
G46.0	Middle cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.1	Anterior cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.2	Posterior cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.3	Brain stem stroke syndrome	Diagnosis	ICD-10-CM
G46.4	Cerebellar stroke syndrome	Diagnosis	ICD-10-CM
G46.5	Pure motor lacunar syndrome	Diagnosis	ICD-10-CM
G46.6	Pure sensory lacunar syndrome	Diagnosis	ICD-10-CM
G46.7	Other lacunar syndromes	Diagnosis	ICD-10-CM
G46.8	Other vascular syndromes of brain in cerebrovascular diseases	Diagnosis	ICD-10-CM
G97.31	Intraoperative hemorrhage and hematoma of a nervous system organ or structure complicating a nervous system procedure	Diagnosis	ICD-10-CM
G97.32	Intraoperative hemorrhage and hematoma of a nervous system organ or structure complicating other procedure	Diagnosis	ICD-10-CM
I60.00	Nontraumatic subarachnoid hemorrhage from unspecified carotid siphon and bifurcation	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I60.01	Nontraumatic subarachnoid hemorrhage from right carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.02	Nontraumatic subarachnoid hemorrhage from left carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.10	Nontraumatic subarachnoid hemorrhage from unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I60.11	Nontraumatic subarachnoid hemorrhage from right middle cerebral artery	Diagnosis	ICD-10-CM
I60.12	Nontraumatic subarachnoid hemorrhage from left middle cerebral artery	Diagnosis	ICD-10-CM
I60.2	Nontraumatic subarachnoid hemorrhage from anterior communicating artery	Diagnosis	ICD-10-CM
I60.20	Nontraumatic subarachnoid hemorrhage from unspecified anterior communicating artery	Diagnosis	ICD-10-CM
I60.21	Nontraumatic subarachnoid hemorrhage from right anterior communicating artery	Diagnosis	ICD-10-CM
I60.22	Nontraumatic subarachnoid hemorrhage from left anterior communicating artery	Diagnosis	ICD-10-CM
I60.30	Nontraumatic subarachnoid hemorrhage from unspecified posterior communicating artery	Diagnosis	ICD-10-CM
I60.31	Nontraumatic subarachnoid hemorrhage from right posterior communicating artery	Diagnosis	ICD-10-CM
I60.32	Nontraumatic subarachnoid hemorrhage from left posterior communicating artery	Diagnosis	ICD-10-CM
I60.4	Nontraumatic subarachnoid hemorrhage from basilar artery	Diagnosis	ICD-10-CM
I60.50	Nontraumatic subarachnoid hemorrhage from unspecified vertebral artery	Diagnosis	ICD-10-CM
I60.51	Nontraumatic subarachnoid hemorrhage from right vertebral artery	Diagnosis	ICD-10-CM
I60.52	Nontraumatic subarachnoid hemorrhage from left vertebral artery	Diagnosis	ICD-10-CM
I60.6	Nontraumatic subarachnoid hemorrhage from other intracranial arteries	Diagnosis	ICD-10-CM
I60.7	Nontraumatic subarachnoid hemorrhage from unspecified intracranial artery	Diagnosis	ICD-10-CM
I60.8	Other nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I60.9	Nontraumatic subarachnoid hemorrhage, unspecified	Diagnosis	ICD-10-CM
I61.0	Nontraumatic intracerebral hemorrhage in hemisphere, subcortical	Diagnosis	ICD-10-CM
I61.1	Nontraumatic intracerebral hemorrhage in hemisphere, cortical	Diagnosis	ICD-10-CM
I61.2	Nontraumatic intracerebral hemorrhage in hemisphere, unspecified	Diagnosis	ICD-10-CM
I61.3	Nontraumatic intracerebral hemorrhage in brain stem	Diagnosis	ICD-10-CM
I61.4	Nontraumatic intracerebral hemorrhage in cerebellum	Diagnosis	ICD-10-CM
I61.5	Nontraumatic intracerebral hemorrhage, intraventricular	Diagnosis	ICD-10-CM
I61.6	Nontraumatic intracerebral hemorrhage, multiple localized	Diagnosis	ICD-10-CM
I61.8	Other nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I61.9	Nontraumatic intracerebral hemorrhage, unspecified	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
I62.00	Nontraumatic subdural hemorrhage, unspecified	Diagnosis	ICD-10-CM
I62.01	Nontraumatic acute subdural hemorrhage	Diagnosis	ICD-10-CM
I62.02	Nontraumatic subacute subdural hemorrhage	Diagnosis	ICD-10-CM
I62.9	Nontraumatic intracranial hemorrhage, unspecified	Diagnosis	ICD-10-CM
I63.00	Cerebral infarction due to thrombosis of unspecified precerebral artery	Diagnosis	ICD-10-CM
I63.011	Cerebral infarction due to thrombosis of right vertebral artery	Diagnosis	ICD-10-CM
I63.012	Cerebral infarction due to thrombosis of left vertebral artery	Diagnosis	ICD-10-CM
I63.013	Cerebral infarction due to thrombosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.019	Cerebral infarction due to thrombosis of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.02	Cerebral infarction due to thrombosis of basilar artery	Diagnosis	ICD-10-CM
I63.031	Cerebral infarction due to thrombosis of right carotid artery	Diagnosis	ICD-10-CM
I63.032	Cerebral infarction due to thrombosis of left carotid artery	Diagnosis	ICD-10-CM
I63.033	Cerebral infarction due to thrombosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.039	Cerebral infarction due to thrombosis of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.09	Cerebral infarction due to thrombosis of other precerebral artery	Diagnosis	ICD-10-CM
I63.10	Cerebral infarction due to embolism of unspecified precerebral artery	Diagnosis	ICD-10-CM
I63.111	Cerebral infarction due to embolism of right vertebral artery	Diagnosis	ICD-10-CM
I63.112	Cerebral infarction due to embolism of left vertebral artery	Diagnosis	ICD-10-CM
I63.113	Cerebral infarction due to embolism of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.119	Cerebral infarction due to embolism of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.12	Cerebral infarction due to embolism of basilar artery	Diagnosis	ICD-10-CM
I63.131	Cerebral infarction due to embolism of right carotid artery	Diagnosis	ICD-10-CM
I63.132	Cerebral infarction due to embolism of left carotid artery	Diagnosis	ICD-10-CM
I63.133	Cerebral infarction due to embolism of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.139	Cerebral infarction due to embolism of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.19	Cerebral infarction due to embolism of other precerebral artery	Diagnosis	ICD-10-CM
I63.20	Cerebral infarction due to unspecified occlusion or stenosis of unspecified precerebral arteries	Diagnosis	ICD-10-CM
I63.211	Cerebral infarction due to unspecified occlusion or stenosis of right vertebral artery	Diagnosis	ICD-10-CM
I63.212	Cerebral infarction due to unspecified occlusion or stenosis of left vertebral artery	Diagnosis	ICD-10-CM
I63.213	Cerebral infarction due to unspecified occlusion or stenosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.219	Cerebral infarction due to unspecified occlusion or stenosis of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.22	Cerebral infarction due to unspecified occlusion or stenosis of basilar artery	Diagnosis	ICD-10-CM
I63.231	Cerebral infarction due to unspecified occlusion or stenosis of right carotid arteries	Diagnosis	ICD-10-CM
I63.232	Cerebral infarction due to unspecified occlusion or stenosis of left carotid arteries	Diagnosis	ICD-10-CM
I63.233	Cerebral infarction due to unspecified occlusion or stenosis of bilateral carotid arteries	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
I63.239	Cerebral infarction due to unspecified occlusion or stenosis of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.29	Cerebral infarction due to unspecified occlusion or stenosis of other precerebral arteries	Diagnosis	ICD-10-CM
I63.30	Cerebral infarction due to thrombosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.311	Cerebral infarction due to thrombosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.312	Cerebral infarction due to thrombosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.313	Cerebral infarction due to thrombosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.319	Cerebral infarction due to thrombosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.321	Cerebral infarction due to thrombosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.322	Cerebral infarction due to thrombosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.323	Cerebral infarction due to thrombosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.329	Cerebral infarction due to thrombosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.331	Cerebral infarction due to thrombosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.332	Cerebral infarction due to thrombosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.333	Cerebral infarction due to thrombosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.339	Cerebral infarction due to thrombosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.341	Cerebral infarction due to thrombosis of right cerebellar artery	Diagnosis	ICD-10-CM
I63.342	Cerebral infarction due to thrombosis of left cerebellar artery	Diagnosis	ICD-10-CM
I63.343	Cerebral infarction due to thrombosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.349	Cerebral infarction due to thrombosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.39	Cerebral infarction due to thrombosis of other cerebral artery	Diagnosis	ICD-10-CM
I63.40	Cerebral infarction due to embolism of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.411	Cerebral infarction due to embolism of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.412	Cerebral infarction due to embolism of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.413	Cerebral infarction due to embolism of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.419	Cerebral infarction due to embolism of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.421	Cerebral infarction due to embolism of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.422	Cerebral infarction due to embolism of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.423	Cerebral infarction due to embolism of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.429	Cerebral infarction due to embolism of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.431	Cerebral infarction due to embolism of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.432	Cerebral infarction due to embolism of left posterior cerebral artery	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I63.433	Cerebral infarction due to embolism of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.439	Cerebral infarction due to embolism of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.441	Cerebral infarction due to embolism of right cerebellar artery	Diagnosis	ICD-10-CM
I63.442	Cerebral infarction due to embolism of left cerebellar artery	Diagnosis	ICD-10-CM
I63.443	Cerebral infarction due to embolism of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.449	Cerebral infarction due to embolism of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.49	Cerebral infarction due to embolism of other cerebral artery	Diagnosis	ICD-10-CM
I63.50	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.511	Cerebral infarction due to unspecified occlusion or stenosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.512	Cerebral infarction due to unspecified occlusion or stenosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.513	Cerebral infarction due to unspecified occlusion or stenosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.519	Cerebral infarction due to unspecified occlusion or stenosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.521	Cerebral infarction due to unspecified occlusion or stenosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.522	Cerebral infarction due to unspecified occlusion or stenosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.523	Cerebral infarction due to unspecified occlusion or stenosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.529	Cerebral infarction due to unspecified occlusion or stenosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.531	Cerebral infarction due to unspecified occlusion or stenosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.532	Cerebral infarction due to unspecified occlusion or stenosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.533	Cerebral infarction due to unspecified occlusion or stenosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.539	Cerebral infarction due to unspecified occlusion or stenosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.541	Cerebral infarction due to unspecified occlusion or stenosis of right cerebellar artery	Diagnosis	ICD-10-CM
I63.542	Cerebral infarction due to unspecified occlusion or stenosis of left cerebellar artery	Diagnosis	ICD-10-CM
I63.543	Cerebral infarction due to unspecified occlusion or stenosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.549	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I63.59	Cerebral infarction due to unspecified occlusion or stenosis of other cerebral artery	Diagnosis	ICD-10-CM
I63.6	Cerebral infarction due to cerebral venous thrombosis, nonpyogenic	Diagnosis	ICD-10-CM
I63.8	Other cerebral infarction	Diagnosis	ICD-10-CM
I63.81	Other cerebral infarction due to occlusion or stenosis of small artery	Diagnosis	ICD-10-CM
I63.89	Other cerebral infarction	Diagnosis	ICD-10-CM
I63.9	Cerebral infarction, unspecified	Diagnosis	ICD-10-CM
I67.841	Reversible cerebrovascular vasoconstriction syndrome	Diagnosis	ICD-10-CM
I67.848	Other cerebrovascular vasospasm and vasoconstriction	Diagnosis	ICD-10-CM
I67.89	Other cerebrovascular disease	Diagnosis	ICD-10-CM
I97.810	Intraoperative cerebrovascular infarction during cardiac surgery	Diagnosis	ICD-10-CM
I97.811	Intraoperative cerebrovascular infarction during other surgery	Diagnosis	ICD-10-CM
I97.820	Postprocedural cerebrovascular infarction following cardiac surgery	Diagnosis	ICD-10-CM
I97.821	Postprocedural cerebrovascular infarction following other surgery	Diagnosis	ICD-10-CM

Appendix E. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Characteristics in this Request

Non-Proprietary Name	Proprietary Name
Obesity	
benzphetamine HCl	Regimex
benzphetamine HCl	benzphetamine
diethylpropion HCl	diethylpropion
liraglutide	Saxenda
liraglutide	Victoza 2-Pak
liraglutide	Victoza 3-Pak
liraglutide	liraglutide
lorcaserin HCl	Belviq
lorcaserin HCl	Belviq XR
naltrexone HCl/bupropion HCl	Contrave
orlistat	Alli
orlistat	Xenical
phendimetrazine tartrate	phendimetrazine tartrate
phentermine HCl	Adipex-P
phentermine HCl	Lomaira
phentermine HCl	phentermine
phentermine HCl/topiramate	Qsymia
semaglutide	Ozempic
semaglutide	Wegovy
tirzepatide	Mounjaro
tirzepatide	Zepbound
Smoking	
nicotine	Nicoderm CQ
nicotine	Nicotrol
nicotine	Nicotrol NS
nicotine	nicotine
nicotine bitartrate	Nicotine Tartrate
nicotine polacrilex	Nicorelief
nicotine polacrilex	Nicorette
nicotine polacrilex	Quit 2
nicotine polacrilex	Quit 4
nicotine polacrilex	Stop Smoking Aid
nicotine polacrilex	nicotine (polacrilex)
nicotine polacrilex	nicotine polacrilex (bulk)
varenicline tartrate	Chantix
varenicline tartrate	Chantix Continuing Month Box
varenicline tartrate	Chantix Starting Month Box
varenicline tartrate	Tyrvaya

Appendix E. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Characteristics in this Request

Non-Proprietary Name	Proprietary Name
varenicline tartrate	varenicline tartrate

Specifications for Type 5 Request: cder_mpl1r_wp313_nsdp_v01

This request executes the Cohort Identification and Descriptive Analysis (CIDA) tool, version 14.2.0, to assess utilization and uptake of the 2021, part 1 (Approved January 2021-June 2021) New Molecular Entities (NMEs) in the Sentinel Distributed Database (SDD).

Query period:	01/01/2021 - 04/30/25
Coverage requirement:	Medical and Drug Coverage
Minimum Pre-Index Enrollment Days:	183 days
Minimum Post-Index Required Days:	0 days
Enrollment Gap:	45 days
Age Groups:	0-17, 18-24, 25-40, 41-64, 65+ years
Sex:	M, F
Other Demographic Restrictions:	n/a
Stratifications:	Age group, Sex, Calendar Month (for Figures only)
Data Restrictions:	None
Chart Availability Restriction Indicator:	No
Envelope macro:	Reclassify encounters during inpatient stay as inpatient
Freeze data:	No
Drop Censor Output Indicator:	Yes (Indicates if counts of episodes censored by death and query end should be excluded from output to prevent death small cells from being sent to SOC.)

Exposure

Scenario	Index Exposure/ Event	Cohort definition	Type 5 Exposure Washout Period	Exclude evidence of days supply if exposure washout includes dispensing	Care Setting and Diagnosis Position Requirements	Treatment Episode Gap Type	Exposure Episode Gap	Exposure Episode Extension Period	Create Baseline Table?	End At-Risk Period at Evidence of
1	vericiguat	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Scenario	Index Exposure/ Event	Cohort definition	Type 5 Exposure Washout Period	Exclude evidence of days supply if exposure washout includes dispensing	Care Setting and Diagnosis Position Requirements	Treatment Episode Gap Type	Exposure Episode Gap	Exposure Episode Extension Period	Create Baseline Table?	End At-Risk Period at Evidence of
					Exposure					
2	cabotegravir	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
3	voclosporin	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
4	tepotinib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
5	umbralisib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
6	evinacumab-dgnb	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

			Exposure							
Scenario	Index Exposure/ Event	Cohort definition	Type 5 Exposure Washout Period	Exclude evidence of days supply if exposure washout includes dispensing	Care Setting and Diagnosis Position Requirements	Treatment Episode Gap Type	Exposure Episode Gap	Exposure Episode Extension Period	Create Baseline Table?	End At-Risk Period at Evidence of
7	trilacicilib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
8	casimersen	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
9	fosdenopterin	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
10	melphalan flufenamide	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
11	tivozanib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Scenario	Index Exposure/ Event	Cohort definition	Type 5 Exposure Washout Period	Exclude evidence of days supply if exposure washout includes dispensing	Care Setting and Diagnosis Position Requirements	Treatment Episode Gap Type	Exposure Episode Gap	Exposure Episode Extension Period	Create Baseline Table?	End At-Risk Period at Evidence of
				Exposure						
12	ponesimod	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
13	dasiglucagon	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
14	viloxazine	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
15	drospirenone and estetrol	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
16	dostarlimab-gxly	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Scenario	Index Exposure/ Event	Cohort definition	Exposure								
			Type 5 Exposure Washout Period	Exclude evidence of days supply if exposure washout includes dispensing	Care Setting and Diagnosis Position Requirements	Treatment Episode Gap Type	Exposure Episode Gap	Exposure Episode Extension Period	Create Baseline Table?	End At-Risk Period at Evidence of
17	loncastuximab tesirine-lpyl	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
18	serdexmethylphenidate and dexmethylphenidate	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
19	pegcetacoplan	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
20	amivantamab-vmjw	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
21	piflufolastat F 18	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

					Exposure					
Scenario	Index Exposure/ Event	Cohort definition	Type 5 Exposure Washout Period	Exclude evidence of days supply if exposure washout includes dispensing	Care Setting and Diagnosis Position Requirements	Treatment Episode Gap Type	Exposure Episode Gap	Exposure Episode Extension Period	Create Baseline Table?	End At-Risk Period at Evidence of
22	sotorasib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
23	infigratinib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
24	olanzapine and samidorphan	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
25	ibrexafungerp	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
26	aducanumab-avwa	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

			Exposure								
Scenario	Index Exposure/ Event	Cohort definition	Type 5 Exposure Washout Period	Exclude evidence of days supply if exposure washout includes dispensing	Care Setting and Diagnosis Position Requirements	Treatment Episode Gap Type	Exposure Episode Gap	Exposure Episode Extension Period	Create Baseline Table?	End At-Risk Period at Evidence of
27	asparaginase erwinia chrysanthemi (recombinant)-rywn	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

ICD-9, ICD-10, HCPCS, and CPT codes are provided by Optum360.

NDC codes are checked against First Data Bank's FDB MedKnowledge®.

N/A: Not applicable

Baseline Characteristics

Covariate Name	Covariate Number	Code Category	Complex Covariate Components	Care Setting and Diagnosis Position Requirements	Number of Instances the Covariate Should be Found in Evaluation Period	Covariate Evaluation Period Start	Covariate Evaluation Period End	Forced Supply to Attach to a Code *(only applies to RX codes)*	Lookback Period Date Only
Chronic Conditions Data Warehouse									
Acute Myocardial Infarction	**1**	DX		IPP, IPS	1	-183	-1	N/A	Y
Alzheimer's Disease	**2**	DX		Any	1	-183	-1	N/A	Y
Non-Alzheimer's Dementia	**3**	DX		Any	1	-183	-1	N/A	Y
Atrial Fibrillation	4	DX		IPP, IPS	1	-183	-1	N/A	Y
	5	DX		AV*, ED*, OA*	2	-183	-1	N/A	Y
	6	CC	4 or 5		1			N/A	Y
Diabetes	7	DX		IP*, IS*	1	-183	-1	N/A	Y
	8	DX		AV*, ED*, OA*	2	-183	-1	N/A	Y
	9	CC	7 or 8		1			N/A	Y
Heart Failure	**10**	DX		IP*, AV*, ED*, OA*	1	-183	-1	N/A	Y
Hyperlipidemia	11	DX		IP*, IS*	1	-183	-1	N/A	Y
	12	DX		AV*, ED*, OA*	2	-183	-1	N/A	Y
	13	CC	11 or 12		1			N/A	Y
Hypertension	14	DX		IP*, IS*	1	-183	-1	N/A	Y
	15	DX		AV*, ED*, OA*	2	-183	-1	N/A	Y
	16	CC	14 or 15		1			N/A	Y
Depression	**17**	DX		Any	1	-183	-1	N/A	Y
Ischemic Heart Disease	**18**	DX		Any	1	-183	-1	N/A	Y
Rheumatoid Arthritis/Osteoarthritis	**19**	DX		Any	2	-183	-1	N/A	Y
Stroke/Transient Ishemic Attack (TIA)	20	DX		IP*	1	-183	-1	N/A	Y
	21	DX		AV*, ED*, OA*	2	-183	-1	N/A	Y
	22	CC	20 or 21		1			N/A	Y

Baseline Characteristics

Covariate Name	Covariate Number	Code Category	Complex Covariate Components	Care Setting and Diagnosis Position Requirements	Number of Instances the Covariate Should be Found in Evaluation Period	Covariate Evaluation Period Start	Covariate Evaluation Period End	Forced Supply to Attach to a Code (only applies to RX codes)	Lookback Period Date Only
Breast Cancer	23	DX		IP*, IS*	1	-183	-1	N/A	Y
	24	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	25	CC	23 or 24		1			N/A	Y
Colorectal Cancer	26	DX		IP*, IS*	1	-183	-1	N/A	Y
	27	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	28	CC	26 or 27		1			N/A	Y
Prostate Cancer	29	DX		IP*, IS*	1	-183	-1	N/A	Y
	30	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	31	CC	29 or 30		1			N/A	Y
Lung Cancer	32	DX		IP*, IS*	1	-183	-1	N/A	Y
	33	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	34	CC	32 or 33		1			N/A	Y
Endometrial Cancer	35	DX		IP*, IS*	1	-183	-1	N/A	Y
	36	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	37	CC	35 or 36		1			N/A	Y
Acquired Hypothyroidism	38	DX		IP*, IS*,	1	-183	-1	N/A	Y
	39	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	40	CC	38 or 39		1			N/A	Y
Anemia	**41**	DX		Any	1	-183	-1	N/A	Y
Asthma	42	DX		IP*, IS*,	1	-183	-1	N/A	Y
	43	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	44	CC	42 or 43		1			N/A	Y
Benign Prostatic Hyperplasia	45	DX		IP*, IS*,	1	-183	-1	N/A	Y
	46	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	47	CC	45 or 46		1			N/A	Y

Baseline Characteristics

Covariate Name	Covariate Number	Code Category	Complex Covariate Components	Care Setting and Diagnosis Position Requirements	Number of Instances the Covariate Should be Found in Evaluation Period	Covariate Evaluation Period Start	Covariate Evaluation Period End	Forced Supply to Attach to a Code *(only applies to RX codes)*	Lookback Period Date Only
Chronic Kidney Disease	48	DX		IP*, IS*,	1	-183	-1	N/A	Y
	49	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	50	CC	48 or 49		1			N/A	Y
Chronic Obstructive Pulmonary Disease (COPD) and Bronchiectasis	51	DX		IP*, IS*,	1	-183	-1	N/A	Y
	52	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	53	CC	51 or 52		1			N/A	Y
Glaucoma	**54**	DX		AV*, ED*, OA*	1	-183	-1	N/A	Y
Osteoporosis	55	DX		IP*, IS*,	1	-183	-1	N/A	Y
	56	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	57	CC	55 or 56		1			N/A	Y
Other									
Obesity (Diagnosis or Procedure Codes)	**58**	DX, PX		Any	1	-183	-1	N/A	Y
Obesity (Dispensing Codes)	**59**	RX		Any	1	-183	-1	N/A	Y
Overweight	**60**	DX		Any	1	-183	-1	N/A	Y
Smoking (Diagnosis or Procedure Codes)	**61**	DX, PX		Any	1	-183	-1	N/A	Y
Smoking (Dispensing Codes)	**62**	RX		Any	1	-183	-1	N/A	Y
Alcohol Abuse or Dependence	**63**	DX, PX		Any	1	-183	-1	N/A	Y
Drug Abuse or Dependence	**64**	DX, PX		Any	1	-183	-1	N/A	Y
History of Cardiac Arrest	**65**	DX		Any	1	-183	-1	N/A	Y
History of Coronary Angioplasty or Bypass	**66**	DX		Any	1	-183	-1	N/A	Y

Baseline Characteristics

Covariate Name	Covariate Number	Code Category	Complex Covariate Components	Care Setting and Diagnosis Position Requirements	Number of Instances the Covariate Should be Found in Evaluation Period	Covariate Evaluation Period Start	Covariate Evaluation Period End	Forced Supply to Attach to a Code *(only applies to RX codes)*	Lookback Period Date Only
	67	DX		IP*, IS*	1	-183	-1	N/A	Y
	68	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	69	CC	67 or 68		1			N/A	Y
	70	PX		AV*	1	-183	-1	N/A	Y
	71	DX		AV*	1	-183	-1	N/A	Y
	72	CC	70 and 71		1			N/A	Y
	73	PX		ED*	1	-183	-1	N/A	Y
	74	DX		ED*	1	-183	-1	N/A	Y
Liver Disease CCW	75	CC	73 and 74		1			N/A	Y
	76	PX		OA*	1	-183	-1	N/A	Y
	77	DX		OA*	1	-183	-1	N/A	Y
	78	CC	76 and 77		1			N/A	Y
	79	PX		IS*	1	-183	-1	N/A	Y
	80	DX		IS*	1	-183	-1	N/A	Y
	81	CC	79 and 80		1			N/A	Y
	82	CC	69 or 72 or 75 or 78 or 81		1			N/A	Y

Baseline Characteristics

Covariate Name	Covariate Number	Code Category	Complex Covariate Components	Care Setting and Diagnosis Position Requirements	Number of Instances the Covariate Should be Found in Evaluation Period	Covariate Evaluation Period Start	Covariate Evaluation Period End	Forced Supply to Attach to a Code *(only applies to RX codes)*	Lookback Period Date Only
	83	DX		IP*, IS*,	1	-183	-1	N/A	Y
	84	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	85	CC	83 or 84		1			N/A	Y
	86	PX		AV*	1	-183	-1	N/A	Y
	87	DX		AV*	1	-183	-1	N/A	Y
	88	CC	86 and 87		1			N/A	Y
	89	PX		ED*	1	-183	-1	N/A	Y
	90	DX		ED*	1	-183	-1	N/A	Y
Liver Disease Extended	91	CC	89 and 90		1			N/A	Y
	92	PX		OA*	1	-183	-1	N/A	Y
	93	DX		OA*	1	-183	-1	N/A	Y
	94	CC	92 and 93		1			N/A	Y
	95	PX		IS*	1	-183	-1	N/A	Y
	96	DX		IS*	1	-183	-1	N/A	Y
	97	CC	95 and 96		1			N/A	Y
	98	CC	85 or 88 or 91 or 94 or 97		1			N/A	Y

					Baseline Characteristics				
Covariate Name	**Covariate Number**	**Code Category**	**Complex Covariate Components**	**Care Setting and Diagnosis Position Requirements**	**Number of Instances the Covariate Should be Found in Evaluation Period**	**Covariate Evaluation Period Start**	**Covariate Evaluation Period End**	**Forced Supply to Attach to a Code** *(only applies to RX codes)*	**Lookback Period Date Only**
		RX: Drug code **DX:** Diagnosis code **PX:** Procedure code **CC:** Complex covariates (multiple COVARNUM values are used to define a covariate)		**IP*:** inpatient hospital stays, any diagnoses **IS*:** non-acute institutional stays, any diagnoses **ED*:** emergency department encounters **AV*:** ambulatory visits **OA*:** other ambulatory visits					**N:** Lookback period should search for evidence of a date or an interval **Y:** Lookback period should search for evidence of a date only

*The wildcard symbol (*) can be used to represent 'any' values of either the care setting or principal discharge diagnosis flag. Wildcard does not restrict a specific principal diagnosis position. The principal discharge diagnosis flag is only relevant for diagnosis codes.

The (P) at the end of the care setting refers to the primary diagnosis position, while the (S) refers to the secondary diagnosis position. This indicates that only the first or second diagnosis on the claims should be used for specified codes. For example, IPP (Inpatient Primary) uses the first diagnosis position, and IPS (Inpatient Scondary) uses the second diagnosis position.

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Baseline Characteristics

Covariate Name	Covariate Number	Code Category	Complex Covariate Components	Care Setting and Diagnosis Position Requirements	Number of Instances the Covariate Should be Found in Evaluation Period	Covariate Evaluation Period Start	Covariate Evaluation Period End	Forced Supply to Attach to a Code *(only applies to RX codes)*	Lookback Period Date Only

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Principal Diagnosis (PDX) **-** diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Care setting/PDX parameter.

N/A: Not applicable

Cohort Design for QF-9684[1]

Query start date
1 Jan 2021

Cohort entry date[2]
First dispensing of NME
Day 0

Query end date
End of data

Enrollment requirement
Drug and Medical Coverage

Pre-index: [-183,-1]

Allowed coverage gap

45 days

Episode length

Episode gap

Episode extension

Exposure Episode 1 (NME days supply)

None (0 days)

None (0 days)

Exposure Episode 2 or more (NME days supply)

Baseline Characteristics[3]

I

II: (-183, -1)

Follow-Up

(0, censoring[4])

[1] Includes all valid exposure during the query period; only the first valid episode's incidence is assessed using the washout period.
[2] 28 scenarios defined on initiation of NMEs approved in 2021 part 1 (one scenario per NME); Cohort entry date = first dispensing date for qualifying NME.
[3] Baseline characteristics:
     Window I: Age, Sex, Year
     Window II: Chronic conditions warehouse (CCW), alcohol abuse or dependence, drug abuse or dependence, history of cardiac arrest, history of coronary angioplasty or bypass, obesity, overweight, and smoking
[4] Censoring: earliest of death, disenrollment, data partner data end date, query end date